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  Foreword 
 
 
International drug control efforts cannot be successful in the long term without 
continuous efforts to reduce illicit drug demand. That is why the drafters of the 
international drug control conventions made demand reduction an obligation for 
Governments. Another important step forward was the adoption in 1998 of the 
Declaration on the Guiding Principles of Drug Demand Reduction, a globally 
accepted set of standards, at the twentieth special session of the General Assembly.  
The first chapter of the present report of the International Narcotics Control Board 
focuses on preventing drug abuse, a crucial area of demand reduction. Primary 
prevention encompasses measures taken to prevent and reduce drug abuse in 
populations that are either not abusing or not seriously involved with drugs. There is 
good reason for society to take concerted action to prevent drug abuse. Even a 
single early experience with drug abuse can have serious consequences, such as 
unintentional injury, overdose or arrest. 
Primary prevention strategies need to address both the general population and 
groups that are particularly vulnerable to drug abuse. While large-scale efforts can 
go a long way towards raising awareness and can reduce illicit drug demand, they 
may lack the focus or intensity to address effectively the needs of vulnerable 
population groups. An effective drug abuse prevention strategy should include both 
types of measures: measures targeting the general population and measures targeting 
the more vulnerable population groups. 
For primary prevention strategies to be effective, it must be possible to put them 
into action. All too often, priority is given to highly visible but short-lived responses 
such as a stand-alone media campaign. To result in significant social and economic 
benefits, prevention measures need to be complemented by other measures.  
As drug abuse is a continuous challenge, it requires constant attention and action. 
Drug abuse prevention is a fundamental health issue. Drug abuse prevention 
activities should be integrated into public health, health promotion and child and 
youth development programmes. Policymakers need to commit resources to such 
activities.  
Primary prevention efforts that involve the Government alone cannot be effective. 
Partnerships with civil society need to be forged at the local, national and 
international levels to ensure the most efficient use of scarce resources and to 
increase effectiveness in reducing the prevalence of drug abuse. Credible non-
governmental organizations promoting children and youth and accustomed to 
working alongside community representatives can lead prevention efforts at the 
local level that are evidence-based and culturally appropriate. Because of their 
extensive direct involvement in that area, such organizations have an important 
perspective that needs to be heard at the policymaking level. 
One disturbing trend highlighted in the present report is the increasing abuse of 
pharmaceutical preparations containing substances under international control. In 
the United States of America, where the problem is well documented, the abuse of 
prescription medicines is more prevalent than the abuse of cocaine, heroin or 
methamphetamine. One matter of particular concern is that people often do not 
associate any particular risk with the non-medical use of pain medication. The 
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extent of such abuse is underreported and not adequately studied. The Board 
recommends that Governments launch prevention programmes to make youth and 
families more aware of the dangers of abusing controlled medicines.  
Drugs containing substances such as oxycodone, methadone and hydrocodone are 
subject to strict international control. States that are parties to the international drug 
control conventions are obliged to regulate access to those drugs and prevent their 
abuse. Illegal Internet pharmacies violate those regulations by making prescription 
drugs available to persons without the necessary prescription, which puts consumers 
of those substances at an inordinate risk. To assist Governments in addressing that 
problem, the Board issued, in 2009, the Guidelines for Governments on Preventing 
the Illegal Sale of Internationally Controlled Substances through the Internet, 
together with a framework of action to help Governments to prevent the illegal 
online sale of prescription drugs. Governments should make use of the Guidelines 
and take further action to control the illegal sale of prescription drugs. The Board is 
ready to support Governments in their efforts to combat the abuse of prescription 
medicines.  
The Board has been the leading advocate of increasing the licit use of opioid-based 
medications. The consumption of those substances for medical purposes is regularly 
reviewed in the reports of the Board. The Board has worked with the World Health 
Organization (WHO) in preparing guidelines for the assessment of national laws and 
policies with a view to identifying ways to improve the availability of medications. 
The Board has developed with WHO the Access to Controlled Medications 
Programme. In addition, the Board has convened a joint working group with WHO 
to assist Governments in establishing more realistic estimates of requirements for 
medications containing internationally controlled substances. Overly restrictive 
policies are contrary to one of the principles enshrined in the international drug 
control conventions: that the medical use of narcotic drugs is indispensable for the 
relief of pain and suffering and that adequate provisions must be made to ensure 
their availability for such purposes. 
           
Sevil Atasoy 
President 
International Narcotics Control Board 
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frontiers or boundaries.  
 Countries and areas are referred to by the names that were in official use at the 
time the relevant data were collected. 
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Explanatory notes 
 
The following abbreviations have been used in this report: 
ACCORD ASEAN and China Cooperative Operations in Response to 
Dangerous Drugs 
ADD attention deficit disorder 
AIDS acquired immunodeficiency syndrome 
ANVISA National Health Surveillance Agency (Brazil) 
ASEAN Association of Southeast Asian Nations 
BIMSTEC Bay of Bengal Initiative for Multi-Sectoral Technical and 
Economic Cooperation 
BKA Federal Criminal Police Office (Germany) 
BZP N-benzylpiperazine 
CARICC Central Asian Regional Information and Coordination Centre 
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GABAC Action Group against Money Laundering in Central Africa 
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 I. Primary prevention of drug abuse 
 
 
1. As the global community renews its commitment 
to tackling the world drug problem over the next  
10 years, policymakers are increasingly looking to 
demand reduction to make a key contribution.1 The 
term “demand reduction” refers to all activities aimed 
at reducing demand for drugs and includes primary, 
secondary and tertiary prevention. The present chapter 
focuses on primary prevention, that is, measures to 
prevent and reduce drug use in populations that are 
either not using or not seriously involved with drugs. 
The chapter includes a brief review of the extent of 
drug use and factors associated with such use, a 
description of primary prevention measures supported 
by scientific evidence, a discussion on the positioning 
of a focal point for prevention at the national level and 
recommendations for action to enable societies to build 
their capacity for prevention. 
2. In the present chapter, the term “drugs” refers to 
narcotic drugs and psychotropic substances covered by 
the international drug control conventions: the Single 
Convention on Narcotic Drugs of 1961 as amended by 
the 1972 Protocol;2 the Convention on Psychotropic 
Substances of 1971;3 and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988.4 The distribution of 
those narcotic drugs and psychotropic substances are 
permitted by law only if they are distributed through 
medical and pharmaceutical channels for medical and 
scientific purposes. In this chapter, the term “drug use” 
should be understood to mean illicit use of those drugs. 
3. International drug policy is led by the 
international drug control conventions. The supervision 
of the conventions and the monitoring of their 
implementation by States rest with the Commission on 
Narcotic Drugs and the International Narcotics Control 
Board, respectively. The conventions are concerned 
with the public health and social problems resulting 
__________________ 
 1  See, for example, the Political Declaration and Plan of 
Action on International Cooperation towards an 
Integrated and Balanced Strategy to Counter the World 
Drug Problem (A/64/92–E/2009/98, sect. II.A); and 
World Drug Report 2008 (United Nations publication, 
Sales No. E.08.XI.11). 
 2  United Nations, Treaty Series, vol. 976, No. 14152. 
 3  Ibid., vol. 1019, No. 14956. 
 4  Ibid., vol. 1582, No. 27627. 
from drug use. The conventions stress the need for 
demand reduction and prevention, along with measures 
to control the supply of narcotic drugs and 
psychotropic substances. For example, article 38 of the 
1961 Convention as amended by the 1972 Protocol 
states: 
  “The Parties shall … take all practicable 
measures for the prevention of abuse of drugs and 
for the early identification, treatment, education, 
aftercare, rehabilitation and social reintegration 
of the persons involved, and shall coordinate their 
efforts to these ends.” 
4. In the Declaration on the Guiding Principles of 
Drug Demand Reduction,5 adopted by the General 
Assembly at its twentieth special session, in 1998, it is 
stated that demand reduction efforts should be 
integrated into broader social welfare and health 
promotion policies and preventive education 
programmes. Health promotion and primary, secondary 
and tertiary prevention together contribute to the 
overall aim of reducing problems associated with drug 
use. Treatment activities are aimed at individuals 
diagnosed with drug dependence. Secondary 
prevention measures are aimed at reaching early those 
individuals who are seriously involved with drugs but 
are not dependent on drugs. Primary prevention, the 
third critical and complementary element in a demand 
reduction framework, is directed at populations not 
currently using or not seriously involved with drugs. 
Such populations are much larger than those targeted 
by secondary and tertiary prevention; hence their 
potential for reducing rates of drug use in a jurisdiction 
is significant. 
5. Primary prevention promotes the non-use of 
drugs and is aimed at preventing or delaying the first 
use of drugs and the transition to more serious use of 
drugs among occasional users. Most drug use begins 
during adolescence and early adulthood, when young 
people are developing cognitively and socially. For that 
reason, primary prevention is mainly directed at those 
life stages and those before them. Primary prevention 
activities may be directed at whole populations (also 
referred to as universal prevention) or at particular 
groups of people who may be vulnerable because of 
__________________ 
 5  General Assembly resolution S-20/3, annex. 
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risk conditions in their lives (i.e. selective 
prevention).6 Drug use may be prevented, directly 
through activities aimed at preventing drug use or 
indirectly through activities that prevent drug use by 
promoting the overall health of a population.7 
6. There is good reason for society to give 
considerable attention to preventing drug use. There is 
no doubt that a single drug-using experience can have 
unpredictable and serious consequences (such as injury 
or overdose), particularly for naive users. Immediate 
problems are more likely to occur if large amounts of 
drugs are used and if particularly hazardous modes and 
contexts of drug use are involved (e.g. use of drugs by 
injection, use of multiple drugs, use of drugs in 
association with work or sexual activity or use of drugs 
while pregnant). Frequent use of drugs over a long 
period can have a number of consequences for the 
individual, the community and society. Personal 
consequences can include structural damage to the 
brain (e.g. due to chronic cocaine or methamphetamine 
use) or other organs, deteriorating family relations, 
poorer performance in school or work, unwanted 
and/or unprotected sexual activity, violence and trouble 
with the authorities. Of particular concern is the greatly 
increased risk for blood-borne infection (HIV,  
hepatitis B and C) associated with the use of drugs by 
injection. Widespread use of drugs by injection and 
other forms of chronic drug use in a community can 
result in reduced community safety and cohesion and 
elevated criminal activity. Drug use exacts a significant 
economic toll on communities and societies due to 
increased law enforcement, social welfare and health 
care and lost productivity. According to the World 
Health Organization (WHO), close to 1 per cent of ill 
health in the world can be attributed to drug use; for 
developed countries, the figure is 2.3 per cent.8 
 
 
__________________ 
 6  Individuals who are more seriously involved with drugs 
but are not drug-dependent are also addressed through 
targeted services referred to as “indicated prevention”. 
Those services are not part of primary prevention. 
 7  For the remainder of this chapter, it should be assumed 
that primary prevention includes health promotion 
measures and principles. 
 8  World Health Organization, World Health Report 2002: 
Reducing Risks, Promoting Healthy Life (Geneva, 2002). 
 A. Extent and nature of drug use 
 
 
7. Societal efforts to prevent drug use need to be 
based on the best possible available data. It is 
challenging to generate reliable information on the 
nature and extent of the drug use situation; without a 
good understanding of the situation, it is impossible to 
plan properly or know whether strategies are having a 
positive effect. School and household surveys on the 
prevalence of drug use provide a broad view of the 
situation regarding drugs of concern and age and 
gender differences. Other sources of useful data on 
drug use vary from region to region but may include 
hospital emergency units, drug treatment centres, 
medical networks, police departments, government 
health and social service offices and university 
research institutes. In some jurisdictions, networks 
with representation from these groups have been 
established to monitor trends in drug use at the 
municipal, district or national level. However it is 
gathered, relevant information for primary prevention 
aimed at preventing or delaying the onset of drug use 
includes information on the prevalence of drug use, the 
age of first drug use, gender differences, factors linked 
to the use and non-use of drugs and the socio-cultural 
context of drug use. A primary prevention strategy 
aimed at preventing in a population the transition of 
occasional drug use into serious involvement with 
drugs should include the collection of information on 
the frequency of drug use, the amount of drugs used 
and the factors linked to making the transition to more 
serious drug use. 
8. It is estimated that between 172 million and 
250 million persons in the world used a drug in the 
past year.9 What that estimate does not reveal is that 
rates of drug use vary greatly depending on the drug 
type, region, age group and gender: 
• Cannabis is by far the most commonly used 
drug among young and older adults: in 2007, 
3.3-4.4 per cent of the world’s population aged 
15-64 years reported having used that drug in 
the past year. The next most commonly used 
drugs among person aged 15-64 years are 
amphetamine-type stimulants (including 
methamphetamine (0.4-1.2 per cent) and 
methylenedioxymethamphetamine (MDMA, 
__________________ 
 9  World Drug Report 2009 (United Nations publication, 
Sales No. E.09.XI.12). 
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commonly known as “ecstasy”) (0.3-0.5 per 
cent)), followed by cocaine (0.4-0.5 per cent) 
and opiates (0.3-0.5 per cent).10 
• Rates and patterns of drug use in different 
regions are constantly in flux, affected by 
socio-economic forces and the availability of 
various drugs. Generally, the highest rates of 
drug use are found in North America, Oceania 
and Western Europe, although countries in 
those regions and subregions have reported 
drug use to be stable or declining in recent 
years. While cannabis is the most commonly 
used drug in most regions, the use of 
amphetamine-type stimulants is more common 
in East and South-East Asia. The highest rates 
of opiate use in the world are reported in 
countries along the main drug trafficking 
routes leading from Afghanistan. Increases in 
the use of drugs by injection and the HIV 
infection rate in Central Asian countries are 
among the steepest in the world, partly because 
those countries are used as transit areas for 
Afghan heroin bound for the Russian 
Federation and other countries in Europe. 
While rates of drug use are currently stable or 
declining in regions and subregions with high 
drug use rates, countries with economies in 
transition (e.g. countries in Eastern Europe and 
South America) and countries used as illicit 
drug production or transit areas (e.g. Central 
Asian countries) are at risk for and, in some 
cases, show signs of increasing drug use. This 
shift may be part of a larger phenomenon of 
“risk transition” resulting from marked 
changes in living patterns in many parts of the 
world.11 
• The abuse of prescription drugs is common in 
most regions, although comprehensive data on 
prevalence rates are difficult to obtain because 
data on the abuse of prescription drugs are not 
systematically collected in most countries. 
Where the abuse of prescription drugs is 
monitored, the prevalence of abuse of such 
drugs has been found to be high. In North 
America, for example, the abuse of 
__________________ 
 10  Ibid. 
 11  World Health Organization, World Health Report 
2002 … . 
prescription drugs is second only to the 
prevalence of cannabis abuse. In the United 
States, 6.2 million persons aged 12 or older, or 
2.5 per cent of the population, abused 
prescription drugs in the past month, and 
15.2 million persons in that age group, or 
6.1 per cent of the population, abused 
prescription drugs in the past year. 
• Rates of drug use tend to be higher during the 
teenage and early adult years. First use of 
drugs most often occurs in adolescence. In the 
past, it could generally be said that if young 
persons had not begun using drugs by the end 
of their adolescent years, they were unlikely to 
begin; however, an increase in the number of 
persons first using drugs in their early adult 
years has been reported in numerous countries, 
perhaps partly because of marriage being 
delayed: getting married (and beginning a 
family) generally has the effect of reducing 
drug use. In the past, young males were more 
likely to use drugs; while that is generally still 
the case, the gap between drug use among 
females and drug use among males has 
narrowed for certain drugs in various countries 
throughout the world.12 
9. The question of why some young people begin to 
use drugs and others do not is complex. It is 
understood to hinge on the interplay of a number of 
factors, including genetic and environmental factors. 
The terms “risk factor” and “protective factor” refer to 
those attributes or conditions that serve to either 
increase or decrease the likelihood of drug use. 
Everyone possesses or experiences a combination of 
those factors, in their personal, family, social, school, 
community and societal environments. Drug use or any 
other problematic behaviour (such as violence, 
criminal activity or poor school performance) or less 
socially disruptive internalized problems (such as 
extreme shyness, depression or anxiety) share many of 
the same risk and protective factors. 
10. Risk and protective factors can affect an 
individual’s development at any point, from conception 
through childhood to adolescence and adulthood. Some 
children become vulnerable because of risk factors 
accumulating early in life. For example, weak 
__________________ 
 12  World Drug Report 2009 … . 
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child-parent attachment at infancy may contribute to 
early behavioural problems, which can affect school 
performance and engagement with peers. In other 
cases, young people who are faring well can become 
vulnerable as a result of the onset of risk factors at a 
particular life stage (such as feeling abandoned by one 
or both parents due to their parents’ separation, life in a 
new community or lack of school attachment). 
Protective factors help set a healthy pathway and 
provide a buffer against risk factors, particularly 
through challenging periods in life. Some children 
have certain innate traits and abilities that confer 
protection (see paragraph 11 below), but all children 
benefit from the protective effects of healthy family, 
social, school and community environments. 
 
 1. Personal factors 
 
11. A number of personal factors, including genetics, 
biology, personality, mental health and life skills, help 
to determine whether a young person engages in drug 
use or other problematic behaviour. A person’s genetic 
make-up may lead to vulnerability to drug use 
problems that may or may not be expressed, depending 
on the person’s environment (e.g. parent and 
community attitudes towards drug use) and specific 
individual experiences. Exposure to substances such as 
drugs, alcohol or tobacco during pregnancy can either 
subtly or dramatically affect a child’s future 
development and vulnerability, depending on the 
substance and the timing and extent of the exposure. 
Childhood mental health problems, especially conduct 
disorder and attention deficit disorder (ADD), are 
associated with later drug use. Use of tobacco and 
alcohol in late childhood or early adolescence may 
stem from earlier challenges and is a risk factor for 
later drug use. Mental health issues tend to become 
more prevalent during adolescence and are often 
associated with increased risk for drug use. Drug use 
by some youth may be an attempt to relieve mental 
health problems. In adolescence, a sensation-seeking 
personality is a risk factor for drug use, but so are 
internalized problems (such as anxiety). In early 
childhood, an easy-going temperament is a protective 
factor that buffers the influence of risk factors, 
reducing the likelihood of later drug use and other 
problematic behaviour. Important protective traits or 
abilities throughout childhood include being able to 
trust, having confidence in oneself and in one’s ability 
to meet life’s demands, being able to take initiative, 
having a well-formed sense of identity and being able 
to experience and express intimacy. In terms of drug 
use, as a child proceeds into adolescence, a cautious 
temperament is a protective factor.  
 
 2. Family factors 
 
12. The quality of family life is a large factor 
affecting health and behaviour throughout childhood 
and adolescence. Early deprivation (e.g. lack of 
affection from caregivers, neglect or abuse) often has a 
profound affect on a child’s pathway through life. 
Children of drug- or alcohol-dependent parents are at 
particular risk for later drug use. In adolescence, 
discipline and family rules are factors, and extreme 
approaches (i.e. being either too permissive or too 
punitive) are associated with problems. Transitions or 
significant changes in family life (such as parental 
separation, loss of a close family member or moving to 
a new neighbourhood or school) can place any young 
person at risk. Parents who are good listeners, set 
reasonable expectations, monitor their child’s activities 
and model healthy attitudes and behaviour (e.g. in 
relation to use of medication) have a protective effect. 
 
 3. Social factors 
 
13. Social influences play an increasingly prominent 
role as children approach adolescence. In some 
societies, the media have contributed to a 
normalization of drug use. That is important because 
young people tend to be influenced by their perception 
of how common or “normative” drug use is in their 
networks. If a young person’s friends or peers smoke, 
drink or use drugs or it is believed that they do, the 
young person is more likely to do those things, too. 
However, the phenomenon of peer influence as a risk 
factor is complex; peer influence rarely takes the form 
of overt coercion to try drugs, as is sometimes 
assumed. Decisions on the use of a particular drug are 
also linked to perceptions of the risk associated with 
the use of that drug. An emerging drug may go through 
a phase in which there is little information available 
about the risks or consequences of its use. Inaccurate 
information often fills that void, leading to an image of 
the drug being safe or of its users being somehow 
different from other drug users. As the perceived risk 
associated with the use of the drug increases, the rate 
of its use tends to decline. However, the concept of 
drug-related risk is best considered in relation to the 
benefits perceived by the young person. Some young 
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people may perceive unhealthy behaviour such as drug 
use as having important social benefits (for example, 
supporting a desired identity or making friends). 
Consequently, knowledge about drug risks does not 
serve as a protective factor in itself, but belief that the 
relative risks of drug use outweigh the benefits does. 
Spiritual engagement, active involvement in healthy 
recreational activities and service to a community are 
all important social factors that provide protection 
during adolescence. 
 
 4. Gender factors 
 
14. It is important to consider gender differences for 
protective and risk factors in relation to drug use. 
Certain protective and risk factors may hold equal 
importance for boys and girls (e.g. social support, 
academic achievement, poverty) but may be expressed 
in different ways. Boys have a higher prevalence of 
conduct disorder and ADD13 during childhood, which 
can lead to them having earlier association with 
deviant peers and earlier initiation into drug use than 
girls. Other risk factors tend to be more important for 
girls; such risk factors include negative self-image or 
self-esteem, weight concerns, early onset of puberty, or 
a higher level of anxiety or depression. During 
adolescence, girls tend to give greater priority to social 
relationships than do boys; girls also appear to be more 
vulnerable to the influence of drug-using friends. 
Certain protective factors, such as parental support and 
consistent discipline, tend to be more important for 
girls than for boys. 
 
 5. School factors 
 
15. The opportunity to attend school is an important 
protective factor; for children who are able to attend 
school, the quality of the school experience has an 
impact on their health and on their likelihood of 
engaging in risky behaviour, including drug use. Young 
people who are not engaged in learning and who have 
poor relationships with their peers and teachers (e.g. 
young people who are bullied or who experience a 
feeling of not belonging or who are not engaged in 
__________________ 
 13  See World Health Organization, The ICD-10 
Classification of Mental and Behavioural Disorders: 
Clinical Descriptions and Diagnostic Guidelines 
(Geneva, 1992); and American Psychiatric Association, 
Diagnostic and Statistical Manual of Mental Disorders: 
DSM-IV-TR, 4th ed. (Washington, D.C., 2000). 
their schoolwork or other activities) are more likely to 
experience mental health problems and to be involved 
in various types of health-risk behaviour, including 
drug use. Students with positive teacher, learning and 
social connectedness fare best in terms of mental 
health and resistance to health-risk behaviour and are 
more likely to have a good educational outcome. 
Schools that give systematic attention to promoting 
bonds among teachers, parents and students provide an 
important protective effect in terms of both learning 
and well-being. Students in secondary school are less 
likely to use drugs when the norms in school reflect a 
clear disapproval of drug use.  
 
 6. Community and societal factors 
 
16. Many of the above-mentioned factors affecting 
young people arise from community conditions and 
other broad social factors (e.g. adequacy of income, 
employment and housing and the quality of social 
support networks). Internal migration, in particular 
migrating from a rural setting to an urban one, may be 
a risk factor when it causes a sense of uprooting, loss 
of traditional family values and relationships, loss of 
social structure with respect to the community of 
origin, difficult cultural adaptation or a feeling of 
alienation. Not having a reasonable income is a risk 
factor, as are having jobs with boring tasks, having no 
supervision and having no opportunity for promotion. 
Insufficient financial resources are deepened by poor 
community conditions such as badly maintained 
schools and lack of access to community services. 
Weak communities are more likely to experience 
crime, public drug use and social disorder, which, in 
turn, can further weaken those communities. Social 
capital (a community’s cohesiveness and ability to 
solve common problems) is an indicator of community 
health that may have a bearing on a number of issues, 
including drug use. 
 
 7. Vulnerable populations 
 
17. Young people around the world live in a vast 
range of circumstances. Many young people are 
exposed to ordinary levels of risk in the various areas 
of their lives, and most choose not to use drugs. 
However, some young people at least try drugs, 
particularly cannabis and amphetamine-type stimulants 
(along with alcohol, tobacco and, increasingly, without 
a doctor’s supervision, psychoactive medicines), and 
some experience problems as a result. In every region, 
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however, there is a population of children and young 
people exposed to more than an average level of risk. 
That risk may be manifested in various ways; if drugs 
are available to young people during adolescence and 
adulthood (e.g. as a result of drug use in the family or a 
high level of drug trafficking in the neighbourhood), 
they are more likely to use drugs. The challenge (and 
opportunity) for society is to systematically offer 
protective conditions and experiences to all children 
and youth, particularly those who are more vulnerable.  
 
 
 B. Strategies for preventing drug use  
 
 
18. Primary prevention strategies need to ensure that 
attention is given to both whole (or universal) 
populations as well as targeted (selective) populations. 
Well-based whole population initiatives can both 
reduce demand and help identify gaps or population 
groups that are not being sufficiently addressed. To 
effectively address their needs, particular groups or 
vulnerable populations may benefit from initiatives 
with greater focus or intensity. Consequently, a 
prevention plan needs to include both types of 
measures: measures targeting the general population 
and measures targeting the more vulnerable population 
groups. Research provides good direction on the most 
fruitful whole population and targeted approaches for 
the various life stages. 
 
 1. Early childhood 
 
19. Initiatives to promote the health and social 
development of children in their preschool years 
(children up to 6 years of age) can have the effect of 
averting a range of problems, including drug use, 
during adolescence and later. Prevention needs to begin 
with prospective parents, raising their awareness of the 
harm caused by using drugs, alcohol or tobacco during 
pregnancy. Home visit initiatives directed at young 
families experiencing problems (parental mental health 
problems or drug abuse, lack of partner support etc.) 
are a very effective intervention for preschool children. 
Such programmes typically involve a longer-term 
intensive relationship with the mother and family, 
beginning prior to or just after delivery. The aim of 
visit programmes is to support the mother with her own 
health needs, with child development issues and with 
help in accessing services. Higher-quality early 
childhood education programmes have been shown to 
improve academic performance and social skills among 
vulnerable children, yielding long-term dividends, 
including reduced drug use, in a range of life areas. 
Programmes directed at families of preschool children 
can identify and reduce behavioural problems in early 
childhood (such as non-compliance and conduct 
disorder), improve parenting practices and help parents 
to create an environment promoting positive child 
development. 
 
 2. Later childhood 
 
20. Primary prevention resources for the later 
childhood years are best devoted to family-based 
initiatives. Most parents benefit from support, and the 
extended family can play a crucial supportive role, 
particularly in societies without established welfare 
systems. Circumstances and needs vary considerably, 
however. Brief advice may suffice in some cases; in 
others, parenting training involving the whole family 
or therapeutic support may be most beneficial. A tiered 
arrangement offering services for a variety of needs or 
levels of risk is ideal. It has the effect of exposing all 
families in the community to programming support 
while allowing families with particular challenges to 
access services without being stigmatized.  
21. In some regions, family skills training 
programmes are becoming increasingly common, 
bringing groups of families together for approximately 
eight sessions. They have been found effective for 
groups of families assembled on the basis of shared 
risk factors (e.g. families with a drug-dependent 
parent), as well as those assembled without regard to 
their risk level. In both cases, the programmes 
typically help parents to improve their ability to listen 
and communicate effectively, solve problems, provide 
appropriate discipline and monitor their children’s 
activities during adolescence. The sessions need to be 
interactive (instead of in a lecture format) and to 
include opportunities for parents and children to test 
new ideas and skills together. The sessions are often 
organized in concert with the local school, 
emphasizing mutual support between parents and 
teachers. Providing incentives such as paid 
transportation, arrangement for childcare, free 
communal meals and vouchers for consumer goods at 
the end of the programme can greatly enhance the 
participation of parents and families. On the whole, 
family skills training programmes are among the most 
effective drug use prevention options; they have also 
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been shown to decrease other types of problem 
behaviour (aggressiveness, truancy) and increase 
attachment to school.14 
 
 3. Early and middle adolescence 
 
22. For children in early adolescence who are able to 
attend school, education aimed at raising awareness of 
the risks of drug use is an important prevention 
component. The ability of classroom instruction to 
prevent drug use is much strengthened when such 
instruction is delivered in the context of a “health-
promoting school” approach integrating attention to the 
environment in and around schools, good access to 
services and strong parent and community 
involvement. The most promising classroom models 
for such education ensure that accurate, balanced 
information on the risks and consequences of drug use 
is provided in the context of exploring social 
influences and teaching key life skills (such as coping, 
decision-making, critical thinking and assertiveness).15 
But in order to be manageable for schools, such 
education needs to be woven with other issues (e.g. 
mental health problems) that share the same risk and 
protective factors. Interactive teaching approaches are 
essential to effective education about the risks of drug 
use, as simply providing information has been found to 
be ineffective. Because relevance is critical, culturally 
appropriate education programming is likely to 
increase the potential of programmes for educating 
students of differing ethnicity about the risks of drug 
use.16 The effectiveness of even the best programmes 
is limited given that many of the risk factors lie beyond 
the school grounds. However, such programmes are 
viewed as cost-effective because they are relatively 
inexpensive to deliver and have been shown to have an 
impact on other types of behaviour and because 
delaying the onset of drug use by even a year or two 
__________________ 
 14  Guide to Implementing Family Skills Training 
Programmes for Drug Abuse Prevention (United Nations 
publication, Sales No. E.09.XI.8). 
 15  World Health Organization, Skills for Health: Skills-
Based Health Education Including Life Skills – An 
Important Component of a Child-Friendly/Health-
Promoting School, Information Series on School Health, 
No. 9 (Geneva, 2003). 
 16  Drug Abuse Prevention among Youth from Ethnic and 
Indigenous Minorities (United Nations publication, Sales 
No. E.04.XI.17). 
for a few students helps avoid significant social costs 
in the future. 
23. Having school policies on substance use is 
important as it enables the school to address drug use 
issues and to influence the norms and culture within 
the school. The content of school policies on substance 
use is important, but so is the process by which such 
policies are developed, communicated and enforced. 
While a participatory approach to that process is time-
consuming, it has a positive effect in that it gives 
students and staff a sense of ownership over that part 
of their lives. It will lead to greater support for policies 
and decisions. School policies on substance use should 
cover the use of drugs, alcohol and tobacco among 
students and staff. A balanced policy on substance use 
is one that seeks instructive and health-promoting 
solutions to issues, including logical consequences for 
infractions, and minimizes punitive action such as 
suspension. Suspension often leads to increased 
antisocial behaviour, so policies on substance use 
should foster creative ways to help youth who are at 
higher risk to maintain their links with school. 
24. All students may potentially benefit from 
universal prevention measures aimed at imparting 
knowledge or life skills or improving the overall 
environment in school. However, some students (e.g. 
those who are not succeeding in school, those who 
have behavioural issues or learning disabilities or those 
who are not involved in extra-curricular activities) are 
at risk for a variety of problems, including drug use, 
and may benefit from targeted prevention measures. 
Initiatives that help students at higher risk by 
supporting them academically, teaching them life skills 
or engaging them in sports and recreation programmes 
can be effective. Some initiatives that have brought 
together higher-risk students in targeted programmes 
have had negative effects because they resulted in the 
students having relationships with deviant peers and 
spending less time in a regular class with more 
conventional peers; hence caution is advised. Brief 
interventions using motivational approaches have 
shown particular promise for students who use alcohol 
and may have a similar effect on students who use 
drugs. 
25. Agencies serving youth, sports clubs and other 
entities providing out-of-school activities offer good 
opportunities to promote youth development and 
health. By simply providing alternative activities for 
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children and youth, they play an important role in 
promoting healthy use of leisure time. However, such 
entities can strengthen that role by building 
programmes in which: all youth feel physically and 
psychologically safe; rules and expectations are clear 
and age-appropriate; and there are plentiful 
opportunities to assume increasing responsibilities. 
Much of the potential of those entities depends on the 
quality of the young people’s relationships with the 
adult leaders and coaches. If they are characterized by 
respect, warmth and good communication, child health 
is promoted. The challenge for adult leaders is to make 
every effort to ensure that all children and youth feel 
included, particularly those who might otherwise feel 
excluded due to their gender, sexual orientation, 
disability, ethnicity or religion. Community 
programmes for vulnerable adolescents and young 
adults should be evidence-based, work hard to engage 
participants (e.g. through sports and the arts), be of 
sufficient duration to cultivate trusting, supportive 
relationships between staff and all participants and pay 
more attention to learning and skill development than 
results. 
26. Mass media campaigns are used by societies 
around the world to support primary prevention. 
Campaigns may have a variety of aims such as 
promoting healthy lifestyles, shifting community 
norms in relation to drug use and supporting parents in 
their preventive role. Keys to an effective campaign are 
having a good understanding of the targeted youth or 
parents and having sufficient resources to reach the 
target group. Evidence suggests that the following are 
also important:  
• When presenting drug-specific information, 
campaigns need to ensure that the information 
is accurate and balanced. 
• While noting longer-term consequences, it is 
important to emphasize immediate personal 
and social consequences (e.g. looking 
unattractive, being embarrassed by intoxication 
and antisocial behaviour the next day, growing 
apathy, inability to concentrate, getting 
arrested). 
• Because youth are a very diverse population, it 
is important to be clear about the target group 
and the image or social representation that the 
group applies to a drug; for example, a media 
message developed for adventurous youth 
should differ from a message directed at youth 
who may find drug use appealing because of 
their anxiety issues. 
• It is extremely difficult for most adults to keep 
abreast of youth trends and age-specific 
considerations; hence, it is important to involve 
members of the target group in designing 
media initiatives. 
27. It is challenging for drug prevention media 
campaigns to be noticed in the midst of unprecedented 
media traffic. Partnerships in which the public sector 
and the private sector pool their resources are effective 
in extending the reach of prevention campaigns. Used 
creatively, both traditional (e.g. street interviews) and 
newer media approaches (e.g. social networking on the 
Internet) can provide access to target groups among 
youth without being prohibitive in cost.  
 
 4. Late adolescence and early adulthood 
 
28. Given their dominant role in the lives of many 
older adolescents and young adults, the workplace, 
nightlife settings (such as clubs, discotheques, bars, 
parties and music festivals) and post-secondary 
institutions (e.g. colleges and universities) are 
important for primary prevention.17 A “healthy-setting” 
approach that recognizes their potential to either 
promote or hinder health can be effective in all cases: 
• Working conditions and organizational 
practices can either alleviate or aggravate 
stress on workers, which has a large influence 
on workers’ health and drug use. Giving 
employees input into the way their work is 
organized can help reduce stress, as can 
measures such as providing regular feedback 
on performance and having work schedules 
that are reasonable and flexible. Companies, 
large and small, can also reduce drug use by 
raising the awareness of employees and 
supervisors about drug issues, implementing an 
effective approach to identifying drug users 
__________________ 
 17  In all societies, there is a population of older adolescents 
and young adults who have less access to resources. 
Young people who are unemployed and living in poor 
housing or on the street (for example, due to an abusive 
or unstable upbringing, or mental illness) are more likely 
to benefit from intensive targeted services than primary 
prevention activities. 
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and achieving a balance between disciplinary 
measures and access to assistance.18 
• Prevention of drug use in nightlife settings is 
best addressed through comprehensive 
interventions aimed at promoting the health 
and safety of both staff and customers. Health 
and safety issues within those settings are 
wide-ranging; such issues may include 
ventilation, fire, sound levels, sexually 
transmitted infections and unwanted 
pregnancies, unintentional injuries due to falls 
or violence, and impaired driving upon leaving 
the workplace. Such issues are best addressed 
by a combination of basic venue policies, 
training serving staff and door supervisors and 
helping with access to treatment for staff if 
necessary. 
• Post-secondary institutions are also advised to 
take a comprehensive approach that ideally 
combines awareness and education, as well as 
the training of peer leaders, with policy that is 
consistently applied. Initiatives in such 
institutions should be based on understanding 
that drug use interferes with academic 
performance. 
 
 5. All life stages 
 
29. Societies clearly have a wide range of 
opportunities (e.g. in terms of population targets, life 
stages and settings) to promote the health of young 
people and to prevent drug use. While adolescence is 
often the focus of primary prevention, the early and 
middle childhood years also offer good opportunities. 
Primary prevention opportunities are more limited as 
young people make the transition into adulthood, but 
attention at that life stage is also important. During all 
life stages, prevention needs to be infused into the way 
all members of the community (i.e. families, schools, 
media, youth agencies, religious groups and nightlife 
establishments) view their responsibilities. For 
prevention policymakers and programmers, the 
challenge is to show how incorporating prevention-
oriented policies and approaches can support the core 
__________________ 
 18  International Labour Office, Management of Alcohol- 
and Drug-Related Issues in the Workplace, ILO Code of 
Practice (Geneva, 1996). Available from 
http://www.ilo.org/public/libdoc/ilo/1996/ 
96B09_297_engl.pdf. 
mission of those members of the community, so that, 
for example, nightclub owners come to see that a 
healthy setting can make good business sense and 
school authorities understand that prevention 
contributes directly to educational objectives. Ideally, 
everyone in a community should see the prevention of 
drug use and the promotion of health as their business 
and regard them not as projects but as the best way to 
do their work. 
30. Every single initiative, when based on evidence 
and carefully designed and delivered, makes an 
important contribution to prevention; however, positive 
outcomes are much more likely when individual 
initiatives are brought together into comprehensive, 
long-term community action. Nurturing healthy young 
people who do not use drugs means engaging all 
members of the community in helping children and 
youth develop strong personal and social capabilities. 
Skill-building opportunities are most powerful when 
presented in the context of day-to-day living (e.g. 
coping with relationships, drugs or bullying). These 
skills are best groomed by families (including extended 
families), schools, recreational associations and others 
in the community working together to support healthy 
development. 
31. Well-coordinated, long-term community 
programmes for preventing drug use are complex 
undertakings that require commitment, partnership-
building, leadership development and public 
participation. The challenges are not small but the 
rewards can be significant. Even in weak communities 
caught in a downward spiral, collective efforts can 
bring about small but important changes (e.g. a 
reduction in the amount of drugs sold or in the extent 
of drug use in public places) that strengthen cohesion 
and a sense of common purpose. Because poor social 
conditions can contribute to drug use, prevention 
professionals need to work with others to monitor 
conditions and advocate creative policies and 
initiatives to reduce social inequality and alleviate 
poverty (e.g. promoting access to adequate housing and 
food, quality jobs and early childhood education and 
care). Governments have a definite role to play in 
supporting local action but they need to exercise care. 
With their access to data and research, professionals 
can unintentionally intimidate citizens into thinking 
that they do not have the competence to address their 
own local issues. The residents (including the youth) of 
a community need to define their concerns and arrive 
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at a sustainable plan, and prevention professionals need 
to support that role and help build the capacity of the 
community to do that work. 
 
 
 C. Building capacity for primary 
prevention at the national level: 
challenges and opportunities 
 
 
32. Primary prevention strategies based on evidence 
have considerable potential to reduce drug demand; to 
realize that potential, however, Governments need to 
bring primary prevention out of the shadows of other 
strategic measures and be committed to that work. 
Drug control strategies aim to achieve a balance 
between various components, yet primary prevention 
continues to suffer from lack of attention relative to 
other components. Supply reduction is a vitally 
important part of the mixture of components needed to 
effectively address drug problems. Although evaluation 
and cost-benefit analyses of drug supply reduction 
measures are scarce, it is assumed that those activities 
have the effect of raising drug prices and making drugs 
less accessible in communities. To the extent that that 
is the case, supply reduction activities have the effect 
of reducing demand. The reverse is also likely to be 
true: effective drug demand reduction, including 
primary prevention, has the effect of reducing drug 
supply in communities. Primary prevention also needs 
to re-establish its place alongside secondary 
prevention, which has dominated the discussion in 
recent years. While the needs of those seriously 
involved with drugs must be addressed, promoting the 
non-use of drugs has obvious public health benefits as 
well. Finally, it is important for primary prevention to 
come out of the shadow of treatment for drug abuse. 
Historically, much of the work in the area of 
prevention of drug use has been done by treatment and 
medical practitioners. Their close knowledge of drug 
use problems has provided important insight into 
prevention work; however, clinicians tend to deal with 
problems using an individual, case-by-case approach 
rather than a “system” approach. It is vital to adopt a 
“system” approach that takes into account the various 
contexts or environmental factors that influence drug 
use. 
33. In fact, the greatest challenge of primary 
prevention may be to clearly organize and account for 
the range of linkages that need to be a part of an 
effective primary prevention plan. The Board calls for 
policymakers to establish a clear focal point for 
primary prevention and to develop both vertical and 
horizontal linkages in Government:  
• Vertical linkages: drug use issues are 
fundamentally health issues, and prevention is 
most closely connected to public health, health 
promotion and child and youth development; 
consequently, health authorities at all levels of 
government need to be an integral part of 
primary prevention efforts. Vertical linkages 
are necessary because a focal point for drug 
use prevention should have input into social 
policy decision-making at the highest levels of 
government. Risk for drug use most often 
originates in broad socio-economic factors, and 
prevention policy needs to advocate social 
policy at the government level that promotes 
more equitable access to protective factors for 
children and families (e.g. anti-poverty and 
social inclusion initiatives).  
• Horizontal linkages: early factors can render a 
child at risk for drug use later in life. Thus, 
strategies for drug use prevention need to be 
linked with and support child development 
initiatives. Ministries of education have a large 
role to play in primary prevention but often 
experience severe constraints, so it is critical 
for authorities responsible for prevention and 
those responsible for education to arrive at 
plans for drug use prevention in school that are 
both feasible and effective. The factors that 
contribute to drug use also contribute to other 
behavioural and social problems such as poor 
school performance, mental health problems, 
violence and criminal activity; therefore, it is 
important for a focal point for drug use 
prevention to link with strategies directed at 
those other types of behaviours that represent a 
health risk. A priority topic of inter-strategy 
discussions is the need for other strategies to 
include drug use prevention among their 
objectives and in their evaluations and for 
strategies for drug use prevention to 
reciprocate. Because early use of legally 
available substances is linked to later drug use, 
a plan for drug use prevention needs to include 
or be linked to efforts to address the abuse of 
such substances. Finally, primary prevention 
 E/INCB/2009/1
 
 11 
 
services need to be linked with secondary 
prevention and treatment components of a 
demand reduction continuum to ensure 
seamless coordination between service levels.  
34. The critical importance of collaborative work 
between Government offices means that system 
capacity should be strengthened in that direction. 
Governments need to establish formal and informal 
mechanisms for coordination and cooperation, to 
assign staff to support interdepartmental and 
interdisciplinary cooperation at all levels and to 
promote the active exchange of knowledge within and 
between sectors.  
35. Government action alone cannot be effective in 
primary prevention; it is essential that focal points for 
primary prevention and non-governmental 
organizations collaborate with one another. 
Partnerships between government and civil society 
need to be forged at the local, national and 
international levels to ensure that scarce resources are 
used as efficiently as possible and to increase the 
effectiveness of efforts to reduce the prevalence of 
drug use. Credible non-governmental organizations 
that help children and youth and that are accustomed to 
working alongside community representatives are best 
able to deliver evidence-based, culturally appropriate 
prevention at the local level. In some regions, the work 
of non-governmental organizations is increasingly 
being evaluated, and that development should be 
encouraged. The large and direct involvement of non-
governmental organizations in that area lends them an 
important perspective that should be taken into account 
by government representatives at the policymaking 
level. 
36. It is important for a strategy for drug use 
prevention to present clear targets and aims:  
• In any population of young people, there is a 
large group of people who are not using drugs 
or use them occasionally; those people would 
benefit from measures and messages that 
promote not using drugs. Some of those young 
people have advantages or protective factors 
and would benefit from broad universal 
prevention measures; others are more 
vulnerable because they have one or more risk 
factors. Governments may be tempted to 
allocate their limited resources to either one 
population group or the other, but they are 
advised to set aside resources for both. 
Universal prevention interventions tend to have 
a limited effect (that is, they prevent only a 
small percentage of the population from 
starting drug use than would otherwise be the 
case); however, because they are serving whole 
populations, that percentage of the population 
may represent a significant number of people 
and provide an important public health benefit. 
Targeting vulnerable population groups allows 
for interventions to be more closely tailored to 
the needs of particular population groups. 
• Key words in statements of long-term 
outcomes include “prevent use”, “delay use”, 
“promote non-use among occasional users” and 
“prevent occasional use from shifting to 
serious use”. More immediate outcomes that 
can contribute to those long-term aims include 
“developing health-related life skills”, 
“building protective factors”, “promoting 
resiliency” and “promoting individual or 
organizational capacity”. All elements of a 
strategy (e.g. targets, aims and activities) need 
to be logically linked in an accountability 
framework. 
37. Governments and other stakeholders (e.g. 
schools, youth agencies, the media, religious groups, 
police, community coalitions and the private sector) 
need to emphasize an evidence-based approach to 
primary prevention work. Most prevention research 
and evaluation continue to be carried out in a handful 
of countries. That is a matter of concern because 
prevention activity is inevitably affected by its social 
and cultural context. To move beyond that situation, 
Governments and funding bodies throughout the world 
need to take greater responsibility, for example, by 
undertaking studies on interventions that have been 
shown to be promising or effective elsewhere. That 
means making more resources (e.g. funding, technical 
assistance) available for the design, implementation 
and evaluation of programmes for drug use prevention.  
38. At the local level, persons responsible for 
programmes for drug use prevention should strive for 
quality in their work. That means that they should be 
able to show that they addressed the identified needs, 
that activities were implemented as planned (e.g. the 
intended number and types of individuals were 
reached), that activities resulted in the desired changes 
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or outcomes (e.g. fewer students using cannabis) and 
achieved the changes at a reasonable cost and so on. If 
local organizers adopt a programme that has been 
found to be effective elsewhere, they will need to 
retain core elements of the programme when adapting 
it to the local culture and circumstances. As 
programmers around the world increasingly evaluate 
and share their work, the understanding of what works 
in different populations and cultures will improve 
considerably.19 
39. A number of Governments and research institutes 
have published summaries of scientific evidence to 
guide prevention strategies and activities. Those 
guidelines on good practice are helpful. They could 
serve as the basis for standards in prevention, 
providing benchmarks for quality prevention. When 
augmented by resources to support continuous 
improvement, such standards could raise the overall 
quality of prevention work. Efforts to improve the 
quality of programming and practice have the effect of 
professionalizing the prevention workforce. That not 
only brings better service to society, it provides 
important support for prevention workers, giving them 
a clearer identity and career path. In an environment 
emphasizing quality standards, it will be easier to 
retain prevention workers and to build organizational 
capacity. Relevant international authorities can 
encourage this development by preparing, in 
consultation with national authorities, experts, service 
providers and young people, international principles of 
effective primary prevention. Such guiding principles 
could lead to broad standards and quality criteria that 
Governments could use in monitoring and reporting 
their performance in primary prevention. 
40. To fulfil the potential of primary prevention, 
society needs to move from rhetoric to action. 
Prevention is too often lauded and poorly supported. In 
response to a perceived drug-related “crisis”, 
Governments often give priority to strong but short-
lived responses such as a stand-alone media campaign 
or heightened law enforcement. Governments need to 
work against the cycles of panic and indifference that 
have often characterized reactions to drug issues. In 
__________________ 
 19  For a useful resource to guide the evaluation of 
prevention at the local level, see Monitoring and 
Evaluating Youth Substance Abuse Prevention 
Programmes (United Nations publication, Sales 
No. E.06.XI.7). 
order to maintain support for prevention strategies over 
the long term, societies need to understand that drug 
problems are not a one-time crisis but an ongoing 
challenge. While it is unrealistic to expect drug use and 
the resulting problems to be eliminated, the prevalence 
of drug use can be reduced and significant social and 
economic benefits can be realized. Increasingly 
rigorous research and practice are showing the way. 
Factors contributing to drug use are better understood, 
realistic aims are being defined and evidence of the 
cost-effectiveness of various primary prevention 
activities is mounting. Policymakers now need to 
commit resources to implement this important work. 
 
 
 D. Recommendations for building 
capacity for primary prevention at the 
national level 
 
 
41. To ensure the implementation of effective 
primary prevention, the Board has made the following 
recommendations: 
 • Governments should establish a clear focal 
point and accountability for primary 
prevention. That will enable primary 
prevention to assume its proper place alongside 
secondary and tertiary prevention. 
 • Governments should integrate primary 
prevention into the national drug control 
strategy and use a public health framework. A 
public health framework provides a scientific 
basis for prevention and ensures that the full 
range of factors that contribute to drug use are 
addressed. 
• Governments should build capacity for and 
ensure collaboration and linkage among all 
government sectors pursuing similar 
prevention aims. Because a wide variety of 
factors contribute to drug use and many of 
those factors also contribute to other kinds of 
health issues or risk behaviour (e.g. mental 
health problems, violence, criminality), 
linkages with other government offices having 
similar aims will lead to synergies at the 
government level. 
 • Governments should encourage various groups 
with a stake in prevention (e.g. families, 
schools, youth agencies and non-governmental 
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organizations, the media, religious groups, 
police, community coalitions and the private 
sector) to work together towards the 
achievement of prevention aims. Limited 
resources are most effectively and efficiently 
utilized when relationships are characterized 
by open communication and commitment to 
collaboration. 
 • Governments should establish mechanisms to 
improve the understanding of drug use and the 
factors that influence drug use. It is important 
that prevention be data-based to the extent 
possible. Only with a clear understanding of 
the current extent and nature of drug use is it 
possible to determine whether prevention 
initiatives are having the desired effect. 
 • Governments should seek to build and 
disseminate knowledge of best practices within 
their jurisdictions. Governments must take the 
lead in preparing and testing innovative local 
models and adapting approaches that have been 
shown to work elsewhere, with a view to 
determining which best practices are locally 
relevant. 
 • Governments should increase their 
commitment to the evaluation of primary 
prevention. It is important to have not only the 
financial resources but also the technical 
assistance to guide programmers in 
undertaking evaluation that is both manageable 
and useful. 
 • Governments should develop the primary 
prevention workforce. That means establishing 
prevention as a defined field of practice, 
ensuring adequate initial and ongoing training 
and promoting practice-based networks. 
 • The United Nations Office on Drugs and Crime 
(UNODC) should collaborate with others to 
develop standards against which Governments 
may measure their efforts in primary 
prevention. Collaboratively prepared standards 
can be used as a benchmark for parties intent 
on continuously improving their primary 
prevention efforts. 
 • UNODC should collaborate with the United 
Nations Children’s Fund (UNICEF), the 
International Labour Organization, the United 
Nations Educational, Scientific and Cultural 
Organization, WHO, relevant non-
governmental organizations and the private 
sector to develop, promote and disseminate 
resources to help Governments strengthen the 
quality of their primary prevention work. 
 
E/INCB/2009/1  
 
14 
 II. Operation of the international drug control system 
 
  
 A. Narcotic drugs 
 
 
 1. Cooperation with Governments 
 
  Submission of annual and quarterly statistical 
reports on narcotic drugs 
 
42. Parties to the Single Convention on Narcotic 
Drugs of 196120 and that Convention as amended by 
the 1972 Protocol have an obligation to furnish to the 
Board statistical information on narcotic drugs 
pursuant to article 20 of the Convention. The Board 
uses the statistical data and other information received 
from Governments to monitor licit activities involving 
narcotic drugs throughout the world. The analysis of 
statistical data allows the Board to determine whether 
Governments have enforced treaty provisions requiring 
them to limit to medical and scientific purposes the 
licit manufacture of, trade in and use of narcotic drugs 
while, at the same time, ensuring the availability of 
narcotic drugs for legitimate purposes. Details of the 
statistical data received, including the status of 
compliance of parties with their reporting obligations, 
are contained in the 2009 technical report of the Board 
on narcotic drugs.21 
43. Parties to the 1961 Convention are required to 
submit to the Board annual statistical reports on 
production, manufacture, consumption, stocks and 
seizures of narcotic drugs. They have also an 
obligation to furnish to the Board quarterly statistics on 
imports and exports of narcotic drugs. As at 
1 November 2009, a total of 169 States and territories 
had submitted annual statistics on narcotic drugs 
for 2008; that figure represents 80 per cent of the 
211 States and territories required to furnish those 
statistics. A total of 192 States and territories provided 
quarterly statistics of imports and exports of narcotic 
drugs for 2008; that figure represents 91 per cent of the 
211 States and territories requested to furnish such 
statistics.  
44. Some States, including India, Japan, Singapore, 
the United Kingdom of Great Britain and Northern 
__________________ 
 20  United Nations, Treaty Series, vol. 520, No. 7515. 
 21  Narcotics Drugs: Estimated World Requirements for 
2010; Statistics for 2008 (United Nations publication, 
Sales No. T.10.XI.2). 
Ireland and the United States of America, did not 
provide in 2009 the requested annual statistical reports 
in a timely manner. The late submission of reports 
makes it difficult for the Board to monitor licit 
activities related to narcotic drugs and delays the 
analysis by the Board of the worldwide availability of 
narcotic drugs for legitimate purposes, as well as its 
analysis of the global balance between the supply of 
opiate raw materials and the demand for those 
materials. The Board requests all States to comply in a 
timely manner with their reporting obligations pursuant 
to the 1961 Convention.  
45. The Board provides assistance to Governments in 
complying with their reporting obligations under the 
1961 Convention. In 2009, the Board provided to 
several Governments, at their request, explanations 
regarding reporting requirements for narcotic drugs. 
Training material on the control of narcotic drugs and 
guidelines on reporting on those drugs for use by 
national competent authorities are available on the 
website of the Board (www.incb.org). Reporting 
requirements were discussed during an informal 
consultation on reporting, organized for selected 
Governments by the Board during the fifty-second 
session of the Commission on Narcotic Drugs, in 
March 2009. All Governments are encouraged to seek 
from the Board any information that they may consider 
useful regarding the control of narcotic drugs  
pursuant to the 1961 Convention, including reporting 
requirements. 
 
  Submission of estimates of requirements for 
narcotic drugs 
 
46. The universal application of the system of 
estimates for narcotic drugs is a prerequisite for the 
functioning of the international control system for 
narcotic drugs. Governments should establish estimates 
at the levels that are adequate to ensure access to 
narcotic drugs for medical treatment and to prevent 
diversion into illicit channels. 
47. As at 1 November 2009, a total of 164 States and 
territories had submitted their estimates of 
requirements for narcotic drugs for 2010; that figure 
represents 78 per cent of the 211 States and territories 
required to furnish the annual estimates for 
confirmation to the Board. For those States and 
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territories that did not submit their estimates in time 
for examination and confirmation, the Board had to 
establish estimates in accordance with article 12, 
paragraph 3, of the 1961 Convention. The estimates 
established by the Board are based on estimates and 
statistics reported in the past by the Governments 
concerned. If Governments have not furnished 
estimates and statistics for several years, the estimates 
established by the Board may be set lower than the 
estimates submitted in the past by the respective 
Governments, as a precaution against diversion. 
Therefore, the Governments for which estimates were 
established by the Board are urged to examine closely 
their requirements for narcotic drugs for 2010 and 
provide their own estimates to the Board for 
confirmation as soon as possible, in order to prevent 
any possible difficulties in importing the quantities of 
narcotic drugs required for legitimate purposes. 
48. The estimates for all States and territories are 
published by the Board in its technical report on 
narcotic drugs. The updates of those estimates, which 
reflect, inter alia, supplementary estimates furnished 
by Governments, are made available on the website of 
the Board (www.incb.org). 
49. The Board examines annual estimates received 
from Governments in order to limit the use of narcotic 
drugs to the amount required for medical and scientific 
purposes and to ensure adequate availability of those 
drugs for such purposes. Governments are requested to 
adjust their estimates or to provide explanations 
whenever the Board considers the estimates to be 
inadequate. In 2009 the Board was, for the most part, 
satisfied with the promptness of the responses from 
Governments that had been requested to adjust their 
estimates or provide clarifications. However, the 
competent authorities in some countries, such as India 
and South Africa, appear to have difficulties in 
estimating their requirements for narcotic drugs. The 
Board has offered assistance to the Governments of 
those countries by providing clarifications on the 
provisions of the 1961 Convention relating to the 
system of estimates.  
50. Supplementary estimates are an important tool 
used to meet shortfalls in the availability of narcotic 
drugs. The Board requests all Governments to 
determine their annual estimates of requirements for 
narcotic drugs as accurately as possible, so that 
resorting to supplementary estimates is reserved  
for unforeseen circumstances. However, when 
developments in medical treatment, including the use 
of new medicaments and scientific research, result in 
additional needs for narcotic drugs, Governments 
should not hesitate to submit supplementary estimates.  
 
 2. Prevention of diversion of narcotic drugs into 
the illicit traffic 
 
  Diversion from international trade 
 
51. The system of control measures laid down in the 
1961 Convention provides effective protection of 
international trade in narcotic drugs against attempts at 
their diversion into illicit channels. In 2009, no cases 
were detected of diversion of narcotic drugs from licit 
international trade into the illicit traffic. 
52. The effective control of international trade in 
narcotic drugs is, to a large extent, a result of the 
vigilance of exporting countries when authorizing the 
export of narcotic drugs. The Board welcomes the 
vigilance of the Government of the Islamic Republic of 
Iran, which, in cooperation with the Board, prevented 
in August 2009 an attempt by traffickers to use a 
falsified import authorization from a country in East 
Africa to divert 100 kg of oxycodone hydrochloride 
from licit international trade. 
53. The vast majority of exporting countries strictly 
observe the limits set in the system of estimates for 
narcotic drugs for the importing countries. However, in 
2008 and 2009, as in previous years, a few cases were 
identified where a specific export of narcotic drugs was 
authorized in excess of the estimates of the respective 
importing countries, thereby contravening the 
provisions of article 31 of the 1961 Convention. Such 
exports of quantities above the estimates set by the 
importing country may result in the diversion of 
narcotic drugs into illicit channels. The Board has 
therefore reminded the Governments concerned of their 
obligation to comply with the provisions of article 31 
and has requested them, when authorizing exports of 
narcotic drugs in the future, to always consult the 
annual estimates of requirements for narcotic drugs for 
each importing country and territory, which are 
published by the Board. 
 
  Diversion from domestic distribution channels 
 
54. The diversion of pharmaceutical preparations 
containing narcotic drugs from domestic distribution 
E/INCB/2009/1  
 
16 
channels and the abuse of those preparations are taking 
place in an increasing number of countries. The 
narcotic drugs most often diverted and abused  
include codeine, dextropropoxyphene, dihydrocodeine, 
fentanyl, hydrocodone, methadone, morphine, 
oxycodone, pethidine and trimeperidine. Data received 
from Governments suggest that the most often diverted 
and abused pharmaceutical preparations are usually 
those which are also the most available on the licit 
market. 
55. Pharmaceutical preparations containing narcotic 
drugs are diverted in some countries for subsequent 
smuggling to other countries where illicit markets for 
those preparations exist. Illegal Internet pharmacies are 
increasingly involved in trafficking in pharmaceutical 
preparations diverted from domestic distribution 
channels (see paragraphs 228-231 below). Mail and 
courier services are misused by traffickers for 
smuggling diverted pharmaceutical preparations 
containing narcotic drugs.  
56. The Board has examined in detail the issue of the 
diversion and abuse of pharmaceutical preparations 
containing narcotic drugs for which prescriptions are 
required under the international drug control treaties. 
(For the findings and recommendations of the Board 
regarding that issue, see paragraphs 229-241 below.) 
57. Governments need to be aware that increased 
availability of narcotic drugs for legitimate medical 
purposes may raise the risk of diversion and abuse of 
those drugs. In the United States, the most frequently 
diverted and abused pharmaceutical preparations are 
those containing hydrocodone and oxycodone. In 2008, 
the United States accounted for over 99 per cent of 
global consumption of hydrocodone and 77 per cent of 
global consumption of oxycodone. The medical use of 
hydrocodone reached 18 defined daily doses for 
statistical purposes (S-DDD) per 1,000 inhabitants 
per day, and the medical use of oxycodone reached 
5 S-DDD per 1,000 inhabitants per day. The Board 
wishes to remind all Governments of the need to 
closely monitor trends in the consumption of 
pharmaceutical products containing narcotic drugs and 
to adopt measures to counter their diversion and abuse, 
as necessary. 
58. In several countries, the diversion and abuse of 
narcotic drugs involve preparations for which certain 
control measures, such as the requirement for 
prescription, are not mandatory under the 
1961 Convention. Such preparations include, for 
example, cough syrups containing codeine, 
dihydrocodeine, ethylmorphine and pholcodine. The 
Board again calls on all Governments to be on the alert 
for problems involving the abuse of pharmaceutical 
preparations not requiring prescriptions, and to adopt, 
if necessary, measures to effectively prevent the 
diversion into the illicit traffic and abuse of such 
preparations. 
59. For some narcotic drugs, such as oxycodone, the 
risk of diversion increased when they became available 
in larger single dosages in slow-release preparations, 
which were more liable to abuse. Abusers have 
attempted to circumvent the time-release properties of 
such preparations by chewing or crushing the tablets. 
The Board has also informed Governments of reports 
from several countries about the abuse of fentanyl 
patches. The Board has recommended to Governments 
that specific measures be taken for the safe disposal of 
used fentanyl patches.22 The Board calls upon all 
Governments to be on the alert with respect to the 
abuse of pharmaceutical preparations containing large 
single dosages of narcotic drugs. 
60. Cases involving the diversion of opioids, 
prescribed for substitution treatment, in particular 
methadone and buprenorphine, have been reported in 
many countries. The Board again requests the 
Governments of countries where opioids are used for 
substitution treatment to take all measures necessary to 
prevent their diversion into the illicit traffic and, at the 
same time, to ensure that those substances are available 
for use in such treatment. The Board notes that 
measures that have been found to be effective in 
several countries to prevent diversion include treatment 
according to clinical standards, supervised 
consumption, application of appropriate conditions for 
drugs to be taken at home, prescription monitoring 
systems and mandatory training of health-care 
professionals. 
 
 3. Cannabis used for medical or scientific 
purposes 
 
61. Cannabis is included in Schedules I and IV of the 
1961 Convention. Substances in Schedule IV are those 
__________________ 
 22  Report of the International Narcotics Control Board for 
2007 (United Nations publication, Sales No. E.08.XI.1), 
paras. 242-249. 
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considered particularly liable to abuse and to produce 
ill effects. 
62. For several years there has been scientific 
research in the therapeutic usefulness of cannabis or 
cannabis extracts in several countries. The Board 
welcomes sound scientific research on the therapeutic 
usefulness of cannabis and cannabis extracts, as stated 
in previous reports,23 and invites all Governments 
concerned to share the results of such research, when 
available, with the Board, WHO and the international 
community. The Board is concerned that, without 
having appropriate scientific confirmation of its 
efficacy, a few Governments authorized the use of 
cannabis for medical purposes.  
63. Pursuant to article 28 of the 1961 Convention, a 
State that permits the cultivation of the cannabis plant 
for the production of cannabis is required to establish a 
national cannabis agency to carry out the functions 
stipulated under article 23 of that Convention. The 
agency designates the areas in which cultivation is 
permitted, licenses cultivators, purchases and takes 
physical possession of crops and has the exclusive 
right of wholesale trading and maintaining stocks. As 
for all narcotic drugs, parties to the Convention have 
the obligation to submit to the Board each year their 
estimates and statistical reports with respect to 
cannabis. 
64. Failure of a party to comply with mandatory 
control measures for the cultivation of the cannabis 
plant or the production or use of cannabis may 
facilitate the diversion of cannabis into illicit channels. 
The Board requests all Governments concerned to 
ensure full compliance with the control measures for 
cannabis as stipulated in the 1961 Convention.  
 
 4. Control over trade in opium poppy seeds 
 
65. According to reports received by the Board, drug 
traffickers continue to smuggle opium poppy seeds 
from countries where the cultivation of opium poppy is 
not permitted and to attempt to sell those seeds on the 
world market. In 2009, the customs authorities of 
Pakistan seized more than 50 tons of opium poppy 
seeds that were being smuggled. Large shipments of 
opium poppy seeds were detained in two other 
__________________ 
 23  Report of the International Narcotics Control Board for 
2005 (United Nations publication, Sales No. E.06.XI.2), 
para. 80. 
countries in Asia, pending clarification of the country 
of origin of the seeds.  
66. The Economic and Social Council, in its 
resolution 1999/32, called upon Member States to take 
the following measures to fight the international trade 
in opium poppy seeds from countries not permitting 
the cultivation of opium poppy: 
 (a) Poppy seeds should only be imported if they 
originated in countries where opium poppy was grown 
licitly in accordance with the provisions of the 
1961 Convention; 
 (b) Governments should be encouraged, to the 
extent possible and where national circumstances so 
required, to obtain an appropriate certificate from the 
exporting countries on the country of origin of opium 
poppy seeds as the basis for importation and should 
give notification of export of opium poppy seeds,  
as far as possible, to the competent authorities of the 
importing countries; 
 (c) Information on any suspicious transactions 
involving poppy seeds should be shared with other 
Governments concerned and with the Board. 
67. The Board has repeatedly encouraged 
Governments to implement Economic and Social 
Council resolution 1999/32 and has reported on the 
control over trade in opium poppy seeds in various 
countries.24 In its resolution 51/15, the Commission on 
Narcotic Drugs requested the Board to continue 
gathering information regarding the implementation of 
Council resolution 1999/32 by Member States and to 
share that information with Member States. To that 
end, the Board sent a questionnaire to the Governments 
of the countries most involved in the international 
trade in poppy seeds and the Governments of countries 
neighbouring those countries where opium poppy is 
illicitly cultivated.  
68. The responses received by the Board from 
Governments revealed that, with the exception of 
India, no major importers of opium poppy seeds have 
implemented the key control provisions recommended 
in Economic and Social Council resolution 1999/32. 
Among the major importers of poppy seeds, India is 
the only country that requires a certificate of origin of 
the seeds as a condition for approval of imports.  
__________________ 
 24  Ibid., paras. 76-78. 
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69. The Governments of the Czech Republic and 
Turkey, the world’s two largest exporters of opium 
poppy seeds, have identified authorities responsible for 
issuing certificates of origin of seeds to exporters who 
request such certificates. Such authorities have also 
been identified by the Governments of Austria and 
Spain. The Board invites the Governments of the other 
countries where opium poppy is licitly cultivated and 
from where poppy seeds are exported to identify such 
authorities so that certificates of origin can be issued to 
exporters if such certificates are required in the 
importing country.  
70. The Board calls upon the Governments of 
countries that are permitting the import of opium 
poppy seeds to implement the provisions of Economic 
and Social Council resolution 1999/32 and, in 
particular, to require a certificate on the country of 
origin of the seeds as the basis for importation. The 
Board has requested the Governments of the main 
countries importing poppy seeds, including Germany, 
the Netherlands, Poland, the Russian Federation and 
the United States, to consider the establishment of such 
controls for opium poppy seeds.  
71. The import, export and transit of opium poppy 
seeds are prohibited in many countries adjacent to 
countries where opium poppy is illicitly cultivated. 
The Board requests the Governments of countries 
where opium poppy is illicitly cultivated to cooperate 
closely with the Governments of their neighbouring 
countries in order to prevent the smuggling of poppy 
seeds. The Board invites all Governments to inform it 
of any suspicious transactions involving poppy seeds. 
The Board would also appreciate being informed by 
Governments of any measures for the control of poppy 
seeds that are to be adopted with a view to 
implementing Economic and Social Council 
resolution 1999/32.  
 
 5. Use of cannabis seeds for illicit purposes 
 
72. The Commission on Narcotic Drugs, in its 
resolution 52/5, requested the Board, in cooperation 
with other competent international bodies, to gather 
from Member States regulatory information on 
cannabis seeds, including on the sale of cannabis seeds 
through the Internet, and to share that information with 
Member States. 
73. In order to collect the requested information, the 
Board has sent to all Governments a questionnaire on 
regulations pertaining to cannabis seeds. The 
questionnaire is to be used to identify whether any 
provisions in national laws or administrative 
regulations are aimed at preventing the use of cannabis 
seeds for the illicit cultivation of cannabis plants and to 
obtain a detailed description of the various regulations 
on cannabis seeds that are applied in countries 
worldwide. Such provisions may include, for instance, 
regulation of the production of, trade in or use of 
cannabis seeds in general or of cannabis seeds of 
certain varieties of the cannabis plant (for example, 
varieties with a tetrahydrocannabinol (THC) content 
above a certain level). Information gathered on other 
control provisions, including authorizations and 
licences, may also be useful. The Board trusts that 
Governments will furnish the requested information in 
due time. The Board will examine the information 
received and report on the results of the analysis. 
74. A number of Governments have reported an 
increase in the illicit cultivation of cannabis plants, 
particularly cannabis plants cultivated indoors, and an 
increase in the THC content of some varieties of the 
cannabis plant. The wide availability of cannabis seeds, 
which are not controlled under the international drug 
control treaties, is a factor contributing to that 
development. The Board is deeply concerned about the 
wide availability of cannabis seeds sold over the 
Internet. Internet sites selling cannabis seeds and 
related advertisements obviously incite the illicit 
cultivation of cannabis plants. The Board notes that 
article 3, paragraph 1 (c) (iii), of the 1988 Convention 
requires States parties to establish as a criminal 
offence, inter alia, public incitement or inducement of 
others to engage in the illicit cultivation of the 
cannabis plant or to use cannabis illicitly. The Board 
calls upon Governments to implement that provision of 
the 1988 Convention and to take appropriate measures 
against the sale of cannabis seeds for illicit purposes. 
 
 6. Ensuring the availability of narcotic drugs for 
medical purposes 
 
  Supply of and demand for opiate raw materials 
 
75. Pursuant to the 1961 Convention and relevant 
resolutions of the Commission on Narcotic Drugs and 
the Economic and Social Council, the Board examines 
on a regular basis developments affecting the supply of 
and demand for opiate raw materials. The Board 
endeavours, in cooperation with Governments, to 
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maintain a lasting balance between supply and demand. 
When analysing the situation regarding the supply of 
and demand for opiate raw materials, the Board uses 
information from Governments of countries producing 
opiate raw materials, as well as from countries where 
those materials are utilized for the manufacture of 
opiates or substances not controlled under the 
1961 Convention. A detailed analysis of the present 
situation with regard to the supply of opiate raw 
materials and demand for those materials worldwide is 
contained in the 2009 technical report of the Board on 
narcotic drugs.25 
76. Global stocks of opiate raw materials should 
cover global demand for about one year to ensure the 
availability of opiates for medical and scientific 
purposes in case of an unexpected decline in 
production resulting from, for example, adverse 
weather conditions in producing countries.26 At the end 
of 2008, global stocks of opiate raw materials rich in 
morphine were sufficient to cover global demand for 
almost 12 months. Global stocks of opiate raw 
materials rich in thebaine were sufficient to cover 
global demand for less than 12 months; however that 
was compensated by the high level of stocks of 
thebaine and opiates derived from thebaine, which 
were sufficient at the end of 2008 to cover global 
demand for those opiates for almost 14 months.  
77. In 2009, according to the information available to 
the Board, production of opiate raw materials rich in 
morphine was higher than the utilization of those 
materials. The global supply of opiate raw materials 
rich in morphine (production and stocks) was fully 
sufficient to cover global demand. For 2010, 
Governments of producing countries are planning to 
further extend the area cultivated with opium poppy 
rich in morphine to ensure that the production will be 
sufficient to cover the demand during that year and to 
increase the stocks.  
78. For opiate raw materials rich in thebaine, 
information available to the Board indicates that global 
production exceeded global demand in 2009. Total 
stocks of opiate raw materials rich in thebaine were 
sufficient to cover global demand for more than 
__________________ 
 25  Narcotic Drugs: Estimated Requirements for 2010 — 
Statistics for 2008 … . 
 26  Report of the International Narcotics Control Board for 
2005 …, para. 85. 
16 months at the end of 2009. According to the plans 
of the producing countries, global production will 
exceed global demand in 2010 as well. The stocks of 
opiate raw materials rich in thebaine are therefore 
expected to increase further. The global supply of 
opiate raw materials rich in thebaine (production and 
stocks) will continue to be fully sufficient to cover 
global demand.  
79. Global demand for opiate raw materials rich in 
morphine and rich in thebaine is expected to rise in the 
future as well. It is anticipated that, as a result of the 
activities of the Board and WHO to ensure the 
adequate availability of opioid analgesics, global 
demand for opiates and opiate raw materials will 
continue to rise (see paragraphs 83-84 below).  
 
 7. Consumption of narcotic drugs 
 
80. Global consumption of opioid analgesics for the 
treatment of moderate to severe pain (expressed in 
defined daily doses for statistical purposes) increased 
by more than two and one half times during the past 
decade. Of the opioids under international control, 
fentanyl, morphine and oxycodone are those most 
frequently used as analgesics for the treatment of 
moderate to severe pain. The global figures hide large 
and enduring disparities in the consumption of opioid 
analgesics among countries. In 2008, Australia, 
Canada, New Zealand, the United States and the 
member States of the European Union together 
accounted for more than 96 per cent of global 
consumption of fentanyl, 90 per cent of global 
consumption of morphine and 98 per cent of global 
consumption of oxycodone. Although there is 
sufficient supply of opiate raw materials worldwide, 
access to opioid analgesics is non-existent or almost 
non-existent in many countries and in entire regions. 
81. The disparities in the consumption levels of 
opioid analgesics cannot be attributed exclusively to 
differences in economic and social development. There 
continue to be large differences in the consumption of 
opioid analgesics among countries at similar levels  
of economic and social development. The factors 
affecting the availability of opioids include knowledge 
limitations resulting from lack of training for 
health professionals and administrative barriers 
associated with restrictions in national regulations or 
administrative policies on the distribution, stocking 
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and use of opioids that are more strict than those 
required by the 1961 Convention.  
82. Governments need to take specific measures to 
ensure that their populations have adequate access to 
opioid analgesics. The Board again requests all 
Governments concerned to identify any impediments in 
their countries to adequate use of opioid analgesics for 
the treatment of pain and to take steps to improve the 
availability of those narcotic drugs for medical 
purposes, in accordance with the pertinent 
recommendations of WHO. The Board notes with 
appreciation that, in the past few years, in several 
countries with historically low levels of consumption 
of opioids, including Colombia, Panama, Romania and 
Serbia, policies have been adopted to improve access 
to those narcotic drugs for medical purposes while 
measures to prevent the abuse of those drugs are taken.  
83. The Board calls upon Governments to support 
WHO in its ongoing effort to implement the Access to 
Controlled Medications Programme, the framework of 
which was prepared by WHO in cooperation with the 
Board. Activities of the programme are expected to 
address various impediments to adequate availability 
of opioids, focusing on regulatory, attitude and 
knowledge impediments. The Board will continue to 
cooperate with WHO in those areas of the Programme 
related to its mandate.  
84. The Board, together with WHO, convened an 
expert group on estimating requirements for substances 
under international control. The expert group held a 
meeting in Vienna in May 2009 to initiate the process 
of developing guidelines on estimating requirements 
for substances under international control. The purpose 
of the guidelines will be to assist Governments of 
countries with low levels of consumption of controlled 
substances in making better assessments of their 
medical needs for such substances and in calculating 
estimates that accurately reflect their legitimate 
requirements. 
85. A sudden increase in the need for narcotic drugs 
for the treatment of pain and other conditions can arise 
as a result of emergency situations such as epidemics 
and natural disasters. Access to narcotic drugs in such 
situations may be difficult because of the regulatory 
procedures for importing narcotic drugs. The Board 
reminds Governments and humanitarian organizations 
that simplified procedures have been developed to 
facilitate the supply of narcotic drugs to sites of 
emergencies. Those procedures are described in the 
Model Guidelines for the International Provision of 
Controlled Medicines for Emergency Medical Care, 
prepared by WHO in consultation with the Board. The 
Model Guidelines are available on the website of the 
Board (www.incb.org). 
 
 
 B. Psychotropic substances 
 
 
 1. Cooperation with Governments 
 
  Submission of annual and quarterly statistical 
reports on psychotropic substances 
 
86. Parties to the 1971 Convention have the treaty 
obligation to furnish to the Board annual statistical 
reports on psychotropic substances. Under the  
1971 Convention, reporting requirements for 
substances in Schedules I and II are stricter than those 
for substances in Schedules III and IV. For substances 
in Schedules I and II, Governments must submit data 
on quantities of those substances manufactured, 
exported to and imported from each country or region 
and on stocks of those substances held by 
manufacturers. For substances in Schedules III and IV, 
Governments are required to submit data only on the 
quantities manufactured and on the total quantities 
exported and imported. Pursuant to Economic and 
Social Council resolutions 1981/7, 1985/15 and 
1987/30, Governments furnish to the Board 
information enabling the Board to monitor closely the 
manufacture, export and import of substances listed in 
Schedule II and information on the countries of origin 
of imports and the countries of destination of exports 
of substances listed in Schedules III and IV. 
Governments also submit to the Board quarterly 
statistical reports on imports and exports of substances 
listed in Schedule II of the 1971 Convention. In this 
connection, the Board notes with appreciation that 
many Governments are already providing the Board, 
on a voluntary basis, with information on the stocks 
held by manufacturers of substances listed in 
Schedules III and IV, as such information is necessary 
for monitoring the consumption levels of those 
substances. The statistical data received, including the 
status of reporting by Governments, and the analysis of 
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such data are reflected in the technical report of the 
Board on psychotropic substances.27 
87. The majority of States regularly submit the 
mandatory and voluntary statistical reports, and most 
of those reports are provided in a timely manner. As at 
1 November 2009, a total of 156 States and territories, 
or 74 per cent of the States and territories required to 
furnish such statistics, had submitted to the Board 
annual statistical reports on psychotropic substances 
for 2008 in conformity with the provisions of article 16 
of the 1971 Convention. A total of 124 Governments 
submitted details on the countries of origin of imports 
and countries of destination of exports of substances 
listed in Schedules III and IV of the 1971 Convention. 
In addition, for the year 2008, 120 Governments 
submitted all four quarterly statistical reports on 
imports and exports of substances listed in Schedule II. 
88. The Board is concerned that some countries, 
including major manufacturing and exporting countries 
such as India, Ireland and Japan, continue to 
experience difficulties in submitting the annual 
statistical report on psychotropic substances by the 
deadline (30 June). In addition, some Governments 
have not provided information on the countries of 
origin of imports or countries of destination of exports 
(as well as the quantities involved) of substances in 
Schedules III and IV of the 1971 Convention, pursuant 
to Economic and Social Council resolutions 1985/15 
and 1987/30. As has already been pointed out by the 
Board, examination of the statistical reports received 
from Governments is one of the main ways in which 
the Board monitors the compliance of Governments 
with the treaty provisions. Incomplete, late or no 
reporting may indicate deficiencies in the national 
control system. Moreover, incomplete or inaccurate 
information on exports by countries of destination or 
on imports by countries of origin hinders the 
identification of discrepancies in trade statistics, 
thereby jeopardizing international drug control efforts. 
The Board urges the Governments concerned to 
examine their national control mechanisms, to identify 
the reasons that prevented them from submitting 
accurate statistical reports to the Board in a timely 
__________________ 
 27  Psychotropic Substances: Statistics for 2008 — 
Assessments of Annual Medical and Scientific 
Requirements for Substances in Schedules II, III and IV 
of the Convention on Psychotropic Substances of 1971 
(United Nations publication, Sales No. T.10.XI.3). 
manner and to take all measures necessary to  
ensure their compliance with the provisions of the  
1971 Convention and related Council resolutions.  
 
  Submission of assessments of requirements for 
psychotropic substances 
 
89. Pursuant to Economic and Social Council 
resolutions 1981/7 and 1991/44, Governments are 
requested to provide to the Board assessments of 
annual domestic medical and scientific requirements 
for psychotropic substances in Schedules II, III and IV 
of the 1971 Convention. The assessments received are 
communicated to all States and territories to assist the 
competent authorities of exporting countries when 
approving exports of psychotropic substances. As at  
1 November 2009, the Governments of all countries 
and territories had submitted at least once their 
assessments of annual medical requirements for 
psychotropic substances.  
90. The Board recommends that Governments review 
and update the assessments of their annual medical and 
scientific requirements for psychotropic substances at 
least every three years. As at 1 November 2009, 
93 Governments had provided to the Board, pursuant 
to a request sent in January 2009, a full revision of the 
assessments of their requirements for psychotropic 
substances and an additional 89 had submitted 
modifications to assessments for one or more 
substances.  
91. However, 23 Governments have not submitted a 
revision of their legitimate requirements for 
psychotropic substances for at least three years. The 
assessments valid for those countries and territories 
may therefore no longer reflect their actual medical 
and scientific requirements for psychotropic 
substances. When assessments are lower than the 
actual legitimate requirements, the importation of 
psychotropic substances needed for medical or 
scientific purposes may be delayed. When assessments 
are significantly higher than legitimate needs, they may 
increase the risk of psychotropic substances being 
diverted into illicit channels. The Board calls upon all 
Governments to review and update their assessments 
on a regular basis and to keep it informed of all 
modifications, with a view to preventing any 
unnecessary importation and, at the same time, 
facilitating the timely importation of psychotropic 
substances needed for medical purposes.  
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 2. Prevention of diversion of psychotropic 
substances into the illicit traffic 
 
  Diversion from international trade 
 
92. Through better implementation by Governments 
of the provisions of the 1971 Convention and the 
application of voluntary control measures set forth in 
the relevant Economic and Social Council resolutions, 
diversions of psychotropic substances from 
international trade have decreased considerably. For 
instance, no diversion of a substance in Schedule I 
from licit international trade has ever been reported, 
and there have been hardly any attempts to divert such 
substances from international trade. The last attempt to 
divert a substance in Schedule I took place in 
December 2000, and it was unsuccessful. Because of 
the limited medical use of the substances in Schedule I 
and the strict control requirements of the 
1971 Convention over their manufacture, import and 
export, which restrict the use of those substances to 
scientific and very limited medical purposes, licit 
international trade in those substances is extremely 
limited, involving only sporadic transactions of no 
more than a few grams each year.  
93. The diversion of substances in Schedule II of the 
1971 Convention has also declined significantly. 
While, in the past, the diversion of those substances 
from licit international trade was one of the main 
means used to supply illicit markets, nowadays the 
diversion or attempted diversion of such substances 
from international trade has become rare. Of the 
substances in Schedule II of the 1971 Convention, only 
amphetamines and methylphenidate are manufactured 
and traded for licit purposes in large quantities. While 
amphetamines are mostly used for industrial purposes, 
methylphenidate is used in large quantities for medical 
purposes, mostly for the treatment of ADD. Since 
1990, no diversion of amphetamines from licit 
international trade has been identified. That positive 
development is attributable to the comprehensive 
control measures set forth in the 1971 Convention for 
substances in Schedule II, notably the import and 
export authorization system, as well as the application 
of additional voluntary control measures recommended 
by the Board and endorsed by the Economic and Social 
Council, such as the assessment by Governments of 
their licit requirements for psychotropic substances and 
the quarterly reporting of trade statistics. 
94. With regard to the substances in Schedules III 
and IV of the 1971 Convention, there has been a 
similar decline in cases involving their diversion or 
attempted diversion from international trade. Although 
licit international trade in substances in Schedules III 
and IV is widespread, involving thousands of 
individual exports each year and most of the countries 
in the world, only isolated cases involving the 
attempted diversion of such substances were reported 
to the Board and their diversion was prevented with the 
assistance of the Board. That positive development is 
directly attributable to the introduction, by many 
Governments, of the requirement of import 
authorizations at the national level for all substances in 
Schedules III and IV of the 1971 Convention and to the 
use of the assessed requirements for substances in 
Schedules III and IV. The Board urges those 
Governments which have not yet done so to extend 
those voluntary control measures to include all 
substances in Schedules III and IV because the 
universal application of those measures has proved to 
be the most effective tool in preventing the diversion 
of substances in Schedules III and IV of the 
1971 Convention.  
 
  Diversion from domestic distribution channels 
 
95. While the diversion of psychotropic substances 
from licit international trade has almost stopped in the 
past two decades, the diversion of such substances 
from licit domestic distribution channels has become 
the main source used to supply illicit markets.  
96. Psychotropic substances are no longer diverted 
from domestic distribution channels in bulk form; 
nowadays, they are diverted mainly in the form of 
pharmaceutical preparations containing those 
substances. Reports received from many countries on 
seizures and the abuse of psychotropic substances often 
indicate that the substances diverted from domestic 
distribution channels may not be destined for the illicit 
market of the country in which they were diverted; in 
many cases, the diverted pharmaceutical preparations 
are smuggled into other countries, particularly 
countries in which there is considerable illicit demand 
for a specific substance with a relatively high  
street price. Such pharmaceutical preparations are 
increasingly being marketed via illegal Internet sites. 
97. The diversion of psychotropic substances from 
domestic distribution channels often involves either 
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relatively small quantities, to be abused by individuals 
or sold on a small scale, or large quantities, several 
thousands of tablets in a single consignment. The usual 
modus operandi include falsified prescriptions, the 
supplying of substances by pharmacies without the 
required prescriptions, or theft from pharmacies, 
wholesalers or factories. In addition, modern 
telecommunication and information technologies, such 
as the Internet or call centres, are used for such 
diversions. The substances most often diverted are 
stimulants (methylphenidate), benzodiazepines 
(especially diazepam, alprazolam, lorazepam, 
clonazepam and flunitrazepam) and buprenorphine, an 
opioid analgesic listed in Schedule III of the 
1971 Convention and used since the early 1990s, 
predominantly in the detoxification and substitution 
treatment of heroin addicts. In many cases, 
preparations containing stimulants are obtained from 
persons to whom they were prescribed by physicians. 
98. Since 2008, two significant cases involving the 
diversion or attempted diversion of psychotropic 
substances from domestic distribution channels have 
been brought to the attention of the Board. The first 
case involved the falsification of orders for a 
preparation containing methylphenidate, in Israel; 
according to information made available to the Board, 
a criminal network in Israel that was involved in 
falsifying orders for that preparation was dismantled in 
that year. The second case involved the theft of 
80,000 tablets containing flunitrazepam in Dublin in 
2009. Both cases are currently under investigation by 
the national police authorities. 
99. Flunitrazepam continues to be one of the most 
frequently abused benzodiazepines in Schedule III of 
the 1971 Convention, despite the fact that many 
countries, including the main countries manufacturing 
and importing the substance, have adopted strict 
policies to control flunitrazepam in close cooperation 
with the pharmaceutical industry. Flunitrazepam and 
other benzodiazepines are diverted not only to be 
abused by individuals but also to be used in 
drug-facilitated crimes such as “date rape”, a form of 
sexual assault (see paragraphs 260-268 below). 
100. Buprenorphine (Subutex) tablets continue to be 
diverted from licit domestic channels, mainly in 
countries where buprenorphine is used in substitution 
treatment programmes for opioid addicts. The abuse of 
buprenorphine tablets smuggled in large quantities out 
of France continues to be a matter of concern in 
countries in Europe and in other regions (see 
paragraphs 110-116 below). 
101. The Board urges Governments to continue 
monitoring all stages of the movement of psychotropic 
substances, in the form of bulk material and 
particularly in the form of pharmaceutical preparations, 
with a view to preventing their diversion. To be 
effective, such action needs to be complemented by 
improved cooperation among the regulatory police, 
customs and postal authorities, at the national and 
international levels, with a view to identifying diverted 
pharmaceutical preparations containing psychotropic 
substances on illicit markets and taking appropriate 
countermeasures. 
 
 3. Control measures 
 
  Assistance to Governments in verifying the 
legitimacy of international trade in psychotropic 
substances 
 
102. The Governments of many exporting countries 
continue to request the assistance of the Board in 
verifying the legitimacy of import authorizations for 
psychotropic substances. The Board maintains a 
collection of samples of official certificates and 
authorizations used for importing narcotic drugs, 
psychotropic substances and precursor chemicals, 
which can be compared with questionable import 
documents, thus assisting Governments in the 
verification of the authenticity of such documents. As 
at 1 November 2009, 124 Governments (about 60 per 
cent of those requested to do so) had provided the 
Board with a copy of the import authorization currently 
used by their authorities when authorizing imports of 
controlled substances into their countries. Since 
1 November 2008, the Board has received updated 
samples of the document used for import authorization 
in 24 countries and territories. The Board wishes to 
point out that any Government that has not yet 
provided a sample of its import authorization document 
or for which the sample made available to the Board is 
no longer valid may risk considerable delays of 
legitimate imports. The Board therefore calls on those 
Governments which have not yet done so to provide 
samples of their import authorization document 
without further delay and to provide updated samples if 
necessary. 
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103. The Board notes that in some cases responses to 
its requests for confirmation of the legitimacy of 
import orders are considerably delayed. The Board 
would like to draw the attention of the Governments 
concerned to the importance of responding in a timely 
manner. Failure to quickly confirm the legitimacy of 
import orders may hinder the investigation of diversion 
attempts and/or cause delays in legitimate trade in 
psychotropic substances, thus adversely affecting the 
availability of psychotropic substances for legitimate 
purposes. 
 
  National control measures regarding international 
trade 
 
104. Experience has shown that the import and export 
authorization system is the most effective tool for 
preventing the diversion of controlled substances from 
international trade. The Board notes with appreciation 
that since November 2008 the Governments of Bosnia 
and Herzegovina and Seychelles have made the issuing 
of import authorizations a requirement for all 
substances in Schedules III and IV of the 
1971 Convention. In addition, in Austria, Azerbaijan, 
India, Ireland, Kenya, Lebanon, Malta, South Africa 
and the United Kingdom, the system of import and 
export authorizations has been extended to include 
some substances that had previously not been covered.  
105. At present, 180 countries and territories require 
by law import and export authorizations to be issued 
for at least some substances in Schedule III of the 1971 
Convention; however, in only 127 countries and 
territories that requirement applies to all substances in 
Schedule III that they trade in. For substances in 
Schedule IV, more than 170 countries and territories 
require import authorizations, but only 112 countries 
require such authorizations for all substances in 
Schedule IV that they trade in. The Board notes that, in 
many countries, changes in national legislation to 
extend the requirement for import authorizations to 
include newly scheduled substances appear to have 
been unduly delayed. For example, the Governments of 
110 countries (more than half of all countries) have not 
yet informed the Board of having extended the 
requirement for import authorizations to include 
gamma-hydroxybutyric acid (GHB) and zolpidem, 
although both substances were added to Schedule IV of 
the 1971 Convention in 2001, more than eight years 
ago.  
106. As cases involving diversion have shown, drug 
traffickers often divert substances into illicit channels 
in countries that have not yet begun to apply the 
necessary controls. The Board therefore urges all States 
in which national legislation does not yet require 
import and export authorizations to be issued for all 
psychotropic substances, regardless of whether or not 
those States are parties to the 1971 Convention, to 
extend such controls to all substances in Schedules III 
and IV of the 1971 Convention as soon as possible.  
107. Twice a year, the Board circulates to all 
Governments a table showing the countries in which 
national legislation requires the issuing of import 
authorizations for substances in Schedules III and IV 
of the 1971 Convention. Governments should carefully 
examine the table and inform the Board of any 
revisions that may have become necessary. 
108. Another important control measure applied to 
international trade is the system for the assessment of 
medical and scientific requirements for psychotropic 
substances, established by the authorities of each 
country and territory. Experience has shown that the 
diversion of psychotropic substances can be prevented 
if exporting countries verify whether the quantities 
ordered by importing countries are within the 
assessments established by the importing countries. 
The Board appreciates the cooperation of authorities of 
exporting countries who contact the Board when they 
receive import authorizations for imports of 
psychotropic substances in excess of the assessed 
legitimate requirements or who remind importing 
countries of any failure to comply with the system of 
assessments.  
109. During 2008, the authorities of seven countries 
issued import authorizations for substances in  
Schedule IV of the 1971 Convention without having 
established any assessments for those substances. With 
one exception, the quantities involved were very small. 
In addition, the authorities of 14 countries and 
territories issued import authorizations for substances 
in Schedule II, III or IV in quantities that significantly 
exceeded their assessments. The Board notes that, in 
each case, the number of countries are fairly low and 
that the system of assessments is respected by most 
countries. The Board calls again on Governments that 
have not yet done so to establish a mechanism for 
ensuring that their assessments are in line with their 
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actual legitimate requirements and that no imports 
exceeding the assessments are authorized. 
 
  Buprenorphine 
 
110. Buprenorphine is an opiate analgesic listed in 
Schedule III of the 1971 Convention. Since the late 
1990s, buprenorphine has increasingly been used in 
detoxification and substitution treatment for opioid 
addicts. New preparations containing high doses of 
buprenorphine (Subutex) or buprenorphine combined 
with naloxone (Subuxone) have been introduced in 
several countries. Buprenorphine is currently being 
used mostly for the treatment of opioid addiction. The 
number of patients under buprenorphine substitution 
therapy continues to increase in many countries. That 
has fuelled the licit demand for buprenorphine. As a 
result, global manufacture and use of buprenorphine 
have been increasing substantially. In the period 1998-
2009, global manufacture of buprenorphine rose  
from 460 kg to almost 4 tons. Global calculated 
consumption of buprenorphine, which in 
1998 amounted to 333 million defined daily doses for 
statistical purposes (S-DDD), reached 3.7 billion  
S-DDD in 2008. During the same period, the number 
of countries reporting imports of buprenorphine rose 
from 10 to 62.  
111. The increased use of buprenorphine for medical 
purposes has been accompanied by increased diversion 
and abuse. In some countries, buprenorphine has 
become the most important illicitly used substance 
among opiate addicts. The illicit market for 
buprenorphine has always been entirely supplied by 
diversion, mainly the diversion of preparations 
containing that substance. The abuse of such 
preparations occurs, above all, in countries where 
buprenorphine is used for the treatment of opioid 
addicts. Frequently diverted preparations are smuggled 
out of the countries in which they have been diverted 
and into other countries, including countries in other 
regions.  
112. To determine whether the control measures 
applied to buprenorphine by some Governments were 
sufficiently effective to prevent its diversion, the Board 
analysed the control status of buprenorphine in 
countries where the substance was used for medical 
purposes. The Board’s analysis focused on the controls 
applied to domestic distribution channels of 
buprenorphine, from where the substance was mainly 
diverted. 
113. In one third of the countries in the Board’s 
analysis, buprenorphine was controlled in accordance 
with its international scheduling status under the 
1971 Convention. The Board notes that, in the 
remaining two thirds of the countries, additional 
control measures were applied to the manufacture, 
storage or distribution of buprenorphine. Furthermore, 
in almost half of those countries, buprenorphine was 
controlled, in every aspect, as a narcotic drug under the 
1961 Convention; in the remainder of those countries, 
buprenorphine was controlled basically as a 
psychotropic substance, but the control measures 
applied to the domestic distribution of buprenorphine 
were stricter than those required for substances in 
Schedule III of the 1971 Convention. Some of those 
countries indicated that the stricter controls were 
considered necessary in view of the presence of 
buprenorphine on the illicit market.  
114. In the countries most affected by the diversion of 
buprenorphine, the substance continued to be 
controlled primarily in accordance with its 
international scheduling status under the 
1971 Convention. In some countries, where stricter 
control measures had been introduced in response to 
the abuse of buprenorphine, its diversion from 
domestic distribution channels virtually stopped even 
though the substance continued to be smuggled into 
those countries. 
115. In view of the continued diversion and abuse of 
buprenorphine, the Board wishes to remind all 
Governments of their obligation to cooperate with each 
other under the international drug control treaties to 
prevent trafficking in and abuse of psychotropic 
substances. The Board urges the Governments of all 
countries in which the substance is used for licit 
purposes to review the adequacy of the current control 
measures applied to buprenorphine on their territory 
with a view to identifying any gaps that might need to 
be closed and, in particular, enhancing the existing 
control measures applied to the distribution of 
buprenorphine.  
116. The Board calls upon all Governments to inform 
the Board of new developments regarding trafficking 
in and abuse of preparations containing buprenorphine. 
Governments of countries into which buprenorphine is 
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smuggled are encouraged to intensify their cooperation 
with the Governments of the countries of origin. 
 
 4. Consumption of psychotropic substances  
 
117. Governments are not required to furnish to the 
Board statistical data on consumption of psychotropic 
substances. The Board therefore calculates the 
approximate consumption levels of psychotropic 
substances, based on statistical data on manufacture 
and trade received from Governments, with a view to 
identifying unusual patterns that might warrant closer 
examination. Those calculated consumption levels of 
psychotropic substances continue to differ widely 
between countries and regions, reflecting differences in 
health services and related variations in prescription 
patterns. However, as the Board has repeatedly pointed 
out, high or low levels of drug consumption in a 
country should be a matter of concern to the 
Government. High levels of consumption of 
psychotropic substances that are not medically justified 
may lead to the diversion and abuse of the substances 
in question, as shown in the examples below. Very low 
levels of consumption of psychotropic substances in 
some countries may reflect the fact that those 
substances are almost inaccessible to certain parts of 
the population. Where substances are not accessible on 
the licit market for genuine medical purposes, those 
substances, or counterfeit medicaments allegedly 
containing those substances, may appear on 
unregulated markets. The Board reiterates its 
recommendation to all Governments to compare the 
consumption levels in their countries with those in 
other countries and regions, with a view to identifying 
unusual trends requiring attention, taking remedial 
action where necessary. At the same time, the Board 
encourages all Governments to promote the rational 
use of internationally controlled substances, in 
accordance with the pertinent recommendations of 
WHO.  
 
  Stimulants in Schedule II of the 1971 Convention 
that are used for the treatment of attention deficit 
disorder 
 
118. Methylphenidate, amphetamine and dex-
amphetamine, substances in Schedule II of the 
1971 Convention, are used mainly for the treatment of 
ADD (primarily in children) and narcolepsy. Those 
substances have traditionally been used for medical 
purposes much more extensively in the Americas than 
elsewhere.  
119. Methylphenidate is the most widely used 
stimulant in Schedule II of the 1971 Convention. Its 
manufacture and use have continued to increase. 
During the five-year period 2004-2008, global 
calculated consumption of methylphenidate rose by 
almost 80 per cent, from 28.6 to 52 tons. Most of the 
methylphenidate continues to be consumed in the 
United States, where the use of the substance for the 
treatment of ADD is frequently promoted in various 
communication channels, including in advertisements 
directed at potential consumers (see recommendation 9 
in chapter IV below). However, the use of 
methylphenidate for the treatment of ADD has also 
increased (albeit from a much lower level) in many 
other countries. Ten years ago, the United States 
accounted for over 80 per cent of the calculated global 
consumption of methylphenidate; its share has 
gradually declined since then, amounting to less than 
75 per cent in 2008, although the consumption of 
methylphenidate in the United States in absolute terms 
continues to increase. In the past three years, the 
highest average per capita rates of consumption were 
observed in the following countries (listed in 
decreasing order): Iceland, United States, Canada, 
Norway, Israel, Netherlands and Switzerland. 
120. The Board notes that the diversion and abuse of 
stimulants in Schedule II of the 1971 Convention,  
such as, amphetamine, dexamphetamine and 
methylphenidate, have taken place in some countries, 
in particular in countries with high levels of 
consumption of those substances. The Board requests 
all Governments to ensure that the control measures 
foreseen in the 1971 Convention are applied to 
stimulants in Schedule II. The Board calls on the 
Governments concerned to inform it of any new 
development with regard to the diversion of, 
trafficking in and abuse of those substances.  
 
  Stimulants in Schedule IV of the 1971 Convention 
that are used as anorectics 
 
121. The stimulants in Schedule IV of the 
1971 Convention are mainly used as anorectics. Of 
those substances the one most frequently used is 
phentermine, followed by fenproporex, amfepramone 
and mazindol. The diversion and abuse of those 
substances pose problems in some countries, in 
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particular in countries with high prescription levels. 
The Board follows closely developments in the 
consumption of those substances to identify 
consumption levels that may be inappropriate for 
medical purposes and might be indicative of activities 
not in line with the provisions of the Convention. 
122. Calculated consumption levels of stimulants in 
Schedule IV of the 1971 Convention have traditionally 
been highest in the Americas. The Board notes that, 
after 2006, a slight decline in the average consumption 
rate in the Americas was reported. In the period 2006-
2008, average calculated consumption amounted to 
10 S-DDD per 1,000 inhabitants per day in the 
Americas, compared with 3 S-DDD in Oceania, 
2 S-DDD in Europe, 1 S-DDD in Asia and 0.25 S-DDD 
in Africa. In 2008, the United States, followed by 
Argentina, was the country with the highest calculated 
per capita consumption of stimulants in Schedule IV, 
the United States alone accounting for 58 per cent of 
global calculated consumption of such stimulants, 
expressed in defined daily doses for statistical purposes 
per 1,000 inhabitants. 
123. The Board appreciates the measures taken by 
Argentina and Brazil, which succeeded in curbing the 
consumption of stimulants in Schedule IV in recent 
years by amending national legislation to allow better 
monitoring of the domestic distribution of such 
substances, strictly enforcing the prescription 
requirement and taking action against members of the 
medical professions who were found to have acted in 
an unlawful manner. The Board appreciates also the 
fact that consumption decreased in the Republic of 
Korea, where the levels of consumption of those 
stimulants had been high. 
124. In 2008, calculated consumption of stimulants in 
Schedule IV of the 1971 Convention decreased in some 
other countries in Asia, where the level of consumption 
of those stimulants had been high; as a result, the 
average consumption level in Asia also declined. The 
Board notes with concern that in other regions, the 
calculated average consumption of anorectics increased 
in 2008 because of a marked increase in consumption 
in some countries, in particular Australia, Chile, South 
Africa, Switzerland, the United Kingdom and the 
United States. 
125. The Board encourages all Governments that are 
reporting high or rising levels of consumption of 
stimulants in Schedule IV of the 1971 Convention to 
monitor the situation closely, determine whether those 
substances might have been illegally used, take 
measures to identify cases involving the use of 
falsified prescriptions or the overprescribing of 
anorectics and ensure that domestic distribution 
channels are adequately controlled (for additional 
measures to be taken, see recommendations 9, 19 and 
36-38 in chapter IV below). Governments should also 
coordinate their efforts to reduce excessive 
consumption levels with Governments of other 
countries in the region or subregion, so that measures 
taken in one country do not result in problematic 
consumption patterns shifting to its neighbouring 
countries. 
 
 
 C. Precursors 
 
 
 1. Cooperation with Governments 
 
  Submission of statistical data on seizures 
 
126. Pursuant to article 12 of the 1988 Convention, 
parties are obliged to report information on substances 
frequently used in the illicit manufacture of narcotic 
drugs and psychotropic substances. As at 1 November 
2009, such information had been submitted for 2008 by 
a total of 132 States and the European Community (on 
behalf of its member States). The rate of submission is 
comparable to that of previous years. The Board urges 
Burundi, Gabon and the Gambia, all of which are 
States parties to the 1988 Convention that have never 
submitted form D, to do so without further delay. 
127. According to data provided on form D for 2008, 
47 Governments effected seizures of substances in 
Tables I and II of the 1988 Convention. While such 
seizure data are useful, they could be more meaningful 
if they included important details related to the 
seizures, such as identified methods of diversion or 
illicit manufacture. Moreover, parties to the 
Convention are required to provide data on stopped 
shipments and seizures of substances not under 
international control. The Board calls upon 
Governments to furnish information on the results of 
investigations concerning seizures and intercepted 
shipments of precursors, in order to prevent similar 
diversions in the future. 
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  Annual submission of information on the licit 
trade in and uses of substances in Tables I and II 
of the 1988 Convention 
 
128. In accordance with Economic and Social Council 
resolution 1995/20, the Board has been requesting 
Governments to voluntarily furnish data on licit trade 
in, uses of and requirements for scheduled substances. 
As at 1 November 2009, 108 Governments, including 
Governments of countries that are major exporters and 
manufacturers of precursors, had reported data for 
2008 on the licit movement of precursor chemicals, 
and 101 States and territories had provided information 
on licit uses of and requirements for such substances. 
129. The Board continues to encourage Governments 
to provide comprehensive information on licit trade in 
and uses of substances in Tables I and II of the 
1988 Convention, as that information has proved to be 
an essential tool in identifying irregular transactions 
and preventing diversion. 
 
 2. Control measures 
 
130. Experience has shown that a proper system for 
monitoring the domestic movement of precursors is a 
prerequisite for preventing the diversion of precursors 
into illicit channels. The Board has noted that 
additional control measures were recently adopted in a 
number of countries, including Afghanistan, Argentina, 
Chile, China, Colombia, the Czech Republic, 
Guatemala, Jordan, Nicaragua, Panama, Peru, the 
United Kingdom and the United States. 
131. As monitoring and controls over ephedrine and 
pseudoephedrine in the form of raw material are 
strengthened, traffickers are increasingly attempting to 
divert pharmaceutical preparations containing those 
substances, particularly through countries or regions 
where controls over such preparations are less stringent 
or non-existent. In 2008, Mexico prohibited the 
importation of pharmaceutical preparations containing 
ephedrine or pseudoephedrine. Since then, the 
Governments of several countries in the region have 
adopted similar control measures. For example, in 
2009, Guatemala prohibited the import of 
pseudoephedrine in all forms; in addition, the 
movement within its national territory of all 
pharmaceutical products containing the substance was 
also prohibited. Also in 2009, Colombia prohibited the 
manufacture and import of and trade in pharmaceutical 
products containing pseudoephedrine. Argentina, 
Chile, China, the Czech Republic, Iceland, Nicaragua, 
Peru, the United Kingdom and the United States have 
also recently introduced or strengthened control 
measures over pharmaceutical preparations containing 
ephedrine or pseudoephedrine. 
 
  Estimates of legitimate requirements for 
precursors 
 
132. In response to Commission on Narcotic Drugs 
resolution 49/3, entitled “Strengthening systems for the 
control of precursor chemicals used in the manufacture 
of synthetic drugs”, a total of 120 Governments have 
furnished estimates of their annual requirements for 
selected amphetamine-type stimulant precursors.28 
Those estimates are published each year in the report 
of the Board on the implementation of article 12 and 
are posted on the website of the Board (www.incb.org). 
Governments are encouraged to review the estimates 
they have furnished and to inform the Board of any 
necessary changes or updates so that the figures will be 
as accurate as possible. In response to requests from 
Governments to provide guidance in calculating such 
estimates, the Board has circulated a document on 
issues that Governments may consider when 
determining annual legitimate requirements for 
ephedrine and pseudoephedrine. The document is also 
available on the website of the Board (www.incb.org). 
 
 3. Online system of pre-export notifications 
 
133. The rapid exchange of information between 
exporting and importing countries through the pre-
export notification system has proved to be one of the 
most effective and efficient ways of identifying the 
legitimacy of shipments of precursor chemicals. Since 
2006, Pre-Export Notification Online (PEN Online), 
the system for the exchange of pre-export notifications 
has been used as the main mode for the exchange of 
such information. By 1 November 2009, 111 States and 
territories had registered as users of the system. Since 
March 2006, when the system was introduced, 
29,500 notifications have been sent to 181 countries 
through PEN Online. The PEN Online system has 
demonstrated its usefulness in Project Prism and 
Project Cohesion. The Board again encourages all 
Governments that have not yet done so to register with 
__________________ 
 28  3,4-Methylenedioxyphenyl-2-propanone (3,4-MDP-2-P), 
1-phenyl-2-propanone (P-2-P), ephedrine and 
pseudoephedrine. 
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and utilize the PEN Online system, pursuant to 
Security Council resolution 1817 (2008). 
134. Although PEN Online has been available only 
since 2006, in many ways it has already increased the 
speed and efficiency of the exchange of information 
between countries; however, there is always room for 
improvement. Importing countries should provide 
feedback to the exporting country in the event that a 
transaction appears suspicious or additional time is 
required for checking. Delays in responses from 
importing countries may unduly hamper licit trade or 
unwittingly allow suspicious shipments to proceed. 
Therefore, the Board encourages Governments to 
facilitate the exchange of accurate information through 
PEN Online. 
 
 4. Prevention of diversion of precursors into the 
illicit traffic 
 
135. The Board has continued to support 
Governments’ activities under Project Cohesion and 
Project Prism, as those initiatives have proved to be 
indispensable in monitoring the international 
movement of precursor chemicals and have yielded 
tangible results, including the identification of: 
weaknesses in control measures; diversion methods 
and routes used by traffickers; and cases involving 
trafficking in substances not under international 
control.  
136. In 2009, activities under Project Prism were 
extended, focusing on trade in ephedrine and 
pseudoephedrine, including pharmaceutical preparations, 
1-phenyl-2-propanone (P-2-P) and phenylacetic acid. 
As a result of Project Prism activities, an estimated  
10 tons of ephedrine and pseudoephedrine in the form 
of raw material, as well as 31 million tablets 
containing one of the two substances, were prevented 
from reaching illicit drug manufacturing laboratories. 
While, in the majority of cases the intended destination 
continued to be North America, the precursor 
chemicals were frequently diverted in Central America 
and trans-shipped through Europe. 
137. From January to September 2008, the majority of 
the transactions identified in the framework of Project 
Prism involved ephedrine and pseudoephedrine in raw 
material form; of the 49 suspicious transactions 
detected, only 11 involved preparations. The situation 
has changed since then: the data currently available to 
the Board show a significant decline in identified 
attempts to divert ephedrine and pseudoephedrine in 
the form of raw material from international trade 
channels. In 70 per cent of all suspicious shipments, 
the substances were pharmaceutical preparations in 
tablet form. 
138. Coinciding with the shift towards the diversion of 
precursors in the form of pharmaceutical preparations, 
the diversion routes identified also changed 
significantly during 2009. Activities carried out under 
Project Prism resulted in Africa being identified as the 
region in which the greatest number of diversions or 
attempted diversions of precursors took place, and over 
half of the quantity of precursor chemicals in 
shipments identified as suspicious were prevented from 
being diverted. However, in terms of suspicious or 
seized shipments in 2009, only two attempted 
diversions to countries in Africa (Central African 
Republic and Kenya) were reported to the Board. There 
were numerous instances of suspicious shipments and 
seized shipments in Central American countries that 
had been intended for Mexico. The supply routes 
through which the diverted preparations were being 
transported were more complex than those previously 
identified for raw material shipments. What is perhaps 
even more significant is that the countries of origin for 
raw material shipments included not only those  
with domestic ephedrine and pseudoephedrine 
manufacturing industries, but also intermediate 
countries where raw ephedrines were imported and 
then formulated into pharmaceutical preparations. In 
many instances, the route by which tableted 
preparations had been shipped to destinations in 
Central America led through European Union member 
States. 
139. Shipments of pharmaceutical preparations 
containing ephedrine or pseudoephedrine that have 
been diverted or seized in Central America have 
originated in Bangladesh, India and, to a lesser extent, 
the Syrian Arab Republic.  
140. In response to the recent increase in the diversion 
of ephedrine and pseudoephedrine in the form of 
pharmaceutical preparations, several countries in the 
Americas have changed their national legislation, 
either banning trade in pharmaceutical preparations 
containing those substances or enabling the control 
over those preparations to be much stricter. 
141. Reports on seizures by Mexican authorities of 
phenylacetic acid made also indicated that traffickers 
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were reducing their need for ephedrines by substituting 
phenylacetic acid as the starting point for illicit 
methamphetamine manufacture. An increasing  
number of laboratories illicitly manufacturing 
methamphetamine have been dismantled and, as a 
result, seizures of that substance have increased. 
Therefore, the rescheduling of phenylacetic acid from 
Table II to Table I of the 1988 Convention is necessary 
to ensure that adequate control measures are in place to 
prevent the diversion of that substance for use in illicit 
drug manufacture. Moreover, the introduction of  
pre-export notifications as a treaty obligation for 
phenylacetic acid will facilitate licit international trade 
by expediting the clearance of shipments, without 
adverse effects on the availability of the substance for 
licit purposes at the national level. In the meantime, the 
Board requests Governments to remain vigilant with 
regard to the diversion of phenylacetic acid into illicit 
channels. 
142. The seizure of chemicals and equipment made in 
Guinea in July 2009 indicates that illicit manufacturers 
of amphetamine-type stimulants are active in West 
Africa. The Board encourages Governments and 
relevant international organizations to assist countries 
in Africa in the provision of appropriate training and 
the development of capacity-building programmes to 
counter trafficking in precursors and illicit drug 
manufacture in the region.  
143. In 2008, global seizures of acetic anhydride, the 
key precursor chemical used in the illicit manufacture 
of heroin, amounted to 199,300 litres, 3.5 times as high 
as the figure for 2007 and the second largest figure 
ever reported to the Board. That result can, to a large 
extent, be attributed to law enforcement activities and 
cooperation among States. One activity of Project 
Cohesion focused on the exchange of information 
related to seizures and diversions of acetic anhydride, 
as well as other chemicals used in the illicit 
manufacture of heroin. Similar law enforcement 
activities were implemented in the framework of 
Project Cohesion in 2009. 
144. Backtracking investigations into seizures of 
acetic anhydride once again confirmed the Board’s 
previous concerns about traffickers diverting 
precursors from domestic distribution channels rather 
than from international trade. Most of the acetic 
anhydride seized in 2008 was diverted at the national 
level. Investigations in 2008 and 2009, in addition to 
producing valuable intelligence, facilitated the 
identification of legislative gaps and weaknesses in 
control systems in some countries, including countries 
in Europe and in East and South-East Asia. In 2009, 
the number of unauthorized shipments destined for 
countries in West Asia, in particular Iraq, significantly 
increased. Africa emerged as a new target area for 
traffickers in search of acetic anhydride. The threat of 
diversion from domestic distribution channels 
continued to be a problem. The Board reiterates its call 
to Governments to put in place effective measures for 
controlling the movement of precursor chemicals at the 
national level. 
145. In 2008, the Government of Afghanistan 
informed the Board that there was no legitimate use for 
acetic anhydride in Afghanistan and requested all 
producing and trading countries not to authorize any 
exports of acetic anhydride to that country. In 2008, 
most of the seizures of acetic anhydride occurred in 
source countries outside of Central Asia. Seizures of 
acetic anhydride and other chemicals used in the illicit 
manufacture of heroin remained relatively low in 
Afghanistan and countries around it, in particular when 
compared with the amounts of chemicals smuggled 
into the illicit heroin manufacturing laboratories in the 
region. Nevertheless, the increased black market prices 
for acetic anhydride may indicate some shortages of 
the substance in Afghanistan. The Board hopes that 
anti-smuggling activities in West Asia and Central Asia 
will complement the intelligence-based activities 
carried out under Project Cohesion and will contribute 
to preventing the diversion of chemicals to the illicit 
heroin manufacturing laboratories in Afghanistan.  
146. The paucity of the information available on 
trends in trafficking in precursors of cocaine remains a 
concern of the Board. Although seizures of large 
amounts of chemicals, under international control as 
well as other chemicals under national control, 
continue to be reported in South America, information 
on trafficking routes, diversion methods and, in 
particular, sources of seized chemicals is scarce. The 
large amount of potassium permanganate seized in 
countries in South America, in particular Colombia, in 
the past few years indicates that current control 
measures may not be sufficient to deal with the 
smuggling and the illicit manufacture of potassium 
permanganate in the region. The Board again calls on 
Governments of countries in South America to design 
strategies similar to those developed in the framework 
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of Project Cohesion, which led to an increased 
interception rate and the identification of sources of 
precursors used in the illicit manufacture of heroin. 
 
 
 D. Promoting universal application of the 
international drug control treaties 
 
 
147. In discharging its mandate under the international 
drug control treaties, the Board maintains an ongoing 
dialogue with Governments through various forms, 
such as regular consultations and country missions. 
That dialogue has been instrumental to the Board’s 
efforts to assist Governments in complying with the 
provisions of the treaties. 
 
 1. Status of adherence to the international drug 
control treaties 
 
148. Since the 2008 report of the Board was published, 
the Lao People’s Democratic Republic has acceded to 
the 1972 Protocol amending the 1961 Convention29 
and Namibia has acceded to the 1988 Convention; 
thus, both States have become parties to all three of the 
international drug control treaties.  
149. As at 1 November 2009, the number of States 
parties to the 1961 Convention or that Convention as 
amended by the 1972 Protocol reached 186, accounting 
for 96 per cent of all States. Of those States, 184 were 
parties to the 1961 Convention as amended by the 
1972 Protocol. Afghanistan and Chad continue to be 
parties to the 1961 Convention in its unamended form 
only. A total of eight States have yet to accede to the 
1961 Convention: one State in Africa (Equatorial 
Guinea), one in Asia (Timor-Leste) and six in Oceania 
(Cook Islands, Kiribati, Nauru, Samoa, Tuvalu and 
Vanuatu).  
150. The number of States parties to the 
1971 Convention stood at 183, accounting for 95 per 
cent of all States. A total of 11 States have yet to 
become parties to that convention: two States in Africa 
(Equatorial Guinea and Liberia), one in the Americas 
(Haiti), one in Asia (Timor-Leste) and seven in 
Oceania (Cook Islands, Kiribati, Nauru, Samoa, 
Solomon Islands, Tuvalu and Vanuatu).  
151. With the accession by Namibia to the 
1988 Convention, the number of States parties to that 
__________________ 
 29  United Nations, Treaty Series, vol. 976, No. 14151. 
convention increased to 183, accounting for 95 per cent 
of all States. A total of 11 States have yet to become 
parties to that convention: two States in Africa 
(Equatorial Guinea and Somalia), one in Asia (Timor-
Leste), one in Europe (the Holy See) and seven in 
Oceania (Kiribati, the Marshall Islands, Nauru, Palau, 
Papua New Guinea, Solomon Islands and Tuvalu). 
152. The Board welcomes the accession by the Lao 
People’s Democratic Republic to the 1972 Protocol 
amending the 1961 Convention and the accession by 
Namibia to the 1988 Convention. The Board once 
again urges those States which have not done so to take 
steps necessary to accede to all the international drug 
control treaties without further delay. The Board notes 
that 10 of the 18 States that are not yet parties to all of 
those treaties (63 per cent) are in Oceania. 
 
 2. Evaluation of overall treaty compliance in 
selected countries 
 
153. The Board reviews, on a regular basis, the drug 
control situation in various countries and 
Governments’ overall compliance with the provisions 
of the international drug control treaties. The review 
covers various aspects of drug control, including the 
functioning of national drug control administrations, 
the adequacy of national drug control legislation and 
policy, measures taken by Governments to combat drug 
trafficking and abuse, and Governments’ fulfilment of 
their reporting obligations under the treaties. 
154. The findings of the review, as well as the Board’s 
recommendations for remedial action, are conveyed to 
the Governments concerned as part of the ongoing 
dialogue between the Board and Governments to 
ensure that the international drug control treaties are 
fully implemented.  
155. In 2009, the Board reviewed the drug control 
situation in Bolivia (Plurinational State of), Colombia, 
Mauritania and Morocco, as well as measures taken by 
the Governments of those countries to implement the 
international drug control treaties. In doing so, the 
Board paid particular attention to new developments in 
drug control in those countries. 
 
  Bolivia (Plurinational State of) 
 
156. The Board, as part of its ongoing review of 
compliance by States parties with their treaty-based 
obligations, has closely followed recent developments 
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in the Plurinational State of Bolivia with regard to its 
policies on coca bush cultivation and coca leaf 
production. The Board notes with concern that, despite 
the social control measures currently being pursued by 
the Government with the aim of reducing coca bush 
cultivation and coca leaf production in the country, 
both the reported total area under coca bush cultivation 
and the expected coca leaf production have increased 
over the past few years.  
157. In 2008, the total area under coca bush 
cultivation in the Plurinational State of Bolivia 
increased for the third consecutive year, to 
30,500 hectares (ha), 6 per cent more than in 2007. 
Compared with 2000, the total area under illicit coca 
bush cultivation doubled. The potential manufacture of 
cocaine in the country also increased in 2008, by 9 per 
cent to 113 tons, and accounted for 13 per cent of the 
potential global production of cocaine.30 Furthermore, 
the total area of coca bush eradicated in the country in 
2008 amounted to 5,483 ha, the second smallest figure 
recorded since 1995. The Board is concerned that those 
developments have had a negative impact on the 
Government’s strategy to reduce the availability of 
coca leaves and have increased the risk of coca leaves 
being diverted for use in the illicit manufacture of 
cocaine. 
158. The Board recalls the expressed commitment of 
the Bolivian Government when introducing its present 
policies towards coca bush cultivation and coca leaf 
production, namely, zero tolerance to illicit 
manufacture and trafficking in cocaine. That view has 
been reiterated by the Government on numerous 
occasions, particularly by representatives of the 
Government attending the ninety-third session of the 
Board, in November 2008, at the Board’s request. 
159. The Board urges the Bolivian Government to 
adopt more effective policies and to take a more 
proactive role in the elimination of illicit coca bush 
cultivation and coca leaf production in the country, as 
well as to address in a decisive manner the illicit 
manufacture of and trafficking in cocaine. The Board 
underlines that measures to promote alternative 
development in areas affected by coca bush cultivation, 
accompanied by sustained law enforcement efforts to 
prevent the re-emergence of such cultivation, are 
essential to the achievement of a lasting reduction in 
__________________ 
 30  World Drug Report 2009 …, pp. 63-65. 
and the eventual elimination of the illicit production of 
coca leaf and manufacture of cocaine in the country. 
This illustrates the fact that it is difficult for a 
Government to control licit drug production when 
faced with thriving local drug trafficking. 
160. Having reviewed the drug control situation in the 
Plurinational State of Bolivia, the Board takes note of 
the country’s new declarations concerning coca leaf, 
the statement by the country’s President during the 
high-level segment of the fifty-second session of the 
Commission on Narcotic Drugs and the Government’s 
proposed amendment to article 49 of the 
1961 Convention as amended by the 1972 Protocol, 
notified to the Secretary-General on 12 March 2009. 
The Board, bearing in mind its mandate under the 
international drug control treaties, wishes to restate its 
position on those issues. 
161. Coca leaf is defined as a narcotic drug in the 
1961 Convention and listed in Schedule I of the 
Convention, among those narcotic drugs to which the 
strictest control measures are applicable. Those 
controls include the provisions of article 4, 
paragraph (c), on the general obligation for States 
parties to “limit exclusively to medical and scientific 
purposes the production, manufacture, export, import, 
distribution of, trade in, use and possession of drugs”; 
articles 23 and 26, on the control regimes applicable to 
cultivation and production for parties permitting 
cultivation and production for the extraction of 
alkaloids; and article 27, on the possibility for parties 
to permit cultivation and production “for the 
preparation of a flavouring agent, which shall not 
contain any alkaloids”. 
162. The Board is aware of the right of States parties 
to the 1961 Convention to propose amendments to the 
Convention in accordance with article 47. In fact, the 
Board has provided the Bolivian Government with 
relevant information on the proper mechanism for 
changing the scope of the Convention. The Board 
wishes to remind the Government that until such 
amendments are effected, all the uses of coca leaf 
considered by the Government as traditional, including 
coca-leaf chewing and the manufacture and 
consumption of coca tea, as well as all other products 
derived from the coca leaf of which alkaloids have not 
been removed, continue to be illicit activities under the 
terms of the Convention.  
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163. In so far as coca leaf remains under international 
control, the Plurinational State of Bolivia, as a party to 
the 1961 Convention as amended by the 1972 Protocol, 
must ensure full compliance with its obligations under 
the Convention, including the obligation to eliminate 
all uses of coca leaf for purposes other than those 
provided for in the Convention.  
164. The Board, in response to the above-mentioned 
developments in drug control in the country, has 
strengthened its dialogue with the Bolivian 
Government over the past few years. In particular, the 
Board sent a mission to the country in 2007, to discuss 
with competent national authorities the Government’s 
policies on coca bush cultivation and coca leaf 
production, as well as progress made by the 
Government in that regard since the previous mission 
of the Board to that country, in 2001. The Board notes 
with regret that the Government has yet to implement 
almost all the recommendations made pursuant to the 
2001 mission.  
165. During its ninety-third session, in 
November 2008, the Board heard a presentation by a 
delegation of the Plurinational State of Bolivia on the 
drug control situation in that country. The Board, while 
noting its agreement with the Government’s position 
on cocaine, reiterates its concerns over the 
Government’s policies with regard to coca bush 
cultivation and coca leaf production.  
166. The Board will continue to monitor drug control 
developments in the country and to maintain an 
ongoing dialogue with the Bolivian Government. 
 
  Colombia 
 
167. The illicit cultivation of coca bush in Colombia is 
closely intertwined with the ongoing armed conflict: 
many of the armed factions involved in the conflict 
finance themselves through drug trafficking activities. 
Though the Government has been conducting a 
vigorous coca bush eradication campaign, the country 
remains the source of half of the world’s illicitly 
manufactured cocaine.  
168. The Board notes that the Government of 
Colombia continues to make efforts in its eradication 
programme. Surveys conducted by the Government 
and UNODC indicate that in 2008 illicit coca bush 
cultivation in Colombia declined substantially 
compared with the previous year and that such 
cultivation returned to levels recorded at the beginning 
of the decade. That significant decline contributed to 
the global reduction of potential cocaine manufacture 
for that year.  
169. Nevertheless, the Board is concerned that in 2008 
the illicit manufacture of cocaine hydrochloride in 
Colombia was estimated at 430 tons — about 51 per 
cent of the world total. The Board urges the 
Government to continue taking effective measures to 
address that problem. The Board underlines the 
necessity of ensuring alternative livelihoods for 
farmers currently engaged in coca bush cultivation and 
encourages the Government to strengthen its 
programmes in that area.  
170. The Board notes that Colombia has continued to 
strengthen its efforts in the area of law enforcement, in 
particular its efforts to fight the powerful drug 
trafficking organizations in that country. Since 2005, 
Colombia has extradited several high-ranking drug 
traffickers to the United States of America and other 
countries. Furthermore, Colombia has taken an active 
part in regional activities in the area of demand 
reduction. The Board encourages the Government to 
enhance its efforts to ensure that progress is made in 
addressing drug abuse and drug trafficking in the 
country and to increase its cooperation with countries 
in Africa in an effort to address the problem of illicit 
drug consignments entering that region.  
 
  Mauritania 
 
171. The Board had long-standing concerns regarding 
the compliance of the Government of Mauritania with 
the international drug control treaties, as well as its 
cooperation with the Board in matters related to drug 
control. The Board notes with satisfaction that the 
Government of Mauritania has significantly improved 
the functioning of its national drug control system and 
its responses to the Board’s concerns have been 
satisfactory, as a result of the ongoing dialogue of the 
Board with the Government. 
172. In particular, the Government of Mauritania has 
made sustained progress in submitting statistical 
information to the Board, thus fulfilling its reporting 
obligations under the international drug control 
treaties. The Government has also amended national 
legislation on drug control, adopted a national drug 
control strategy and further strengthened the inter-
ministerial body to improve cooperation and 
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coordination in drug control at the national level. The 
Board welcomes those important measures taken by the 
Government to increase its capacity in drug control.  
173. The Board notes that, in response to the emerging 
drug abuse and drug trafficking in Mauritania, the 
Government has given priority to a number of areas, as 
reflected in its current national drug control strategy, 
including strengthening law enforcement; taking 
measures to reduce the illicit manufacture of synthetic 
drugs; strengthening control of licit activities related to 
controlled substances with a view to preventing 
diversion, particularly with regard to prescription 
drugs; and increasing efforts in the area of drug abuse 
prevention.  
174. The Board remains concerned, however, about 
the increase in cocaine trafficking through West Africa. 
Like many countries in West Africa, Mauritania lacks 
the resources and the capacity to effectively address 
the emerging problem of drug trafficking and drug 
abuse. Drug seizures have rarely been made or 
recorded in Mauritania.  
175. The Board reiterates the importance of 
international cooperation in drug control in West Africa 
and urges the Government of Mauritania to strengthen 
its cooperation with the Governments of neighbouring 
countries and international organizations. The Board 
trusts that the Government of Mauritania will step up 
its efforts to ensure that further progress is made 
towards compliance with the international drug control 
treaties. 
 
  Morocco 
 
176. In recent years, the Government of Morocco has 
continued its efforts in the area of drug control, making 
considerable progress in the elimination of illicit 
cultivation of cannabis in the country. The total area 
under cannabis cultivation was reduced by 55 per cent, 
from 134,000 ha in 2003 to 60,000 ha in 2008. The 
Government aims to reduce the total area under 
cannabis cultivation even further, to 50,000 ha in 2009.  
177. The Board notes the improvement in the 
cooperation of the Government of Morocco with the 
Board. The Government has complied with its 
reporting obligations under the international drug 
control treaties by submitting regularly to the Board 
statistical information on the licit movement of 
narcotic drugs, psychotropic substances and precursors. 
The Government has also provided additional 
information, including statistical data on drug seizures, 
arrests and prosecutions for drug-related offences. 
Such information facilitates the Board’s assessment of 
the drug control situation in Morocco.  
178. While recognizing the above-mentioned positive 
developments, the Board wishes to point out that 
significant challenges remain. Morocco continues to be 
one of the countries in the world with extensive illicit 
cultivation of cannabis and is an important source of 
illicitly produced cannabis and cannabis resin, in 
particular for North Africa and Western Europe. The 
Board encourages the Government of Morocco to 
continue its efforts to carry out eradication measures, 
alternative livelihood programmes and awareness-
raising campaigns in areas where illicit cannabis 
cultivation takes place, with a view to ensuring that 
further progress is made in addressing that problem.  
179. The Board notes that the Government of Morocco 
has been implementing a national drug control strategy 
that rests on four pillars: interdiction, eradication, 
international cooperation and demand reduction. The 
Board also notes that the Government has been 
reviewing the strategy and that a survey has been 
planned for 2010 to assess the illicit cultivation of 
cannabis in Morocco. The Board welcomes those 
developments and encourages the Government, taking 
into account the outcome of the review, to step up 
efforts in areas where progress is lacking and to ensure 
that the progress already achieved is sustained. 
 
 3. Country missions 
 
180. In pursuing its mandate under the international 
drug control treaties and as part of its dialogue with 
Governments, the Board undertakes a number of 
country missions every year to discuss with competent 
national authorities measures taken and progress made 
in various areas of drug control. The missions provide 
the Board with an opportunity to obtain not only first-
hand information, but also a better understanding of 
the drug control situation in each country it visits, 
thereby enabling the Board to provide the Government 
with relevant recommendations and to promote treaty 
compliance.  
181. In 2009, the Board sent missions to the following 
countries: Angola, Australia, Finland, Holy See, 
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Hungary, Ireland, Jordan, Malta, Spain, Sudan and 
Syrian Arab Republic.31 
 
  Angola 
 
182. A mission of the Board visited Angola in 
February 2009. The Board notes that, since its last 
mission to Angola, in 1999, the Government has taken 
a series of measures to implement the international 
drug control treaties and has made some progress in 
certain areas of drug control. In particular, national 
drug control legislation was adopted in 1999, a 
national committee for drug control coordination was 
established in 2001, a national drug control strategy 
was developed in 2003 and Angola acceded to the 
international drug control treaties in 2005. The 
Government has also taken steps to address the 
emerging problems of drug abuse and drug trafficking 
in the country, for example by strengthening border 
control, building law enforcement capacity and 
carrying out drug abuse prevention programmes 
targeting young persons.  
183. Significant challenges remain, however. Like 
many other countries in the region, Angola is faced 
with growing drug problems. It has increasingly been 
used as a trans-shipment area for cocaine destined for 
countries in Western Europe and other countries in 
Africa. The illicit cultivation of cannabis is taking 
place in almost all provinces in Angola, and the high 
profits being made in drug trafficking have led an 
increasing number of people to become involved in 
that illicit activity. While cannabis remains the most 
commonly abused drug in the country, there appears to 
be a growing problem involving the abuse of cocaine 
and prescription drugs in urban areas. The Board 
encourages the Government to continue its efforts in 
drug control and strengthen its cooperation with other 
countries in the region aimed at addressing the drug 
problems. 
 
  Australia 
 
184. A mission of the Board visited Australia in 
February 2009. The Board commends the Government 
for its balanced drug control policy, based on both 
demand reduction and supply reduction measures. 
__________________ 
 31  The findings and recommendations of the missions of 
the Board to Hungary, Ireland, Jordan, Malta and Spain 
will be reported on in the report of the Board for 2010. 
Several initiatives targeting the illicit manufacture of 
amphetamine-type stimulants have been implemented 
in Australia. The Board invites the Government to 
continue to share its experiences in the implementation 
of those initiatives with the Board, other Governments 
and international organizations. The Board notes with 
appreciation that the cultivation of opium poppy, the 
production of poppy straw and the extraction of 
alkaloids from poppy straw are under strict and 
effective control in Australia. 
185. In spite of a significant decrease in the abuse of 
some narcotic drugs and psychotropic substances, the 
levels of abuse of certain narcotic drugs and 
psychotropic substances continue to be high in 
Australia. The Board encourages the Government to 
implement comprehensive measures to counter the 
abuse of narcotic drugs and psychotropic substances 
and pay due attention to new developments, such as the 
increase in the abuse of cocaine. The Board 
recommends the Government to further strengthen 
primary prevention of drug abuse and the 
comprehensive treatment and rehabilitation of abusers 
of narcotic drugs and psychotropic substances. The 
Board requests the Government to terminate the 
operation of the “drug injection room” in Sydney and 
provide drug abusers who will be affected by the 
closure with access to appropriate social and health 
services, including for the treatment and rehabilitation 
of drug abusers. 
 
  Finland 
 
186. A mission of the Board visited Finland in 
January 2009. Finland is a party to all the international 
drug control treaties and has adopted comprehensive 
drug control legislation. Finland’s drug control strategy 
is based on a sound general welfare approach and on 
ensuring a balance between reducing supply and 
reducing demand, with emphasis on the promotion of a 
healthy lifestyle and early prevention of drug abuse. 
Adequate resources are provided for the 
implementation of the national drug control policy. The 
legislative and administrative structures for drug 
control are efficient, and the coordination of the 
various Government authorities is excellent.  
187. The Board notes that the quality of the drug 
prevention efforts in Finland continues to be high. The 
system for community-based drug abuse prevention 
has been further improved in the past few years, and 
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the involvement of the relevant parties, such as the 
police, in prevention efforts at the community level has 
been intensified. However, the Board continues to be 
concerned about the problem of the abuse of 
buprenorphine, which is smuggled in large quantities, 
mainly out of France, into Finland via Estonia. The 
Board wishes to encourage the authorities of Finland to 
continue to look for a solution to that problem together 
with the Governments concerned.  
 
  Holy See 
 
188. A mission of the Board visited the Holy See in 
November 2008, in an effort to promote universal 
ratification and implementation of the international 
drug control conventions. The Board commends the 
authorities of the Holy See for having ratified the 
1961 Convention and the 1971 Convention. While 
there are apparently no cases of drug abuse or drug 
trafficking in the Vatican City, drug problems have 
been prevented through work in demand reduction, 
pastoral care, capacity-building and making controlled 
drugs available for pain treatment. The Board 
encourages the Holy See to pursue efforts to remove 
obstacles to its accession to the 1988 Convention and, 
at the same time, to continue taking practical measures 
to deal with potential problems and difficulties that 
might arise from the implementation of the provisions 
of the 1988 Convention. 
 
  Hungary 
 
189. A mission of the Board visited Hungary in 
October 2009. It was the first time since 1999 that a 
mission of the Board had visited that country. The 
mission met with officials from the Ministry of Social 
Affairs and Labour, the Ministry of Health and the 
Ministry of Agriculture and Rural Development to 
discuss the implementation of the international drug 
control conventions, to which Hungary is a party. The 
issues discussed included the licit cultivation of opium 
poppy in Hungary, the availability of opioids for the 
treatment of pain and progress in implementing the 
first Hungarian National Strategy to Combat the Drug 
Problem. Representatives of the police and customs 
authorities discussed recent developments in 
trafficking in drugs and precursor chemicals in 
Hungary. The mission included a visit to a treatment, 
rehabilitation and reintegration centre for drug addicts, 
in Budapest. 
 
  Ireland  
 
190. A mission of the Board visited Ireland in 
October 2009. It was the first time since 2000 that a 
mission of the Board had visited that country. The 
objective of the mission was to review the 
implementation of the three international drug control 
conventions, to which Ireland is a party. Deliberations 
focused on the Government’s experience in 
implementing those conventions through national 
legislation and national drug control policy. Recent 
developments in drug trafficking and abuse in Ireland 
were discussed, as well as measures taken by the 
Government to counteract those developments. 
Meetings were held with the Minister for Drugs, the 
Minister of Education, the Minister for Health and the 
Minister for Justice, as well as with senior police and 
customs officials. The mission included visits to a 
youth centre active in the area of drug abuse 
prevention and two centres providing treatment, 
counselling and aftercare for drug-dependent persons. 
 
  Jordan 
 
191. A mission of the Board visited Jordan in 
August 2009. It was the first time since 2001 that a 
mission of the Board had visited that country. The 
objective of the mission was to review the 
implementation of the three international drug control 
conventions, to which Jordan is a party. Deliberations 
focused on recent developments in drug trafficking and 
abuse in Jordan, as well as on measures taken or 
planned to address those problems. The issues 
discussed included the continued smuggling of 
amphetamine-type stimulants through Jordan and the 
legislative and administrative measures adopted to 
control narcotic drugs, psychotropic substances and the 
chemicals needed for their illicit manufacture. 
Meetings were held with senior officials of the 
Ministry of Health, the Ministry of Justice, the 
Ministry of Foreign Affairs, the Jordan Food and Drug 
Administration, the national drug control authorities, 
the national anti-corruption commission and the 
customs authorities. The mission included visits to two 
centres that provide treatment, counselling and 
aftercare for drug-dependent persons.  
 
  Malta  
 
192. A mission of the Board visited Malta in 
October 2009. Meetings were held with senior 
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representatives of the Ministry for Justice and Home 
Affairs, the Ministry for Social Policy, the Ministry of 
Finance, the Economy and Investment and the Malta 
National Laboratory. The mission included visits to the 
Freeport Zone at Kalafrana and facilities for the 
treatment and rehabilitation of drug abusers. The 
objective of the mission was to discuss the 
implementation of the international drug control 
conventions and cooperation with the Board. The 
discussions focused on reporting obligations under the 
conventions, as well as legislative and administrative 
measures to address the situation with regard to 
trafficking in drugs and their precursors. The 
availability of opiates for medical needs was also 
discussed. 
 
  Spain  
 
193. A mission of the Board visited Spain in 
July 2009. It was the first time since 2000 that a 
mission of the Board had visited that country. Spain is 
party to the three main drug control conventions. The 
purpose of the mission was to review the Government’s 
experience in implementing those conventions through 
national legislation and national drug control policy, as 
well as to discuss with the authorities legislative  
and administrative measures and policies aimed  
at strengthening the control of narcotic drugs, 
psychotropic substances and chemicals used in their 
illicit manufacture. The issues discussed included the 
following: the latest developments in the smuggling of 
drugs, particularly cocaine, through Spain; the abuse of 
amphetamine-type stimulants and other illicit drugs; 
cannabis cultivation; action against money-laundering; 
recent changes in precursor control legislation; the licit 
production of opiate raw materials; and demand 
reduction policies. In addition, meetings were held on 
the National Plan on Drugs with a representative of the 
Government of Spain, as well as other senior officials 
from ministries or other Government entities involved 
in the fight against drug abuse and trafficking. 
 
  Sudan  
 
194. A mission of the Board visited the Sudan in 
June 2009. The Sudan has been a party to the 
international drug control treaties since 1993. The 
Board notes that the Government’s ability to 
adequately meet its obligations under the treaties has 
been affected by the ongoing conflict in that country. 
The Government has established a number of bodies 
and institutions to deal with drug control, and  
it has recently indicated its commitment to  
fighting the drug problem. However, the Government 
requires comprehensive drug control legislation,  
well-functioning drug control bodies and adequately 
trained personnel to fulfil that commitment.  
195. The Board urges the Government of the Sudan to 
take appropriate measures to make its drug control 
efforts more effective. The Board also urges the 
Government to take measures that would ensure the 
availability of internationally controlled substances for 
medical purposes for the peoples of Southern Sudan 
while complying with the provisions of the 
international drug control treaties relating to 
international trade. Any measures adopted in that 
regard should also take due account of the work being 
done by humanitarian organizations involved in the 
field of health. 
 
  Syrian Arab Republic 
 
196. In February 2009, the Board sent a mission to the 
Syrian Arab Republic to review the drug control 
situation in that country. The mission discussed with 
the Government such issues as drug trafficking and the 
emerging problem of the diversion of precursor 
chemicals, as well as measures taken by the 
Government to resolve those issues. The Board notes 
that counterfeit Captagon tablets continue to be seized 
in the country. Recent evidence indicates that 
traffickers have targeted the Syrian Arab Republic as 
part of their efforts to find new sources of chemicals 
used in the illicit manufacture of amphetamine-type 
stimulants and heroin. The Board has identified 
shortcomings in the established national control system 
and has noted the limited awareness among the 
competent national authorities of emerging trends in 
precursor trafficking. The Board urges the Government 
to further strengthen precursor control mechanisms and 
to take measures to enhance the exchange of 
information among regulatory and law enforcement 
authorities responsible for precursor control. 
197. The Board notes the commitment of the 
Government of the Syrian Arab Republic to the aims of 
the international drug control treaties and the 
Government’s efforts to prevent drug abuse. The Board 
notes that, although drug abuse does not appear to be 
significant in the country, no recent epidemiological 
studies of the drug abuse situation in the country have 
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been carried out and that information on the extent of 
drug abuse in the country is limited. The Board notes 
that, in the Syrian Arab Republic, the treatment for 
drug addiction provided in specialized facilities does 
not include a system of rehabilitation and social 
reintegration. The Board encourages the Government 
to establish a system for the collection, analysis and 
reporting of information on drug abuse and to develop 
a comprehensive system for the treatment of drug 
addicts. 
 
 4. Evaluation of the implementation by 
Governments of recommendations made by the 
Board following its country missions 
 
198. As part of its ongoing dialogue with 
Governments, the Board also conducts, on a yearly 
basis, an evaluation of Governments’ implementation 
of the Board’s recommendations pursuant to its country 
missions. 
199. In 2009, the Board invited the Governments of 
the following seven countries, to which it had sent 
missions in 2006, to provide information on progress 
made in the implementation of its recommendations: 
Argentina, Brazil, Democratic People’s Republic of 
Korea, Gambia, Latvia, Luxembourg and Myanmar. 
200. The Board wishes to express appreciation to the 
Governments of the Democratic People’s Republic of 
Korea, Latvia and Luxembourg for their timely 
submission of the information, which facilitated the 
Board’s assessment of the drug control situation in 
those countries and the Governments’ compliance with 
the international drug control treaties. Information 
provided by the Governments of Argentina, Brazil and 
Myanmar was received too late to be included in the 
present report and will therefore be reported on in the 
report of the Board for 2010. 
201. The Board regrets that no information was 
received from the Government of the Gambia. The 
Board requests that Government to provide the 
requested information without further delay. 
 
  Democratic People’s Republic of Korea 
 
202. The Government of the Democratic People’s 
Republic of Korea has acted upon the 
recommendations of the Board made following the 
mission to that country in June 2006 and some progress 
has been made in a number of areas of drug control in 
recent years. Most notably, the Democratic People’s 
Republic of Korea has acceded to the international 
drug control treaties and has strengthened its 
cooperation with the Board.  
203. The Board notes that, in March 2008, in an effort 
to comply with its reporting obligations under the 
international drug control treaties, the Government of 
the Democratic People’s Republic of Korea set up a 
monitoring system for the collection of statistical data 
on the production, consumption, import and export of 
internationally controlled substances. Model forms 
were developed and distributed for use by relevant 
authorities at the national, provincial and municipal 
levels. Such a system has enabled the Government to 
monitor the licit movement of controlled substances 
and prevent their diversion.  
204. The Government of the Democratic People’s 
Republic of Korea has continued developing its 
legislative and administrative framework for drug 
control by adopting rules and regulations for the 
implementation of national drug control legislation. 
Plans have been made to revise some articles of the 
current drug law with a view to bringing them more in 
line with the provisions of the international drug 
control treaties. In April 2007, the Government 
conducted the first national survey of drug abuse, and 
the results suggested that drug abuse was not a problem 
in the country.  
205. While acknowledging the significant progress the 
Government of the Democratic People’s Republic of 
Korea has made in complying with its obligations 
under the international drug control treaties, the Board 
wishes to underline the significant challenges in drug 
control in East and South-East Asia and the need for 
the Government to develop a national drug control 
strategy focusing on prevention and capacity-building.  
 
  Latvia 
 
206. Efforts have been made by the Government of 
Latvia to implement the Board’s recommendations 
following the 2006 mission of the Board to that 
country. In particular, the Board notes that the Latvian 
authorities have made considerable effort to address 
drug-related corruption. The Board welcomes the 
political will and commitment of the Government to 
fight drug abuse and trafficking and its readiness to 
cooperate with the Board.  
 E/INCB/2009/1
 
 39 
 
207. The Board notes that, pursuant to its 
recommendations, the Government of Latvia allocated 
additional resources to the implementation of national 
drug control measures. Within the framework of the 
national programme for combating drug abuse for the 
period 2005-2008, new drug detection equipment was 
purchased for use by the state police in operational 
activities. Similar measures were taken to address the 
problem of drug trafficking and drug abuse in prisons. 
208. Since 2006, the Government of Latvia has 
increased its capacity-building efforts among law 
enforcement authorities and has provided training for 
police officers, border guards and customs officers to 
improve their professional skills. Training has also 
been provided to law enforcement authorities and 
forensic laboratory staff organized in cooperation with 
the Drug Enforcement Administration (DEA) of the 
United States, the European Police College (CEPOL) 
and others. 
209. The Government of Latvia has acted on the 
Board’s recommendations regarding systematic 
collection and regular analysis of data on drug abuse. 
Data on drug abusers are analysed by the authorities 
responsible for the registration and treatment of drug 
addiction, and the results are made available to the 
general public through annual reports. The Board notes 
that the national commission for coordinating drug 
control and fighting drug addiction has indicated its 
plan to conduct an evaluation of the implementation of 
drug demand reduction policies and strategies; the 
results will be used to formulate a national drug abuse 
prevention programme. The Board welcomes such 
initiatives and encourages the Government to continue 
expanding its activities in that area. 
 
  Luxembourg  
 
210. Following its 2006 mission to Luxembourg, when 
members of the Board visited a so-called “drug 
consumption room”, the Board, in a letter to the 
Government, reiterated its view that such facilities 
violated the international drug control treaties, 
particularly the 1961 Convention, and recommended 
that the Government take immediate measures to 
terminate the operation of that facility.  
211. The Board notes with concern, however, that the 
policy of the Government of Luxembourg in that area 
has not changed and that a room for the 
“consumption”, including by injection, of drugs 
acquired on the illicit market, continues to be in 
operation in the country. The Board urges the 
Government to provide adequate services to those in 
need of treatment, rehabilitation and social integration, 
in conformity with the provisions of the international 
drug control treaties.  
212. The Board notes that there appears to be a lack of 
progress in the implementation of its recommendations 
on the prevention of diversion of methadone prescribed 
as part of substitution treatment for heroin addiction in 
Luxembourg. The Board calls upon the Government to 
take effective measures to ensure that progress is made 
in addressing that situation, bearing in mind the aims 
of the international drug control treaties and 
Luxembourg’s obligations under those treaties.  
 
 
 E. Measures to ensure the implementation 
of the international drug control 
treaties 
 
 
 1. Action of the Board taken pursuant to article 14 
of the 1961 Convention and article 19 of the 
1971 Convention 
 
213. Article 14 of the 1961 Convention (and that 
Convention as amended by the 1972 Protocol) and 
article 19 of the 1971 Convention set out measures that 
the Board may take to ensure the execution of the 
provisions of those conventions. Such measures, which 
consist of increasingly severe steps, are taken into 
consideration when the Board has reason to believe 
that the aims of the conventions are being seriously 
endangered by the failure of a State to carry out the 
provisions of those conventions.  
214. The Board has invoked article 14 of the 
1961 Convention and/or article 19 of the 
1971 Convention with respect to a limited number of 
States. The Board’s objective has been to encourage 
compliance with those conventions when other means 
failed. The States concerned are not named until the 
Board decides to bring the situation to the attention of 
the parties, the Economic and Social Council and the 
Commission on Narcotic Drugs (as in the case of 
Afghanistan). Following continuous dialogue with the 
Board pursuant to articles 14 and 19, most of the States 
concerned have taken remedial measures, resulting in 
the Board’s decision to terminate action taken under 
those articles vis-à-vis those States. 
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215. During the reporting period, the Board, while 
reviewing the status of overall treaty compliance, 
decided to terminate action taken pursuant to article 14 
of the 1961 Convention as amended by the 
1972 Protocol and article 19 of the 1971 Convention 
vis-à-vis one State, in view of substantial progress 
made by that State pursuant to those articles. The 
Board expects that continued efforts will be made by 
that State to ensure further progress in its compliance 
with the international drug control treaties.  
216. Afghanistan is currently the only State for which 
action is being taken pursuant to article 14 of the 
1961 Convention as amended by the 1972 Protocol.  
 
 2. Consultation with the Government of 
Afghanistan pursuant to article 14 of the 
1961 Convention 
 
217. The year 2009 witnessed continued strong 
political support for Afghanistan, as demonstrated by 
the International Conference on Afghanistan: a 
Comprehensive Strategy in a Regional Context, held in 
The Hague on 31 March. The Conference called for 
greater efforts and clearer direction in addressing the 
challenges of Afghanistan, reaffirming the priorities 
agreed at the International Conference in Support of 
Afghanistan, held in Paris on 12 June 2008.  
218. The Board notes that encouraging progress has 
been made following the Paris Conference in some of 
the priority areas, the Joint Coordination and 
Monitoring Board having made important decisions on 
a new national agricultural strategy, police reform and 
private-sector development. In particular, the new 
comprehensive agricultural and rural development 
facility, aimed at reducing opium poppy production by 
increasing incentives for licit crop cultivation, has been 
given priority in the new national agricultural strategy.  
219. The Board welcomes the above-mentioned 
positive developments in areas essential for 
Afghanistan’s long-term economic growth and 
sustainable progress in the elimination of illicit opium 
poppy cultivation in the country. The world drug 
problem undermines sustainable development, political 
stability, democratic institutions and poverty 
eradication efforts and threatens national security and 
rule of law. The problem can only be addressed 
effectively if the drug control situation in Afghanistan 
is resolved.  
220. Since 2000, the Board, in discharging its mandate 
under the international drug control treaties, has 
regularly evaluated the drug control situation in 
Afghanistan and progress made by the Government in 
complying with the provisions of the treaties, in the 
light of the action taken by the Board vis-à-vis 
Afghanistan under article 14 of the 1961 Convention as 
amended by the 1972 Protocol. In addressing the drug 
control situation in the country, significant challenges 
remain; a lot needs to be done by the Government.  
221. The Board notes that in 2009 some progress was 
made by the Government of Afghanistan in the 
elimination of illicit opium poppy cultivation. 
According to the 2009 Opium Poppy Survey conducted 
in Afghanistan by UNODC, between 2008 and 2009, 
the total area under illicit opium poppy cultivation in 
the country decreased by 22 per cent, to 123,000 ha; 
potential opium production decreased by 10 per cent, 
to 6,900 tons; and the number of provinces free of 
opium poppy increased to 20. In Helmand province, 
illicit opium poppy cultivation declined by a third in 
2009, contributing significantly to the decrease in such 
cultivation in the country as a whole. 
222. Efforts were also noted in the provision of 
alternative livelihood and agricultural development 
assistance at the national and international levels. The 
Government of Afghanistan adopted the alternative 
livelihood implementation plan in 2005 and put in 
place the Good Performance Initiatives system in 2006, 
providing development assistance awards to governors 
exhibiting the political will to substantially reduce or 
eliminate opium poppy cultivation in their provinces. 
Renewed alternative livelihood programmes are being 
developed to deliver targeted, agricultural and 
development assistance in the southern provinces, 
focusing on controlling the problem where most of the 
opium poppy is grown.  
223. The Board notes the encouraging results achieved 
in recent years in strengthening the Government’s 
capacity in the area of law enforcement. Ongoing 
training, mentoring and funding provided by the 
international community have led to increases in the 
quantity of drugs seized. In 2008, the Afghan law 
enforcement authorities seized 324 tons of drugs and 
95 tons of precursors, compared with 35 tons of drugs 
and 43 tons of precursors in 2006. In addition, in the 
first half of 2009, 27 clandestine drug manufacturing 
laboratories were destroyed in operations involving the 
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Afghan National Army and forces of the North Atlantic 
Treaty Organization. 
224. The Board remains concerned, however, that the 
drug control situation in Afghanistan has not improved 
significantly, despite the efforts of the international 
community and the Government in the past few years. 
The level of illicit opium poppy cultivation continues 
to be high, with 99 per cent of the cultivation 
concentrated in seven provinces in the southern and 
western parts of Afghanistan. Although in some parts 
of the country, the area under illicit opium poppy 
cultivation has been reduced, little progress has been 
made in preventing the re-emergence of such 
cultivation. In addition, Afghanistan has become a 
significant manufacturer of heroin and other opiates, as 
well as a major source of cannabis. Afghanistan has 
also one of the highest rates for the abuse of opiates in 
the world: an estimated 1.4 per cent of its population 
abuse opiates.  
225. Among other long-term challenges in Afghanistan 
is the continued high level of corruption, involving 
high-ranking Government officials, police commanders 
and governors, an immense obstacle to efforts to 
address the drug problem. In many areas, markets for 
opium are under the control of local warlords who also 
engage in other criminal activity. The Board reiterates 
that, unless the Government of Afghanistan takes 
serious and firm measures to address the problem of 
corruption, the Government’s efforts in drug control 
will be undermined, further hindering political 
progress, economic growth and social development in 
the country.  
226. The Board notes that Afghanistan remains one of 
the two States worldwide that have yet to accede to the 
1972 Protocol amending the 1961 Convention, an issue 
that the Board has discussed with the Government on 
many occasions over the past few years. Although the 
Council of Ministers of Afghanistan endorsed the 
1972 Protocol and the process of accession commenced 
some years ago, no further progress appears to have 
been made. The Board urges the Government to take 
the necessary steps to enable Afghanistan to accede to 
the 1972 Protocol as soon as possible. 
227. Despite the fact that training has been provided to 
competent national authorities, Afghanistan has 
continued to fail to comply with its reporting 
obligations under the international drug control 
treaties. Submission by the Government of statistical 
data on narcotic drugs, psychotropic substances and 
precursors remains sporadic, an indication of the lack 
of adequate control mechanisms at the national level to 
prevent the diversion of internationally controlled 
substances from licit channels to the illicit market. In 
particular, the Government has, for eight consecutive 
years, failed to submit information on seizures of 
precursors as required under article 12, paragraph 12, 
of the 1988 Convention. The Board recommends that 
UNODC continue providing needed assistance with a 
view to increasing the Government’s overall capacity 
to implement the international drug control treaties. 
228. The Board, while noting positive developments in 
drug control in Afghanistan, urges the Government to 
pursue its National Drug Control Strategy in order to 
ensure that further progress is made in various areas of 
drug control. In particular, the Government, bearing in 
mind its obligations under the international drug 
control treaties, should endeavour to achieve a 
substantial and permanent reduction in opium poppy 
and cannabis cultivation and in opium and cannabis 
production, trafficking and abuse in the country. The 
Board calls upon the international community to 
continue providing assistance to the Government in 
fighting drug abuse and trafficking. 
 
 
 F. Special topics 
 
 
 1. Abuse of prescription drugs containing 
controlled substances 
 
229. Under the international drug control treaties, 
States have the obligation to prevent trafficking in and 
abuse of narcotic drugs and psychotropic substances. 
That obligation also refers to pharmaceutical 
preparations containing controlled substances. For 
most of those products, prescriptions are mandatory 
according to the relevant treaties and national 
legislation in effect in individual countries.  
230. In many countries, the illicit supply of 
prescription drugs containing narcotic drugs or 
psychotropic substances, through what used to be the 
main channels, such as diversion from international 
trade, has been significantly reduced. Attempts at 
diversion from international trade have been impeded 
by Governments in cooperation with the Board. 
However, the Board has noted that, in some countries, 
the diversion of such prescription drugs from domestic 
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distribution channels has increased. In addition, new 
channels of trafficking have been opened, such as 
illegally operating Internet pharmacies and the use of 
the mail for smuggling. 
231. As the Board mentioned in its report for 2006,32 
the diversion of pharmaceutical preparations from 
domestic distribution channels continues to be 
underreported. Despite the fact that the abuse of 
prescription drugs is a fast-growing global problem, it 
continues to be difficult to obtain comprehensive data 
on the actual level of abuse of such drugs, as 
systematic data collection is lacking in most countries. 
The information available on the abuse of prescription 
drugs is mostly limited to anecdotal evidence or to data 
collected for one or two specific substances (such as 
morphine or methadone). 
232. In 2009, the abuse of prescription drugs came to 
the attention of the general public as a result of 
reporting on cases involving the deaths of prominent 
entertainers. However, there is still significant lack of 
awareness among the general public and the media 
about the nature of the problem. Very often the abuse 
of prescription drugs is characterized as the misuse of 
pharmaceutical preparations, which have been 
inappropriately used to treat pain, depression, insomnia 
and anxiety. The abuse potential of prescription drugs 
containing narcotic drugs or psychotropic substances, 
which leads to their use as recreational drugs or to 
addiction, is often overlooked. That problem, in 
addition to their wide availability, contributes to the 
increase in the abuse of those controlled substances. 
233. Information reported by countries to the 
Secretary-General in the annual reports questionnaire 
shows that almost all countries are confronted with 
trafficking in and abuse of prescription drugs. Most 
countries do not systematically collect data on the 
abuse of and/or trafficking in pharmaceutical 
preparations containing controlled substances. For 
countries where the abuse of prescription drugs is 
systematically monitored in surveys of the general 
population or specific population groups, the data 
indicate that such abuse is widespread and in many 
cases a major problem. 
__________________ 
 32  Report of the International Narcotics Control Board for 
2006 (United Nations publication, Sales 
No. E.07.XI.11), paras. 54-58. 
234. In many countries, prescription drugs are the 
second or third most abused category of drugs. The 
most often mentioned prescription opioids are 
buprenorphine and methadone. Other opioids 
specifically mentioned are morphine, codeine and 
pethidine, while several Governments have reported 
abuse of drugs in the category “Other opioids”. The 
category reported in practically every country as being 
abused are sedatives and tranquillizers, the substances 
most often mentioned being the benzodiazepines such 
as alprazolam, clonazepam, diazepam, flunitrazepam 
and lorazepam. 
235. The abuse of benzodiazepines, alone or in 
combination with alcohol and/or illicitly manufactured 
drugs such as cocaine, heroin or MDMA (“ecstasy”), is 
a problem the extent of which remains largely 
unrecognized in most countries. In the annual reports 
questionnaire, many Governments have indicated that, 
in their country, persons received treatment for the 
abuse of benzodiazepines or undefined sedative-type 
substances and that the abuse of benzodiazepines was 
rising, although reliable data were not available.  
236. In some countries, the collection of data on the 
abuse of prescription drugs is more systematic and, 
therefore, more precise information is available. For 
example, according to the 2008 National Survey on 
Drug Use and Health, 6.2 million persons in the United 
States abuse prescription drugs, more than the total 
number of persons who abuse cocaine, heroin, 
hallucinogens, MDMA and inhalants. A similar 
situation has been reported in Canada. Data for 2005 
indicate that most of the users of street drugs in almost 
all of the main cities in Canada (the exceptions being 
Vancouver and Montreal) are non-medical users of 
prescription opioids. It has been estimated that 1-3 per 
cent of the national population of Canada abuse 
prescription opioids. In Germany, an estimated 
1.4 million-1.9 million persons are addicted to 
pharmaceutical preparations. German authorities have 
started a programme for monitoring the abuse of 
pharmaceutical preparations among clients in centres 
for the treatment of drug addiction. In France, where a 
system for the countrywide evaluation of dependence 
on pharmaceutical preparations has been operating for 
many years, the abuse of pharmaceutical preparations, 
particularly those containing benzodiazepines, 
buprenorphine and methadone, have been reported. 
Similar reports have been received from the 
Governments of several Scandinavian countries. 
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237. One particular concern is the rise in the misuse of 
prescription drugs among youth in recent years. In the 
United States, for example, opioid pain relievers are 
abused primarily by young adults (persons 18-25 years 
old) and adolescents (persons 12-17 years old). Data 
collected for the 2007 report of the European School 
Survey Project on Alcohol and Other Drugs (ESPAD) 
indicate that, in several countries in Europe, about 
15 per cent of the total student population uses 
sedatives or tranquillizers without a prescription. 
238. In countries in which prescription drug abuse is 
systematically monitored, prescription drugs have been 
identified as one of the main drugs involved in 
overdose deaths. In the United States, for example, the 
Florida Medical Examiners’ Commission has reported 
that the abuse of prescription drugs containing an 
internationally controlled substance (hydrocodone, 
oxycodone or methadone) was the cause of death of 
2,184 individuals in 2008. In the United Kingdom, 
methadone was the principal drug implicated in 27 per 
cent of drug-related deaths among persons 16-24 years 
old in 2008. 
239. The most frequently mentioned methods used for 
the diversion of pharmaceutical preparations 
containing controlled substances are forged 
prescriptions, sold prescriptions, theft (from 
pharmacies, hospitals and doctors’ offices) and 
“doctor-shopping”. In recent years, however, organized 
criminal groups have recognized the potential demand 
for trafficked prescription drugs and have added 
diverted prescription drugs to their drug supplies. 
Illegally operating Internet pharmacies play a major 
role in the increasing illicit market for prescription 
drugs. 
240. The Board is of the opinion that competent 
national authorities need to give increased attention to 
the problem of prescription drug abuse when 
formulating public health policies. The Board calls 
upon Governments to consider introducing the 
following measures to counteract the growing problem 
of abuse of prescription drugs containing 
internationally controlled substances. Governments 
should include, as far as possible, prescription drug 
abuse in their national surveys on drug abuse in order 
to obtain information on the extent of drug abuse and 
the types of drugs abused, which would allow them to 
introduce the most appropriate drug control strategies. 
It is equally important for law enforcement authorities 
to regularly report seizures of pharmaceutical 
preparations to drug control authorities, in addition to 
reporting to the relevant international organizations 
seizures of pharmaceutical products containing 
internationally controlled substances. 
241. The Board encourages Governments to introduce 
or expand programmes for monitoring prescription 
drugs. Furthermore, in order to reduce improper 
prescribing practices, Governments should consider 
enhancing programmes to promote rational use of 
prescription drugs. The Board suggests programmes 
should be launched to make national and international 
law enforcement authorities aware that prescription 
drug abuse is a drug control problem comparable to the 
abuse of illicit drugs. When unlawful action by 
individual medical or pharmaceutical professionals has 
been identified, appropriate sanctions need to be 
applied. The Board wishes to remind Governments that 
the sale of internationally controlled substances by 
Internet pharmacies should be either prohibited or 
closely controlled (see paragraph 269-272 below). 
Governments should be aware that changes in drug 
abuse patterns may require adjustments in programmes 
for the treatment of drug addiction. If the controlled 
substance that is abused is contained in a prescription 
drug, adequate treatment options will need to be 
identified and implemented. 
 
 2. Herbal mixtures containing synthetic 
cannabinoids 
 
242. Herbal mixtures under the name “Spice” have 
recently been the focus of attention of health 
authorities and drug regulators in many countries. 
Although advertised as plant mixtures that are not for 
human consumption, Spice products are smoked and 
have been reported to induce in users psychoactive 
effects similar to those produced by cannabis. The 
identification of small amounts of synthetic 
cannabinoids in those herbal mixtures has raised 
concern about their abuse liability and their potential 
health effects. 
243. To receive more information on abuse of Spice 
products, the Board sent a letter to Governments of 
selected countries in all regions to request information 
regarding the prevalence of the use of Spice products, 
the profile of Spice product users, health problems 
arising from the use of Spice products and the abuse 
liability of their constituents. The Board has reviewed 
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the information provided by Governments, as well as 
reports on Spice products by bodies monitoring 
substance abuse, such as the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA). 
244. Spice products are purchased primarily via the 
Internet and are also available from shops in a few 
large cities. Spice products are advertised as mixtures 
of several plant species, but there are reports that the 
plant materials listed as ingredients may not be present 
in some Spice products. Forensic investigations carried 
out in several European countries and the United States 
to determine the psychoactive components of Spice 
products have revealed the presence of several 
synthetic cannabinoids, namely JWH-018, CP 47,497 
and its homologues and HU-210 — all substances not 
under international control. Those synthetic 
cannabinoids were not present in all Spice products or 
batches of the same product. Although Spice products 
can be purchased in many countries, it is not currently 
known where they are manufactured. 
245. Information about the psychoactive effects of 
using Spice products has been obtained primarily from 
anecdotal reports on Internet forums, where users of 
Spice products mentioned experiencing a “high” 
similar to that induced by cannabis. The synthetic 
cannabinoids detected in Spice products were 
originally produced for research on the endogenous 
cannabinoid receptors and have not been developed as 
pharmaceutical products; consequently, little is known 
about their toxicological effects in humans. However, 
although information from studies on the effects of 
those synthetic cannabinoids on humans is lacking, 
studies of their effects on animals in vitro studies 
suggest that the substances may be even more potent 
than cannabis. That raises concerns about the potential 
health risks associated with the use of those synthetic 
cannabinoids and with the consumption of unknown 
quantities of such substances surreptitiously introduced 
in herbal mixtures such as the Spice products. 
246. The Board notes that health concerns have 
prompted the authorities of several countries to adopt 
measures to regulate the use of and trade in some 
synthetic cannabinoids and products that contain them. 
In several countries, including Austria, France, 
Germany, Luxembourg and Poland, some or all of the 
synthetic cannabinoids most commonly detected in 
Spice products (JWH-018, CP 47,497 and its three 
homologues and HU-210) were added to the national 
list of controlled substances. In the United States, 
HU-210 was already under control as a structural 
analogue of THC.  
247. In addition to the synthetic cannabinoids 
identified in Spice products, numerous other synthetic 
substances are known to act as agonists of the 
endocannabinoid receptors and potentially have effects 
similar to cannabis. The chemical structure of many of 
those synthetic cannabinoids is different from that of 
THC; thus, the substances cannot be detected using 
conventional drug-screening methods. Non-controlled 
synthetic cannabinoids could appear on the market to 
circumvent existing drug control regulations. To 
address that problem, the Advisory Council on the 
Misuse of Drugs has recommended the Government of 
the United Kingdom to adopt legislation that targets 
groups of structurally related cannabinoids rather than 
specific cannabinoids. Similarly, in Luxembourg, all 
synthetic agonists of cannabinoid receptors have been 
added to the list of psychotropic substances under 
control. 
248. The Board urges Governments to closely monitor 
new developments with regard to the abuse of 
synthetic cannabinoids, which are often marketed as 
innocuous products such as herbal incense in order to 
escape detection by drug control authorities. By 
monitoring user forums on the Internet and online 
shops, Governments could be alerted to the abuse of 
products that may contain synthetic cannabinoids as 
soon as they appear on the market. In addition, 
investigations should be made to determine the 
location of the manufacturers of Spice products and, in 
particular, the source of the synthetic cannabinoids 
used in such products. The Board invites all 
Governments to provide to the Board and to WHO all 
information available regarding the abuse in their 
countries of herbal mixtures such as Spice products 
and the synthetic cannabinoids contained therein. 
 
 3. Control of ketamine 
 
249. During the past several years, the Board has taken 
note with concern of reports on the abuse of and 
trafficking in ketamine, a substance currently not under 
international control. Through its annual reports, the 
Board has repeatedly drawn the attention of 
Governments to the problems of the widespread abuse 
of ketamine, particularly among youth, in East and 
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South-East Asia and of trafficking in ketamine in that 
region and in other regions, including in the Americas.  
250. According to the International Criminal Police 
Organization (INTERPOL), trafficking in and abuse of 
ketamine constitute an emerging area of concern. The 
abuse of ketamine is increasing in countries in Europe, 
particularly Spain and the United Kingdom. 
Trafficking in ketamine is attractive to organized 
criminal groups because of its high profitability: 
hundreds of kilograms of the substance are seized 
every year in Europe and other regions. 
251. In March 2006, ketamine was the subject of 
critical review by the WHO Expert Committee on Drug 
Dependence. At that time, however, the Committee 
concluded that the information presented to it on 
ketamine was not sufficient to warrant the international 
scheduling of that substance. 
252. In the light of those developments, the Commission 
on Narcotic Drugs adopted resolution 49/6, entitled 
“Listing of ketamine as a controlled substance”, in 
order to enable Governments to take appropriate 
measures against the diversion and abuse of ketamine. 
In that resolution, the Commission called upon 
Member States to consider controlling the use of 
ketamine by placing it on the list of substances 
controlled under their national legislation, where the 
domestic situation so required. 
253. In its report for 2006,33 the Board welcomed the 
adoption of resolution 49/6 by the Commission on 
Narcotic Drugs and called upon all Governments to 
implement that resolution without delay. In particular, 
the Board encouraged all Governments concerned to 
take steps to determine the size of the population 
abusing ketamine and, wherever warranted, to place 
ketamine under their national legislation. Furthermore, 
the Board urged all Governments to provide to WHO, 
and to the Board, all available information on the abuse 
of ketamine in their countries, in order to assist the 
WHO Expert Committee on Drug Dependence in its 
efforts to assess ketamine for possible scheduling 
under the 1971 Convention.  
254. In March 2007, the Commission on Narcotic 
Drugs adopted resolution 50/3, in which it encouraged 
Member States to consider adopting a system of 
__________________ 
 33  Report of the International Narcotics Control Board for 
2006 …, para. 202. 
precautionary measures for use by their Government 
agencies to facilitate the timely detection of the 
diversion of ketamine. 
255. In August 2008, the Board sent out a 
questionnaire to all Governments requesting them to 
provide it with information on the specific legal or 
administrative measures adopted pursuant to 
Commission on Narcotic Drugs resolution 49/6, 
including information on measures to control ketamine 
and on ketamine imports, exports, seizures, abuse and 
trafficking.  
256. As at 1 November 2009, the Board had received 
the requested information from 87 countries and 
7 territories. A total of 48 Governments reported that 
ketamine had already been placed on the list of 
substances controlled under national legislation, 
pursuant to Commission on Narcotic Drugs 
resolution 49/6, and 43 Governments reported that 
legal provisions or administrative measures had been 
adopted to implement that resolution. Of the countries 
and territories that had not yet placed ketamine under 
control, 12 reported that their domestic situation would 
require doing so, mainly because of the extent of abuse 
of the substance. 
257. With regard to the control of licit international 
trade in ketamine, 50 of the countries responding to the 
questionnaire had introduced the requirement of import 
and export authorization for imports and exports of 
ketamine, and one country was in the process of doing 
so; two other countries had introduced the requirement 
of import authorizations only. The vast majority (67) of 
the responding countries and territories were in a 
position to provide precise information on total 
manufacture, imports and exports of ketamine per year. 
A total of 31 countries and territories provided details 
on the abuse of and illicit trafficking in ketamine, 
including information on seizures of ketamine. While 
most countries reported many seizures involving small 
quantities of ketamine, some, including China, 
Germany, Malaysia, Philippines and Thailand, reported 
having seized large quantities of the substance. 
258. The Board has continued to communicate to 
WHO, on a regular basis, the information received 
from Governments, for use in the critical review of 
ketamine by WHO, in its efforts to assess ketamine for 
possible inclusion in one of the schedules of the 
international drug control conventions. The Board calls 
upon all Governments to continue to furnish it and 
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WHO with all relevant information on trafficking in 
and abuse of ketamine in their countries.  
259. The Board has started to publish, on a secure 
page of its website, information on the national 
requirements already in place in individual countries 
for authorizing the import and export of ketamine.  
 
 4. Use of pharmaceutical products to facilitate 
sexual assault and other crimes 
 
260. The Board welcomes the adoption by the 
Commission on Narcotic Drugs of resolution 52/8, in 
which the Commission urged Member States to adopt 
measures to address the emerging problem of the use 
of substances to facilitate sexual assault (“date rape”). 
The substances covered by that resolution include 
cannabis, a narcotic drug controlled under the  
1961 Convention; substances such as alprazolam, 
clonazepam, diazepam, flunitrazepam, GHB, 
lorazepam, meprobamate, midazolam, phencyclidine, 
secobarbital, temazepam, triazolam and zolpidem, 
which are controlled under the 1971 Convention; and 
alcohol, 1,4-butanediol, gamma-butyrolactone (GBL), 
chloral hydrate, ketamine and scopolamine, substances 
not under international control. In addition, in its 
resolution 52/8, the Commission urged member States 
to enhance public awareness of that problem, to 
consider imposing stricter controls or taking other 
measures aimed at discouraging the use of such 
substances for the commission of drug-facilitated 
sexual assault, including with regard to those 
substances not under international control and to share, 
through bilateral, regional and international channels, 
information on emerging trends in the use of drugs to 
commit such offences. Moreover, the Commission 
invited the concerned industries to develop 
formulations with safety features, such as dyes and 
flavourings, to alert possible victims to the 
contamination of their drinks without affecting the 
bioavailability of the active ingredients in legitimate 
drugs. 
261. The misuse of substances, regardless of whether 
they were illicitly manufactured or diverted from 
legitimate channels, for the commission of sexual 
assault or other crimes is not new. In particular, the 
benzodiazepines, many of which are controlled under 
the 1971 Convention, have a history of such misuse 
that is well documented in scientific and legal 
literature. They have been used with criminal intent to 
weaken the resistance of individuals, for example to 
exploit their property or body with their apparent 
consent, without them having the slightest recollection 
afterwards of what happened. Unwanted behaviour 
induced by the unknowing consumption of 
benzodiazepines includes revealing credit card 
information, making purchases in a number of shops 
and signing cheques or charging credit cards, giving 
away a motor vehicle (together with the key and 
vehicle registration papers) and perceiving being raped 
as a pleasurable experience. The drug doses involved 
in such criminal activities are higher than those used 
for therapeutic purposes, and food or drinks are used to 
disguise the drugs, which are often consumed in 
combination with alcohol. Such crimes may be 
committed not only in places such as bars, restaurants, 
nightclubs and airports, but also in private 
surroundings, for example, at a friend’s house. 
262. Of the benzodiazepines, flunitrazepam was once 
so commonly misused for the commitment of sexual 
assault that it was called the “date-rape drug”. 
Flunitrazepam was first included in Schedule IV of the 
1971 Convention in 1984 but was transferred to 
Schedule III of the Convention in 1995; after that, its 
diversion from international trade34 was successfully 
stopped. However, the diversion of flunitrazepam from 
domestic distribution channels continued in the 1990s. 
Concerted action by Governments of all major 
manufacturers and importers of the substance, in close 
cooperation with the pharmaceutical industry, has 
proved effective: reports of seizures of diverted 
flunitrazepam have decreased significantly since 
2004.35 The measures taken by industry to stop the 
misuse of flunitrazepam to commit sexual assault 
include: termination of the worldwide manufacture and 
distribution of high-dosage tablets; development and 
marketing of a new small dosage tablet; and inclusion 
of a dye in the core and surface of the new tablet to 
make it easily detectable in liquid and to prolong its 
dissolution time.  
263. Despite the above-mentioned successes, the 
misuse of a number of substances for the commitment 
of sexual assault and other crimes continues in many 
__________________ 
 34  Flunitrazepam was diverted mainly for abuse by heroin 
addicts. Only a small portion of the flunitrazepam 
diverted was misused to commit sexual assault. 
 35  Report of the International Narcotics Control Board for 
2005 …, paras. 37-39. 
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countries. Criminals tend to use other substances to 
facilitate the commitment of their offences, among 
them, GHB, a substance that is not yet fully under 
national control in all countries in spite of the fact that 
it was put under international control in 2001. 
Criminals also tend to use substances currently not 
under international control, such as ketamine, 
1,4-butanediol and GBL, since they are easily available 
in legitimate channels. Drug traffickers obtain the 
substances in question through Internet pharmacies and 
the mail system, or from illicit manufacture. 
264. The Board urges all Governments to implement 
Commission on Narcotic Drugs resolution 52/8 as soon 
as possible to address the emerging trend of using a 
variety of substances to facilitate the commission of 
criminal offences. Most importantly, the Board 
encourages Governments to make the general public 
(and, where appropriate, vulnerable segments of the 
population in their territories) aware of the fact that 
food or drink left unattended might be contaminated 
with certain substances to facilitate the commission of 
other crimes, such as sexual assault. 
265. Governments should alert law enforcement 
agencies and the judiciary to such practices, to enable 
them to take appropriate countermeasures, wherever 
possible under the national legislation. In many 
countries, the use of substances to facilitate the 
commission of crime does not constitute a criminal 
offence and therefore cannot be properly sanctioned. 
The Board encourages all Governments that are 
already affected by the misuse of substances for such 
purposes to take all steps necessary to adopt or amend 
national legislation as soon as possible to deal with that 
problem.  
266. The Board wishes to remind all Governments of 
the need to ensure that all control measures required 
under the international drug control treaties, such as 
the requirement of prescriptions and the system of 
inspection of operators, are strictly applied to the 
substances under international control in order to 
prevent those substances from being used with criminal 
intent. The Board encourages Governments to consider, 
pursuant to Commission on Narcotic Drugs 
resolution 52/8, imposing stricter controls than those 
currently foreseen under the international drug control 
treaties, where necessary, to prevent the diversion of 
substances from domestic distribution channels for the 
purpose of committing a crime. As an example, since 
ketamine is one of the substances most often used for 
the commission of crime, Governments should 
consider controlling ketamine by placing it on the list 
of substances controlled under their national legislation 
if the situation in their territories so requires. 
267. The cooperation of industry has been extremely 
important in limiting the misuse of licitly 
manufactured flunitrazepam as a “date-rape drug”. The 
Board calls on the pharmaceutical industry and the 
chemical industry to assist in addressing the emerging 
misuse of other substances with the intent of 
committing a crime and to consider appropriate 
countermeasures. The Board encourages Governments 
to ensure that all manufacturing and trading companies 
in their territories that trade in the above-mentioned 
substances are made aware that those substances might 
be used to facilitate the commission of crimes. The 
Board also encourages Governments to solicit the 
support of the companies in question in dealing with 
that problem.  
268. There is no systematic way of collecting 
information on such offences at the national and 
international levels, as those offences are often not 
dealt with in national legislation and such activities are 
often not covered in drug abuse surveys. The extent of 
the problem is therefore not known. The Board calls on 
all Governments to share with other Governments and 
international bodies, including the Board, any 
information they might have on new trends in the 
misuse of substances to commit sexual assault or other 
offences, as the international community needs to have 
a more thorough understanding of the extent of the 
problem so that it may decide whether any additional 
measures should be taken to prevent such misuse. 
 
 5. Illegal Internet pharmacies 
 
269. The Guidelines for Governments on Preventing 
the Illegal Sale of Internationally Controlled 
Substances through the Internet,36 developed by the 
Board, were launched in March 2009, during the fifty-
second session of the Commission on Narcotic Drugs. 
The Guidelines were then sent to the competent 
authorities of all countries. The Board hopes that the 
Guidelines will help each Government to identify the 
control measures most appropriate for its country. 
Some of the recommendations will need to be 
__________________ 
 36  United Nations publication, Sales No. E.09.XI.6. 
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implemented by all Governments, particularly those 
recommendations relating to the provisions of the three 
international drug control treaties. Furthermore, in 
order to ensure concerted action at the international 
level, basic requirements on information exchange and 
cooperation should be met by all States. The Board 
calls upon all Governments to implement the 
recommendations contained in the Guidelines without 
delay and to the fullest extent possible. Using a 
questionnaire to be distributed to all Governments in 
2010, the Board will assess the progress achieved in 
implementing the Guidelines. 
270. Pursuant to Commission on Narcotic Drugs 
resolution 50/11, the Board distributed in  
February 2009 to all Governments a standard format to 
be used by countries for reporting on seizures of 
internationally controlled substances ordered via the 
Internet and delivered through the mail. The Board has 
received the first set of replies, containing data for 
2008, which indicate the wide geographical 
distribution of shipments of a variety of illegally sold 
pharmaceutical preparations containing controlled 
substances. The Board will continue to collect 
information on seizures and will provide in its annual 
reports a detailed analysis of the information received. 
The Board invites all Governments that have not yet 
done so to establish national mechanisms for collecting 
and reporting data to the Board as requested by the 
Commission in its resolution 50/11. 
271. The Board notes with appreciation that in some 
countries legislation has been introduced to counteract 
the illegal sale of controlled substances through 
Internet pharmacies. In the United States, the Ryan 
Haight Online Pharmacy Consumer Protection Act of 
2008 (see paragraph 411 below), which was enacted in 
October 2008, amended the Controlled Substances Act 
and Controlled Substances Import and Export Act by 
adding several new provisions to prevent the illegal 
distribution and dispensing of controlled substances by 
means of the Internet. In January 2009, Belgium 
adopted new legislation containing legal requirements 
specifically for Internet pharmacies and prohibiting the 
sale of prescription drugs through the Internet.  
272. An increasing number of illegal transborder trade 
transactions of internationally controlled substances is 
carried out by the use of modern information and 
communication technology, such as the Internet and 
international call centres. The Board calls upon 
Governments to take appropriate action to prevent such 
misuse of modern communication technology. The 
Board also requests all Governments to consider 
measures to influence those responsible for the 
management of Internet websites and other modern 
communication technologies to ensure that illegal 
activities are prevented or terminated. 
 
 6. Follow-up to Commission on Narcotic Drugs 
resolution 51/13: responding to the threat posed 
by the distribution of internationally controlled 
substances on the unregulated market 
 
273. The distribution of internationally controlled 
drugs through the unregulated market, often 
characterized by the involvement of organized criminal 
networks and increasingly facilitated by the Internet, 
has become a global problem, mostly affecting 
developing countries. The use of medicaments 
containing internationally controlled substances 
obtained on the unregulated market, regardless of 
whether they have been diverted from licit channels or 
are counterfeit drugs, may result in serious health 
problems, including dependence, or even death. 
274. The Board drew in the past the attention of the 
international community to the widespread practice of 
distributing medicaments through the unregulated 
market and recommended that concerted measures be 
taken by all Governments, the pharmaceutical  
industry, professional associations and international 
organizations, to deal with that problem.37 In 2007,  
the Commission on Narcotic Drugs adopted 
resolution 51/13 to address the problem of distributing 
internationally controlled substances through the 
unregulated market and invited relevant international 
bodies, such as WHO, INTERPOL and UNODC, to 
assist member States in their efforts to deal with that 
problem, as necessary. 
275. The cooperation of the pharmaceutical industry 
and professional associations is needed to obtain 
lasting results in reducing the distribution of 
medicaments on unregulated markets worldwide and, 
in particular, in reducing sales of counterfeit 
medicaments. The Board appreciates the efforts of the 
International Medical Products Anti-Counterfeiting 
Taskforce of WHO, together with INTERPOL, the 
__________________ 
 37  Report of the International Narcotics Control Board for 
2006 …, paras. 1-39. 
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World Customs Organization, UNODC and other 
relevant partners, including pharmaceutical 
associations, to combat problems related to the 
unregulated markets and to prevent trade in and 
distribution of counterfeit products or medicaments of 
poor quality. The Board notes with appreciation that 
UNODC conducted a threat assessment of 
transnational trafficking and the rule of law in West 
Africa, which addressed, among other issues, the 
problem of counterfeiting medicines in that subregion, 
one of the areas most affected by that problem, and that 
UNODC is continuing its efforts to formulate an 
effective response to the problem. 
276. The Board reiterates the need for all parties 
concerned to strictly apply the control measures 
foreseen under the international drug control treaties 
and enforce existing legislation to ensure that 
controlled substances are not illegally manufactured, 
imported or exported and are not diverted to the 
unregulated market. All Governments should further 
implement the recommendations on that subject 
contained in the report of the Board for 2006.38 The 
Board notes that the range of products that can be 
found on the unregulated market, including those 
containing narcotic drugs or psychotropic substances, 
has been expanding. Competent national authorities, in 
particular customs authorities, are therefore frequently 
unaware of the varieties of medicaments entering their 
countries to be distributed on the unregulated market. 
In addition, such authorities often lack the expertise 
necessary to identify consignments of counterfeit 
medicaments that may be destined for the unregulated 
market. The Board therefore encourages all 
Governments to consider providing training and 
introducing technology for use by customs authorities 
to identify counterfeit medicaments. 
 
 7. Treaty obligations applicable in the entire 
territory of a State party 
 
277. During the last few decades, the majority of 
States parties to the international drug control treaties 
have applied adequate control measures, as required 
under the treaties, to ensure that narcotic drugs and 
psychotropic substances are used only for medical and 
scientific purposes.  
__________________ 
 38  Ibid., paras. 37-39. 
278. Despite the almost universal application of the 
international drug control treaties, the Board has noted 
with concern that a number of States parties to the 
treaties have been turning to and persisting in the 
implementation of national policies that are not in line 
with the treaties. In particular, the Board has noted that 
a number of States parties have permitted the use of 
“safer crack kits”, the “medical” use of cannabis, 
“coffee shops” and the establishment and operation of 
so-called “drug injection rooms”, which contravene the 
international drug control treaties.  
279. In response to the Board’s repeated warnings that 
those measures promote social and legal tolerance of 
drug abuse and drug trafficking and run counter to the 
provisions of the international drug control treaties, 
those States parties continue to argue that their 
domestic legal systems prevent them from fully 
complying with the treaties, as their state and/or 
provincial legislative and judicial structures and 
competencies are independent and prevail over their 
national or federal legislation and jurisdiction. 
280. The Board is aware that current international law 
recognizes the various national legal traditions and 
systems. The Board also acknowledges that all States 
parties to the international drug control treaties follow 
differing legal systems and apply legal traditions in 
which, in some instances, the relationship between 
state or provincial and national or federal legislative, 
judiciary and jurisdictional issues is highly complex, 
sensitive and even controversial. 
281. In this connection, the Board wishes to stress the 
basic principles of international law enshrined in the 
provisions of articles 26 (on the obligation of parties to 
fulfil their treaty-based obligations in good faith)  
and 27 (on the primacy of international law over 
national legislation) of the Vienna Convention on the 
Law of Treaties,39 as well as the international drug 
control treaties. 
282. Moreover, the 1961 Convention and that 
Convention as amended by the 1972 Protocol sets very 
strict and unavoidable control measures for cannabis, 
limiting its use to medical and scientific purposes by 
defining it as a drug under the terms of article 1 
(Definitions) and including it in Schedule I. Besides 
those general provisions, specific obligations are set 
for parties on the control of cannabis (in article 28) and 
__________________ 
 39  United Nations, Treaty Series, vol. 1155, No. 18232. 
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penal provisions (in article 36). The 1988 Convention 
goes much further into the detailed penal provisions 
related to the illicit traffic in narcotic drugs and 
psychotropic substances (in article 3) and with a non-
derogation clause (in article 25), solves all possible 
arguments on any perceived contradiction vis-à-vis the 
other international drug control treaties. 
283. The Board recognizes the fact that certain state, 
regional and/or provincial powers, jurisdictions and 
delegated competencies are expressly granted and 
guaranteed in the constitutional frameworks of some 
States parties. Legislation and policies adopted by 
provinces or federated states are enacted in 
concordance with the constitution of the State party. 
Acceding to the international drug control treaties 
should result in States parties adopting national 
strategies and measures that ensure their full 
compliance with the treaties. Those treaty obligations 
are applicable in the entire territory of each State party, 
including its federated states and/or provinces. 
284. According to internationally accepted law and 
practice, as well as the international obligations of all 
parties to the international drug control treaties, state 
and/or provincial legislative and/or judicial measures 
and actions should be in compliance with each State’s 
policies and obligations at the international level. If a 
State, irrespective of its constitutional framework and 
legal system, enters into an international agreement by 
acceding to the international drug control treaties, that 
State must ensure that all state and/or provincial 
policies and measures do not undermine its efforts to 
combat drug abuse and trafficking in narcotic drugs, 
psychotropic substances and precursor chemicals. 
285. The Board wishes to emphasize that the structure 
of all States parties (whether federal, state, regional or 
provincial) should contain, develop and continually 
evaluate a comprehensive system of intergovernmental 
coordination procedures in order to ensure that drug 
control laws and policies are nationally consistent.  
286. The Board reiterates that article 4 of the 
1961 Convention and that Convention as amended by 
the 1972 Protocol obligates States parties to “limit 
exclusively to medical and scientific purposes the 
production, manufacture, export, import, distribution 
of, trade in, use and possession of drugs”, while 
article 35 of that Convention obliges States parties to 
“make arrangements at the national level for 
coordination of preventive and repressive action 
against the illicit traffic” in drugs.  
 
 8. Event commemorating the centennial of the 
convening of the International Opium 
Commission in Shanghai 
 
287. The International Opium Commission, the first 
multinational initiative in drug control, was convened 
in Shanghai, China, in February 1909, in response to 
the need to address the problem of opium production 
and trade. The Commission, which laid the 
groundwork for the elaboration of the first 
international drug control treaty, the International 
Opium Convention signed at The Hague on 23 January 
1912, a landmark event in the history of international 
drug control. 
288. For several years, the Board worked closely with 
the Government of China and UNODC to prepare for 
the centennial of the convening of the International 
Opium Commission. The result of the cooperation was 
the commemoration of the centennial of the 
International Opium Commission in Shanghai, China, 
in February 2009. 
289. More than 100 delegates from around the world 
participated in the commemorative event, including 
delegates from the 13 countries40 that had originally 
been represented in the International Opium 
Commission in 1909. The State Councillor and 
Minister of Public Security of China, the Mayor of 
Shanghai, the President of the Board (see annex III) 
and the Executive Director of UNODC took part in the 
opening ceremony and made statements. Also 
participating in the event were two other members of 
the Board, the Secretary of the Board and the Chief of 
the Convention Evaluation Section of the Board’s 
secretariat.  
290. In the Shanghai Declaration adopted by 
consensus at the event on 26 February 2009 
commemorating (see annex IV) the centennial of the 
convening of the International Opium Commission, the 
representatives reaffirmed their political commitment 
to a comprehensive, balanced and mutually reinforcing 
approach to supply and demand reduction, reaffirmed 
__________________ 
 40  Austria, China, France, Germany, Iran (Islamic Republic 
of), Italy, Japan, Netherlands, Portugal, Russian 
Federation, Thailand, United Kingdom and United 
States. 
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also that international drug control cooperation must be 
in full conformity with the purposes and principles of 
the Charter of the United Nations, and urged States to 
fully implement the international drug control treaties 
and fulfil other relevant international drug control 
obligations. 
 
291. The Board expresses its great appreciation to the 
Government of China for organizing and hosting this 
important event to mark the beginning of a century of 
multilateral drug control. 
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III. Analysis of the world situation 
 
 
 A. Africa 
 
 
 1. Major developments 
 
 
292. Drug trafficking in Africa has gained 
international attention in recent years. This is 
demonstrated by the fact that the Security Council has 
repeatedly discussed the issue of the smuggling of 
cocaine through countries in West Africa, notably 
Guinea-Bissau, in particular the threats posed by such 
smuggling to regional stability and the possible impact 
on international security. In July 2009, the Executive 
Director of UNODC presented to the Council a report 
on transnational trafficking and the rule of law in West 
Africa. In November 2009, the Council welcomed the 
progress in implementing the West Africa Coast 
Initiative (involving the Economic Community of West 
African States (ECOWAS), UNODC, other United 
Nations entities and INTERPOL) and urged the 
Government of Guinea-Bissau to take action within the 
framework of the ECOWAS plan of action against  
drug trafficking and organized crime. Also in 
November 2009, the Executive Director addressed the 
Security Council on the problem of drug trafficking in 
Guinea-Bissau and elsewhere in West Africa and was 
subsequently requested to provide the Council with 
updates, starting in December 2009, on progress made 
by West African States in dealing with drug-related 
organized crime. 
293. Since 2004, drug trafficking organizations have 
been increasingly using West Africa as a transit area 
for smuggling large amounts of cocaine from South 
America into Europe and, to a lesser extent, North 
America, taking advantage of the fact that certain 
problems in West African countries, such as conflict, 
lack of rule of law, corruption and poverty, have made 
those countries more vulnerable. Most of the cocaine 
transiting West Africa is transported across the Atlantic 
on large ships and then off-loaded to smaller vessels 
along the West African coast; from there, the cocaine is 
smuggled northwards by a variety of means, including 
boats, land vehicles and air couriers. While until 2007, 
the amount of cocaine seized, either on the high seas 
en route to West Africa or in the subregion itself, 
increased markedly every year, there has been a 
decline in the number of seizures of cocaine in West 
Africa since 2008. The decline in the number of 
cocaine seizures might suggest that the smuggling of 
that drug through the subregion is decreasing, as a 
result of action taken by African Governments with the 
support of the international community. Despite that 
development, the smuggling of cocaine through West 
Africa continues to be a serious problem that is 
contributing to an increase in the abuse of cocaine in 
the subregion.  
294. Africa continues to be vulnerable to the diversion 
of precursor chemicals, notably ephedrine and 
pseudoephedrine. While most of the ephedrine and 
pseudoephedrine smuggled through Africa into Central 
America and North America, for use in the illicit 
manufacture of methamphetamine, some illicit 
methamphetamine manufacture and abuse are also 
occurring in countries in Africa, in particular in South 
Africa. In the past few years, a number of  
large suspicious shipments of ephedrine and 
pseudoephedrine have been stopped on their way to 
African countries, including Botswana, the Democratic 
Republic of the Congo, Ethiopia, Nigeria, Togo, 
Uganda, the United Republic of Tanzania and Zambia. 
Since 2008, the smuggling of ephedrine and 
pseudoephedrine through Africa has markedly 
decreased, which might be attributable to, inter alia, 
action taken by some African countries to better 
control the importation of those precursor chemicals. 
However, the seizure in Guinea in July 2009 of large 
amounts of chemicals and equipment suspected of 
being intended for use in the processing of illicit 
synthetic drugs such as MDMA (“ecstasy”) shows that 
the region remains at risk of being used by traffickers 
for the diversion of precursor chemicals and 
underscores the urgent need for African countries to 
improve their national mechanisms for precursor 
control, with the support of the international 
community.  
295. The continued availability of illicitly 
manufactured or diverted pharmaceutical products 
containing narcotic drugs and psychotropic substances 
on unregulated markets presents a serious public health 
problem in many African countries. Because of 
weaknesses in national systems for the control of the 
licit manufacture and distribution of pharmaceutical 
products, internationally controlled substances can be 
obtained without prescription or on unregulated 
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markets in most countries in Africa. The Board urges 
the Governments concerned to design and implement 
policies to effectively prevent diversion of 
internationally controlled substances from domestic 
distribution channels into unregulated markets, in 
conformity with Commission on Narcotic Drugs 
resolution 51/13, entitled “Responding to the threat 
posed by the distribution of internationally controlled 
drugs on the unregulated market”. 
 
 2. Regional cooperation 
 
296. Under the African Union’s current Plan of Action 
on Drug Control and Crime Prevention, the African 
Union Commission has strengthened its cooperation in 
the areas of drug control and crime prevention with 
relevant international organizations, such as 
INTERPOL, the African Institute for the Prevention of 
Crime and the Treatment of Offenders and UNODC, 
and with the European Commission within the 
framework of the Africa-European Union Strategic 
Partnership. 
297. The regional economic communities in Africa are 
to play a key role in the implementation of the African 
Union Plan of Action. In that regard, particular 
progress has been made by the member States of 
ECOWAS, which adopted a subregional action plan on 
drug trafficking, organized crime and drug abuse in 
2008 and, at the mid-year summit meeting of 
ECOWAS Heads of State and Government held in 
Abuja in June 2009, endorsed an operational plan to 
combat drug trafficking and related organized crime, 
and a mechanism elaborated by the ECOWAS 
Commission for monitoring and evaluation, including 
by reporting progress at the level of the Security 
Council. The Board notes that the Security Council has 
called on the international community to continue to 
support the implementation of the ECOWAS Plan of 
Action and the Guinea-Bissau operational plan.  
298. In April 2009, UNODC, the Department of 
Peacekeeping Operations and the Department of 
Political Affairs of the Secretariat, the United Nations 
Office for West Africa and INTERPOL launched a joint 
programme to build national and regional law 
enforcement capacity including in the areas of drug 
interdiction, forensics, intelligence, border 
management, money-laundering and criminal justice. 
One of the key elements of the programme is the 
establishment of specialized units to counter 
transnational crime, initially in Côte d’Ivoire, Guinea-
Bissau, Liberia and Sierra Leone. In 2009, West 
African countries benefited from two regional training 
activities on identifying and securing physical evidence 
at the scene of a crime. The activities were conducted 
in Côte d’Ivoire and Nigeria and sponsored by the 
INTERPOL Providing of Operational Assistance, 
Services and Infrastructure Support to African Police 
Forces (OASIS Africa) programme. 
299. In order to strengthen transatlantic cooperation 
between Latin American and West African drug law 
enforcement agencies, ECOWAS member States were 
invited to attend the Nineteenth Meeting of Heads of 
National Drug Law Enforcement Agencies, Latin 
America and the Caribbean, held on Isla Margarita, 
Bolivarian Republic of Venezuela, in September 2009. 
Drug law enforcement agencies of Latin American and 
West African countries subsequently signed a 
memorandum of understanding to promote the joint 
investigation of specific cases at a meeting organized 
by UNODC in Bogota in November 2009. 
300. The Board notes the activities undertaken by 
UNODC to assist the countries of West Africa in their 
efforts to combat drug trafficking. For instance, 
UNODC launched in 2007 a project on cooperation in 
the areas of law enforcement and intelligence to 
combat the smuggling of cocaine from Latin America 
into West Africa, with the aim of establishing 
interregional law enforcement and exchange of 
intelligence in the area of drug interdiction. In 
addition, transatlantic cooperation is to be promoted 
under the ongoing UNODC-World Customs 
Organization Container Control Programme and the 
Airport Communication Project recently developed by 
UNODC. Within the framework of South-South 
cooperation, Brazil, through UNODC, has been 
assisting Guinea-Bissau in the implementation of a 
drug control programme in Guinea-Bissau by 
providing specialized training to the Judicial Police of 
that country and by assisting in the establishment of a 
national police academy. 
301. The Nineteenth Meeting of Heads of National 
Drug Law Enforcement Agencies, Africa, was held in 
Windhoek in October 2009. The participants examined 
the current situation with respect to regional and 
subregional cooperation in countering drug trafficking 
and formulated strategies to improve cooperation and 
mutual support in drug interdiction efforts.  
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302. In July 2009, INTERPOL convened its twentieth 
African Regional Conference in Cairo. Some 160 law 
enforcement officials from 40 countries and 
8 international organizations took part in the 
Conference, which addressed, inter alia, drug 
trafficking, maritime piracy and counterfeit medicines. 
INTERPOL cooperates with African law enforcement 
authorities in combating drug trafficking, notably 
through its projects White Flow, COCAF and Proteus, 
and provides assistance in the investigation of major 
drug seizures, such as the cocaine seizures effected in 
2009 in Angola (57 kg), Ghana (71 kg) and South 
Africa (270 kg). 
303. A regional workshop for drug law enforcement 
officers was held in Tripoli in December 2008 as 
follow-up to the Tripoli Action Plan on Countering 
Drug Trafficking and Money-Laundering using the 
Mail, which had been adopted in November 2007.  
The workshop participants adopted the Tripoli 
Recommendations, a set of recommendations to further 
strengthen communication and cooperation with regard 
to drug-related matters between drug law enforcement 
agencies operating in the region. The Tripoli 
Recommendations have been communicated to the 
Council of Arab Ministers of the Interior for further 
follow-up.  
304. In February 2009, a regional expert meeting, 
convened jointly by the Government of Kenya and 
UNODC in Nairobi, elaborated a programme for East 
Africa for the period 2010-2012, the aim of which is to 
promote the rule of law, health and human security in 
that subregion. 
305. The Board notes that steps have been taken by 
Governments of African countries and relevant 
international organizations, such as INTERPOL and 
WHO, to strengthen cooperation in combating the 
problem of counterfeit goods, notably counterfeit 
medical and health products, in the region. In 
November 2008, some 150 representatives of police, 
customs and drug regulatory authorities of 26 East and 
Southern African countries took part in training 
workshops on intellectual property crime; the 
workshops were co-hosted by INTERPOL and the 
Kenyan police in Nairobi. In December 2008, the third 
annual meeting of the WHO International Medical 
Products Anti-Counterfeiting Taskforce (IMPACT) was 
held in Hammamet, Tunisia. The objective of the 
meeting, which was supported by INTERPOL and 
which brought together 100 representatives from 
40 countries, was to raise awareness of the dangers of 
counterfeit medical products and to counter their 
manufacture and distribution. 
306. In May 2009, the Governments of the Niger and 
Nigeria signed a protocol of cooperation in combating 
drug trafficking, money-laundering and related 
fraudulent practices. 
307. African Governments continue to take efforts to 
counter money-laundering in cooperation with the 
relevant subregional groups, notably the Eastern and 
Southern Africa Anti-Money Laundering Group 
(ESAAMLG) and the Intergovernmental Action Group 
against Money Laundering in West Africa (GIABA). In 
Namibia, to counter money-laundering legislation (the 
Financial Intelligence Act) entered into force in 
May 2009, while Senegal recently adopted legislation 
aimed at combating the financing of terrorism, 
supplementing its existing legislation against money-
laundering. Malawi and Senegal were admitted as 
members of the Egmont Group of Financial 
Intelligence Units in May 2009. The Board encourages 
the countries of Central Africa to take appropriate 
measures to make the Action Group against Money 
Laundering in Central Africa (GABAC) fully 
operational. The Board also encourages the 
Governments of Angola, Burundi, Comoros, the 
Democratic Republic of the Congo, Madagascar and 
Rwanda to join ESAAMLG as soon as possible. 
 
 3. National legislation, policy and action 
 
308. A number of African countries have taken steps to 
strengthen their national drug control legislation and to 
improve their mechanisms for administrative 
monitoring and control in implementation of the 
international drug control treaties. 
309. The Government of Ethiopia has adopted a 
national drug control master plan and is now in the 
process of establishing an inter-ministerial body to 
facilitate implementation of that plan. 
310. The Government of Kenya has introduced a drug 
control component in its system for the performance 
appraisal of civil servants, who are now required to 
carry out a drug control activity as one of their duties. 
This measure is expected to contribute significantly to 
advocacy, training and drug abuse prevention in 
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several sectors, including in schools and the 
workplace. 
311. A number of African countries have established 
or are in the process of establishing integrated national 
programmes to combat drug trafficking, drug abuse 
and associated transnational organized crime. The 
programmes, which have been developed by UNODC 
in partnership with national authorities, tackle a variety 
of issues such as capacity-building in law enforcement, 
drug supply and demand reduction, treatment for drug 
abusers, criminal justice, regional cooperation and 
activities to counter money-laundering, and are 
currently being implemented in Cape Verde, Guinea-
Bissau and Mali. Integrated programmes have been 
developed for Mauritania, the Niger and Togo, while 
those for Benin, Burkina Faso and Ghana will be 
prepared later in 2009. 
312. The National Drug Law Enforcement Agency of 
Nigeria achieved a significant increase in drug seizures 
in 2007 and 2008. The total quantity of cannabis seized 
in 2008 exceeded 335 tons, an increase of 62 per cent 
compared with 2007, when a total of 210 tons was 
seized. Also in 2008, a total of 530 kg of psychotropic 
substances and 365 kg of cocaine were seized. Most of 
the cocaine was seized at the main international 
airports in the country. 
313. In 2009, the law enforcement authorities of 
Lesotho and Nigeria conducted successful operations 
to combat the problem of counterfeit medical products. 
In a police operation in Lesotho conducted with the 
support of INTERPOL in June 2009, large amounts of 
counterfeit and illicit medical products were seized, 
including products subject to medical prescription that 
had been illegally repackaged for sale on the streets. In 
Nigeria, similar activities were conducted by the 
National Agency for Food and Drug Administration 
and Control in May 2009. The Agency continues to 
enforce a zero-tolerance policy with regard to 
counterfeit drugs and foods marketed under counterfeit 
brand names, in view of the serious danger posed to 
public health by such counterfeit products.  
314. In South Africa, the Prevention of and Treatment 
for Substance Abuse Act, 2008, was adopted in  
April 2008. The Act regulates the establishment, 
registration and management of treatment centres and 
inpatient, outpatient and community-based services for 
drug abusers and defines the mandate of the Central 
Drug Authority, whose responsibility is to monitor and 
oversee the implementation of the national drug control 
master plan. Moreover, in view of the large-scale 
diversion of ephedrine and pseudoephedrine for use in 
the illicit manufacture of methamphetamine in South 
Africa, those substances have now been placed under 
stricter control in that country. Specifically, the 
Government of South Africa has amended the national 
drug control legislation, placing the substances under 
the same national controls as psychotropic substances, 
which are subject to import and export authorization 
and medical prescription (see paragraph 324 below). 
 
 4. Cultivation, production, manufacture and 
trafficking 
 
  Narcotic drugs 
 
315. Cannabis production, trafficking and abuse have 
been reported in practically all countries in Africa. 
Cannabis herb continues to be the illicit drug most 
frequently abused in most countries in the region. The 
production of cannabis resin is concentrated in 
countries in North Africa, mainly Morocco. Seizure 
data indicate that most of the cannabis resin produced 
in that country is smuggled into Europe. The drug is 
also smuggled into or through North African and sub-
Saharan countries. In 2008, as in previous years, 
Morocco seized more cannabis resin than any other 
African country, reporting 114 tons as the total quantity 
seized. The Government of Morocco estimates that the 
area under illicit cannabis cultivation in that country 
has been significantly reduced, from 134,000 ha in 
2003 to 60,000 ha in 2008, which represents a decrease 
of 55 per cent. The Government also estimates that the 
total amount of illicitly produced cannabis resin fell 
from 3,070 tons in 2003 to 877 tons in 2008, a decrease 
of 71 per cent. Eradication measures in Morocco have 
been supplemented by alternative livelihood 
programmes in rural areas in the country’s northern 
provinces and local awareness-raising campaigns. The 
Board encourages the Government of Morocco to 
continue its efforts against illicit cannabis cultivation. 
316. Cannabis herb is illicitly produced in all 
subregions of Africa. In North Africa, it is produced on 
a large scale in Egypt and Morocco. In West and 
Central Africa, cannabis plants are cultivated for 
commercial purposes in Cameroon, Ghana, Nigeria, 
Senegal and Togo. Cannabis plants are also cultivated 
in most countries of East Africa, especially in 
Comoros, Ethiopia, Kenya, Madagascar, Uganda and 
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the United Republic of Tanzania, while in Southern 
Africa, cannabis plants are cultivated on a significant 
scale in the Democratic Republic of the Congo, 
Lesotho, Malawi, South Africa and Swaziland. While 
cannabis herb is usually trafficked within Africa for 
local consumption a proportion is smuggled into other 
regions, mostly Europe.  
317. Large consignments of cannabis herb are seized 
in Africa, which in 2007 accounted for 11 per cent of 
global seizures of that illicit drug. The amount of 
cannabis herb seized in Morocco has increased 
significantly in recent years, from 116 tons in 2005 to 
222 tons in 2008. Large consignments of the drug have 
been seized in several countries in East Africa. The 
number of drug seizures and related arrests at the 
international airports of Nairobi and Addis Ababa 
continued to rise in 2008. The United Republic of 
Tanzania continues to report the largest seizures of 
cannabis herb in East Africa. Most of the cannabis herb 
produced in West Africa is trafficked and abused 
within the subregion. In 2008, several tons of cannabis 
herb seized in two separate incidents in Europe were 
traced to Ghana, where the Ghanaian authorities were 
able to identify and arrest the persons involved in 
supplying and smuggling those consignments.  
318. There have been no reports of coca bush 
cultivation or cocaine manufacture in Africa. Since 
2005, however, West Africa has increasingly been used 
as a transit area for cocaine consignments bound for 
Europe and, to a lesser extent, North America. That is 
evidenced by large seizures of cocaine, effected either 
on the high seas en route to West Africa or in the 
subregion itself, which have totalled several tons per 
year, according to UNODC data. The cocaine seized in 
Africa originates mainly in Colombia and Peru and, in 
many cases, has been smuggled through Brazil and 
Venezuela (Bolivarian Republic of). Since 2004,  
at least 1,400 couriers on commercial flights from  
West Africa to Europe have been arrested for carrying 
cocaine. 
319. Since 2008, Africa appears to have declined in 
importance as a transit area for cocaine trafficking, as 
reflected in the reduced number and size of seizures 
effected in 2008 and the first half of 2009. In 2008, 
there was a sharp decrease in seizures in Europe of 
cocaine originating in Africa. No large seizures of 
cocaine that could be traced to Africa were reported in 
2009. That decline may be attributed in part to 
increased international drug control efforts in the 
region. However, according to UNODC data, cocaine 
worth an estimated 1 billion United States dollars 
continues to be trafficked through the region each year, 
and West African distribution networks in Europe 
appear to have remained intact. That concern is 
supported by evidence uncovered in Guinea in 
July 2009 suggesting that some degree of processing of 
cocaine may have taken place in that country.  
320. Some cocaine is smuggled into countries in 
Southern Africa, notably South Africa, to be abused 
locally or to be smuggled into other countries. Cocaine 
from South America is also smuggled through the 
United Arab Emirates into Zimbabwe. Mozambique 
has emerged as an area where cocaine enters into 
Africa to be smuggled through South Africa into the 
United Kingdom and other European countries. The 
subregion of East Africa continues to be used as a 
transit area for cocaine consignments destined for 
illicit markets in Europe.  
321. Opium poppy cultivation in Africa is confined to 
Algeria and the Sinai peninsula in Egypt and is thought 
to be limited in scale in both countries. In Algeria, 
about 80,000 opium poppy plants are eradicated every 
year. The opium produced is abused locally, and there 
is no evidence of it being used for the manufacture of 
heroin.  
322. Heroin continues to enter Africa mainly though 
the countries in East Africa. Countries in that 
subregion have been identified as both countries of 
destination of heroin consignments and transit 
countries; moreover, trafficking in and abuse of heroin 
have recently increased. Most of the heroin seized had 
been transported by passengers on commercial flights 
arriving at or departing from the international airports 
of Addis Ababa and Nairobi; both airports provide 
flight connections between West Africa and  
heroin-manufacturing countries in South-West and  
South-East Asia. From West Africa, heroin is 
frequently smuggled into Europe and North America in 
operations often organized by West African criminal 
organizations. Heroin smuggled by sea enters East 
Africa through the ports of Djibouti, Eritrea, Kenya 
and the United Republic of Tanzania. In addition, 
postal and courier services are increasingly being used 
to smuggle heroin.  
323. Heroin traffickers in Africa also use land routes, 
taking advantage of the porous borders and weak 
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border control of many countries in the region. There is 
evidence of an increase in the smuggling of heroin to 
the islands of the Indian Ocean, particularly Mauritius. 
Opiates from India and Pakistan are smuggled into 
Mozambique and then South Africa and from South 
Africa into Europe, as well as into East African 
countries, notably Mauritius and Seychelles. Mauritius 
now has one of the highest levels of opiate abuse in 
Africa, a spillover effect of the heroin trafficking in 
that country. While the number and size of heroin 
seizures reported in West Africa each year remain very 
small, organized crime networks based in the subregion 
are playing a key role in supplying heroin to countries 
throughout the world and are involved in both 
importing heroin and street-level dealing in heroin. 
Côte d’Ivoire is considered a significant transit country 
for heroin trafficking. 
 
  Psychotropic substances 
 
324. The illicit manufacture of psychotropic 
substances, notably methaqualone (Mandrax), 
methamphetamine, methcathinone and MDMA 
(“ecstasy”) remains limited to South Africa and  
some countries in Southern and East Africa,  
where those substances are also abused. About  
30 laboratories illicitly manufacturing drugs, mainly 
methamphetamine and methcathinone, are dismantled 
every year in South Africa. The precursor chemicals 
used in the manufacture of those drugs, namely 
ephedrine and pseudoephedrine, are imported legally 
into South Africa on a large scale. However, a 
proportion of those imports are diverted from domestic 
distribution channels for use in the illicit manufacture 
of amphetamine-type stimulants. In an effort to stem 
such diversion, the Government of South Africa has 
recently tightened national measures to control 
ephedrine and pseudoephedrine (see paragraph 314 
above).  
325. Preparations containing buprenorphine continue 
to be smuggled into and abused in Mauritius. In 2008, 
customs officers in Mauritius seized 21,727 tablets 
containing buprenorphine (Subutex) from a passenger 
arriving from France by air. 
326. In many African countries, the availability of a 
wide range of preparations containing psychotropic 
substances on unregulated markets continues to be a 
cause for concern. The psychotropic substances in 
question include benzodiazepines (notably diazepam, 
clonazepam, lorazepam, clorazepate), phenobarbital, 
slimming tablets and analgesics. Such preparations are 
often counterfeit products. Large seizures of such 
tablets are reported in the region each year.  
 
  Precursor chemicals 
 
327. In recent years, Africa has become an area used 
for the diversion of ephedrine and pseudoephedrine, 
often in the form of pharmaceutical preparations, 
mainly for use in illicit methamphetamine manufacture 
in Central and North America. However, analysis of 
trafficking trends indicates that the diversion of those 
substances in Africa is decreasing. While a total of  
75 tons of ephedrine and pseudoephedrine was 
prevented from being diverted through African 
countries in 2007, only 22 tons were stopped in 2008 
and none was stopped in the first nine months of 2009. 
In 2008, customs officers in Côte d’Ivoire seized a 
total of 159 kg of ephedrine from a vehicle arriving 
from Ghana. It appears that most illicit shipments of 
ephedrine and pseudoephedrine are being smuggled 
into Central America and North America through 
Europe, as had been the case in earlier years. 
Meanwhile there has been a decline of up to 40 per 
cent in licit exports of ephedrine and pseudoephedrine 
to Africa since 2008. 
328. In addition, Africa has been used for the 
diversion of acetic anhydride (a key chemical used in 
the illicit manufacture of heroin) into illicit channels. 
For instance, in December 2008, a shipment of 15 tons 
of acetic anhydride was stopped en route from Italy to 
Egypt, and two shipments of acetic anhydride totalling 
36 tons were suspended in early 2009 while being 
transported from India and Iran (Islamic Republic of) 
to Djibouti. There is also concern regarding the threat 
posed by transnational organized criminal groups 
involved in the manufacture of and trafficking in 
amphetamine-type stimulants and psychotropic 
substances. For instance, in January 2009, a planned 
export of 2 kg of ergotamine (a precursor chemical that 
can be used in the illicit manufacture of lysergic acid 
diethylamide (LSD)) from the Czech Republic to 
Guinea-Bissau was stopped when the competent 
authorities of Guinea-Bissau failed to respond to a 
request by the Board to confirm the legitimacy of the 
transaction. In July 2009, significant quantities of 
chemicals suspected of being intended for use in the 
illicit manufacture of drugs were seized in Conakry. 
Most of those chemicals were solvents commonly used 
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for licit industrial purposes but  
which could be used in the illicit manufacture  
of cocaine, heroin, methamphetamine or methaqualone. 
Large amounts of sassafras oil and 
3,4-methylenedioxyphenyl-2-propanone (3,4-MDP-2-P) 
— precursor chemicals used in the synthesis of  
MDMA (“ecstasy”) — and laboratory equipment were 
discovered together with other chemicals indicating 
that those chemicals were intended for use in the illicit 
manufacture of drugs. 
329. In countries throughout Africa, there is a 
demonstrated need among law enforcement authorities 
for exchanges of experts, awareness-raising with 
regard to precursor control and training initiatives, 
including training in forensic skills. There is also a 
need to improve the reporting of precursor-related data 
to the Board and to enhance cooperation in the area of 
investigations. The Board therefore calls upon the 
Governments of all African countries and the regional 
economic communities to improve their national 
mechanisms for precursor control and encourages the 
regional economic communities in Africa to consider a 
coordinated response in that regard. 
 
  Substances not under international control 
 
330. Khat, which is not currently under international 
control, continues to be cultivated in some countries of 
East Africa and in parts of the Arabian Peninsula and is 
commonly chewed as a stimulant in those areas. 
Although khat consumption is associated with health 
risks and may have detrimental social consequences, 
the prohibition of khat in the region is limited to some 
countries in East Africa, such as Eritrea, Madagascar, 
Rwanda and the United Republic of Tanzania. As a 
result of an increase in the smuggling of khat into 
countries in Europe and the Americas, khat has also 
been prohibited in a number of countries in Europe and 
in Canada and the United States.  
 
 5. Abuse and treatment 
 
331. Most African States continue to lack proper 
systems for monitoring drug abuse and are therefore 
unable to gather sufficient data on the extent and 
patterns of drug abuse or to carry out accurate 
assessments of prevalence rates. The only systematic 
monitoring of drug abuse in the region is taking place 
in South Africa, through the South African Community 
Epidemiology Network on Drug Use (SACENDU), a 
drug abuse monitoring system based on demand for 
treatment. Consequently, neither the success of 
prevention campaigns nor the need for the treatment 
and rehabilitation of drug abusers can be properly 
assessed. Most national estimates of the prevalence of 
drug abuse are based only on rapid assessments of drug 
abuse among specific groups within the drug-abusing 
population and a limited number of school surveys. 
The cross-country comparability of national drug abuse 
estimates is therefore severely limited in Africa.  
332. Furthermore, in most countries in Africa, national 
health-care systems are not able to meet needs of the 
population with regard to the treatment and 
rehabilitation of drug-dependent persons. National 
medical facilities for such treatment and rehabilitation 
are often seriously inadequate or simply non-existent. 
Frequently, only small numbers of drug-dependent 
persons can be accommodated in the psychiatric wards 
of general hospitals. Treatment and rehabilitation of 
drug-dependent persons in Africa often depend on 
assistance provided by relevant international 
organizations, such as WHO and UNODC, and non-
governmental organizations. The Board therefore 
encourages the Governments of African countries to 
undertake systematic assessments of the extent of drug 
abuse on their territory and to give priority to the 
development of programmes for drug abuse prevention 
and demand reduction, particularly programmes 
targeting young people, including out-of-school youth. 
The Board also urges those Governments to provide 
adequate support to existing treatment services and 
medical structures in order to ensure proper treatment 
for drug-dependent persons, to provide the support 
necessary to establish and maintain suitable 
rehabilitation facilities for such persons and to evaluate 
the quality of the treatment. 
333. Cannabis is generally regarded as the most 
problematic illicit drug in Africa, where an estimated 
8 per cent of the population use cannabis and where 
that drug accounts for an estimated 64 per cent of the 
demand for treatment of drug abuse. Available 
information suggests that cannabis abuse is continuing 
to increase in Africa, albeit at a slower pace than 
previously. The widespread abuse of cannabis by 
children is of particular concern; in some countries, 
even children 7-10 years old are reported to have 
abused cannabis.  
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334. Cocaine abuse appears to be rising in Africa, 
particularly along emerging cocaine trafficking routes 
in West and Southern Africa. Data on treatment for 
drug abuse in South Africa show a strong increase in 
cocaine-related treatment between 1998 and 2008. In 
2008, demand for treatment for cocaine abuse 
fluctuated between 11 and 25 per cent of total 
treatment demand in different provinces of that 
country.  
335. Heroin abuse also appears to be increasing in 
Africa. Heroin is the drug most commonly abused by 
problem drug abusers in countries such as Kenya, 
Mauritius, Nigeria, the United Republic of Tanzania 
and Zambia. Rwanda and Seychelles have also 
reported an increase in the abuse of heroin. In South 
Africa, heroin abusers frequently use a mixture of 
poor-quality heroin and cocaine commonly called 
“sugar”, which is administered mostly by smoking. 
Drug abuse by injection is still limited in South Africa 
and other countries in the region. UNODC recently 
estimated the number of persons in Africa who have 
abused opiates at least once in the past year at between 
1 million and 2.8 million or between 0.2 and 0.5 per 
cent of the population 15-64 years of age. 
336. Between 1.4 million and 4 million persons in 
Africa are estimated to have abused amphetamine-type 
stimulants at least once over the past 12 months. 
Nigeria and South Africa have reported the highest 
annual prevalence rates of abuse of such stimulants. 
Burkina Faso, Côte d’Ivoire, Egypt, Ghana, Kenya, 
Senegal, Sierra Leone and several other African 
countries have also reported the abuse of 
amphetamine-type stimulants; however, no reliable 
quantitative estimates have been available in recent 
years. The abuse of methaqualone and 
methamphetamine remains of concern in South Africa; 
the abuse of methamphetamine occurs predominantly 
in and around Cape Town. The abuse of over-the-
counter and prescription medicines, such as slimming 
tablets, analgesics and benzodiazepines (including 
diazepam and flunitrazepam) continues to be a problem 
in many African countries.  
337. The Board notes that the international network of 
drug dependence treatment and rehabilitation resource 
centres (Treatnet) was recently launched jointly by 
UNODC and WHO to improve the quality of treatment 
for drug-dependent persons through cooperation, 
information exchange and the empowerment of 
selected resource centres in all regions of the world.  
In Africa, Cape Verde, Côte d’Ivoire, Kenya, 
Mozambique, Nigeria, Sierra Leone, the United 
Republic of Tanzania and Zambia are currently 
participating in Treatnet. In addition, capacity-building 
initiatives have been launched in Algeria, Egypt and 
Morocco to provide a comprehensive response to drug 
abuse and HIV/AIDS, including community outreach 
services for drug abusers, drug abuse prevention 
services and treatment services for drug abusers, 
including prison inmates. In East Africa, an opiate 
substitution programme is being implemented in 
Mauritius, while treatment for drug abusers is being 
provided in Kenya, Seychelles and Uganda. In 2009, a 
programme for opioid substitution therapy was 
launched in Morocco.  
 
 
 B. Americas 
 
 
  Central America and the Caribbean 
 
 1. Major developments 
 
338. The region of Central America and the Caribbean 
continues to be used as a major trans-shipment area for 
consignments of drugs originating in South America 
and destined for North America and Europe. Impunity, 
corruption and weak institutions undermine drug 
control efforts and the rule of law in the region, despite 
attempts to reform judicial systems. Drug trafficking 
activities are often carried out under the protection of 
local gangs (maras) operating in border areas, 
especially in El Salvador, Guatemala and Honduras. 
There are indications that criminal associations have 
been established between members of Mexican drug 
cartels and gang members. Furthermore, the region is 
becoming used for trafficking in precursor chemicals. 
Despite new regulations banning ephedrine and 
pseudoephedrine in several countries, the region 
continues to be used as a trans-shipment area for the 
smuggling of precursor chemicals into Mexico, where 
the illicit manufacture of amphetamine-type stimulants 
continues. The Board notes that precursors of 
amphetamine-type stimulants are increasingly being 
trafficked in the form of pharmaceutical preparations. 
339. Drug trafficking by sea remains a major problem 
in countries in Central America and the Caribbean. In 
El Salvador, for example, 85 per cent of the trafficked 
cocaine is transported along sea routes. Furthermore, 
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light aircraft, operating from clandestine airstrips and 
landing in remote areas, are increasingly being used to 
transport cocaine. Drug traffickers are increasingly 
using stolen or falsified aircraft registration numbers 
when transporting illicit consignments by air. The 
Board encourages Governments to monitor the sale and 
movement of light aircraft more closely, step up 
airspace security and strengthen control of privately 
owned landing fields.  
340. Drug trafficking has become a major security 
threat and is contributing to an increase in drug abuse. 
The number of homicides linked to organized crime 
has risen in areas where criminal groups fight to gain 
control of local drug distribution. The increase in 
criminal acts, such as robbery and kidnappings, may be 
linked to the increasing availability of drugs, which in 
turn may be attributable to the fact that drug traffickers 
are frequently paid in drugs rather than cash. 
Moreover, major tourist areas in the Caribbean 
continue to be a hub for drug abuse. There are 
indications that the abuse of psychotropic substances, 
particularly benzodiazepines, is increasing in the 
region. In view of the lack of up-to-date data on drug 
abuse and the treatment of drug abusers in the region, 
the Board strongly encourages all Central American 
and Caribbean States to improve their data collection 
systems, monitor trends in drug abuse and take 
appropriate prevention measures. The Board also 
invites Governments of countries in the region and the 
Pan American Health Organization to work together on 
training programmes for health authorities in order to 
ensure the proper prescription and adequate control of 
psychotropic substances and other controlled drugs. 
 
 2. Regional cooperation 
 
341. The Board welcomes the recommendation of the 
Eighteenth Meeting of Heads of National Drug Law 
Enforcement Agencies, Latin America and the 
Caribbean, held in Tegucigalpa in October 2008, that 
the Governments of countries in the region should take 
further steps to ensure that national legislation and 
administrative procedures are adequate and flexible 
enough to control internationally scheduled precursors 
and their substitute chemicals and thus prevent the 
establishment of the manufacture of amphetamine-type 
stimulants in the region. The Board has taken note of 
the recommendation by Inter-American Drug Abuse 
Control Commission (CICAD) experts on chemical 
substances and pharmaceutical products that a guide be 
prepared on mechanisms to assess the national 
requirements for substances frequently misused in the 
illicit manufacture of drugs. 
342. The Ministerial Conference on Illicit Drug 
Trafficking, Transnational Organized Crime and 
Terrorism as Challenges for Security and Development 
in the Caribbean, organized by UNODC, was held in 
Santo Domingo in February 2009. In the Political 
Declaration on Combating Illicit Trafficking, 
Organized Crime, Terrorism and Other Serious Crime 
in the Caribbean, which was adopted at that 
Conference, Caribbean States pledged to continue to 
accord priority to the prevention of organized crime 
and drug trafficking and to implement related actions. 
They also undertook to conduct public awareness 
campaigns on drug abuse prevention, improve their law 
enforcement capacity and strengthen judicial 
cooperation. The Board highlights the important role of 
UNODC in the subregion and welcomes efforts to 
convene ministerial meetings and foster regional 
cooperation. 
343. CICAD continued to organize regional 
cooperation activities in Central America and the 
Caribbean. In particular, CICAD conducted training 
and organized workshops in Costa Rica, the Dominican 
Republic, Guatemala and Panama to strengthen those 
countries’ capacity to investigate, prevent and 
prosecute drug-related crime. Within CICAD, the 
Multilateral Evaluation Mechanism continues to 
promote the exchange of information among countries 
in the region, to stimulate the adoption of joint 
measures and the application of inter-American 
legislation and to facilitate the provision of technical 
assistance to Governments at their request.  
344. In March 2009, a meeting on standards of care at 
treatment and rehabilitation facilities for substance 
abusers was held in Montego Bay, Jamaica, under the 
auspices of CICAD and the Caribbean Community 
(CARICOM). The meeting established the basis for the 
development of common subregional guidelines for 
standardized procedures to be followed by 
professionals working at facilities for the treatment and 
care of drug abusers. The guidelines are expected to be 
finalized by 2010. The Board welcomes this initiative 
and encourages States to establish a harmonized 
regional system for epidemiological surveillance to 
detect and diagnose disease and illness linked to drug 
addiction. 
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345. Under the Drug Treatment City Partnership 
initiative, which is implemented by CICAD and funded 
by the European Union Commission, European, Latin 
American and Caribbean cities continued to cooperate 
in developing policies on drug demand reduction at the 
local level, and seminars and forums were organized in 
several countries of Central America and the 
Caribbean, such as Costa Rica, the Dominican 
Republic and Jamaica. 
346. In March 2009, the European Union launched a 
project entitled “Prevention of the diversion of drug 
precursors in the Latin American and Caribbean 
region” (PRELAC). The objectives of the project are to 
strengthen the capacity of national authorities 
responsible for precursor control and to improve 
communication and cooperation between countries 
through greater exchange of information on national 
drug control systems and trends in the diversion of 
precursor chemicals in the region. 
347. On 24 April 2009, the Vice-Presidents of Belize, 
the Dominican Republic, El Salvador, Guatemala, 
Honduras, Nicaragua and Panama gathered together in 
Antigua, Guatemala, to discuss mechanisms for 
combating organized crime, drug trafficking, 
corruption, human rights violations and money-
laundering. The Vice-Presidents agreed to establish a 
regional technical secretariat tasked with strengthening 
existing regional mechanisms in order to tackle those 
issues and increase transparency in public 
administration. 
348. The fifth annual international Anti-Gang 
Conference was held in San Salvador in April 2009. 
More than 300 security experts from more than 
12 countries gathered to establish strategies for 
combating the gang phenomenon and its expansion into 
the illicit traffic in drugs and arms. The participants 
agreed to implement a number of comprehensive 
initiatives, including prevention and intervention 
programmes.  
349. A ministerial meeting was held in Managua in 
June 2009 under the auspices of the Central American 
Integration System (SICA) and UNODC. Ministers 
from Belize, the Dominican Republic, El Salvador, 
Guatemala, Honduras, Mexico, Nicaragua and Panama 
declared their strong commitment to the fight against 
drug trafficking, organized crime and terrorism and the 
financing of such crime. In the political declaration on 
illicit drug trafficking, transnational organized crime 
and terrorism as challenges to security and 
development in Central America, the ministers 
emphasized the need to improve the prevention of drug 
abuse and the treatment of drug abusers and to 
strengthen the prevention and control of organized 
crime. The Board hopes that the political declaration 
will translate into effective regional cooperation in 
combating organized crime and drug trafficking. 
 
 3. National legislation, policy and action 
 
350. The Government of Costa Rica launched a 
national drug control plan for the period 2008-2012, 
establishing a national policy on drug abuse 
prevention. The plan also targets vulnerable groups 
such as indigenous communities and farmers, whose 
livelihood depends on illicit cannabis cultivation. 
351. In March 2009, the Attorney-General of the 
Dominican Republic established a national directorate 
for the prosecution of drug trafficking and complex 
crime. The role of the directorate is to support 
prosecutors leading investigations on drug-related 
crime by coordinating the activities of the relevant 
State institutions. The directorate is also responsible 
for developing institutional policies to combat and 
prevent drug trafficking and for coordinating training 
activities for investigative authorities. 
352. The citizens’ security council of the Dominican 
Republic, chaired by the President of that country, 
carries out investigations to identify officials involved 
in organized crime. In February 2009, the council 
reported the incarceration of 22 members of the 
National Police and three members of the National 
Drug Control Directorate for having links to organized 
crime. 
353. In 2009, El Salvador issued a regulation revoking 
its new ban on ephedra, pseudoephedrine and 
ephedrine and establishing that ephedrine may 
continue to be sold subject to certain conditions, with 
the exception of injectable preparations containing 
ephedrine, such preparations being subject to special 
control. In order to continue to monitor the movement 
of preparations containing ephedrine, a list of 
enterprises and institutions acquiring and maintaining 
stocks of such preparations and the quantities acquired 
and stored is to be maintained and monitored. The 
Board notes that this change will affect precursor 
control efforts in Central America and the Caribbean 
and encourages the Government of El Salvador to 
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continue its efforts to strengthen the control of 
ephedra, pseudoephedrine and ephedrine. 
354. In February 2009, the Government of Guatemala, 
following steps taken by Governments of countries in 
Central America and the Caribbean to ban ephedrine 
and pseudoephedrine as part of efforts to combat the 
illicit manufacture of synthetic drugs, imposed a 
nationwide blanket ban on pseudoephedrine. The 
Guatemalan authorities established 15 April 2009 as 
the deadline by which pharmacies were required to use 
up their stocks of pharmaceutical preparations 
containing pseudoephedrine. 
355. In June 2009, the Government of Guatemala 
launched a programme entitled “Safe Schools” to 
prevent drug abuse and gang activity among 
schoolchildren. The plan includes the installation of 
surveillance equipment in schools and education for 
families on drug abuse prevention. Guatemala has also 
initiated a programme to evaluate standards for the 
treatment of drug abusers. The objective of the 
programme is to collect information on treatment 
institutions and their patients in order to standardize 
procedures for the medical treatment of drug abusers. 
356. A new police force has been established in 
Guatemala with the assistance of the United States. 
The new body, called the counter-narcotics and 
counter-terrorism air intervention force, will focus on 
combating drug trafficking, particularly in the north-
western and southern parts of the country. 
357. In February 2009, the Government of Honduras 
issued a regulation prohibiting the import, export, 
possession, synthesis, use, manufacture, sale, storage, 
distribution and transportation of pseudoephedrine. 
The regulation entered into force immediately 
following its official publication. 
358. The Government of Honduras has implemented 
drug abuse prevention programmes for primary and 
secondary school students and conducted workshops 
on drug abuse prevention for new students at the 
National University of Honduras as part of a project 
that the Government plans to expand to include other 
universities. 
359. In December 2008, Nicaragua introduced new 
measures for the control of ephedrine and 
pseudoephedrine. Under the measures, the acquisition 
and use of those substances are prohibited, except in 
the manufacture of pharmaceutical injections and in 
research. The import and distribution of, or trade in, 
ephedrine are also prohibited. 
360. On 17 June 2009, the President of Panama issued 
a decree aimed at eliminating barriers to the 
availability of and access to opioids for medical 
purposes, including those used in the treatment of pain. 
The decree recognizes the need for opioids in the 
treatment of pain in persons suffering from cancer or 
other conditions. Until the decree was enacted, opioids 
could be prescribed only by oncologists and 
anaesthesiologists. 
361. Panama joined the Container Control Programme, 
which is coordinated by the World Customs 
Organization and UNODC. The programme is designed 
to assist port authorities in modernizing control 
techniques for the detection of illicit shipments, 
including illicit shipments of drugs and precursor 
chemicals, without disrupting licit commerce. The 
Board welcomes the opening by UNODC of a regional 
office in Panama, since the geographical location of 
that country makes it a major transit area for illicit 
shipments of drugs, precursor chemicals and weapons. 
362. In December 2008, Panama issued a list of 
substances subject to national control. The list includes 
all 22 substances listed in Tables I and II of the 
1988 Convention and certain substances included in 
the INCB limited international special surveillance list 
of non-scheduled substances. The substances included 
in the national list will be subject to strict trade, import 
and export controls. Companies engaged in their 
handling or trade must be registered, and a licence is 
required in order to trade in those substances.  
363. In Trinidad and Tobago, officials and law 
enforcement personnel from the ministries of energy 
and energy industries, finance, health, national security 
and trade and industry received training in how to raise 
public awareness of the illicit manufacture of, 
trafficking in and abuse of synthetic drugs and the 
diversion of precursor chemicals and in how to identify 
such drugs and precursors. 
 
 4. Cultivation, production, manufacture and 
trafficking 
 
  Narcotic drugs 
 
364. Jamaica continues to be a major producer and 
exporter of cannabis in the Caribbean, despite the 
efforts of its law enforcement agencies. In 2008, 
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Jamaican authorities stepped up eradication 
programmes and operations to combat drug trafficking, 
targeting major drug production areas, as a result of 
which 35,507 kg of cannabis herb were seized and 
street prices for cannabis herb increased.  
365. Cannabis plants are also cultivated in other 
Caribbean countries, such as the Dominican Republic 
and Saint Vincent and the Grenadines, where the 
cannabis produced is destined mostly for local markets. 
In 2008, authorities of the Dominican Republic 
reported a considerable decrease in cannabis 
trafficking in that country, a total of 379 kg having 
been seized in that year. In Saint Vincent and the 
Grenadines, however, an increase in cannabis 
trafficking was noted in 2008, over the course of which 
a total of 47 kg of cannabis was seized. 
366. Illicit cannabis cultivation has decreased slightly 
in Honduras, where an estimated 102 ha of cannabis 
plants were illicitly cultivated in 2008. The ministries 
of security and defence of Honduras have carried out 
joint crop eradication operations. Both eradication and 
drought in illicit cultivation areas have caused the price 
of cannabis to increase by 40 per cent. In 2008, a total 
of 424 kg of cannabis was seized, half of which had 
been destined for Mexico and half for local markets. 
367. Cannabis cultivation and trafficking appears to be 
decreasing in other countries in the region. In 2008, 
Cuba registered its lowest amount of drugs seized in 
14 years. During that year, Cuban authorities seized 
916 kg of cannabis, almost half the amount seized 
during 2007. In Costa Rica, a total of 
1,397,449 cannabis plants were seized in 2008, 
representing a decrease of almost 50 per cent compared 
with 2007. 
368. The authorities of Guatemala reported a decrease 
in illicit cannabis cultivation and trafficking in that 
country, particularly in the areas of Petén and San 
Marcos, which lie along the country’s border with 
Mexico. Some 11 million cannabis plants and 709 kg 
of cannabis herb were seized in Guatemala in 2008. 
369. Cocaine trafficking in Guatemala remained at the 
same level as in previous years, during 2008. A total of 
2,200 kg of cocaine was seized, of which 80 per cent 
originated in Colombia and the remaining 20 per cent 
in Bolivia. Data obtained as the result of seizure 
operations indicate that in Guatemala, cocaine is 
trafficked mainly by sea using speedboats.  
370. In 2008, the law enforcement authorities of Costa 
Rica seized 16,582 kg of cocaine, approximately half 
the amount seized in 2007. A marginal increase in drug 
trafficking by land and sea was reported in that 
country. The number of cases of trafficking by air 
registered in 2008 decreased by 26 per cent compared 
with the figure for 2007. 
371. There is evidence that Belize is becoming a major 
trans-shipment area for cocaine consignments from 
Colombia destined for illicit markets to the north. 
Belizean authorities continue to find abandoned boats 
and aircraft suspected of having been used in criminal 
activity. The Board welcomes the fact that the 
Government of Belize has officially requested 
technical assistance from UNODC in order to fully 
implement its national security strategy. 
372. Cocaine continues to be trafficked in large 
quantities in Nicaragua. Cocaine shipments enter 
Nicaragua through the southern part of the country, to 
be stored in clandestine warehouses along the coastal 
areas before being moved out of the country towards 
final destinations in North America and Europe. While 
the majority of cocaine seizures in 2007 occurred on 
the Pacific coast, trafficking organizations appear to 
have shifted their illicit activities to the Atlantic 
region, where most seizures took place in 2008. 
373. The quantity of cocaine seized in El Salvador 
increased from 39 kg in 2005 to 108 kg in 2006 to 
4,074 kg in 2007. That figure fell to 1,354 kg in 2008. 
The authorities in El Salvador have increased police 
operations and checks along highways and at borders, 
ports and the El Salvador International Airport. All of 
the cocaine seized in El Salvador originates in 
Colombia, and most of it is destined for the United 
States or countries in Europe, the remainder (some 
10 per cent) being destined for local markets. 
374. The number of incidents of cocaine trafficking by 
air in Honduras has increased. To date in 2009, several 
light aircraft, most of which were identified by their 
Venezuelan registration numbers and Venezuelan flag, 
have landed illegally or crashed on Honduran territory. 
For example, in May 2009, a light aircraft bearing a 
Venezuelan flag and operated by Colombian nationals 
crashed in the department of Islas de la Bahía. 
Approximately 1,647 kg of cocaine was seized at the 
scene of the crash.  
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375. There has also been an increase in drug 
trafficking by air in Haiti. The number of light aircraft 
landing on clandestine airfields has increased over the 
past three years. Haiti is used as a trans-shipment area 
for drug consignments bound for the Dominican 
Republic and Bahamas en route to North America and 
Europe. Cocaine from South America reaches Haiti 
mainly by air or via that country’s border with the 
Dominican Republic or the southern Haitian coastline. 
376. The Dominican Republic remains a major trans-
shipment area for cocaine originating in Colombia, 
although Dominican authorities reported a decrease in 
cocaine trafficking in 2008, having seized a total of 
2,723 kg of the drug in that year.  
377. Jamaica appears to be gaining importance as a 
trans-shipment area for South American cocaine bound 
for the United States of America and the United 
Kingdom. In 2008, Jamaican authorities seized 266 kg 
of cocaine, almost three times the amount seized in 
2007. In Jamaica, drugs are trafficked by local criminal 
groups, some of which are linked to Colombian or 
Haitian criminal organizations.  
378. Cocaine is also trafficked in other Caribbean 
countries, but on a smaller scale. A total of 21.6 kg of 
cocaine was seized in Trinidad and Tobago in 2008, all 
of it having been bound for the United Kingdom and 
detected at Crown Point International Airport. In Saint 
Vincent and the Grenadines, a total of 3 kg was seized 
in 56 incidents. Authorities of that country noted a 
decrease in the number of cocaine trafficking incidents, 
believed to be the result of increased surveillance 
along the coastline.  
379. Levels of opium poppy cultivation and heroin 
trafficking in Guatemala are significant. While 
cannabis cultivation and trafficking have diminished 
and cocaine trafficking remains essentially at the same 
level in that country, there is a rising trend in 
trafficking in opium and heroin, which the Guatemalan 
authorities attribute to the establishment in Guatemala 
of an armed group known as Los Zetas, which is linked 
to the Mexican Gulf Cartel. 
380. In 2008, the Government of Guatemala eradicated 
almost 300 million opium poppy plants and seized 
10 kg of heroin. In February 2009, it eradicated 
596 fields of opium poppy plants, covering 739 ha, in 
the department of San Marcos during an operation 
conducted jointly with the United States authorities. 
The number of opium poppy plants destroyed during 
that operation alone accounted for more than 60 per 
cent of the total number eradicated during 2008. 
381. There was a significant increase in the number of 
cases involving heroin trafficking through the 
Dominican Republic in 2008, during which a total of 
120 kg was seized. The largest heroin consignments 
were seized at airports, where the drug was concealed 
in luggage. All of the heroin seized had originated in 
Colombia and had been bound for the United States. 
382. In February 2009, Costa Rican authorities 
informed the Board of the seizure of a laboratory 
where they had found a large amount of 
pharmaceutical preparations and cocaine 
hydrochloride. The preparations were in the form of 
tablets containing oxycodone, hydrocodone and 
codeine. The drugs were purportedly intended for sale 
over the Internet. The Board has been warning 
Governments of the dangers posed by illegal Internet 
pharmacies since 2006. The Board wishes to emphasize 
the importance of activating regional cooperation 
systems for the control of Internet pharmacies. 
 
  Psychotropic substances 
 
383. MDMA (“ecstasy”) continues to be trafficked in 
the Caribbean, particularly in tourist areas. In 2008, 
authorities of the Dominican Republic reported having 
seized 17,885 “ecstasy” tablets, 88 per cent of which 
originated in the Netherlands and was destined for 
local consumption. In 2008, Costa Rican authorities 
seized 342 “ecstasy” tablets, a significant decrease 
compared with 2007, when 19,021 tablets were seized.  
384. There appears to have been a resurgence of LSD 
trafficking in Central America. Costa Rica reported its 
first four seizures of the drug, amounting to 117 doses, 
since 2001. 
 
  Precursors 
 
385. Incidents of trafficking in pseudoephedrine and 
ephedrine have been reported in Guatemala, where 
990,300 tablets of pseudoephedrine were seized in 
2008. In February 2009, the Government of 
Guatemala adopted a new regulation to control the 
movement of both substances in that country. 
Guatemalan law enforcement agencies seized 
3,900,000 pseudoephedrine capsules in February 2009 
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and a shipment of 17 million tablets of the substance in 
June 2009. 
386. Honduras reported the seizure of a total of  
2,000 kg of pseudoephedrine in 2008. All of the 
shipments seized had been bound for Mexico. Seizures 
of pseudoephedrine in tablet form have continued in 
2009. In April 2009, Honduran authorities reported 
having seized a record amount of pharmaceutical 
preparations containing that substance in a 
consignment of more than 2 million tablets found in a 
private residence. The shipment had reportedly been 
imported from Bangladesh and had been addressed to a 
fictitious pharmacy in Tegucigalpa. 
387. In 2008, El Salvador reported the seizure of 
157,926 tablets, 219,065 capsules, 11,620 bottles and 
1,078 envelopes containing pseudoephedrine, as well 
as the seizure of 3 kg of ephedrine. In the same year, 
the Dominican Republic seized 14 kg of 
pseudoephedrine and almost 1 million tablets of 
pharmaceutical preparations containing that substance, 
while Belize reported having seized more than 
10 million such tablets. 
 
 5. Abuse and treatment 
 
388. In Guatemala, the drug most commonly abused is 
cannabis, followed by cocaine and psychotropic 
substances. During 2008, Guatemalan authorities 
registered an increase in the use of heroin and cocaine. 
The number of Guatemalan nationals deported from 
Mexico and the United States has increased 
considerably over the past five years, and the drug 
abuse problem among that returning population is 
contributing to an increase in drug abuse in Guatemala. 
The increase in heroin abuse in particular is attributed 
to those returning migrants.  
389. In 2008, a total of 3,500 people in Guatemala 
received treatment for drug abuse. Most of the patients 
were treated for cocaine addiction. The average age of 
the patients was 22. 
390. In 2008, the Government of El Salvador 
conducted its second national survey on drug abuse 
prevalence among primary and secondary school 
students in cities with a population of more than 
30,000. The preliminary results of the survey showed 
that the lifetime prevalence rate of cannabis abuse 
among persons aged 13-17 was 5.5 per cent. The 
second most abused drug type was the benzodiazepines 
group (prevalence rate: 2.8 per cent), followed by 
inhalants (2.7 per cent).  
391. In 2008, the Anti-Drugs Foundation of 
El Salvador (FUNDASALVA) treated 263 patients for 
drug abuse, 60 per cent of whom were first-time 
patients who were treated for cannabis and cocaine 
abuse. 
392. In 2008, the Government of Honduras estimated 
the annual prevalence rate for the abuse of drugs 
among persons aged 13-25 in that country’s Central 
District to be 1.1 per cent for cannabis abuse, 1 per 
cent for cocaine abuse and 2.7 per cent for the abuse of 
sedatives and tranquillizers. 
393. There are indications that drug abuse is 
increasing in Nicaragua, in particular in the Atlantic 
region, where the increase in drug trafficking has led to 
increased availability of drugs. The Board invites the 
Government of Nicaragua to conduct an assessment of 
the drug abuse situation in the country and to take 
appropriate measures to remedy the situation. 
394. The drug most commonly abused in Jamaica is 
cannabis, followed by cocaine. In 2008, the 
Government of Jamaica reported a slight increase in 
the abuse of those drugs. The most recent national 
assessment of drug abuse prevalence among the 
general population was carried out in 2001, and that 
among youth in 2006. The Board therefore encourages 
the Government of Jamaica to assess the extent of drug 
abuse in that country in order to develop a prevention 
strategy and prevent further increases.  
395. In 2008, the Dominican Republic, with support of 
CICAD and the National Drug Council, conducted a 
drug use survey among the school population (students 
aged 12-18). Anxiolytics and hypnotics (mostly 
benzodiazepines) accounted for the highest lifetime 
prevalence rate (12.8 per cent). Abuse of stimulants 
(containing amphetamine and caffeine) accounted for 
the second highest lifetime prevalence rate (9.1 per 
cent). Forty per cent of the students who reported 
having abused medications containing such substances 
obtained the medications from their homes. The 
lifetime prevalence rate of cannabis abuse was 
estimated at 1.7 per cent and that of cocaine use at  
0.8 per cent. The survey also revealed that 
approximately half of the students had never attended 
courses on drug abuse prevention. The Board invites 
the Government of the Dominican Republic to take 
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appropriate action with regard to its drug abuse 
prevention programmes. 
 
 
  North America 
 
 
 1. Major developments 
 
396. The United States continues to be the world’s 
largest market for illicit drugs and a major destination 
of illicit drug consignments. Except for cannabis and 
methamphetamine, illicit drugs are not produced 
domestically but are largely smuggled into the United 
States. Cannabis remains the most commonly abused 
drug. It is encouraging, however, that the abuse of 
cannabis and other illicit drugs among youth is 
declining in the United States. One matter of concern is 
the fact that in the United States, according to the latest 
national survey on drug abuse, the prevalence of abuse 
of prescription drugs containing controlled substances 
continues to be high and that such drugs are now 
among the most abused types of drug in the country, 
second only to cannabis.  
397. In addition to being used as a major transit area 
for illicit drug consignments, Mexico is experiencing 
increasing problems related to the abuse of cocaine and 
other drugs. The level of drug-related violence in the 
country remains high. Between 2007 and 2008, the 
death toll doubled. Drug cartels, in addition to fighting 
each other, are violently resisting efforts of the 
Government to counter drug trafficking and organized 
crime. Anti-corruption measures and large-scale law 
enforcement operations in Mexico that include the 
deployment of military troops have resulted in the 
disruption of drug trafficking operations throughout 
North America and the arrest of a number of high-level 
drug traffickers. The Board recognizes the vigorous 
measures taken by the Government of Mexico to 
combat illicit drug production and trafficking. 
398. Canada remains one of the primary countries 
supplying MDMA (“ecstasy”) to illicit markets in 
North America and in other regions; it is also a source 
country of high-potency cannabis. One positive 
development is the decline in the abuse of drugs, in 
particular the abuse of cannabis, among adults and 
youth in Canada. 
399. Organized criminal groups have maintained and 
expanded their control over drug trafficking operations 
in North America; that represents a major challenge to 
the countries in the region. Drug trafficking 
organizations based in Mexico predominate in illicit 
drug production, trafficking and distribution in North 
America. They have expanded their control to cover 
the entire supply chain for illicit drugs, shipping illicit 
drugs from South America and distributing them in the 
United States. They are particularly involved in the 
smuggling and distribution of cocaine and heroin and 
the illicit cultivation of and trafficking in cannabis. In 
addition, organized criminal groups are engaged in the 
illicit cultivation of opium poppy and, albeit to a 
diminishing extent, the manufacture of and trafficking 
in methamphetamine. Drug trafficking organizations 
based in Canada are involved in the illicit production 
of and trafficking in high-potency cannabis and the 
manufacture of methamphetamine for the illicit 
markets in Canada and the United States. Violent gangs 
affiliated with drug trafficking organizations are 
largely in control of the distribution of illicit drugs at 
the street level in the United States and are increasing 
their position in the distribution of illicit drugs at the 
wholesale level. 
400. While the consumption and cultivation of 
cannabis, except for scientific purposes, are illegal 
activities according to federal law in the United States, 
several states have enacted laws that provide for the 
“medical use” of cannabis.41 The control measures 
applied in those states for the cultivation of cannabis 
plants and the production, distribution and use of 
cannabis fall short of the control requirements laid 
down in the 1961 Convention. The Board is deeply 
concerned that those insufficient control provisions 
have contributed substantially to the increase in illicit 
cultivation and abuse of cannabis in the United States. 
In addition, that development sends a wrong message 
to other countries. The Board welcomes the 
reaffirmation by the Government of the United States 
that cannabis continues to be considered a dangerous 
drug. The Government has also underscored that it is 
the responsibility of the Food and Drug Administration 
to approve all medicines in the United States. The 
Board notes with appreciation that the Government, 
following new guidelines on prosecution, which 
stipulate that activities should not focus on individuals 
who comply with “medical” cannabis regulations in 
states, has confirmed that it has no intention to legalize 
__________________ 
 41  Report of the International Narcotics Control Board for 
2008 …, para. 432. 
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cannabis. The Board is concerned over the ongoing 
discussion in several states on legalizing and taxing the 
“recreational” use of cannabis, which would be a 
serious contravention of the 1961 Convention. The 
Board emphasizes that it is the responsibility of the 
Government of the United States to fully implement 
the provisions of the 1961 Convention with respect to 
all narcotic drugs, including cannabis (see 
paragraphs 61-64 above). 
 
 2. Regional cooperation 
 
401. Cooperation efforts at the regional level to 
counter drug trafficking and related forms of organized 
crime have intensified. The Merida Initiative, a multi-
year security cooperation programme involving 
Mexico, the United States and countries in Central 
America, is a major element in those cooperation 
efforts. In the short term, the Merida Initiative is to 
provide training and equipment to increase law 
enforcement capabilities. The long-term aim is to 
enhance the capacity of the judicial systems to carry 
out investigations and prosecutions through technical 
assistance. Within the framework of the initiative, the 
United States considerably increased its funding to 
Mexico, from US$ 400 million in 2008 to 
US$ 720 million in 2009 (an additional US$ 65 million 
in 2008 and US$ 110 million in 2009 were 
appropriated for Central America within the framework 
of the initiative). A letter of agreement between 
Mexico and the United States on implementing the first 
phase of the initiative was signed in December 2008. 
The first Merida Initiative projects included the 
establishment of a document analysis and verification 
laboratory, the funding of a bilateral conference to 
address arms trafficking and training for new 
correctional officers and federal police investigators. 
The issue of combating drug trafficking was a major 
point of discussion at a meeting between the 
Governments of Mexico and the United States held in 
April 2009.  
402. At the forty-fifth regular session of CICAD, held 
in Washington, D.C., in May 2009, the discussion 
focused on the control of precursors, the progress made 
in the implementation of the Anti-Drug Strategy in the 
Hemisphere and the reinforcement of systems for the 
treatment and rehabilitation of drug abusers. The 
CICAD Expert Group on Demand Reduction aims to 
link the scope and quality of treatment services with 
the general health-care system. Through its 
Inter-American Observatory on Drugs, CICAD also 
supports countries in improving the collection and 
analysis of drug-related data. 
403. In Operation All Inclusive 2008, an attempt was 
made to disrupt the flow of illicit drugs, money and 
precursor chemicals from South America through the 
transit zone into the United States. The investigative 
operation provided United States inter-agency 
analytical support to seven countries, resulting in 
considerable seizures of cocaine, cannabis and heroin 
and the arrest of nearly 1,300 persons, including 
several high-level drug traffickers. The operation 
resulted in the first seizure of a self-propelled semi-
submersible vessel involved in drug trafficking; the 
seizure was effected by the Mexican Navy off the 
Pacific coast of Mexico in July 2008. 
404. Cooperation between Canada and the United 
States continued through mechanisms such as the 
Cross-Border Crime Forum, which brings together 
senior law enforcement and justice officials. The 
cooperation involved joint operations, the exchange of 
intelligence and joint training activities. In 2008, 
representatives of Canada and the United States opened 
negotiations concerning a bilateral ship-rider 
agreement, which is intended to allow the exchange of 
ship-riders and improve maritime law enforcement 
operations along the maritime border. The highway 
enforcement programme in the United States expanded 
in 2008 to include coordinated operations involving 
Canadian and United States police forces along major 
corridors used for illicit drug transportation. 
405. At the seventh Binational Drug Demand 
Reduction Conference: Unifying Efforts toward Best 
Practices, held in Monterrey, Mexico, in July 2008, 
participants from Mexico and the United States 
discussed measures to reduce illicit drug demand and 
promote best practices in the prevention and treatment 
of drug abuse. 
406. In August 2009, the Governments of Colombia 
and Mexico agreed to strengthen their cooperation in 
combating drug trafficking. In accordance with the 
agreement, Colombian police forces will provide 
training to Mexican law enforcement officers on tactics 
for countering organized crime. 
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 3. National legislation, policy and action 
 
407. In Mexico, measures to fight corruption continue 
to be taken. In 2008, the Government launched 
Operación Limpieza, aimed at preventing corruption in 
law enforcement agencies responsible for combating 
drug trafficking. A number of Government officials, 
including high-level officials from the special unit for 
organized crime of the Attorney-General’s Office, have 
been arrested for passing on information to drug 
cartels. In 2008, the Government introduced legislation 
to reorganize security forces and improve coordination 
of the local, state and federal law enforcement agencies 
in combating drug cartels and other organized criminal 
groups. The law established a national public safety 
council to support law enforcement institutions and 
evaluate the effectiveness of public safety programmes, 
as well as a national intelligence centre. Information 
exchange is facilitated through a case management 
system, which connects the databases of different 
agencies (Plataforma Mexico). Data-sharing 
agreements with all 31 states are currently in place. 
The Government has made proposals for reforming the 
judicial sector with a view to making it more 
expeditious and transparent. The proposals include 
provisions to introduce oral trials,42 plea-bargaining 
and alternative case resolution methods. The judicial 
reform is currently in the process of being discussed at 
the state level and is being implemented in some states.  
408. In 2009, the Government of Mexico enacted 
legislation, according to which persons found to be in 
possession of a specified quantity of certain illicit 
drugs for personal and immediate consumption will no 
longer face criminal prosecution. The maximum 
quantities for the main illicit drugs are 2 grams of 
opium, 50 milligrams of heroin, 5 grams of cannabis 
and 500 milligrams of cocaine. The legislative measure 
is aimed at regularizing a legal practice. In addition, 
persons detained with quantities of illicit drugs below 
the limit for personal use will be encouraged to seek 
treatment; in the case of persons detained for a third 
time, treatment is mandatory. The Board is concerned 
that this legal act may give the wrong signal. The 
Board would like to remind the Government that 
__________________ 
 42  Within its civil-law system, Mexico, like most States in 
Latin America, has traditionally maintained the practice 
of written trials, both in civil and criminal matters. Oral 
trials correspond to adversarial jury trials provided for in 
countries with a common-law system tradition. 
article 3, paragraph 2, of the 1988 Convention requires 
each party to that Convention to establish as a criminal 
offence under its domestic law, when committed 
intentionally, the possession, purchase or cultivation of 
narcotic drugs or psychotropic substances for personal 
consumption contrary to the provisions of the 
1961 Convention, the 1961 Convention as amended by 
the 1972 Protocol or the 1971 Convention.  
409. Its national border with Mexico being a major 
point of entry for illicit drugs, the Government of the 
United States updated and expanded the National 
Southwest Border Counternarcotics Strategy in 2009. 
The strategy is aimed at reducing the flow of illicit 
drugs, drug proceeds and illegal weapons by enhancing 
drug control capabilities, with a view to facilitating the 
prosecution of cases involving drug trafficking and 
disrupting the operations of drug trafficking 
organizations. 
410. In the United States, 38 states had prescription 
drug monitoring programmes in 2008, compared with 
15 states in 2001. The programmes monitor drug 
prescriptions with a view to preventing the diversion 
and abuse of prescription drugs. A prototype for a 
paperless prescription drug monitoring programme is 
currently being developed; it is to link physicians, 
pharmacists and patients in the process of prescribing 
and dispensing controlled substances. 
411. In the United States, action has been taken  
to counter the widespread sale of prescription  
drugs through illegal Internet pharmacies. In  
September 2008, the United States Congress passed the 
Ryan Haight Online Pharmacy Consumer Protection 
Act of 2008, prohibiting the delivery, distribution or 
dispensing of prescription drugs over the Internet 
without a valid prescription. In order to obtain a 
prescription, at least one in-person medical evaluation 
of a patient by a practitioner is required. DEA is 
targeting the infrastructure of organizations that are 
engaged in drug trafficking and that use electronic 
media to divert drugs. The Internet Distributor 
Initiative of DEA is aimed at cutting supply lines from 
distributors to pharmacies where large-scale diversion 
appears to be occurring. The Board notes with 
satisfaction that measures targeting the illegal sale of 
prescription drugs through the Internet have been 
taken. 
412. In the United States, Oregon, in an attempt to 
enhance the downward trend in methamphetamine 
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abuse, has passed state legislation making it illegal to 
purchase a product containing pseudoephedrine 
without a prescription. Other states are considering 
introducing such legislation. In September 2008, the 
Methamphetamine Production Prevention Act of 2008 
was passed by the United States Congress, expanding 
logbook requirements for sellers and purchasers of 
precursors of methamphetamine. 
413. In order to counteract the increasing use of self-
propelled semi-submersible vessels to smuggle cocaine 
(see paragraph 420 below), the Drug Trafficking Vessel 
Interdiction Act of 2008 was signed into law by the 
President of the United States in October 2008. The act 
provides for the imposition of a fine or a prison term 
for operating or boarding a stateless submersible (or 
semi-submersible) vessel on an international voyage 
with the intent to evade detection; thus, the act allows 
for prosecution even when no illicit drugs are seized. 
414. The Government of Canada continued to 
implement its National Anti-Drug Strategy, which 
consists of action plans to improve law enforcement, 
the prevention of drug abuse and the treatment of drug 
abusers. Law enforcement measures are aimed at 
reducing the illicit manufacture of synthetic drugs, the 
illicit cultivation of cannabis, drug trafficking and the 
cross-border movement of precursor chemicals by, for 
example, building the capacities of police, 
investigation and prosecution units and enhancing 
border control. The action plan on drug abuse 
prevention includes a national awareness-raising 
campaign involving mass media, youth, their parents 
and community-based projects on drug abuse 
prevention. Within the framework of the strategy, the 
Government has allocated the equivalent of 
US$ 94 million to law enforcement (over a five-year 
period), US$ 28 million to drug abuse prevention and 
US$ 93 million to the treatment of drug abusers. The 
Board notes with appreciation the measures taken by 
the Government of Canada, in particular those aimed at 
reducing illicit drug manufacture and trafficking, and 
the action plans on the prevention and treatment of 
drug abuse. 
415. Canada continues to be one of the few countries 
in the world that allows cannabis to be prescribed by 
doctors to patients with certain serious illnesses. In 
2008, nearly 2,900 patients were authorized to possess 
cannabis for medical purposes. Until 2009, cannabis 
could be either obtained from a Government supplier 
or grown in small amounts by the patient, or a person 
designated by the patient, with the sole limitation that 
only one patient could be supplied by a licensed 
supplier. In 2009, following court decisions stipulating 
that that approach unjustifiably restricted the patient’s 
access to cannabis used for medical purposes, the 
Government increased the number of cultivation 
licences a person could hold from one to two. The 
Government intends to reassess the programme for 
controlling medical access to cannabis. According to 
article 23 of the 1961 Convention, a party to the 
Convention, if it is to allow the licit cultivation of 
cannabis, must fulfil specific requirements, including 
the establishment of a national cannabis agency to 
which all cannabis growers must deliver their crops 
(see paragraphs 61-64 above).43 The Board therefore 
requests the Government to respect the provisions of 
article 23.  
 
 4. Cultivation, production, manufacture and 
trafficking 
 
  Narcotic drugs 
 
416. The illicit cultivation of cannabis appears to be 
rising in the United States. It is estimated that the total 
quantity of cannabis illicitly produced in the United 
States may exceed the total quantity of cannabis in the 
country that had been illicitly produced elsewhere. In 
2008, the total quantity of eradicated cannabis plants 
increased by about 14 per cent: over 7,562,300 of the 
plants had been grown outdoors and nearly 
451,000 had been grown indoors. Until recently, much 
of the illicit cannabis in the United States was from 
Mexico, and smaller quantities of cannabis with a 
higher potency were smuggled into the United States 
out of Canada. In recent years, however, drug 
trafficking organizations have expanded their illicit 
cannabis cultivation operations in the United States, 
thus avoiding risky border crossings and keeping 
production sites closer to the market. Drug trafficking 
organizations based in Mexico have expanded their 
illicit cannabis cultivation sites on public lands, 
whereas criminal organizations based in Canada have 
set up operations for growing cannabis indoors, mainly 
in the north-western part of the United States, and are 
expanding their operations to include other 
geographical areas. 
__________________ 
 43  Ibid., para. 431. 
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417. The potency of samples of cannabis seized in the 
United States continued to increase; the average THC 
content of seized cannabis exceeded 10 per cent in 
2008, the highest level ever recorded in that country. 
That increase was mainly attributed to the use of 
technologically advanced methods to maximize the 
THC level of cannabis grown indoors in Canada and 
the United States. The potency of the cannabis seized 
at the south-west border of the United States, which 
has traditionally been low, has increased: the highest 
concentration of THC found among the 1,500 samples 
of seized cannabis was 27.3 per cent, and in 40 per 
cent of the samples the THC level was higher than 
9 per cent. 
418. While in 2007 more cannabis herb was seized in 
Mexico than in any other country in the world, the 
Government reported having seized less cannabis herb 
in 2008. Illicit cannabis production in Mexico declined 
to 22,275 tons in 2008, most of which was destined for 
the United States. The total area of illicitly cultivated 
cannabis eradicated in Mexico dropped from 21,357 ha 
in 2007 to 18,562 ha in 2008. Notwithstanding those 
declining figures, the quantity of cannabis seized along 
the south-west border of the United States in 2008 
indicated a sustained flow of cannabis from Mexico. 
419. Canada only supplies a small proportion of the 
total quantity of illicit cannabis used in the United 
States. British Columbia, Ontario and Quebec remain 
the primary areas of cannabis production in Canada. It 
is estimated that 37 tons of cannabis were seized in 
Canada in 2008. Law enforcement authorities reported 
an increasing number of operations for growing 
cannabis in rural communities and remote areas in the 
country. 
420. The quantity of cocaine intercepted en route to 
the United States increased slightly to 209 tons in 
2007. As a result of those seizures, coca bush 
eradication efforts in Colombia and increased pressure 
on drug cartels in Mexico, cocaine continued to be less 
available in some parts of the United States. In 2008, 
the total quantity of cocaine seized in the United States 
decreased by almost one half, from 97 to 50 tons, the 
lowest level since 1999, reflecting a decline in cocaine 
trafficking. The decline in cocaine trafficking in North 
America, the world’s largest illicit market for cocaine, 
was also reflected in rapidly rising prices and falling 
purity levels. Mexican law enforcement authorities 
reported having seized 60 per cent less cocaine in 2008 
than in 2007. Nevertheless, the estimated quantity of 
cocaine shipped from South America to the United 
States has remained significant. United States 
authorities have estimated that 545-707 tons of cocaine 
departed from South America for the United States in 
2007, a figure slightly higher than the one for 2006. Of 
the cocaine shipments that are detected, approximately 
90 per cent were being transported through the 
Mexican and Central American corridor, mainly 
through the eastern Pacific route. Illicit drug 
consignments are being transported by sea using 
speedboats, fishing vessels and, increasingly, self-
propelled semi-submersible vessels. 
421. Mexico’s role as a transit country for cocaine 
destined for Canada has increased. Cocaine 
consignments are being transported by land (from 
Mexico to the United States and Canada through the 
highway corridor), by sea and by air. 
422. Most of the heroin found on the illicit market in 
the United States originated in Colombia and Mexico. 
The Government of Mexico reported having eradicated 
13,095 ha of opium poppy in 2008, an increase over 
the figure for 2007 (11,046 ha). Drug trafficking 
organizations selling “black tar” and “brown powder” 
heroin have expanded the distribution of those forms of 
heroin in what have traditionally been markets for 
“white heroin” in the eastern part of the United States, 
partly as a result of decreasing heroin manufacture in 
Colombia. 
423. In Canada, the illicit heroin market is dominated 
by South-West Asian heroin. In 2008, 70 per cent of 
the heroin found on the illicit market in Canada 
originated in South-West Asia; it had been smuggled 
into the country mainly by air via India and Pakistan 
with the help of organized criminal groups in British 
Columbia and Ontario. 
424. Internet pharmacies continue to be the main 
channel used for the illicit distribution of 
pharmaceutical preparations in the United States. 
However, authorities have reported that the number of 
Internet pharmacies decreased in 2008, owing to 
increased efforts by law enforcement agencies. The 
total number of Internet pharmacies offering controlled 
prescription drugs for sale (anchor sites) dropped by 
15 per cent, from 187 in 2007 to 159 in 2008; almost 
all of them were operating illegally. In addition, 
according to law enforcement authorities, street and 
motorcycle gangs are becoming increasingly involved 
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in the retail-level distribution of diverted prescription 
drugs. 
 
  Psychotropic substances 
 
425. In the United States, the illicit manufacture  
of methamphetamine decreased following the 
introduction of regulations to increase domestic  
control over the sale, at the retail level, of 
pharmaceutical preparations containing precursors of 
methamphetamine. The number of methamphetamine 
laboratories dismantled in the United States dropped by 
more than 70 per cent from 2004 to 2008. In Mexico, 
new control measures, including a ban on the import of 
medicines containing ephedrine and pseudoephedrine 
and the prohibition of the use of those substances, 
contributed to a significant decrease in the illicit 
manufacture of methamphetamine and a reduction in 
the quantity of methamphetamine smuggled into the 
United States in 2007 and 2008. However, data on 
seizures of methamphetamine in the United States 
suggest that illicit methamphetamine manufacture in 
that country is increasing in some areas. On the one 
hand, that development is attributable to a resumption 
of small-scale methamphetamine manufacture in 
response to the reduced supply of methamphetamine 
from Mexico. On the other hand, some drug trafficking 
organizations have shifted their methamphetamine 
manufacturing operations from Mexico to certain areas 
of the United States, particularly California. In order to 
obtain the required precursors, individuals and criminal 
groups are increasingly circumventing state and federal 
restrictions on the sale of pseudoephedrine and 
ephedrine in the United States; for example by making 
numerous small-quantity purchases from multiple retail 
outlets (“smurfing”) or paying individuals to carry out 
purchases on their behalf. 
426. In Mexico, 21 laboratories illicitly manufacturing 
methamphetamine were seized in 2008; 5 of those 
laboratories had been manufacturing methamphetamine 
on a large scale (compared with 14 in 2007). Those 
figures reflect the fact that, in that country, the illicit 
manufacture of methamphetamine decreased and the 
precursors of methamphetamine became less available 
following the introduction of control measures by the 
Government. 
427. Canada continues to be the primary source of 
MDMA (“ecstasy”) found on the illicit market in the 
United States and a major supplier of the growing 
illicit markets for the substances in other parts of the 
world, in particular in Asia and the Pacific. Drug 
trafficking organizations manufacture “ecstasy” in 
large clandestine laboratories in Canada for 
distribution in the United States. One matter of 
particular concern is the increasing distribution of 
“ecstasy” tablets adulterated with other addictive 
drugs, particularly methamphetamine. According to 
law enforcement authorities, the number of “ecstasy” 
laboratories reported to have been seized in Canada in 
2007 was 18, a figure equal to the highest number of 
such seizures ever recorded. All of the “ecstasy” 
laboratories seized were “super labs”, laboratories 
capable of manufacturing at least 5 kg of “ecstasy” in 
one manufacturing cycle. The quantity of Canadian 
“ecstasy” seized in the United States at the Canadian 
border increased by more than 10-fold from 2003 to 
2007. Most of the seizures of “ecstasy” occurred in 
Washington, a state adjacent to British Columbia, 
where most of the “ecstasy” in Canada is 
manufactured. 
 
  Precursors 
 
428. While the measures to control precursors of 
methamphetamine in Mexico have led to a decrease in 
the illicit manufacture of and trafficking in 
methamphetamine, drug trafficking organizations have 
reacted in two ways: by shifting their operations to 
other countries, such as the United States and countries 
in Central and South America, and by smuggling into 
Mexico diverted precursor chemicals, including 
chemicals from Central and South America.44 In 2008, 
the multilateral initiative Operation Ice Block revealed 
that almost half of the suspicious shipments of 
precursors of amphetamine-type stimulants identified 
during the operation were destined for Mexico. 
429. In Canada, the high level of illicit manufacture of 
amphetamine-type stimulants is fuelled by the 
acquisition of bulk quantities of precursor chemicals 
by organized criminal groups. 
__________________ 
 44  International Narcotics Control Board, Precursors and 
Chemicals Frequently Used in the Illicit Manufacture of 
Narcotic Drugs and Psychotropic Substances: Report of 
the International Narcotics Control Board for 2008 on 
the Implementation of Article 12 of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988 (United Nations 
publication, Sales No. E.09.XI.4), para. 49. 
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  Substances not under international control 
 
430. In the United States, ketamine continues to be 
among the active ingredients found in adulterated 
MDMA (“ecstasy”) tablets. The distribution of such 
tablets originating in Canada appears to be increasing.  
431. In Canada, approximately 23 tons of khat were 
seized in 2008, less than the quantity seized in 2007. 
The majority of the seized khat shipments had arrived 
by courier package or had been concealed in air cargo. 
In Canada, the demand for khat is concentrated in 
urban centres with large East African communities. 
 
 5. Abuse and treatment 
 
432. In 2008, an estimated 35.5 million persons in the 
United States, or 14.2 per cent of the population aged 
12 or older, had used illicit drugs (annual prevalence). 
Thus, the overall declining trend in illicit drug use 
continued. That trend is also substantiated by results of 
workforce drug testing. In general, the drug test results 
indicate the lowest levels of drug abuse in the United 
States workforce since 1988. About 20.1 million 
persons, or 8.0 per cent of the population aged 12 or 
older, are “current users” — that is, they have abused 
illicit drugs in the past month.  
433. The decline in the abuse of drugs, particularly 
cannabis, among youth in the United States is an 
encouraging sign. The use of illicit drugs among 
students aged 13-18 declined significantly during the 
period 1997-2008, according to the 2008 survey 
“Monitoring the Future”. Annual prevalence fell by 
27 per cent: every fourth student reported having used 
illicit drugs in the previous year. The abuse of cannabis 
dropped by 29 per cent in the period 1997-2008, 
reaching an annual prevalence of 21.5 per cent. Even 
greater declines were recorded in the abuse of cocaine 
(-36 per cent), methamphetamine (-68 per cent) and 
MDMA (-52 per cent) compared with their respective 
peak levels during that period; the abuse of those drugs 
continued to fall in 2008. That indicates reduced drug 
abuse and its initiation during a critical age period. 
However, the abuse of OxyContin (annual prevalence: 
3.4 per cent), a product containing oxycodone, and 
Vicodin (annual prevalence: 6.1 per cent),45 a product 
__________________ 
 45  Trade names are used in this particular case, since the 
survey “Monitoring the Future” collects and reports 
prevalence data for those specific preparations. 
containing hydrocodone, remained close to the peak 
levels. 
434. In the United States, cannabis remains the most 
commonly abused drug: 25.8 million persons (or 
10.3 per cent of the population aged 12 or older) 
abused cannabis in 2008, slightly more than in 2007. 
435. In 2008, past-year prevalence of the abuse of 
cocaine (including “crack”) among the United States 
population aged 12 and older was 2.1 per cent: 
5.3 million cocaine abusers (compared with 5.7 million 
in 2007). The proportion of persons who tested positive 
for cocaine in workplace drug tests declined by 38 per 
cent from 2006 to 2008.  
436. In the United States, heroin abuse is stable at a 
relatively low level, annual prevalence amounting to 
0.2 per cent in 2008. Past-year heroin abuse among 
youth has remained at 0.8 per cent for some years, 
according to the annual survey “Monitoring the 
Future”. However, heroin abuse levels may increase, as 
more abusers of prescription drugs containing opiates 
are switching to heroin. 
437. In 2008, the abuse of methamphetamine in the 
United States declined further: 0.3 per cent of the 
population were past-year abusers (compared with 
0.5 per cent in 2007). The proportion of persons who 
tested positive for the abuse of methamphetamine 
dropped by about 50 per cent from 2006 to 2008. There 
has been a steady decline in the abuse of 
methamphetamine among all age groups in recent 
years. 
438. In the United States, the number of persons who 
have abused prescription drugs declined for the second 
consecutive year. In 2008, about 15.2 million persons 
(or 6.1 per cent of the population aged 12 or above) 
reported having abused prescription drugs in the 
previous year; in 2007, the number was 16.3 million. 
About 6.2 million of those who abused prescription 
drugs in the past year were “current users”: persons 
abusing such drugs in the past month. Most of those 
who abused prescription drugs in the past year were 
abusers of pain relievers: they numbered 11.9 million 
in 2008, compared with 12.5 million in 2007. 
Notwithstanding those declines, the number of persons 
abusing prescription drugs remains greater than the 
total number of persons abusing cocaine, heroin, 
hallucinogens and/or inhalants. Prescription drugs are 
the second most abused category of drugs, surpassed 
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only by cannabis. Young adults (persons 18-25 years 
old) have by far the highest rate of abuse of 
prescription drugs, more than twice the level of abuse 
among youth (persons 12-17 years old) and more than 
three times the level of abuse among adults (persons 
aged 26 or older). 
439. One matter of concern in the United States is that 
the number of first-time abusers of prescription drugs 
continues to be high. In 2008, 2.5 million people aged 
12 or above reported having abused prescription drugs 
for the first time, over 300,000 more than the number 
of first-time cannabis abusers. 
440. In the United States, the increase in the number 
of deaths due to overdose is to a significant extent 
related to the abuse of prescription drugs, in particular 
the abuse of opioid pain relievers such as oxycodone, 
hydrocodone, methadone, morphine and fentanyl. The 
number of deaths involving prescription opioids 
increased by two thirds from 2001 to 2005, reaching 
5,789 in 2005. 
441. According to the Canadian Alcohol and Drug Use 
Monitoring Survey, which was newly introduced in 
2008, the abuse of illicit drugs (including cannabis, 
cocaine, “crack”, methamphetamine, hallucinogens, 
MDMA (“ecstasy”) and heroin) among members of the 
population aged 15 and older declined significantly 
from 2004 to 2008. In 2008, 12.1 per cent of the 
population reported having abused illicit drugs in the 
previous 12 months (compared with 14.5 per cent in 
2004). That development is attributable to a reduction 
in the abuse of cannabis (from 14.1 per cent in 2004 to 
11.4 per cent in 2008) and cocaine and “crack” (from 
1.9 to 1.6 per cent). By contrast, the levels of abuse of 
other drugs increased during the same period; for 
instance, the abuse of “ecstasy” increased from 1.1 to 
1.4 per cent. In 2008, the abuse of illicit drugs was 
higher among men (15.3 per cent) than among women 
(9.1 per cent). The past-year use of prescription drugs, 
mainly opioid pain relievers but also stimulants and 
sedatives, was reported by 28.4 per cent of the 
population; however, only 0.6 per cent of the 
population (2.0 per cent of drug abusers) reported the 
non-therapeutic abuse of those preparations, stating 
that they would take prescription drugs “to get high”. 
442. In Canada, past-year abuse of illicit drugs among 
youth (persons 15-24 years old) decreased from 
37.9 per cent in 2004 to 34.0 per cent in 2008, but 
remains significantly higher than illicit drug abuse 
among the adult population (persons 25 years old or 
older) (7.9 per cent in 2008). Past-year abuse of 
cannabis among youth declined from 37.0 to 32.7 per 
cent. The average age of initiation of cannabis abuse 
among youth remained stable at 15.5 years in 2008. 
443. In Mexico, a national household survey 
conducted in 2008 showed a significant increase in 
cocaine abuse in the period 2002-2008: the lifetime 
prevalence rate almost doubled, reaching 2.4 per cent 
of the population aged 12-65. Lifetime prevalence of 
cannabis abuse increased from 3.5 to 4.2 per cent. In 
2008, methamphetamine and inhalants were among the 
most commonly abused drugs in Mexico, second only 
to cannabis and cocaine. Drug abuse, which used to be 
limited to certain areas of Mexico, appears to be 
spreading throughout the country. That may in part be 
attributed to the spillover effect of drug trafficking, as 
well as to attempts by drug trafficking organizations to 
create local markets. 
444. In Mexico, most drug-related deaths in 2008 were 
attributed to the abuse of cocaine (236 deaths). The 
Government reported a sharp increase in the abuse of 
cocaine, particularly “crack”, and methamphetamine in 
2008. The abuse of sedatives and tranquillizers, in 
particular benzodiazepines, was stable. In 2008, the 
number of problematic drug abusers reached 
428,819 (0.6 per cent of the population aged 12-65). 
The prevalence of drug abuse increased more sharply 
among women than among men. 
445. In the United States, most treatment related to 
drug abuse in 2008 was received for cannabis abuse 
(947,000 persons aged 12 and older), followed by 
cocaine abuse (663,000). The proportion of persons 
admitted for treatment of cannabis abuse continued to 
increase. In addition, the number of persons admitted 
for treatment for the abuse of pain relievers increased 
significantly (to 601,000 persons compared with 
360,000 in 2002). The number of persons admitted for 
heroin addiction (341,000 in 2008) may increase, 
according to the National Drug Threat Assessment 
2009,46 as more abusers of prescription opiates are 
switching to heroin, mainly because heroin is cheaper 
and easier to obtain. According to facilities for the 
__________________ 
 46  United States of America, Department of Justice, 
National Drug Intelligence Center, National Drug Threat 
Assessment 2009 (Johnstown, Pennsylvania,  
December 2008). 
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treatment of drug abuse, once a person switches from 
prescription opiates to heroin, it is unlikely that the 
person will switch back to abusing prescription opiates 
only. In some areas, the switching from prescription 
opiates to heroin led to an increase in heroin abusers 
seeking treatment in 2008. 
446. Drug treatment courts have experienced 
significant growth in the United States. Their main 
objective is to divert non-violent, substance-abusing 
offenders from imprisonment into treatment with 
increased supervision, thus breaking the cycle of 
criminal behaviour and improving treatment outcome. 
In 2008, about 2,300 drug treatment courts, some for 
adults and others for juveniles, were operating 
nationwide. New drug treatment courts, including drug 
treatment courts targeting particular groups such as 
veterans, are being developed. 
447. As part of the National Anti-Drug Strategy (see 
paragraph 414 above), the Government of Canada has 
created a programme to ensure funding to enable 
provincial governments to strengthen systems for the 
treatment of drug abuse. The Government has also 
initiated projects to improve the access of First Nations 
and Inuit families, in particular youth, to treatment for 
drug abuse. Drug treatment courts are operating in six 
cities in Canada; they deal only with cases involving 
non-violent accused persons whose criminal activity is 
driven by addiction. A judge may suspend the 
imposition of a sentence to allow the addicted person 
to undergo treatment under certain conditions. 
448. In Mexico, most persons admitted for treatment 
for drug abuse are addicted to cocaine or 
methamphetamine. Although the number of persons 
seeking help for drug problems has risen, only one 
third of drug addicts actually receive treatment. The 
Government is attempting to expand the drug abuse 
treatment capacity in order to cope with the increasing 
demand for such treatment. A pilot programme 
involving drug treatment courts has been introduced in 
the State of Nuevo León with a view to developing 
procedures and instruments to replace penal 
procedures. 
449. The strategy developed by the Government of 
Mexico for reducing illicit drug demand has enhanced 
the infrastructure for treatment. One of the core 
elements is the network of Nueva Vida centres, which 
provides treatment services for different groups of drug 
abusers in the country’s main municipalities, in 
cooperation with civil society organizations. Demand 
reduction initiatives also include a project for the 
development of the national network for technology 
transfer to combat addictions (RENADIC) — a 
platform for the exchange of medical information and 
education in cooperation with the United States.  
 
 
  South America 
 
 
 1. Major developments 
 
450. South America continues to be the sole source of 
illicitly manufactured cocaine, which is smuggled 
primarily into North America and Europe. In 2008, 
potential manufacture of cocaine in South America was 
845 tons, 15 per cent lower than potential manufacture 
in 2007 and the lowest since 2003. That significant 
decline in potential manufacture can, to a large extent, 
be attributed to a significant decrease in the total area 
under coca bush cultivation in Colombia in 2008. In 
Bolivia (Plurinational State of) and Peru, the area 
under illicit coca bush cultivation increased for the 
third consecutive year. The Board, concerned about the 
continued increase in the total area under illicit coca 
bush cultivation in Bolivia (Plurinational State of) and 
Peru, urges the Governments of both countries to take 
appropriate measures to reverse the trend. 
451. In addition to the illicit production and smuggling 
of cannabis, cocaine and heroin, trafficking 
organizations in South America appear to be expanding 
into areas of illicit activity not previously associated 
with drug problems in the region. In recent years, the 
Board has noted an increase in attempts in the region to 
divert precursors of amphetamine-type stimulants, in 
particular ephedrine and pseudoephedrine (including in 
the form of pharmaceutical preparations). Governments 
of several countries in South America responded to the 
emerging trafficking trends by strengthening at the 
national-level measures to control ephedrines. 
Nevertheless, the smuggling of ephedrines, in 
particular into Mexico, continued. Moreover, in 2008, 
the illicit manufacture of synthetic drugs emerged in 
the subregion, as evidenced by the laboratories  
illicitly manufacturing MDMA (“ecstasy”) and 
methamphetamine that were dismantled in Argentina 
and Brazil. The Board urges the Governments of the 
countries in the region to remain vigilant with regard to 
the diversion of precursors of amphetamine-type 
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stimulants, including in the form of pharmaceutical 
preparations. 
452. The abuse of illicit drugs in several countries in 
South America, has continued to increase — a spillover 
effect of drug trafficking in the region. According to 
UNODC, nearly 1 million people in the region are 
treated annually for the abuse of illicit drugs. The 
demand for treatment for the abuse of cannabis has 
increased significantly in the region in the past few 
years. Using strategies ensuring a balance between 
reducing illicit drug supply and demand to tackle illicit 
drug problems is a widely recognized approach in the 
region. The Board notes, however, that in some 
countries demand-reduction activities, including 
education, prevention and rehabilitation programmes, 
remain underdeveloped. In 2009, the Organization of 
American States (OAS), through CICAD, began a 
review of the Anti-Drug Strategy in the Hemisphere 
(adopted in 1996), so that new developments in the 
area of drug control could be taken into account. It is 
anticipated that the new drug control strategy for the 
Americas will focus on the reduction of drug demand 
in the region. 
453. The Board notes with concern that in countries in 
South America, such as Argentina, Brazil and 
Colombia (and in countries in North America, such as 
Mexico and the United States), there is a growing 
movement to decriminalize the possession of 
controlled drugs, in particular cannabis, for personal 
use. Regrettably, influential personalities, including 
former high-level politicians in countries in South 
America, have publicly expressed their support for that 
movement. The Board is concerned that the movement, 
if not resolutely countered by the respective 
Governments, will undermine national and 
international efforts to combat the abuse of and illicit 
trafficking in narcotic drugs. In any case, the 
movement poses a threat to the coherence and 
effectiveness of the international drug control system 
and sends the wrong message to the general public. 
 
 2. Regional cooperation 
 
454. At the forty-fourth regular session of CICAD, 
held in Santiago from 19 to 21 November 2008, 
participants reported on achievements and current 
challenges in drug control, including policymaking in 
the area of treatment and rehabilitation for drug 
abusers. At the session, experts on chemical substances 
and pharmaceutical products discussed problems 
related to the growing number of imports of chemical 
substances in amounts exceeding legitimate 
requirements. 
455. In 2007, the European Commission and OAS 
launched the European Union/Latin American and the 
Caribbean Drug Treatment City Partnership initiative, 
which paired cities in Europe with cities in Latin 
America and the Caribbean, forming partnerships to 
improve the treatment and rehabilitation of problem 
drug abusers and address other aspects of drug 
dependency at the municipal level. Under the initiative, 
a number of activities were organized in South 
American countries in 2008 and 2009. For example, 
representatives of participating cities attended a forum 
on local assessments and information systems in the 
treatment of drug abuse, held in Montevideo from 4 to 
6 December 2008. The objective of the forum was to 
facilitate the exchange of experiences, from the 
perspective of municipalities, on demand for, and 
availability of, treatment services for drug abusers.  
456. On 22 December 2008, Brazil and the European 
Union adopted a joint action plan at the second 
Brazil/European Union summit, held in Rio de Janeiro, 
Brazil. The action plan for the control of illicit drugs 
and drug-related crime recognizes the principle of 
shared responsibility and the need for an approach 
ensuring a balance between reducing the supply of and 
reducing the demand for illicit drugs, and promotes 
bilateral cooperation to combat drug trafficking and 
organized crime.  
457. The project financed by the European 
Commission and UNODC for cooperation among 
national security offices to counter the smuggling of 
cocaine from South America through West Africa into 
Europe has the participation of Bolivia (Plurinational 
State of), Brazil, Colombia, Ecuador, Peru and 
Venezuela (Bolivarian Republic of) and, in  
West Africa, Cape Verde, the Gambia, Ghana,  
Guinea-Bissau, Senegal and Togo. At a training 
seminar held in Bogota in January 2009 as part of that 
project, police officers from 16 countries exchanged 
information on the smuggling of cocaine through West 
Africa to Europe with a view to optimizing drug law 
enforcement operations in those countries.  
458. Bolivia (Plurinational State of), Colombia, 
Ecuador and Peru participated in the activities of the 
project for support for the Andean Community in the 
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area of synthetic drugs (DROSICAN) launched in  
July 2008. The project, financed by the European 
Commission, supports institutions that focus on 
development, the control of synthetic drugs and the 
reduction of demand for those drugs in the Andean 
subregion. The project includes the establishment of a 
reference drug laboratory in Colombia to provide 
support for all countries in the subregion in the area of 
synthetic drugs. The heads of the drug control agencies 
of States members of the Andean Community reviewed 
the operational plan of the project for 2009 at the 
coordination meeting of the project held in Bogota in 
February 2009.  
459. CICAD and the Government of Spain launched 
Health and Life in the Americas (SAVIA), a 
programme for the period 2008-2010 that provides 
direct support to local demand-reduction initiatives in 
Bolivia (Plurinational State of), Colombia, Ecuador, 
Peru, Uruguay and Venezuela (Bolivarian Republic of). 
At a workshop on the quality of local policies to reduce 
consumption of drugs in Latin America, held in 
Cartagena de Indies, Colombia, from 27 April to 1 May 
2009, experts from the above-mentioned countries, as 
well as Argentina, Chile, Mexico and Spain, shared 
experiences in the decentralization of drug control 
policies in their countries and the implementation of 
programmes for the prevention of drug abuse.  
460. The Eleventh High-Level Specialized Dialogue 
on Drugs between the Andean Community and the 
European Union was held in Quito in May 2009. 
Participants from 60 countries adopted the Quito 
Declaration, in which they reaffirmed the importance 
of cooperation in combating illicit drugs including in 
the areas of alternative development and preventive 
alternative development. 
461. Drug-testing laboratories in countries in Latin 
America are participating in the international 
collaborative exercise, a component of the UNODC 
international quality assurance programme, which 
monitors the performance and capacities of forensic 
laboratories worldwide and provides tailored technical 
support and assistance. In March 2009, UNODC 
initiated a national collaborative exercise involving  
35 drug-testing laboratories in Brazil. 
462. In March 2009, Argentina, Bolivia (Plurinational 
State of), Brazil, Chile, Colombia, Ecuador, Venezuela 
(Bolivarian Republic of), together with Jamaica, 
Mexico, Panama and Trinidad and Tobago, joined a 
new project, co-financed by the European Commission, 
for the prevention of the diversion of drug precursors 
in Latin America and the Caribbean (PRELAC). That 
three-year project, which partly builds on the 
achievements of the completed project to counter the 
diversion of drug precursors in the region (PRECAN), 
will focus on preventing the diversion of precursors in 
Latin America and the Caribbean. 
463. The Board notes that in 2009, the Governments of 
Bolivia (Plurinational State of), Brazil, Chile, Peru and 
Venezuela (Bolivarian Republic of) participated in 
Operation PILA, which focused on monitoring trade in 
precursors of amphetamine-type stimulants. In 
addition, Brazil, Colombia, Ecuador and Venezuela 
(Bolivarian Republic of) participated in the second 
phase of Operation Dice, targeting trade in and 
diversion of acetic anhydride, the key precursor used in 
the illicit manufacture of heroin. 
 
 3. National legislation, policy and action 
 
464. In December 2008, the Government of Argentina 
promulgated Decree No. 2094/2008, establishing the 
Interjurisdictional Committee of the National Register 
of Precursor Chemicals. The Board notes that a draft 
law on medicines banning the sale of pharmaceutical 
products through the Internet was submitted to the 
Congress of Argentina for approval.  
465. Following the approval of the new constitution of 
the Plurinational State of Bolivia in January 2009,47 
the Bolivian Government notified the Secretary-
General of its request to amend article 49 of the 
1961 Convention as amended by the 1972 Protocol, 
concerning the abolishment of coca leaf chewing.  
466. In 2009, the Bolivian Observatory on Drugs 
conducted a study on the prevalence of drug abuse 
among students between the ages of 13 and 18 years to 
assist in planning future policies for the reduction of 
drug demand.  
467. The Board wishes to remind the Governments of 
all countries concerned, in particular the Government 
of the Plurinational State of Bolivia, that unless any 
__________________ 
 47  The new constitution of the Plurinational State of 
Bolivia states that the State protects the original and 
ancestral coca as cultural heritage, as a natural and 
renewable resource of Bolivia’s biodiversity and as a 
factor of social cohesion; in its natural state, it is not a 
narcotic drug. 
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further amendments to the 1961 Convention are put 
into effect, the use or importation of coca leaf from 
which cocaine has not been extracted, for purposes 
other than those allowed under the 1961 Convention, 
constitutes a breach of obligations under the 
Convention (see paragraphs 156-166 above). 
468. The Government of Brazil is implementing 
measures to prevent the counterfeiting of 
pharmaceutical products in that country. In 2008, the 
National Health Surveillance Agency (ANVISA) 
carried out inspections to verify the compliance of 
pharmacies with regulations concerning 
pharmaceutical preparations containing controlled 
substances. Starting in 2009, electronic tracing will be 
used with all medicines manufactured in Brazil. The 
Government of Brazil has also strengthened measures 
related to the dispensation and control of anorectics, 
which have high levels of consumption in the country. 
469. In November 2008, the Government of Colombia 
launched the national plan for the reduction of drug 
consumption for the period 2009-2010. The plan, 
among other things, provides for the implementation of 
comprehensive care guidelines for use in the social 
security system that establish clinical standards for 
treatment and rehabilitation services. In January 2009, 
the Government published the executive summary of 
the 2008 national study of abuse of psychoactive 
substances in Colombia. The comprehensive survey is 
the first of its kind in more than 10 years, and the 
Government is committed to conducting such surveys 
every two years.  
470. Governmental and non-governmental 
organizations and health-care professionals of 
Colombia participated in the first national conference 
on heroin abuse, held in Medellín on 4 and 5 December 
2008. The objective of the conference was to raise 
awareness among health-care professionals concerning 
treatment, rehabilitation, prevention programmes and 
aftercare services for heroin abusers. In 2009, the 
Government of Colombia took further measures to 
ensure the availability of opioids for medical use in the 
country. Pain treatment medicine is now accessible at 
all times in at least one place in each state of 
Colombia.  
471. Between August and December 2008, Argentina 
adopted several new regulations that significantly 
restricted trade in ephedrine and pseudoephedrine and 
their use in the manufacture of medicines. In Peru, cold 
medicines containing pseudoephedrine, which had 
previously been sold over the counter, can now be 
purchased only with a medical prescription in 
pharmacies. The Government of Chile took further 
steps to enhance awareness among pharmacists and 
health-care professionals of the possible misuse of 
ephedrine in the illicit manufacture of amphetamine-
type stimulants and proposed further control measures. 
In July 2009, the Government of Colombia adopted 
resolution No. 2335, which prohibits the manufacture 
and import of and trading in medicinal products 
containing pseudoephedrine and restricts trade in and 
use of ephedrine.  
472. In 2008, a number of countries in South America, 
including Brazil, Chile, Ecuador, Paraguay, Peru and 
Venezuela (Bolivarian Republic of), strengthened 
measures to tackle money-laundering. For example, in 
December 2008, the National Council of Justice of 
Brazil, by its resolution No. 63, established the 
National Seized Assets System, which consolidates 
data on assets seized during criminal proceedings 
related to the prosecution of money-laundering. 
Further, in September 2009, the National Secretariat of 
Justice of Brazil organized an international seminar on 
extinction of property rights. 
473. In November 2008, the Government of Ecuador 
adopted a resolution approving the regulation of the 
control of substances subject to control and medicines 
containing such substances, thus strengthening control 
measures on substances listed in the international drug 
control treaties. The new measures also apply to 
pharmaceutical preparations containing controlled 
substances. Preventing the abuse of narcotic drugs and 
psychotropic substances is one of the principal 
objectives of the national plan for the comprehensive 
prevention and control of drugs for the period 2009-
2012 adopted by the Government of Ecuador in 2009. 
The Board also notes that in April 2009, following the 
findings of the national Institute of Public Health, the 
Government of Chile adopted a decree placing six 
synthetic cannabinoid analogues on the national list of 
controlled substances. 
474. In 2009, the Government of Peru adopted 
decree No. 045-2009, which bans the sale, use and 
distribution of kerosene in the country by 2010. 
Kerosene is not controlled at the international level but 
is widely used for the maceration of coca leaves in 
laboratories illicitly manufacturing cocaine. 
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475. In Suriname, programmes to prevent drug abuse 
are incorporated into the curriculum of primary and 
secondary schools. In 2008, a nationwide crisis 
helpline was established in the country to provide 
drug-related information and assistance to the general 
public. In 2008, the Ministry of Justice and Police of 
Suriname drafted legislation for the control of 
chemical substances. The Board urges the Government 
of Suriname to adopt that legislation without further 
delay.  
476. In June 2009, the Government of the Bolivarian 
Republic of Venezuela approved the national drug 
control plan for the period 2008-2013. Under the plan, 
the Venezuelan authorities implemented a number of 
activities to combat illicit drugs, including the 
monitoring by satellite of areas susceptible to illicit 
crop cultivation. Installation of a radar system for air 
traffic control in the country enhanced the protection of 
the national airspace, as well as maritime areas, from 
drug traffickers. Within the framework of a national 
plan to combat the use of clandestine smuggling routes, 
in 2008 the Venezuelan law enforcement authorities 
destroyed more than 220 clandestine airstrips used by 
drug traffickers in the country. In April 2008, the 
Venezuelan Observatory on Drugs initiated a national 
study on the extent of drug abuse among the general 
population.  
477. In Brazil, legislation in place since 2006 
distinguishes between drug traffickers and drug users 
and established alternative sanctions for drug abuse 
without decriminalizing it. In 2009, the Supreme Court 
of Argentina, in a case involving personal use of 
cannabis by adult consumers, ruled that the punishment 
of personal use of cannabis was unconstitutional. The 
Board, concerned that such legal acts may impart a 
wrong message, would like to remind Governments 
that article 3, paragraph 2, of the 1988 Convention 
requires each party to that Convention to establish as a 
criminal offence under its domestic law, when 
committed intentionally, the possession, purchase or 
cultivation of narcotic drugs or psychotropic 
substances for personal consumption contrary to  
the provisions of the 1961 Convention, the 
1961 Convention as amended by the 1972 Protocol, or 
the 1971 Convention.  
 
 4. Cultivation, production, manufacture and 
trafficking 
 
  Narcotic drugs 
 
478. According to UNODC, it is difficult to estimate 
with greater accuracy the magnitude of the illicit 
cultivation of drug crops that takes place in a number 
of countries. In Paraguay, one of the major producers 
of illicit cannabis in South America, the main methods 
used for detecting drug crop cultivation include aerial 
remote sensing and ground surveys. In January 2009, 
the Paraguayan authorities, in cooperation with the 
Government of Brazil, carried out a monitoring 
mission to further identify areas of cannabis cultivation 
in the country. 
479. According to the National Anti-Drug Secretariat 
(SENAD) of Paraguay, illicitly cultivated cannabis 
plants cover an estimated area of 6,000 ha, yielding 
about 16,500 tons of cannabis herb. In 2008, the 
Paraguayan authorities eradicated more than 1,800 ha 
of illicitly cultivated cannabis plants.  
480. Cannabis plants are also illicitly cultivated in 
Colombia. The cannabis plants cultivated in the 
department of Cauca are several times more potent 
than traditional varieties of cannabis plant cultivated in 
the country. According to the National Narcotics 
Directorate (DNE) of Colombia, the highly potent 
variety of cannabis, which contain 17-18 per cent of 
the active ingredient, is cultivated from seeds 
originating in Europe. In Chile, although authorities do 
not consider illicit drug production to be significant in 
the country, the Government is concerned about 
cannabis cultivated for domestic consumption in rural 
mountainous and coastal areas in the central part of the 
country.  
481. In 2008, seizures of cannabis herb increased in 
Bolivia (Plurinational State of), Chile, Ecuador, 
Paraguay and Peru and decreased in Brazil and 
Venezuela (Bolivarian Republic of). Bolivian 
authorities seized the largest total amount of cannabis 
herb in South America in 2008: 1,113 tons in Bolivia, a 
quantity about two-and-a-half times that reported for 
2007. In 2008, seizures of cannabis herb larger than 
100 tons were also reported in Paraguay (208 tons), 
Brazil (187 tons) and Argentina (108 tons). In recent 
years, Paraguay has been named as the source of 
cannabis herb seized in South America more often than 
other countries in the region.  
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482. The total area under coca bush cultivation in 
South America decreased in 2008 to 167,600 ha, 8 per 
cent less than the total area in 2007. Colombia 
accounted for 48.3 per cent of that total; it was 
followed by Peru and the Plurinational State of Bolivia, 
which accounted for 33.5 per cent and 18.2 per cent, 
respectively. Cocaine manufacture in Colombia 
declined by 28 per cent in 2008, a reduction that was 
not fully offset by the increased manufacture of 
cocaine in Bolivia (Plurinational State of) and Peru. As 
a result, the potential global cocaine manufacture 
decreased from 994 tons in 2007 to 845 tons in 2008.  
483. Although sizeable coca bush cultivation is not 
found outside the three main countries of cultivation, 
eradication reports indicate that small-scale coca bush 
cultivation of an exploratory nature takes place in other 
countries in South America. For example, in 2008, 
illicit coca bush was cultivated on small plots of land 
in Ecuador near that country’s border with Colombia.  
484. In 2008, the total area under illicit coca bush 
cultivation in the Plurinational State of Bolivia 
increased to 30,500 ha, 6 per cent more than in 2007. 
The Board notes with concern that as a result of 
repeated small increases, the total area under illicit 
coca bush cultivation in the country doubled between 
2000 and 2008. In 2008, potential manufacture of 
cocaine in the country increased by 9 per cent to 
113 tons, accounting for 13 per cent of potential global 
manufacture of cocaine. In 2008, a total of 5,483 ha of 
coca bush were manually eradicated in the country. 
That total area of annual eradication is the second 
smallest reported since 1995.  
485. The eradication of illicitly cultivated coca bush 
and prevention of coca bush cultivation in new areas 
were among the main objectives of the Peruvian 
national strategy to combat drugs for the period 2007-
2011. In 2008, the total area under coca bush 
cultivation increased in Peru for the third consecutive 
year, amounting to 56,100 ha. The Board notes with 
concern that from 1999 to 2008, the total area under 
illicit coca bush cultivation in the country gradually 
increased by 17,400 ha, or 45 per cent. The Board calls 
on the Governments of Bolivia (Plurinational State of) 
and Peru to enhance their programmes to reduce illicit 
drug supply in order to address the increasing illicit 
cultivation of coca bush in their countries, which is 
apparently a result of drug traffickers’ attempts to 
offset the decline in the total area under coca bush 
cultivation in Colombia.  
486. Potential illicit manufacture of cocaine in Peru 
increased to 302 tons in 2008, accounting for 36 per 
cent of potential global cocaine manufacture. In 2008, 
10,143 ha of illicitly cultivated coca bush were 
eradicated in Peru, slightly exceeding the goal of 
10,000 ha. The forced eradication efforts were 
hampered by incidents of violence, including armed 
attacks. The Government’s eradication goal for 2009 is 
8,000 ha. 
487. The Board urges the Governments of Bolivia 
(Plurinational State of) and Peru, in spite of perceived 
difficulties in combating illicit manufacture of and 
trafficking in cocaine, not to reduce their efforts in 
those areas and to address in a decisive manner the 
increasing illicit cultivation of coca bush on their 
territory. At the same time, the Board believes that 
measures to provide legitimate and sustainable 
alternative livelihoods, accompanied by continued law 
enforcement efforts to prevent the re-emergence of 
illicit crop cultivation, are essential to achieving a 
lasting reduction in the production of coca and other 
narcotic drugs in South America.  
488. In Colombia, illicit coca bush cultivation, as well 
as cocaine manufacture, saw a major decline in 2008. 
The total area under illicit coca bush cultivation in 
2008 decreased by 18 per cent to 81,000 ha, and 
potential manufacture of cocaine decreased by 28 per 
cent, or 170 tons, to 430 tons. Colombia’s share of 
global cocaine manufacture fell to 51 per cent, the 
lowest in a decade. Much of the decline in the illicit 
manufacture of cocaine in Colombia can be attributed 
to the manual eradication efforts targeting areas with 
high-yields. In 2008, a total of 96,115 ha of illicitly 
cultivated coca bush were eradicated manually (an 
increase of 44 per cent), and an additional 133,496 ha 
were subject to aerial spraying.  
489. According to UNODC, in 2007, for the third year 
in a row, the global cocaine interception rate was above 
the 40-per-cent benchmark. South American countries 
accounted for almost half of the total amount of 
cocaine seized worldwide in 2007. 
490. In 2008, all three of the main countries producing 
coca leaf, as well as Argentina, Brazil and Ecuador, 
reported a significant increase in the quantity of 
cocaine seized compared with the figures for 2007. In 
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2008, Bolivian authorities seized 21.6 tons of cocaine 
paste (an increase of 45 per cent) and 7.2 tons of 
cocaine hydrochloride (an increase of 148 per cent). In 
Peru, seizures of cocaine hydrochloride doubled from 
2007 to 2008, reaching 16.8 tons, the largest annual 
total since 2000. In Colombia, seizures of cocaine 
hydrochloride increased by 57 per cent to 198.4 tons. 
In Ecuador, seizures of cocaine hydrochloride totalled 
27.2 tons, an increase of 55 per cent over 2007. Stable 
or declining seizures of cocaine were reported, for 
example, in Chile, Paraguay and Venezuela (Bolivarian 
Republic of). Despite the large quantity of cocaine 
seized in South America, drug control agencies in the 
region emphasized the continued need for the 
exchange, among law enforcement and judicial 
authorities in South America, of real-time information 
in investigative and operational activities in order to 
further enhance the interdiction capacity of those 
authorities.  
491. The permeable borders and long coastlines of 
countries in South America pose challenges to drug 
law enforcement authorities in the region, especially 
considering their limited resources. Drug trafficking by 
sea remains a major problem. For example, in 
Colombia, of a total of 198 tons of cocaine 
hydrochloride seized in 2008, 74.6 tons were seized on 
the high seas and at seaports. In particular, drug 
traffickers have continued using non-commercial 
maritime vessels (fishing vessels, fast boats and semi-
submersibles). Drug traffickers have demonstrated 
their ingenuity by modifying the structure of fishing 
vessels to hide illicit drugs and the building of semi-
submersibles capable of transporting 10 tons of cargo 
with a range of 2,500 km. Throughout South America, 
there has been an increase in the use of light aircraft 
with forged or stolen registration numbers, operating 
out of small, privately owned airstrips in remote areas, 
to transport cocaine. There has also been an increase in 
the use of human couriers (“mules”) and the dissolving 
of cocaine in liquids. 
492. The drug seizures reported by the Governments 
of countries in South America attest to the fact that 
almost all countries in the region are affected by drug 
trafficking. Cocaine smuggled into North America 
typically originates in Colombia and enters the United 
States from Mexico after having passed through 
countries in South America and in Central America and 
the Caribbean. In 2007 and 2008, there was a decline 
in the amount of cocaine smuggled into countries in 
North America, in particular the United States. 
Colombia, Peru and the Plurinational State of Bolivia 
(in that order) were the most frequently named as the 
countries of origin of cocaine consignments destined 
for Europe in 2007. The involvement of Mexican 
cartels in cocaine trafficking has been reported in 
several South American countries, including Ecuador 
and Peru. Large illicit consignments of cocaine are 
transported from countries in Latin America through 
Brazil. About half of the cocaine seized in Brazil in 
2008 had been smuggled using air routes. In Paraguay, 
almost all the cocaine seized in the country originated 
in the Plurinational State of Bolivia. 
493. According to UNODC, in the past few years at 
least 50 tons of cocaine from the Andean countries 
have passed through West Africa each year, destined 
for illicit markets in Europe. In 2008 and 2009, 
UNODC noted an apparent decline in the use of West 
Africa as a transit area for cocaine. The Board wishes 
to encourage the Governments of the countries of 
South America and West Africa to cooperate and 
remain vigilant in their efforts to combat the smuggling 
of drugs through their territory. 
494. In many countries in South America, criminal 
organizations engaged in drug trafficking continued to 
exploit vulnerable population groups. In Ecuador and 
Paraguay, unemployed persons accounted for 34 per 
cent and 90 per cent, respectively, of all persons 
arrested in connection with drug trafficking in 2008. 
Incidents of drug trafficking involving youth under 
15 years of age were reported in several countries in 
the region, including Chile and Ecuador. Drug 
trafficking is accompanied by an increased level of 
other forms of serious crime.  
495. In 2007, over 99 per cent of coca-processing 
laboratories were located in the three main countries 
cultivating coca bush: Bolivia (Plurinational State of), 
Colombia and Peru. By 2007, a small number of 
clandestine cocaine laboratories were dismantled in 
other South American countries, including Argentina, 
Brazil, Chile, Ecuador and Venezuela (Bolivarian 
Republic of). The spreading of coca-processing 
laboratories beyond the main cocaine-producing 
countries resulted in increased abuse of coca paste, in 
particular among adolescents and young people, in the 
countries concerned, in particular Argentina and Brazil. 
496. Since 2001, the number of clandestine coca paste 
and cocaine laboratories identified in the Plurinational 
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State of Bolivia reflected the increasing trend in illicit 
coca bush cultivation in the country, although the 
increase in the number of identified laboratories was 
even more pronounced. Between 2000 and 2008 the 
total area under illicit coca bush cultivation doubled in 
the country, while the number of destroyed coca paste 
and cocaine laboratories increased eightfold over the 
same period. In 2008, Bolivian authorities destroyed 
nearly 5,000 coca paste laboratories, including a 
number of cocaine hydrochloride laboratories and 
7,500 maceration pits. In March 2009, the Bolivian 
police specialized in drug control operations (FELCN) 
dismantled in Ñuflo de Chávez province a clandestine 
laboratory with a capacity to manufacture 3 tons of 
cocaine hydrochloride per month. The size of the 
laboratory raises concerns about the growing capacity 
of traffickers to manufacture cocaine in the country. 
497. In Colombia, traditional use of coca leaf is 
marginal and illegal. Virtually all of the coca leaves 
produced in the country are destined for cocaine 
manufacture. According to UNODC, about 40 per cent 
of coca bush growers in Colombia sell the coca leaves 
without any further processing at the farm, while the 
remaining 60 per cent of growers process the coca 
leaves into coca paste or cocaine base to increase their 
profits. The last step, the processing of the cocaine 
base into cocaine hydrochloride, is carried out by 
traffickers in clandestine laboratories. According to the 
Colombian DNE, the national drug control agency of 
Colombia, of the 3,200 clandestine laboratories 
destroyed in the country in 2008, more than 
2,900 laboratories had been manufacturing coca paste 
or cocaine base, and the remaining laboratories, less 
than 300 had been manufacturing cocaine 
hydrochloride. The number of clandestine laboratories 
dismantled in Colombia in 2008 was 36 per cent 
greater than in 2007.  
498. In 2008, authorities in Peru dismantled over 
1,200 coca paste laboratories (the highest number of 
coca paste laboratories dismantled in that country since 
2000) and 19 laboratories manufacturing cocaine 
hydrochloride. In 2008, clandestine laboratories 
processing cocaine base or cocaine also were 
dismantled in Chile (4 laboratories), Ecuador 
(1 laboratory) and Venezuela (Bolivarian Republic of) 
(13 laboratories). The laboratory dismantled in 
Ecuador was estimated to have manufactured 2 tons of 
cocaine hydrochloride per month.  
499. As a result of continued eradication efforts, the 
total area under illicit opium poppy cultivation in 
Colombia gradually declined to 400 ha in 2008, one 
twentieth the area under such cultivation in 1998. 
Opium poppy is mainly cultivated in small fields on 
mountainsides, where it is interspersed with licit crops, 
in the departments of Cauca, Nariño, Huila and Tolima. 
In most areas of Colombia in which opium poppy is 
cultivated, the illicit crop is harvested twice a year. 
Potential manufacture of heroin in Colombia in 2008 
was calculated to be 1.3 tons, 43 per cent less than in 
2007. 
500. In 2008, 381 ha of illicitly cultivated opium 
poppy were eradicated in Colombia, and 23 ha were 
eradicated in Peru. In the past, the eradication of 
illicitly cultivated opium poppy has also been reported 
by Venezuelan authorities. In 2007, the total amount of 
opium seized in South American countries, was 259 kg, 
or only 0.1 per cent of the amount seized worldwide. In 
2008, heroin seizures in Colombia increased to almost 
650 kg (an increase of 20 per cent) and heroin seizures 
in Ecuador decreased to 144 kg (a decrease of 20 per 
cent). Seizures of heroin by Venezuelan authorities did 
not change significantly, totalling approximately 130 
kg. In 2008, Peruvian authorities destroyed a 
laboratory processing opium and seized 8 kg of heroin.  
 
  Psychotropic substances  
 
501. In the past few years, South American countries 
reported that Europe was one of the main sources of 
MDMA (“ecstasy”) seized in their region. In 2008, 
Brazilian authorities dismantled the first clandestine 
laboratory manufacturing “ecstasy” and seized a total 
of 132,000 units of the substance. A second “ecstasy” 
laboratory was dismantled in Brazil in August 2009. 
An “ecstasy” laboratory was dismantled in Argentina 
in 2008. Seizures of “ecstasy” also took place in 
Argentina, Chile, Ecuador, Peru, Uruguay and 
Venezuela (Bolivarian Republic of). It cannot be 
excluded that South America, in addition to having a 
tradition of being a destination of “ecstasy” 
consignments from other regions, is now becoming a 
source of the substance, as indicated by the World 
Customs Organization. According to the latest report of 
that organization, in 2008, seizures of “ecstasy” from 
Brazil, Chile and Suriname were reported, for example, 
in the Netherlands and Sweden. 
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502. In addition to MDMA (“ecstasy”), drug-testing 
laboratories in South American countries reported 
seizures of less common psychotropic substances such 
as brolamfetamine, mazindol and zolpidem, as well as 
synthetic drugs not controlled internationally such as 
2,5-dimethoxy-4-iodoamphetamine, dihydro-lysergic 
acid diethylamide, meta-chlorophenylpiperazine and 
modafinil (a stimulant used for the treatment of 
narcolepsy). 
 
  Precursors 
 
503. According to a Peruvian national study on the 
diagnosis of the situation concerning the diversion of 
chemical substances to drug trafficking, published in 
2009, the manufacture of 1 kg of cocaine 
hydrochloride requires the use of approximately 100 kg 
of various chemical substances. In 2007 and 2008, 
seizures of potassium permanganate, the key precursor 
used in the illicit manufacture of cocaine 
hydrochloride, were reported in Argentina, Brazil, 
Chile, Colombia, Ecuador and Peru. Since 2000, the 
largest seizures of potassium permanganate have been 
reported by Colombia. Between 2000 and 2008 a total 
of 837 tons of potassium permanganate were seized in 
Colombia. Despite the dismantling of a large number 
of cocaine laboratories in the Plurinational State of 
Bolivia in recent years, the seizures of potassium 
permanganate reported in the country remained low, 
totalling less than 500 kg in the period 2000-2008. The 
Board notes with concern that, with the exception of 
the clandestine potassium permanganate laboratories 
seized in Colombia, the origin of the potassium 
permanganate seized in South American countries 
remains unknown. The Board calls on the Governments 
of countries in the Americas and the regional members 
of the Project Cohesion Task Force to devise strategies 
to address the smuggling of potassium permanganate 
into the cocaine-manufacturing areas of South 
America.  
504. In recent years, there has been an increase in the 
number of attempts by traffickers to secure precursors 
of amphetamine-type stimulants, including ephedrine 
and pseudoephedrine in the form of pharmaceutical 
preparations in both Central America and South 
America. From 2007 to 2009, seizures of sizeable 
amounts of ephedrine and pseudoephedrine were made 
in Argentina, Chile, Paraguay and Venezuela 
(Bolivarian Republic of). The diverted substances were 
destined primarily for clandestine methamphetamine 
laboratories in countries in North America, in 
particular Mexico. However, in 2008, the illicit 
manufacture of methamphetamine was detected in 
Argentina. Investigations into seizures of ephedrines 
indicate Mexican traffickers have increased their 
presence and activities in South America.  
 
  Substances not under international control 
 
505. In 2008, the Bolivarian Republic of Venezuela 
placed under national control four substances currently 
not under international control: butorphanol, 
nalbuphine, ketamine and tramadol. The control 
measures include the issuance of import permits and 
the registration of medicines containing the substances. 
Paraguay also made subject to national control four 
substances not currently controlled under the 
international drug control treaties: ketamine, modafinil, 
oxymethadone and thalidomide. 
 
 5. Abuse and treatment 
 
506. According to the World Drug Report 2009,48 the 
primary drugs of abuse among persons treated for drug 
problems in South America are cocaine-type drugs 
(accounting for 52 per cent of all cases involving 
persons seeking treatment for drug abuse), followed by 
cannabis (accounting for 33 per cent of such cases). 
The demand for treatment for the abuse of 
amphetamine-type stimulants is significantly lower. 
Only 4.8 per cent of those seeking treatment do so for 
the abuse of amphetamines and 5.1 per cent for the 
abuse of MDMA (“ecstasy”). Only 1.7 per cent of drug 
abusers in the region are treated primarily for the abuse 
of opiates. 
507. According to the 2008 Report on the Global AIDS 
Epidemic,49 published by the Joint United Nations 
Programme on HIV/AIDS (UNAIDS), although HIV 
transmission as a result of drug use by injection is still 
high in South America, the number of new infections 
transmitted by injecting drugs appears to be 
decreasing. While the level of HIV infection among 
persons who use drugs by injection has declined in 
some cities of Brazil, HIV transmission among such 
persons remains significant in Montevideo, the capital 
of Uruguay. Brazilian authorities estimate that about 
__________________ 
 48  World Drug Report 2009 …, pp. 14 and 261. 
 49  Joint United Nations Programme on HIV/AIDS, 2008 
Report on the Global AIDS Epidemic (Geneva, 2008). 
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0.2 per cent of drug abusers in Brazil inject drugs. 
Uruguayan authorities estimate that 0.3 per cent of 
drug abusers in their country inject drugs.  
508. The UNODC estimate of the past-year prevalence 
of cannabis abuse among the general population in 
South America is 3.4 per cent. The prevalence of 
cannabis abuse was the highest in Argentina and 
Venezuela (Bolivarian Republic of), exceeding 7 per 
cent of the adult population. According to the eighth 
national survey of drug abuse in Chile, conducted in 
2008, cannabis continues to be the most abused illicit 
drug in the country. About 6.4 per cent of Chileans 
aged 12-64 years reported having abused cannabis at 
least once in the previous year. The national study on 
the use of psychoactive substances in households 
conducted in 2008 showed that cannabis is also the 
most abused drug in Colombia. The past-year 
prevalence of cannabis abuse among persons aged 12-
64 years in Colombia increased slightly from 1.9 per 
cent in 2003 to 2.3 per cent in 2008. Almost half of the 
individuals surveyed responded that cannabis was 
easily available in the country.  
509. The estimated annual prevalence of cocaine abuse 
in South America among persons aged 15-64 was  
0.9 per cent, approximately double the world 
prevalence rate of cocaine abuse (0.4-0.5 per cent). 
Although Colombia is one of the world’s main 
producers of cocaine, according to the 2008 national 
study of drug abuse, past-year prevalence of cocaine 
abuse in Colombia was 0.7 per cent, which is slightly 
less than the prevalence rate for the region as a whole. 
Cocaine abuse has continued to increase in some 
countries in the region. In 2008, the abuse of cocaine 
was reported to have increased in Ecuador, Paraguay 
and Venezuela (Bolivarian Republic of). In Uruguay, 
the annual prevalence of cocaine abuse among persons 
aged 12-65 rose from 0.2 per cent in 2001 to 1.4 per 
cent in 2007. In Chile, the lifetime prevalence of the 
abuse of cocaine, including cocaine base, increased 
from to 3.5 per cent in 1994 to 7.7 per cent in 2008. In 
Peru, the annual prevalence of cocaine abuse was 
stable. The lifetime prevalence of cocaine abuse among 
persons aged 12-64 in Peru was 1.4 per cent.  
510. The past-year prevalence of the abuse of opiates 
in South America was 0.3 per cent. According to 
UNODC, levels of opioid abuse are stable in a number 
of countries in the Americas, including Brazil, Chile 
and Paraguay. Nevertheless, rising levels of opioid 
abuse in 2008 were reported in Ecuador and Venezuela 
(Bolivarian Republic of). The largest population of 
opioid abusers in South America, in particular those 
abusing synthetic opioids, was found in Brazil.  
511. According to the latest data, the annual 
prevalence of the abuse of MDMA (“ecstasy”) among 
the general population in South America is estimated at 
0.2 per cent, which is one of the lowest rates of all 
regions. In the past few years, increased abuse of 
“ecstasy” among secondary school students was 
reported in several countries in the region, including 
Argentina, Chile and Colombia. According to the 2008 
study on drug abuse, an estimated 55,000 Colombians, 
or 0.3 per cent of the population aged 12-64 years, had 
used “ecstasy” in the previous year. Most of those 
persons were men aged 18-24 years. About 1.7 per cent 
of the persons surveyed in Colombia had received an 
offer to try or buy “ecstasy” in the previous year. 
 
 
 C. Asia 
 
 
  East and South-East Asia 
 
 
 1. Major developments 
 
512. States in East and South-East Asia have made 
progress in reducing illicit opium poppy cultivation 
over the years. However, it appears that they have 
recently been experiencing some setbacks. In 2008, the 
area under illicit opium poppy cultivation in the region 
increased by 3.3 per cent compared with 2007. 
513. In addition, there was a significant increase in the 
trafficking in methamphetamine and the illicit 
manufacture of MDMA (“ecstasy”). Moreover, for the 
first time in recent years, the illicit manufacture of 
GHB was reported. 
514. Seizures of new types of products containing 
mixtures of synthetic drugs were reported in China. In 
December 2008, tablets consisting of a mixture of 
methaqualone and ephedrine were seized in northern 
China (in the autonomous region of Inner Mongolia). 
In January 2009, mixtures of GHB, MDMA and 
ketamine concealed in bottles labelled “traditional 
cough medicine” were seized in the autonomous region 
of Guangxi, China.  
515. Drug traffickers are increasingly using social 
networking sites to recruit South-East Asian women to 
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work as “mules” in countries in East and South-East 
Asia, including Singapore. The traffickers are believed 
to be targeting single women between the ages of 20 
and 30 who do not have a criminal record and who are 
unemployed or work in clerical, sales or service jobs.  
516. The Board notes with satisfaction the progress 
made by Viet Nam in the strengthening control 
measures since the mission of the Board visited that 
country in 2007. 
517. Although ketamine is not under international 
control, its illicit manufacture, trafficking and abuse 
are becoming major problems in many countries in 
East and South-East Asia. An increase in the illicit 
manufacture of and trafficking in ketamine was 
reported in the region. In China, 44 laboratories 
involved in the illicit manufacture of ketamine were 
dismantled in 2007. 
518. The link between HIV transmission and drug 
abuse by injection remains a concern in many countries 
in East and South-East Asia.  
 
 2. Regional cooperation 
 
519. The thirtieth meeting of the Association of 
Southeast Asian Nations (ASEAN) Senior Officials on 
Drug Matters was held from 29 September to 
20 October 2009 in Phnom Penh. During the meeting, 
participants endorsed the action-oriented ASEAN Work 
Plan on Combating Illicit Drug Production, Trafficking 
and Use (2009-2015), as well as a mechanism to 
monitor the implementation of the workplan. Aimed at 
making ASEAN member States free of illicit drugs by 
2015, the workplan will guide ASEAN member States 
in reducing, in a sustainable manner, illicit crop 
cultivation, illicit drug production, drug trafficking, the 
prevalence of illicit drug use and drug-related crime. 
The eighth meetings of the ASEAN and China 
Cooperative Operations in Response to Dangerous 
Drugs (ACCORD) Task Force on Civic Awareness and 
of the ACCORD Task Force on Demand Reduction 
were held in Jakarta on 5 and 6 August 2009. The 
purpose of the meetings was to discuss the progress 
made by ACCORD member States in meeting the goals 
set out under the thematic “Pillars” of civic awareness 
and demand reduction, as contained in the ACCORD 
Plan of Action. Participants reiterated the need to shift 
the focus of policy interventions from public security 
to public health. The twenty-ninth ASEAN Chiefs of 
Police Conference was held in Hanoi from 13 to  
15 May 2009. Participants resolved to formulate best 
practices with regard to precursor chemicals in order to 
stem the illicit diversion of those substances for use in 
the manufacture of illicit drugs and to share 
experiences in rehabilitating drug abusers. 
520. The Sixth Asian Youth Congress was held in Bali, 
Indonesia, from 4 to 7 August 2008. During the 
meeting, participants shared their experiences in  
peer-led activities to reduce drug abuse in schools and 
worked together to identify community-based 
strategies to address drug abuse issues among youth. 
The eighteenth Anti-Drug Liaison Officials’ Meeting 
for International Cooperation was held in Busan, 
Republic of Korea, from 24 to 26 September 2008. One 
of the key proposals of the meeting was that the 
participating countries establish a common Internet 
server to exchange information on drug-related crimes. 
The Response Beyond Borders South-East Asia 
Regional Workshop was held in Phnom Penh on 8 and 
9 October 2008. The objective of the workshop was to 
foster greater cooperation in improving the quality of 
life of drug abusers in Asia, by sharing country 
experiences and best practices. The Thirty-third 
Meeting of Heads of National Drug Law Enforcement 
Agencies, Asia and the Pacific, was held in Denpasar, 
Indonesia, from 6 to 9 October 2009. Issues such as 
emerging trends in drug trafficking and measures to 
counter the manufacture of amphetamine-type 
stimulants were discussed at the meeting. Governments 
were encouraged to ensure that their legal framework 
was in compliance with the international drug control 
conventions. In addition, Governments were urged to 
support increased cooperation among their law 
enforcement, forensic and chemical control authorities, 
to ensure a safe and environmentally friendly approach 
to the disposal of seized chemicals and products of 
clandestine laboratories. 
521. In 2008, China continued to provide training at 
its police academies in Yunnan Province and the 
autonomous region of Xinjiang to drug control officers 
from Cambodia, the Lao People’s Democratic 
Republic, Myanmar and Viet Nam. The officers studied 
national drug control efforts in China and were trained 
in drug detection skills. In Thailand, the Office of the 
Narcotics Control Board of the Thai Ministry of 
Justice, with technical assistance provided by Japan, 
implemented a regional cooperation project on 
capacity-building in the area of drug analysis with the 
aim of improving drug law enforcement in Cambodia, 
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the Lao People’s Democratic Republic, Myanmar, 
Thailand and Viet Nam. In 2009, training courses on 
the treatment and rehabilitation of drug abusers were 
conducted by Thai law enforcement authorities for the 
relevant authorities in the Lao People’s Democratic 
Republic. 
522. In October 2008, the National Narcotics Board of 
Indonesia and the Philippine Drug Enforcement 
Agency signed a memorandum of understanding on the 
strengthening of cooperation against the illicit 
production of and trafficking in narcotic drugs, 
psychotropic substances and precursor chemicals, 
including in the area of joint law enforcement 
operations. In April 2009, the national food and drug 
administrations of China and the Republic of Korea 
signed a memorandum of understanding on cooperation 
in ensuring the safety of drugs and medical devices: 
the two administrations will share information on 
licensing and regulatory systems in their respective 
countries. The Board continues to encourage 
international cooperation in drug control and looks 
forward to the signing of similar memorandums of 
understanding in the future. 
523. Countries in East and South-East Asia continued 
to cooperate through joint drug control investigations. 
In February 2008, the cooperation of law enforcement 
authorities from China and Myanmar resulted in the 
arrest of drug traffickers and the seizure of 50 kg of 
methamphetamine. In July 2008, Chinese and 
Philippine law enforcement authorities cooperated in 
an operation that resulted in the dismantling of a 
clandestine methamphetamine laboratory in Quezon, 
Philippines. Methamphetamine, precursor chemicals 
and laboratory equipment were seized at the laboratory 
in Quezon and at a warehouse in Laguna. In early 
2009, Vietnamese border forces, in cooperation with 
law enforcement authorities of the Lao People’s 
Democratic Republic, seized 25,800 tablets of 
amphetamine-type stimulants in Thanh Hoa, Viet Nam. 
524. At the end of June 2008, the Drug Seizure 
Immediate Notification System for Asia and Oceania, 
which had been launched in January 2008 in Hong 
Kong, China, completed its pilot phase, during which 
257 kg of drugs were seized and the participating 
countries issued 78 notifications. On the basis of the 
success of the pilot phase, the participants agreed to 
continue to utilize the system and extend it to other 
regions. 
525. The Board encourages countries in East and 
South-East Asia to continue to cooperate in the areas of 
drug control and drug abuse prevention. 
 
 3. National legislation, policy and action 
 
526. China has established a drug control intelligence 
and forensic centre under its Ministry of Public 
Security to implement its Narcotics Control Law, 
which entered into force in June 2008. The main 
objective of the centre is to enhance the drug control 
intelligence and investigation capacities of law 
enforcement agencies, particularly at the central level. 
The centre is responsible for the collection, research 
and application of drug control intelligence and 
information, the international exchange of drug-related 
intelligence, research on drugs, the study of advanced 
forensic technologies and the provision of drug control 
training. In addition, a circular was issued in July 2008 
to instruct the relevant agencies to strengthen drug 
abuse prevention and education, enhance treatment and 
rehabilitation for addicts, strengthen law enforcement 
and drug control to prevent diversion and reinforce 
international cooperation in the area of drug control. In 
November 2008, the National Narcotics Control 
Commission of China organized a joint meeting to 
provide an overview of national drug control efforts 
and the current drug control situation and to delegate 
tasks in combating drug-related crime. Representatives 
of the police forces, postal services and border control, 
customs and other agencies attended the meeting. 
527. In August 2008, China placed hydroxylamine, a 
precursor for ketamine, under national control. In 
November 2008, China introduced a new requirement 
for drug regulatory agencies to impose further controls 
on compound pharmaceutical preparations containing 
ephedrine (with the exception of traditional medicines 
containing ephedra). In December 2008, China further 
strengthened control measures for compound oral 
solutions containing codeine. In order to prevent the 
diversion of such preparations, measures to control 
their production, wholesale and retail have been 
strengthened. 
528. In May 2008, a seminar on precursor chemical 
control for shipping agents, air freight forwarders and 
cargo operators dealing with precursor chemicals was 
conducted in Hong Kong, China. The seminar was 
aimed at strengthening cooperation between law 
enforcement authorities and industry in preventing the 
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diversion of precursor chemicals, covering such topics 
as legal requirements for the import, export and trans-
shipment of precursor chemicals and the liability of 
operators in handling shipments of such substances. 
529. In 2008, N-methyl-N-[1-(3,4-methylenedioxy- 
phenyl)propan-2-yl]hydroxylamine (N-OH MDMA) 
was designated as a narcotic drug under the Narcotics 
and Psychotropics Control Law of Japan. 
530. In November 2008, the Lao People’s Democratic 
Republic announced that the recent increase in drug 
trafficking would be addressed through its 
comprehensive drug control master plan covering the 
five-year period 2009-2013. The master plan provides, 
inter alia, for the recent increase in and proliferation of 
drug abuse, drug trafficking and other drug-related 
criminal activities. Under the drug law of the Lao 
People’s Democratic Republic adopted by presidential 
decree in 2008, opium is subject to strict control and 
may be used for scientific, medical and industrial 
purposes only. According to the law, the commercial 
cultivation of opium poppy is prohibited, and offenders 
may be punished under civil and criminal law. 
531. In August 2008, the Philippine Drug Enforcement 
Agency joined forces with a telecommunications 
provider to launch a pilot project to combat illegal 
drug-related activities. The project was initially 
implemented for a two-month period in the 
Metropolitan Manila area. Under the project, 
subscribers to the telecommunications provider were 
able to provide information on suspected illegal drug-
related activities through a secure Web-based text 
messaging system. In October 2008, the Philippine 
Drug Enforcement Agency signed a memorandum of 
understanding with chemical and pharmaceutical 
companies to prevent the diversion of precursor 
chemicals. Forty chemical and pharmaceutical 
companies and three associations signed the agreement 
to become proactive counterparts in cutting off the 
supply of precursor chemicals to clandestine 
laboratories. The Board welcomes this initiative in the 
Philippines and encourages the Governments of other 
countries to follow suit. In that regard, Governments 
may wish to consult the Guidelines for a Voluntary 
Code of Practice for the Chemical Industry, developed 
by the Board in 2009. In December 2008, the 
Philippine Drug Enforcement Agency reiterated its 
appeal to judges and prosecutors to expedite trial 
proceedings in connection with drug-related cases. The 
Director-General of the Agency stated that only 21 per 
cent of the 99,434 drug-related cases initiated had been 
resolved, while the remainder were pending. 
532. In March 2008, the Republic of Korea revised its 
Act on the Control of Narcotic Drugs. Under the 
revised Act, the disposal of expired narcotic drugs for 
medical use must be conducted in the presence of a 
competent national authority. In addition, the treatment 
and rehabilitation of persons addicted to narcotic drugs 
was transferred from the Korea Food and Drug 
Administration to the Ministry for Health, Welfare and 
Family Affairs. 
533. In the Republic of Korea, the Decree enforcing 
the Act on the Control of Narcotic Drugs added two 
substances to the list of substances under national 
control: benzylpiperazine was added to the list of 
psychotropic substances under control and GBL was 
added to the list of precursor chemicals under control. 
534. According to the Central Narcotics Bureau of 
Singapore, opiate abusers, who account for the 
overwhelming majority of arrested drug abusers, have 
been undergoing a rehabilitation regime in centres for 
the treatment of drug abuse in Singapore. In  
August 2007, the rehabilitation regime was expanded 
to apply to persons arrested for the first, or second time 
for abusing cannabis or cocaine. Drug abusers who are 
arrested three or more times for the abuse of those 
drugs face imprisonment. Eventually, the system of 
rehabilitating persons arrested for the first or second 
time for the abuse of certain types of drugs and 
imprisoning persons arrested for three or more times 
for that offence will be expanded to cover all drugs of 
abuse. 
535. In April 2008, Singapore strengthened its efforts 
to prevent the abuse of inhalants, particularly among 
youth. The Central Narcotics Bureau of Singapore 
regularly conducts operations to counter the abuse of 
inhalants and has also intensified law enforcement 
efforts by working with the police, teachers and 
counsellors to gather information on meeting points 
used by abusers of inhalants. Preventive education 
campaigns, aimed at raising awareness about the harm 
caused by abusing inhalants, is conducted at schools. A 
referral procedure for cases involving the abuse of 
inhalants or drugs has been developed to guide schools 
in reporting such cases to the Bureau. Parents are 
educated on the dangers of abusing drugs or inhalants 
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through talks organized for parent support groups in 
schools, workplace talks and publications. 
536. In June 2009, the National Assembly of Viet Nam 
passed a law to amend and supplement the Penal Code. 
According to the new law, illicit use of narcotic drugs 
is no longer a criminal offence; moreover, the death 
penalty is no longer imposed for the offence of 
organizing the illicit use of narcotic drugs but remains 
in force for offences related to illegally stockpiling, 
transporting and trading in or appropriating narcotic 
drugs. 
 
 4. Cultivation, production, manufacture and 
trafficking 
 
  Narcotic drugs 
 
537. The illicit cultivation of cannabis continued to be 
reported throughout East and South-East Asia. In 2008, 
290 ha of illicitly cultivated cannabis plants were 
eradicated in Indonesia and 3,385 cannabis plants were 
eradicated in the Republic of Korea. In the Philippines, 
there continued to be reports of the illicit cultivation of 
cannabis for the domestic market. In Mongolia, while 
most of the cannabis seized in 2008 had been illicitly 
cultivated in that country, some of it originated in the 
Russian Federation. Cannabis continues to be 
cultivated illicitly in the south-west provinces of 
Viet Nam; nearly 1 ha of illicit cannabis cultivation 
was reported in 2008. In Japan in 2008, cannabis with 
a high THC content was illicitly cultivated from seeds 
smuggled from overseas and sold over the Internet. 
538. The Philippines continued to seize significant 
amounts of cannabis. In 2008, it seized about 4 million 
cannabis plants (compared with 2.5 million in 2007) 
and 3.7 tons of cannabis (compared with 1.2 tons in 
2007). In 2008, Japan, Mongolia and the Republic of 
Korea reported having seized the largest quantity of 
cannabis in recent years. In November 2008, police in 
the Lao People’s Democratic Republic seized 600 kg of 
cannabis concealed in a truck transporting furniture to 
Thailand. In April 2009, China seized 87 kg of 
cannabis at Beijing International Airport from the 
baggage of a passenger travelling from Qatar to China. 
Vietnamese police reported that a new, more potent 
strain of cannabis was emerging on the illicit market, 
particularly in northern and southern Viet Nam. 
539. Illicit opium poppy cultivation in the Lao 
People’s Democratic Republic and Myanmar has 
recently begun to increase. In Myanmar, despite the 
eradication of 4,820 ha of illicit opium poppy crops (an 
increase of 34 per cent compared with 2007 in terms of 
the total area eradicated), the total area under illicit 
opium poppy cultivation increased by 3 per cent (to 
28,500 ha) in 2008. The area under illicit opium poppy 
cultivation in 2008 also increased to 1,600 ha in the 
Lao People’s Democratic Republic, to 288 ha in 
Thailand and to 99 ha in Viet Nam. Data on the total 
area under illicit opium poppy cultivation in South-
East Asia in 2009 are not yet available. Both the Lao 
People’s Democratic Republic and Myanmar have 
significantly reduced the area under illicit opium 
poppy cultivation in their respective territories in 
recent years, achieving record lows of 1,500 ha in 2007 
and 21,500 ha in 2006, respectively. In order not to 
lose ground on the successes achieved thus far, the 
Board urges the Governments of countries in East and 
South-East Asia to strengthen their efforts to eradicate 
the illicit cultivation of opium poppy. 
540. China reported the seizure of 1.4 tons of opium in 
2008. The opium seized in Mongolia during 2008 
originated in China and had been intended for domestic 
use rather than for re-export. In 2008, 31 kg of opium 
were seized in Viet Nam. Myanmar and Thailand also 
reported seizures of opium in 2008. Seizure data 
indicate that the United Wa State Army in Myanmar is 
attempting to smuggle drugs into other countries, 
mainly into Thailand, in order to procure arms and 
ammunition and is also selling drugs in exchange for 
money in preparation for the possibility of again going 
to war with the Government of Myanmar. The Board 
notes with concern that development and encourages 
the Government of Myanmar to strengthen its control 
over the movement of illicit drugs, particularly along 
its borders. 
541. In 2008, Hong Kong, China, and Thailand were 
identified as trans-shipment areas for heroin 
trafficking. Traffickers attempted to transport the drug 
from countries in South Asia, South-East Asia, West 
Asia and (East, Southern and West) Africa through 
Hong Kong, China, to destinations elsewhere in East 
Asia and Oceania. The route through Thailand 
favoured by heroin traffickers was from South Asia and 
South-East Asia to East Asia, Europe and Oceania. 
Heroin consignments smuggled through Hong Kong, 
China, mainly arrived by air and departed by air or 
train. Heroin consignments were smuggled through 
Thailand mainly along air routes. In 2008, heroin 
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continued to be smuggled mainly from the Lao 
People’s Democratic Republic into Viet Nam and from 
Viet Nam into China. In early 2009, Thai police seized 
16 kg of heroin and arrested a number of persons 
suspected of using a popular Internet chat service to 
trade in illicit drugs. 
542. The decreasing trend in heroin seizures continued 
in China, which reported the seizure of 4.3 tons of 
heroin in 2008 (compared with 4.6 tons in 2007). 
Between November 2008 and April 2009, law 
enforcement authorities in Thailand seized 12 kg of 
heroin in nine separate incidents at Bangkok 
International Suvarnabhumi Airport. In March 2008, 
49 kg of heroin concealed in carpets arriving from 
Karachi, Pakistan, were seized by Chinese authorities 
at Ürümqi Airport. 
543. In 2008, customs authorities in Hong Kong, 
China, seized 21.7 kg of cocaine. In 2008, the Republic 
of Korea seized 8.8 kg of cocaine in two separate 
incidents. In August and September 2008, law 
enforcement authorities at Incheon International 
Airport seized cocaine bound for Japan en route from 
Brazil. 
 
  Psychotropic substances 
 
544. The illicit manufacture of amphetamine-type 
stimulants remained a problem in countries in East and 
South-East Asia. In February 2009, 200 kg of 
amphetamine were seized at a clandestine laboratory in 
Taiwan Province of China. In 2007, two clandestine 
methamphetamine laboratories were dismantled in 
Cambodia and one laboratory was dismantled in the 
Republic of Korea. In 2008, 10 clandestine 
methamphetamine laboratories were dismantled in the 
Philippines. During 2008 and the first half of 2009, 
laboratories involved in the illicit manufacture of 
methamphetamine continued to be dismantled in 
China, particularly in central and southern China, 
where seven such laboratories were dismantled in 
2008. 
545. Traffickers continued to attempt to smuggle 
methamphetamine from Cambodia and China into the 
Republic of Korea and from the Lao People’s 
Democratic Republic into Thailand. While some of the 
methamphetamine seized in the Philippines in 2008 
originated in China (including Taiwan Province of 
China), some had been illicitly manufactured 
domestically. Traffickers had intended to transport the 
methamphetamine through Thailand to countries in 
North America and Europe and to other countries in 
South-East Asia. In early 2009, Thai police seized 
60,000 amphetamine tablets and arrested a number of 
persons suspected of using a popular Internet chat 
service to trade in illicit drugs. 
546. In 2008, most of the countries in East and South-
East Asia, including China, Indonesia, Japan, the Lao 
People’s Democratic Republic, Myanmar, the Republic 
of Korea, Singapore, Thailand and Viet Nam, reported 
seizures of methamphetamine. In 2008, 6.2 tons of 
methamphetamine were seized in China. In 2008, the 
Philippines seized 855 kg of methamphetamine 
(compared with 369 kg in 2007), while the Republic of 
Korea seized 26 kg of the drug. Thailand reported the 
seizure of 22 million tablets of methamphetamine in 
2008, a significant increase over 2007, when 
14 million tablets were seized. In July 2009, law 
enforcement authorities in Quang Binh province, Viet 
Nam, seized 806,000 methamphetamine tablets from 
four persons purportedly attempting to cross the border 
between Viet Nam and the Lao People’s Democratic 
Republic. In August 2008, about 1.7 tons of 
methamphetamine were seized at a clandestine 
laboratory in Guangdong Province, China. In 
November 2008, customs officers in Japan seized 
approximately 300 kg of methamphetamine on a vessel 
in the seaport of Moji (Fukuoka, Japan). In 
March 2009, 90 kg of methamphetamine were seized at 
a laboratory involved in the illicit manufacture of 
methamphetamine in Guangzhou, China.  
547. In 2007, Indonesia dismantled 16 laboratories 
involved in the illicit manufacture of MDMA 
(“ecstasy”). In Mongolia, all the “ecstasy” seized in 
2008 originated in China and had been intended for 
domestic use rather than re-export. “Ecstasy” seized in 
the Philippines in 2008 reportedly originated in 
Thailand. 
548. In 2008, many countries in East and South-East 
Asia, including China, Indonesia, Japan, the 
Philippines, the Republic of Korea, Singapore and 
Thailand, continued to report seizures of MDMA 
(“ecstasy”). Indonesia reported the seizure of 
1,071,266 “ecstasy” tablets, while customs authorities 
in Japan seized 27 kg of the drug from passengers 
arriving from the Netherlands at Narita International 
Airport. In October 2008, 10,000 “ecstasy” tablets 
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were seized in Hong Kong, China. In May 2009, 7.1 kg 
of “ecstasy” were seized in Zhejiang Province, China. 
549. In 2007, the Republic of Korea dismantled a 
laboratory involved in the illicit manufacture of GHB. 
In December 2008, Vietnamese customs officers at the 
international airport at Ho Chi Minh City seized 
796,500 tablets of a pharmaceutical preparation 
containing nimetazepam; the tablets had been 
manufactured in Japan and concealed in a shipment of 
loudspeakers from Taiwan Province of China. Several 
seizures of nimetazepam had also been reported in 
China earlier in 2008. Customs authorities in Thailand 
seized 75 kg of diazepam trafficked by mail in 2008; 
the United Kingdom had been the intended destination 
of the majority of the mailed items. 
 
  Precursors 
 
550. Significant quantities of precursor chemicals 
continued to be seized in countries in East and South-
East Asia. The Philippines reported the seizure of 
numerous precursor chemicals used in the illicit 
manufacture of methamphetamine. For example, more 
than 200 kg of ephedrine were seized at warehouses 
and clandestine laboratories during 2008. In 2008, the 
Philippines also reported having seized a significant 
quantity of acetone (902 litres) and hydrochloric acid 
(385 litres). In 2008, China again reported having 
seized a large quantity of precursor chemicals, 
including acetic anhydride (5.6 tons), ephedrine 
(6.7 tons), P-2-P (2.9 tons) and pseudoephedrine 
(1.1 tons). The Republic of Korea seized acetic 
anhydride (14.8 tons) and pharmaceutical preparations 
containing ephedrine (2.2 kg) in 2008. In 2008, 192 kg 
of pharmaceutical preparations containing 
pseudoephedrine were seized in Thailand, purportedly 
bound for Australia. 
551. In March 2008, law enforcement authorities in 
the Republic of Korea seized 2.8 tons of acetic 
anhydride concealed in used car parts at the port of 
Busan. The consignment was bound for Afghanistan 
via the Islamic Republic of Iran. In April 2008, China 
dismantled two clandestine laboratories and seized 
37.5 kg of pseudoephedrine in Hunan Province. In 
June 2008, three suspects were arrested in the 
Philippines for selling 67 litres of acetone to an 
undercover agent in Quezon. Under Philippine drug 
control legislation, the sale of more than 1 litre of 
acetone to the same individual within a one-month 
period is prohibited. Traffickers have obtained 
precursor chemicals in Viet Nam and smuggled them 
into other countries, where the chemicals are used for 
illicit drug manufacture. In August 2008, Vietnamese 
police dismantled a criminal group involved in 
smuggling a pharmaceutical product containing 
pseudoephedrine into Australia. In October 2008, 
20 tons of sulphuric acid were seized in Yunnan 
Province, China. In February 2009, 119 kg of 
ephedrine were seized at a clandestine 
methamphetamine laboratory in Taiwan Province of 
China. In February 2009, rangers from the Ministry of 
Environment of Cambodia, in cooperation with law 
enforcement authorities, dismantled two clandestine 
sassafras oil laboratories in the western part of the 
Cardamom mountain range. In June 2009, Ministry of 
Environment rangers seized 5.7 tons of sassafras oil in 
Veal Vêng District (Pursat Province). 
 
  Substances not under international control 
 
552. Countries in East and South-East Asia continued 
to report seizures of ketamine. In January 2008, 300 kg 
of ketamine were seized in Chengdu, China. In 
November 2008, 307 kg of ketamine were seized in 
Hong Kong, China. The ketamine was concealed in an 
air freight consignment of loudspeakers arriving from 
Singapore. In April 2009, 246 kg of ketamine were 
seized in Taiwan Province of China. In 2008, the 
Philippines reported a seizure of 10 kg of ketamine. 
Myanmar continued to report seizures of ketamine in 
2009. Singapore also reported the seizure of a small 
amount of ketamine in 2009. The Philippines continued 
to report seizures of precursor chemicals not under 
international control but used in the illicit manufacture 
of methamphetamine; the chemicals seized included 
iodine (4.7 tons), palladium chloride (2 kg), red 
phosphorus (1.5 tons), sodium hydroxide (2.5 tons) and 
thionyl chloride (41 litres). 
 
 5. Abuse and treatment 
 
553. Methamphetamine is the most widely abused 
drug in Japan, the Philippines and the Republic of 
Korea. In Thailand, 69,145 people were treated for 
methamphetamine abuse in 2008. Japan reported a 
significant increase in methamphetamine abuse in 2008 
and, in recent years, an increase in the practice among 
methamphetamine abusers of sharing injection 
equipment. A recent increase in the abuse of MDMA 
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(“ecstasy”), especially among youth, was also reported 
in Japan. 
554. Heroin remained the most commonly abused drug 
in China, Malaysia and Viet Nam. By the end of 2008, 
data on more than 1 million drug abusers had been 
collected and entered in the system for monitoring drug 
abusers in China. Some 877,700 of those drug abusers 
abuse heroin, and 60 per cent are under the age of 35. 
In 2008, 264,000 drug abusers underwent compulsory 
treatment and rehabilitation in China. Between June 
and December 2008, 16,300 drug abusers participated 
in community-based rehabilitation. The HIV epidemic 
in China began among heroin abusers in Yunnan 
Province in the late 1980s. By 2002, HIV had spread 
along drug trafficking routes to all 31 provinces in 
China. By 2007, infected drug abusers accounted for 
more than 38 per cent of the estimated 700,000 persons 
infected with HIV. 
555. In Malaysia, 61 per cent of drug abusers abuse 
heroin and an estimated 120,000 persons abuse drugs 
by injection. The number of new cases of HIV 
infection among persons who abuse drugs by injection 
has been falling since 2002, when it reached a peak of 
more than 5,000. In 2008, under the Malaysian national 
programme to prevent the spread of HIV among 
persons who abuse drugs by injection, 3,495 persons 
were provided with a variety of services at “drop-in” 
centres. The services included the provision of 
information relating to the dangers of drug abuse, basic 
counselling and referrals, basic health care and 
assistance in establishing support groups. 
556. In November 2008, 173,603 drug abusers were 
registered with the Ministry of Labour, Invalids and 
Social Affairs of Viet Nam, representing a decrease of 
2.6 per cent compared with 2007. Of that total, 82 per 
cent were heroin abusers. Fifty-five per cent of drug 
abusers in Viet Nam have become infected with HIV as 
a result of sharing needles. Since May 2008, when a 
pilot project for methadone maintenance therapy was 
launched in Hai Phong and Ho Chi Minh City, 
455 drug abusers have been treated in six clinics in the 
two cities. There are proposals for replicating the pilot 
project in 10 provinces, including Hanoi. 
557. The Lao People’s Democratic Republic reported a 
decrease in the prevalence rate of opium abuse 
(expressed as a percentage of the population aged 
15 and above) in the northern provinces from 0.3 per 
cent in 2007 to 0.2 per cent in 2008. However, the 
relapse of opium addicts continues to be a problem: 
4,906 opium addicts were identified as having relapsed 
in 2008. The total number of opium addicts in the Lao 
People’s Democratic Republic is estimated at 12,680. 
558. Cannabis is the most widely abused drug in 
Mongolia and Thailand and remains the second most 
abused drug in the Philippines and the Republic of 
Korea. In Macao, China, an increase in the abuse of 
ketamine among young persons aged 14-25 has been 
noted in the past two years. 
559. In Singapore, the treatment regime for cocaine 
and cannabis abusers is similar to the current regime 
for opiate abusers, which takes into account the 
individual abuser’s needs and readiness for change and 
treatment and the severity of the addiction. All drug 
abusers undergo a thorough classification and 
assessment process. The treatment programmes focus 
on teaching abusers how to overcome behavioural 
problems resulting from addiction. Key components of 
the regime include motivation to change, skills 
training, family-based programmes and religious 
counselling. 
560. The findings of a survey of students 12-14 years 
old conducted in 2008 in Japan supported the 
hypothesis that there is a close link between abuse of 
organic solvents and abuse of cannabis and 
methamphetamine. In a number of countries in East 
and South-East Asia, an increase in the abuse of 
inhalants was reported. Following the enactment of the 
Intoxicating Substances Act in 1987 in Singapore, the 
number of arrested inhalant abusers decreased from a 
high of 1,112 in 1987 to a low of 120 in 2005. 
However, inhalant abuse has recently been increasing. 
The majority of the inhalant abusers are reported to be 
under the age of 20. 
561. In late 2008 and early 2009, within the 
framework of the HIV/AIDS Asia Regional Program 
(HAARP), country programmes were launched in 
Cambodia and China with the aim of reducing, over a 
five-year period, HIV transmission associated with 
drug abuse by injection. Similar programmes have 
been designed for the Lao People’s Democratic 
Republic, Myanmar and Viet Nam. The United States 
President’s Emergency Plan for AIDS Relief 
(PEPFAR) programme supports HIV prevention, 
treatment and care programming for persons who abuse 
drugs by injection in Viet Nam. Several countries in 
East and South-East Asia also benefit from the Global 
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Fund to Fight AIDS, Tuberculosis and Malaria grants, 
which support national programming to reduce HIV 
transmission among persons who abuse drugs by 
injection. 
562. As problems of drug abuse may not always be 
confined to high-risk groups, the Board encourages the 
Governments of countries in East and South-East Asia 
to remain vigilant with regard to increases in drug 
abuse among the general population. 
 
 
  South Asia 
 
 
 1. Major developments 
 
563. Trafficking in amphetamine-type stimulants has 
increased in South Asia, as evidenced by the fact that 
States in the region continue to report seizures of those 
substances. Neighbouring South-East Asian countries 
have typically been a major source of amphetamine-
type stimulants; however, the discovery of several 
clandestine methamphetamine laboratories in South 
Asia in the past two years indicates that countries in 
that region are increasingly being used as locations for 
the illicit manufacture of amphetamine-type stimulants.  
564. Courier and postal services have become a 
common means of smuggling drugs out of India. A 
broad range of substances under international control 
have been detected by law enforcement authorities in 
parcels transported by courier or post. In recent years, 
heroin and diazepam have been the drugs most 
frequently found in seized parcels, while morphine, 
cannabis herb, cannabis resin, ephedrine and 
pseudoephedrine have been seized occasionally. The 
majority of clandestine shipments of controlled 
substances detected in India were destined for 
Australia and countries in North America and Europe. 
The Board encourages the Government of India to 
increase its vigilance in detecting the misuse of courier 
and postal services to smuggle controlled substances 
out of that country. 
 
 2. Regional cooperation 
 
565. In June 2008, the Ministry of Social Justice and 
Empowerment of India organized a workshop in New 
Delhi on modalities for the establishment of a 
permanent regional forum of non-governmental 
organizations of States members of the South Asian 
Association for Regional Cooperation (SAARC) on 
drug abuse prevention. Recommendations arising from 
the workshop stressed the importance of strengthening 
networking among non-governmental organizations, 
information-sharing and advocacy for drug abuse 
prevention. 
566. The ninth talks at the level of Home Secretary 
between Bangladesh and India were held in Dhaka in 
August 2008. The home secretaries of the two 
countries agreed that cooperation between their 
national drug control agencies needed to be 
strengthened. As follow-up to the talks, the heads of 
the national drug control agencies of Bangladesh and 
India met in New Delhi in March 2009 to discuss ways 
of enhancing cooperation in combating drug 
trafficking. 
567. Bhutan, India, Maldives, Nepal and Sri Lanka 
were among the 16 countries represented at an Asian 
Symposium on recovering from drug abuse, the third in 
a series of such symposiums, held in Tagaytay, 
Philippines, in November 2008. The Symposium 
provided an opportunity for participants to present the 
progress achieved in treating drug addiction in South 
and South-East Asia and for drug abusers who had 
recovered from drug dependence to share their 
experiences.  
568. Heads of State and Government of Bangladesh, 
Bhutan, India, Nepal and Sri Lanka participated in the 
second summit of the Bay of Bengal Initiative for 
Multi-Sectoral Technical and Economic Cooperation 
(BIMSTEC), held in New Delhi in November 2008. 
During the meeting, participants agreed on the final 
text of the BIMSTEC Convention on Combating 
International Terrorism, Transnational Organized 
Crime and Illicit Drug Trafficking, one of the main 
objectives of which is to enhance cooperation among 
the law enforcement agencies of the BIMSTEC 
member States in combating trafficking in narcotic 
drugs, psychotropic substances and their precursors. 
569. Representatives of Bangladesh, Bhutan, India and 
Sri Lanka attended the Thirty-second Meeting of Heads 
of National Drug Law Enforcement Agencies, Asia and 
the Pacific, held in Bangkok in February 2009. 
Participants in the Meeting recommended that 
Governments should develop coordinated strategies to 
address the increase in heroin trafficking by West 
African criminal groups, to implement legislation to 
counter money-laundering and to assess national 
demand for and sources of amphetamine-type 
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stimulants in order to prevent the illicit manufacture of 
and trafficking in those substances more effectively. 
570. During the thirty-first session of the SAARC 
Council of Ministers, held in Colombo in 
February 2009, ministers for foreign affairs of the 
SAARC member States discussed implementation of 
the declaration adopted at the fifteenth summit of 
SAARC in August 2008, entitled “Partnership for 
Growth for Our People”, and adopted the SAARC 
Ministerial Declaration on Cooperation in Combating 
Terrorism, in which the ministers agreed to consider 
the development of an integrated border management 
mechanism in order to improve customs control 
measures and prevent trafficking in narcotic drugs, 
psychotropic substances and other materials intended 
to support terrorism. 
571. Participants from Bangladesh, India, Maldives 
and Sri Lanka were present at the Commonwealth Asia 
Regional Workshop on Drug and Substance Abuse held 
in Brunei Darussalam in March 2009. The workshop 
was organized by the Asia Centre of the 
Commonwealth Youth Programme and the Ministry of 
Culture, Youth and Sports of Brunei Darussalam, with 
the support of UNODC. During the workshop, youth 
leaders were involved in interactive lecture sessions, 
group work, role playing and field visits that helped 
them to develop a viable action plan for drug abuse 
prevention and treatment and care for drug abusers. 
The workshop also provided participants with a 
platform for sharing best practices in dealing with 
problems related to drug abuse. 
572. In March 2009, a South Asia regional workshop 
on HIV related to drug use was held in Kathmandu. 
The workshop was a follow-up to the First Asian 
Consultation on the Prevention of HIV Related to Drug 
Use, which was held in January 2008, and was 
intended as a forum that would address the challenges 
identified during the Consultation in greater depth. The 
workshop focused on country-specific activities and 
regional cooperation in five main areas: the availability 
of community, civil society and government services to 
HIV patients; changes to law enforcement policies and 
practices regarding drug users; responses to the 
hepatitis C epidemic among drug users and to 
challenges in providing services to vulnerable 
populations affected by drug use, HIV and poverty; and 
support for parliamentarians in bringing about change 
in the areas discussed during the workshop.  
 3. National legislation, policy and action 
 
573. In September 2008, the Bhutan Narcotic Control 
Agency, in partnership with UNODC, conducted 
nationwide training on HIV and drug abuse prevention 
in prisons. The aim of the training was to raise 
awareness regarding drug abuse and HIV transmission 
among prison inmates in Bhutan. It was recognized 
that while the prevalence rate of drug abuse and that of 
HIV infection in prisons in Bhutan was still relatively 
low, measures should be taken to prevent their 
occurrence. Participants in the training included 
officials of the Bhutan Narcotic Control Agency, 
prisons, the police and health departments and 
representatives of non-governmental organizations. 
574. A week-long campaign to collect signatures 
against drug abuse, spearheaded by the Citizen’s 
Initiative for Coronation and Centenary Celebrations, 
was conducted in Bhutan in November 2008. During 
the campaign, entitled “We, the children of Bhutan, 
pledge ...”, more than 23,000 signatures were collected 
from children and their parents who pledged to live a 
life free of drugs. The collection of signatures was 
presented to the Prime Minister of Bhutan by 
secondary school students on behalf of the youth 
participating in the campaign.  
575. In January 2009, the Bhutan Narcotic Control 
Agency released three advocacy tools to prevent and 
reduce drug abuse in that country: a version of the 
Implementation Framework for the Narcotic Drugs, 
Psychotropic Substances and Substance Abuse Act of 
2005 in Dzongkha, the national language of Bhutan; a 
flip chart containing 10 key prevention messages on 
drug abuse and HIV; and a report on the drug abuse 
situation in Bhutan. The purpose of the tools is to raise 
public awareness of the risks associated with drug 
abuse, the role of drug abuse in the spread of HIV and 
avenues for seeking help in overcoming drug 
dependence. The flip chart will be distributed to all 
schools in Bhutan in order to promote drug abuse 
prevention among young people.  
576. A revised version of the Scheme of Assistance for 
the Prevention of Alcoholism and Substance (Drug) 
Abuse and for Social Defence Services of the Ministry 
of Social Justice and Empowerment of India became 
effective in October 2008. The Scheme is an ongoing 
programme that was last revised in 1999. It allows 
non-governmental organizations to obtain financial 
assistance from the Government for the 
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implementation of initiatives to reduce drug demand. 
Activities supported by the Scheme include drug abuse 
awareness and prevention programmes and treatment 
and rehabilitation of drug addicts. The revised Scheme 
provides, inter alia, for arrangements for meeting the 
increase in the cost of related services since 1999 and 
for the fostering of more comprehensive approaches to 
the rehabilitation of drug addicts so as to facilitate their 
reintegration into the community. 
577. In November 2008, a programme to provide 
incarcerated drug abusers who abuse drugs by injection 
with substitution drugs that can be taken orally was 
initiated at the Tihar prison complex near New Delhi. 
Many incarcerated drug abusers start injecting drugs 
soon after entering prison, thus becoming exposed to a 
higher risk of contracting and transmitting HIV 
through unsafe practices such as sharing needles. The 
programme, implemented in collaboration with 
UNODC, is the first of its kind to be established in 
prisons in South Asia and may be used by UNODC as a 
model for the development of similar programmes 
elsewhere in the region. 
578. In December 2008, India passed a law amending 
its Drugs and Cosmetics Act of 1940. The revised act 
increases penalties for the manufacture of counterfeit 
drugs and is aimed at combating the growing problem 
of counterfeit and adulterated drugs in that country. 
579. During 2008, the National AIDS Control 
Organisation of India carried out a technical review of 
all institutions providing drug abusers in India with 
drug substitution treatment, with a view to their 
possible accreditation. In order to assist institutions in 
participating in the accreditation exercise, the 
organization released a document entitled “Standard 
operating procedure for substitution treatment using 
buprenorphine”, which outlines the standards to be 
followed by providers of substitution treatment and 
against which institutions providing such therapy 
would be evaluated in order to determine their 
eligibility for accreditation.  
580. An international documentary film festival 
entitled “Drugs: exploring myths, discovering facts, 
reducing harm” was held in New Delhi on 21 and 
22 February 2009. The festival, organized by the 
United Nations Educational, Scientific and Cultural 
Organization in partnership with the National AIDS 
Control Organisation and UNODC, was aimed at 
increasing public understanding of the issues 
surrounding drug abuse. 
581. In India, a series of educational modules designed 
to assist schoolteachers in raising awareness about 
drug abuse was officially released in June 2009. The 
modules were prepared by the Minister of Social 
Justice and Empowerment, in collaboration with 
UNODC, and are part of a programme to prevent drug 
abuse in Indian schools. The Board encourages the 
Government of India to continue to support drug abuse 
prevention activities targeting young people.  
582. In India, the fortieth meeting of the Drugs 
Consultative Committee was held in New Delhi on 
29 June 2009. The meeting was attended by high-level 
officials of the Ministry of Health and Family Welfare, 
the Narcotics Control Bureau and the Department of 
Revenue (of the Ministry of Finance) and by the State 
drug controllers of the Central Drugs Standard Control 
Organization of India. During the meeting, attention 
was drawn to the importance of the country’s 
furnishing to the Board accurate statistics on narcotic 
drugs and psychotropic substances. Participants 
deliberated on mechanisms that could facilitate the 
collection of the requisite information at the State level 
and subsequent reporting to the Drugs Controller 
General of India. The Narcotics Control Bureau agreed 
to organize training workshops for the State drug 
controllers and to work towards developing a system 
for efficient data collection. The Board notes with 
satisfaction the efforts of the Government of India to 
meet its reporting obligations under the international 
drug control conventions. 
583. In March 2009, the Government of Maldives 
announced two new initiatives as part of its ongoing 
efforts to combat the growing problem of drug abuse in 
that country. A comprehensive project to support the 
drug abuse prevention and treatment components of the 
Maldives Drug Control Master Plan was announced. In 
addition, a narcotics control council headed by the 
Vice-President of Maldives and comprising the 
Commissioner of Police and representatives of several 
ministries, was established to facilitate coordinated 
action in the area of drug control.  
584. On 15 July 2009, a parliamentary bill was passed 
in Sri Lanka to establish a coast guard department. The 
new agency is tasked with strengthening security in the 
territorial waters of Sri Lanka and helping to combat 
the smuggling of drugs into that country. 
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 4. Cultivation, production, manufacture and 
trafficking  
 
  Narcotic drugs 
 
585. Trafficking in cannabis herb and cannabis resin 
remains widespread throughout South Asia, where 
climate conditions are highly suitable for cannabis 
plant cultivation. In 2008, special drug law 
enforcement units of Bangladesh seized 2.3 tons of 
cannabis herb in that country. In India in the same year, 
law enforcement authorities seized about 103 tons of 
cannabis herb and 4.1 tons of cannabis resin, and 
routine operations to eradicate illicitly cultivated 
cannabis plants resulted in the eradication of some 
164 ha of those plants. Large areas under illicit 
cannabis plant cultivation were also eradicated in 
Nepal, where more than 7 tons of cannabis herb were 
reported to have been seized in 2008. In Sri Lanka, 
more than 37 tons of cannabis herb were seized 
in 2008. 
586. The widespread abuse of pharmaceutical 
preparations containing narcotic drugs such as codeine 
is an ongoing problem in Bangladesh. Such 
preparations are smuggled into that country from India. 
In 2008, drug law enforcement authorities in 
Bangladesh seized 53,239 bottles containing codeine-
based syrup and 226 ampoules containing pethidine 
and morphine. A total of 554 tablets containing codeine 
were also seized in Bangladesh in 2008, a significant 
decrease compared with 2007, when 70,000 tablets 
were seized. 
587. The drug law enforcement authorities of India 
regularly eradicate opium poppy illicitly cultivated in 
remote areas of the country’s eastern provinces. Drug 
law enforcement authorities at both the federal and 
state levels have stepped up their efforts to gather 
intelligence on illicit opium poppy cultivation and 
improve vigilance with regard to areas under such 
cultivation. The authorities have also conducted regular 
campaigns among villagers in areas where opium 
poppy is illicitly cultivated to raise their awareness 
about the implications of such cultivation. Indian law 
enforcement agencies reported that the total eradicated 
area of land under illicit cultivation had decreased 
from 8,000 ha in 2007 to 631 ha in 2008. 
588. In the past, the low-grade heroin base known as 
“brown sugar” that was found on the illicit market in 
India was suspected of having been derived from 
opium poppy diverted from licit cultivation. However, 
Indian law enforcement authorities estimate that in 
recent years, an increasing proportion of the heroin 
seized in India has originated in Afghanistan. The 
heroin that enters India is abused locally or is 
smuggled out of the country by couriers. That is an 
indication that India is being used as a transit area for 
heroin consignments. Some 4,950 seizures of heroin 
were reported in India in 2008. In most cases, only a 
small amount of heroin was seized. A total of 1,063 kg 
of heroin was seized in 2008. A total of 73 kg of 
morphine, which is also commonly abused in India, 
and 2,033 kg of opium were reported to have been 
seized in 2008. 
589. In India, pharmaceutical preparations containing 
dextropropoxyphene are commonly used by persons 
who abuse drugs by injection. Such preparations are 
often used as an alternative to heroin since they are 
cheaper and more easily available. In 2008, Indian law 
enforcement authorities seized a total of more than 
80,000 tablets containing dextropropoxyphene. 
590. Although India produces and exports large 
quantities of opium derived from licit cultivation, 
access to morphine for the treatment of pain remains 
limited in that country. There have been frequent 
reports of acute shortages of morphine in palliative 
care centres and hospitals. The Board notes that efforts 
have been made at the national and state levels to 
identify the regulatory and legislative measures that 
bar access to morphine and encourages the 
Government of India to take the steps necessary to 
remove those barriers while continuing to prevent the 
diversion of morphine. 
591. The smuggling of heroin into Maldives is an 
ongoing problem that is contributing to an increase in 
drug abuse in that country. In 2008, Maldivian law 
enforcement authorities reported numerous seizures of 
heroin, totalling more than 8 kg. In the majority of 
those cases, the traffickers were arrested at Malé 
International Airport and had travelled to Maldives 
from either India or Sri Lanka.  
592. Sri Lanka continued to report seizures of heroin 
in 2008; in the course of the year, drug law 
enforcement units in that country seized about 17 kg of 
heroin. India and Pakistan were most often identified 
as the source of the seized heroin. The bulk of the 
heroin had been smuggled into Sri Lanka by sea; about 
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20 per cent of it was seized from passengers arriving 
by air.  
 
  Psychotropic substances 
 
593. Bangladesh continues to report large seizures of 
pharmaceutical preparations containing buprenorphine, 
which is widely abused by injection. In 2008, law 
enforcement authorities in that country seized a record 
14,782 ampoules containing buprenorphine, that had 
originated in India and 5,763 methamphetamine 
tablets, known as “yaba”, that had originated in 
Myanmar. “Yaba” is reported to be popular among 
young people in high-income families. In the majority 
of those cases, the preparations were smuggled by 
persons entering Bangladesh by crossing the country’s 
porous land borders. 
594. Pharmaceutical preparations containing 
benzodiazepines are among the drugs most widely 
abused in Bhutan. More than 1,060 tablets containing 
chlordiazepoxide and 240 strips of tablets containing 
nitrazepam were seized in 2007. Bhutan continued to 
report frequent seizures of those drugs in 2008. The 
suspected origin of the seized drugs was India. 
595. Consistent with reports of the increasing 
availability of amphetamine-type stimulants in South 
Asia, several seizures of methamphetamine were made 
in India in 2008. Indian law enforcement agencies 
seized about 7,500 tablets of methamphetamine in 
March 2008 and 3,000 tablets in September of the 
same year. In addition, 11 kg of methamphetamine was 
seized in the course of the year.  
596. Methaqualone continues to be manufactured 
illicitly in India, before being smuggled into countries 
such as South Africa. A total of 2,382 kg of 
methaqualone was seized in 2008, compared with 1 kg 
in 2007, 4,521 kg in 2006 and 472 kg in 2005.  
597. India has become one of the main sources of 
drugs sold through illegally operating Internet 
pharmacies. Orders placed with such pharmacies are 
often dispatched to buyers in other countries using 
courier or postal services. Since 2002, Indian law 
enforcement agencies have detected and disbanded 
several groups that were operating illegal Internet 
pharmacies. In February 2007, Indian authorities 
identified a company that offered software solutions 
allowing illegal transactions involving pharmaceutical 
preparations to be made over the Internet. In 2008, 
three Internet pharmacies that had been operating in 
India and illegally selling psychotropic substances to 
buyers in the United States were shut down. The Board 
urges the Government of India to adopt measures to 
prevent the use of the Internet to divert controlled 
substances. 
598. The abuse of pharmaceutical preparations 
containing psychotropic substances in Nepal is 
facilitated by the open border that that country shares 
with India. In a survey on drug abuse conducted in 
2006, 13 per cent of respondents reported having 
obtained drugs from the border area between the two 
countries. Pharmaceutical preparations commonly 
smuggled out of India and into Nepal contain 
buprenorphine and nitrazepam. In 2007, about 
11,500 vials containing buprenorphine and 92,500 vials 
containing benzodiazepines were seized in Nepal. 
 
  Precursor chemicals 
 
599. Law enforcement agencies in India continue to 
report seizures of acetic anhydride. While an average 
total of 300 litres of that precursor was seized annually 
from 2005 to 2007, a total of about 2,800 litres was 
seized in 2008. The Board encourages the Government 
of India to remain vigilant with regard to the diversion 
of acetic anhydride. 
600. As one of the world’s largest manufacturers of 
ephedrine and pseudoephedrine, India represents one 
of the main sources of those precursor chemicals, 
which are used in the illicit manufacture of 
amphetamine-type stimulants. In recent years, Indian 
law enforcement agencies have seized several large 
consignments of ephedrine and pseudoephedrine 
intended for use in illicit drug manufacture in other 
countries. In February 2008, intelligence provided by 
Indian law enforcement agencies led to the seizure in 
New York of 100 kg of ephedrine originating in India. 
In September 2008, drug control agencies in India 
seized 37 tons of pseudoephedrine and 872 kg of 
ephedrine. Attempts to smuggle ephedrine and 
pseudoephedrine out of India using courier and postal 
services have also been reported: a package containing 
100 kg of ephedrine was seized in December 2007, 
while a consignment of 95 kg of pseudoephedrine was 
seized in January 2009. 
601. Several attempts to smuggle pharmaceutical 
preparations containing ephedrine and 
pseudoephedrine out of India were also detected in 
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2008. In February of that year, a total of 
280,000 tablets containing pseudoephedrine were 
seized in India. Also in 2008, in two separate incidents 
at Le Havre, France, authorities intercepted 11 million 
tablets containing pseudoephedrine in transit from 
India to Honduras and a further 90 kg of such tablets in 
transit from India to Guatemala. Authorities of the 
United Kingdom seized 1,650,000 tablets containing 
pseudoephedrine in a consignment originating in India. 
602. Bangladesh, like India, constitutes a significant 
source in South Asia of preparations containing 
pseudoephedrine. In 2008, 7,132 tablets originating in 
Bangladesh and destined for Guatemala were seized 
while being transported through France. 
603. A number of clandestine methamphetamine 
laboratories have been discovered in South Asia in 
recent years. In May 2008, a clandestine laboratory 
importing substances used for the illicit manufacture of 
methamphetamine was discovered in Kosgama, Sri 
Lanka. In India, a methamphetamine laboratory was 
dismantled by law enforcement agencies in the 
province of Gujarat in November 2008 and another 
was dismantled in the province of Punjab in June 2009.  
 
  Substances not under international control 
 
604. India has reported an increasing number of 
seizures of ketamine. Few seizures of ketamine were 
reported until 2008, when law enforcement authorities 
seized a total of about 575 kg of that drug. Most of the 
consignments seized in India were about to be 
smuggled into countries in South-East Asia. 
 
 5. Abuse and treatment 
 
605. Most countries in South Asia lack recent and 
comprehensive data on the prevalence of drug abuse. 
Information on patterns of drug abuse in the region is 
often based on rapid situation assessments, the habits 
of the patient population in centres for the treatment 
and rehabilitation of drug abusers and the habits of 
persons arrested on drug-related charges. The Board 
reminds the Governments of countries in the region 
that regular and comprehensive surveys of drug abuse 
patterns are essential in developing effective drug 
control policies and strategies to prevent drug abuse.  
606. A rapid situation and response assessment 
conducted by UNODC in Bangladesh in 2005 among 
1,073 drug abusers indicated lifetime prevalence rates 
of 96 per cent for cannabis abuse, 13 per cent for 
opium abuse, 92 per cent for abuse of heroin by 
smoking, 4 per cent for abuse of heroin by injection, 
28 per cent for buprenorphine abuse and less than 1 per 
cent for dextropropoxyphene abuse. In 2008, of 
2,350 patients receiving treatment for drug addiction, 
13 per cent were treated for cannabis abuse, 62 per 
cent for heroin abuse and 10 per cent for the abuse of 
buprenorphine. The use of mixtures of pharmaceutical 
preparations containing buprenorphine, diazepam and 
antihistamines is common among persons who abuse 
drugs by injection. The Government of Bangladesh 
operates several centres for the treatment of drug 
addiction in that country; those centres provided 
services to 3,869 patients in 2008.  
607. In Bhutan, a rapid situation and response 
assessment conducted by UNODC in Thimphu in 2006 
among 200 drug abusers revealed lifetime prevalence 
rates of drug abuse of 86 per cent for cannabis abuse, 
19 per cent for heroin abuse by smoking, 2 per cent for 
heroin abuse by injection, 14 per cent for 
buprenorphine abuse and 16 per cent for 
dextropropoxyphene abuse. Of the total number of 
persons arrested by the police for drug abuse in 2006, 
almost 90 per cent were under 26 years of age, which 
underscores the prevalence of the problem among 
youth. In a survey of drug abuse among secondary 
school students in Phuentsholing, a town near the 
border between Bhutan and India, conducted in 2008 
by the Bhutan Narcotic Control Agency in 
collaboration with UNODC, 9 per cent of respondents 
reported having abused cannabis occasionally, while 
8 per cent reported occasional abuse of 
pharmaceuticals. The Board notes with satisfaction that 
the first national baseline survey of drug abuse in 
Bhutan was conducted in 2009 and looks forward to 
the findings of that survey. 
608. In Bhutan, there are currently no facilities 
specifically for the treatment and rehabilitation of drug 
abusers. Patients seeking treatment for drug abuse 
receive care in the psychiatric wards of major 
hospitals. The Government of Bhutan is planning to 
open a treatment facility dedicated to providing care 
for the growing number of drug abusers in that country. 
609. The most recent national household survey in 
India was conducted during 2000 and 2001. The survey 
indicated lifetime prevalence rates of 0.5 per cent for 
opium abuse, 0.2 per cent for heroin abuse, 0.1 per cent 
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for abuse of cough syrups containing narcotic drugs, 
4.1 per cent for cannabis abuse and 0.1 per cent for 
abuse of sedatives and hypnotics. A rapid situation and 
response assessment conducted by UNODC in India in 
2005 among 5,732 drug abusers indicated lifetime 
prevalence rates of 73 per cent for cannabis abuse, 
27 per cent for opium abuse, 52 per cent for abuse of 
heroin by smoking, 28 per cent for abuse of heroin by 
injection, 30 per cent for dextropropoxyphene abuse 
and 26 per cent for buprenorphine abuse. In India, 
treatment and rehabilitation services for drug abusers 
are provided by centres operated by the Government 
and by non-governmental organizations. The 
Government of India currently operates 100 treatment 
centres and provides financial support to 361 voluntary 
organizations that operate 376 treatment rehabilitation 
centres and 68 counselling and awareness centres 
nationwide. 
610. According to an estimate by the National 
Narcotics Control Bureau of Maldives, there were 
between 2,000 and 3,000 drug addicts in that country 
in 2006. A rapid situation assessment conducted in 
2003 indicated that opioids were abused by 76 per cent 
of respondents and cannabinoids by 12 per cent. The 
increase in drug abuse in recent years has prompted the 
Government of Maldives to develop a comprehensive 
drug control master plan, which was launched in 2008. 
A centre for the rehabilitation of drug abusers on the 
island of Himmafushi, established by the Government 
of Maldives in 1997, can accommodate about 
125 patients. There are reports of insufficient access to 
treatment and rehabilitation services in Maldives, 
notably for repeat offenders arrested on drug-related 
charges and drug abusers in prisons. The Board notes 
with satisfaction that in 2009 the Government of 
Maldives established a new detoxification centre to 
treat drug addicts.  
611. According to a survey conducted by the 
Government of Nepal in 2006, there were some 
46,000 drug abusers in that country. The survey 
revealed lifetime prevalence rates of 87 per cent for 
cannabis abuse, 86 per cent for abuse of 
pharmaceutical preparations, 61 per cent for abuse of 
low-grade heroin base (“brown sugar”), 14 per cent for 
heroin abuse and 7 per cent for opium abuse. Similarly, 
a rapid situation and response assessment carried out 
by UNODC among 1,322 drug abusers in 2005 
revealed a lifetime prevalence rate of 92 per cent for 
cannabis abuse, 14 per cent for opium abuse, 88 per 
cent for abuse of heroin by smoking, 46 percent for 
abuse of heroin by injection, 11 per cent for 
dextropropoxyphene abuse and 77 per cent for 
buprenorphine abuse. In 2007, 617 people were 
reported to have been arrested on drug-related charges. 
In Nepal, treatment services are provided to drug 
addicts by non-governmental organizations rather than 
by the Government. The Board encourages the 
Government of Nepal to ensure that adequate resources 
are allocated for the treatment and rehabilitation of 
drug addicts. 
612. A rapid situation and response assessment 
conducted by UNODC among 1,016 drug abusers in 
Sri Lanka in 2005 revealed lifetime prevalence rates of 
72 per cent for cannabis abuse, 11 per cent for opium 
abuse, 55 per cent for abuse of heroin by injection, 
2 per cent for abuse of heroin by smoking, 4 per cent 
for dextropropoxyphene abuse and less than 1 per cent 
for buprenorphine abuse. The Government of Sri Lanka 
operates four treatment centres for drug addicts and 
special programmes in prisons to treat incarcerated 
drug abusers. Additional rehabilitation programmes are 
run by a number of non-governmental organizations 
nationwide. In 2007, 3,413 drug abusers were admitted 
for treatment at facilities operated by the Government. 
613. The high prevalence of drug abuse by injection in 
several countries in South Asia and the common 
practice among persons who abuse drugs by injection 
of sharing needles are important factors contributing to 
the spread of HIV. In response to this problem, the 
Governments of several countries in the region have 
established opioid substitution programmes. In 
August 2008, the Government of Bangladesh approved 
a pilot study on the use of methadone in substitution 
treatment for drug abuse, to be conducted in Dhaka in 
collaboration with UNODC. In India, about 4,500 drug 
abusers receive substitution treatment using 
buprenorphine at 47 centres run by non-governmental 
organizations and accredited by the Government. In 
Nepal, methadone substitution treatment is provided to 
some 250 drug abusers in a programme implemented 
by the Government. In October 2008, the Government 
of Maldives, in collaboration with UNODC, initiated a 
pilot programme of opioid substitution treatment using 
methadone for 45 drug addicts. 
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  West Asia 
 
 
 1. Major developments 
 
614. After peaking in 2007, the illicit cultivation of 
opium poppy and the illicit production of opium in 
Afghanistan decreased in 2008 and 2009. UNODC 
reports also indicate that in Afghanistan prices of 
opiates continued to fall in 2009, fewer people were 
involved in opium poppy cultivation and opium 
production and the proceeds of the illicit drug industry 
decreased. At the same time, the number of Afghan 
provinces free of opium poppy in Afghanistan and the 
total quantity of drugs seized continued to rise. In 
addition, farm-gate prices of opium poppy have fallen 
due to oversupply, and food prices have risen due to 
undersupply. Given those circumstances, now is an 
opportune moment for the Government of Afghanistan 
and the international community to give higher priority 
to improving governance and economic development 
and to provide sustainable support for legitimate 
alternative livelihoods for farming communities. 
615. Many countries in West Asia reported positive 
developments in drug control in 2009 as a result of 
national and multilateral efforts by Governments and 
the allocation of increased resources to fight the 
scourge of Afghan opiates. In particular, the Board 
commends the Government of Afghanistan on its 
recent decision not to authorize any import of acetic 
anhydride into the country. At the same time, the Board 
stresses that Afghanistan remains by far the largest 
illicit producer of heroin and other opiates in the world 
and is becoming a major producer of illicitly cultivated 
cannabis. The magnitude of the drug problem is such 
that it poses a serious threat to the political, economic 
and social stability of not only Afghanistan but also 
other countries, both in West Asia and in other regions. 
Iran (Islamic Republic of), Pakistan, the Russian 
Federation and countries in Central Asia and the 
Caucasus and on the Arabian Peninsula remain 
particularly vulnerable to drug trafficking and abuse. 
616. The Middle East has become a market for illicit 
drugs such as cocaine that had not previously been 
known to be abused to any significant extent in the 
subregion and some countries in the region are 
confronted with new drug smuggling trends. 
617. Trafficking in and abuse of amphetamine-type 
stimulants continue to increase in the countries of West 
Asia, particularly in the eastern Mediterranean and on 
the Arabian Peninsula. In 2007, almost 30 per cent of 
global seizures of amphetamine-type stimulants were 
effected in West Asia. The most significant seizures 
were reported in Saudi Arabia (27 per cent of all 
amphetamine-type stimulants seized). In recent years, 
West Asia’s share of global seizures of synthetic drugs, 
including Captagon, amphetamines and MDMA 
(“ecstasy”), has risen from 1 to 25 per cent. 
618. Counterfeit Captagon tablets, often containing 
amphetamine, continue to be abused and seized in West 
Asia. In 2008, most of the seizures of such tablets were 
reported in Jordan, Saudi Arabia and the Syrian Arab 
Republic. Many of the seized consignments had been 
sent from the Syrian Arab Republic. Several other 
countries in the region have reported dramatic 
increases in seizures of Captagon tablets. Bulgaria and, 
to a lesser degree, Turkey are believed to be the 
sources of the counterfeit Captagon, although there are 
several indications that undetected amphetamine 
manufacture may also be occurring elsewhere in the 
region, in particular in Jordan and the Syrian Arab 
Republic, countries in which it is suspected that 
clandestine laboratories are manufacturing counterfeit 
Captagon tablets. 
 
 2. Regional cooperation 
 
619. Afghanistan, Iran (Islamic Republic of) and 
Pakistan are increasingly cooperating through the 
Triangular Initiative, an initiative brokered by UNODC 
to improve the sharing of intelligence with a view to 
combating the smuggling of opiates out of Afghanistan 
and to enhancing joint interdiction operations. Several 
high-level meetings on combating trafficking in drugs 
were held, including the third ministerial meeting, held 
in Vienna in October 2009, and related meetings held 
in Vienna in March 2009, Kabul in May 2009 and 
Tehran in July 2009. The three countries continued the 
deployment at their borders of border liaison officers to 
plan joint operations targeting the smuggling of opiates 
out of Afghanistan. The members of the Triangular 
Initiative also announced that they would strengthen 
efforts to counter the illicit trade in precursor 
chemicals used in processing opium in Afghanistan and 
its neighbouring countries. 
620. A joint planning cell was established in Tehran in 
March 2009 to enhance cooperation among the three 
countries of the Triangular Initiative and launch joint 
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field operations against international drug trafficking 
networks in West Asia. In order to plan for full 
deployment of border liaison officers in common 
border areas, the Government of the Islamic Republic 
of Iran hosted the International Conference of Drug 
Liaison Officers on 28 and 29 April 2009. The main 
purpose of the Conference was to reach agreement on a 
comprehensive cross-border communication plan and 
cooperation to stop precursor chemicals from entering 
Afghanistan. Some success has already been achieved 
by means of joint operations at Afghanistan’s borders 
with the Islamic Republic of Iran and Central Asian 
States. The Board notes, however, that although one 
fourth of all narcotic drugs of Afghan origin is 
smuggled through Pakistan, no seizures of drugs of 
Afghan origin were reported in the Federally 
Administered Tribal Areas of Pakistan bordering 
Afghanistan. 
621. At key international summits, emphasis was 
placed on adopting a truly regional approach to 
combating Afghanistan’s illicit drug industry. On 
27 March 2009, the Special Conference on Afghanistan 
was convened in Moscow under the auspices of the 
Shanghai Cooperation Organization, with the 
participation of, among others, the United Nations 
(represented by the Secretary-General, the Board and 
UNODC), the European Union, the Organization for 
Security and Cooperation in Europe (OSCE), the North 
Atlantic Treaty Organization (NATO) and the 
Collective Security Treaty Organization (CSTO). The 
declaration adopted at the Special Conference, inter 
alia, stressed the importance of strengthening efforts to 
combat illicit drug production and promote the 
development of the licit economy of Afghanistan and 
underlined the importance of close regional 
cooperation, more active collaboration among 
neighbouring States to combat drug trafficking and 
efforts to prevent precursors from entering the country.  
622. Representatives of 73 countries and 
20 international organizations attended an international 
conference on Afghanistan that was held in The Hague 
on 31 March 2009. The conference presented a strategy 
for leveraging, in a regional context, international will 
and resources to address the remaining challenges in 
Afghanistan, including the illicit production of, 
trafficking in and abuse of narcotic drugs. The 
conference stressed the need for a well-coordinated and 
strategically integrated approach for Afghanistan, 
focusing on the priority goals of promoting good 
governance and stronger institutions, generating 
economic growth, strengthening security and 
enhancing regional cooperation. 
623. Governments of countries in Central Asia are 
increasing their bilateral and multilateral cooperation 
in areas such as reduction of illicit drug supply and 
demand, precursor control, border management, 
countering the spread of HIV/AIDS and combating 
organized crime and money-laundering. Those 
countries have also carried out various regional 
projects and international operations under the auspices 
of the Commonwealth of Independent States (CIS), 
CSTO and the Shanghai Cooperation Organization and 
within the framework of the Memorandum of 
Understanding on Subregional Drug Control 
Cooperation signed in Tashkent in 1996 as well as joint 
programmes supported by the United Nations, the 
World Bank, the European Union, OSCE, the World 
Customs Organization, INTERPOL, the Paris Pact 
Policy Consultative Group, NATO–Russia Council, 
mini-Dublin groups and individual Governments.  
624. The Board urges the Governments participating 
in the Central Asian Regional Information and 
Coordination Centre (CARICC) to actively include 
Afghanistan, as well as its neighbouring countries, in 
that initiative, in order to ensure greater cooperation in 
collecting, exchanging and analysing drug-related 
intelligence, organizing and coordinating joint 
international operations and carrying out other supply 
and demand reduction efforts and training in West 
Asia.  
625. Joint measures taken by Governments of 
countries in the Middle East to combat drug trafficking 
have continued to yield good results. For example, 
Jordanian authorities reported that in 2007 and 2008, 
they conducted 22 operations in which they 
coordinated efforts with Saudi Arabian and Syrian 
authorities. Jordan remains committed to existing 
bilateral agreements providing for drug control 
cooperation, with Egypt, Hungary, Iran (Islamic 
Republic of), Iraq, Israel, Lebanon, Pakistan, Saudi 
Arabia, the Syrian Arab Republic and Turkey. Jordan 
also cooperates with UNODC and the European 
Commission in a number of projects funded by the 
European Union. 
626. Close cooperation in particular in controlled 
deliveries and the sharing of information on drug 
trafficking, especially between Turkey and other 
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countries in West Asia, has proved effective, resulting 
in significant drug seizures in 2007 and 2008. The 
Board encourages the Governments of countries in 
West Asia to intensify their cooperation in order to 
achieve good results in joint efforts to combat drug 
trafficking in the region.  
627. In January 2009, with technical assistance from 
UNODC, a number of drug law enforcement officers of 
the Dubai Police participated in a workshop held in 
Beirut on the design, drafting and marketing of 
projects related to drug control. Training covered the 
topics of surveillance and awareness of suspicious 
behaviour by individuals.  
628. At a workshop on border control held in Košice, 
Slovakia, in April 2009, law enforcement officers from 
Egypt, Jordan, Morocco and Palestine, as well as from 
countries of South-Eastern Europe, discussed new 
methodologies and equipment used to control borders 
and combat drug smuggling.  
629. At the eighth annual regional coordination 
meeting on HIV and AIDS in the Middle East, 
convened by UNAIDS in Beirut in March 2009, 
participants discussed, among other topics, the 
harmonization of regional approaches, universal access 
to HIV prevention, treatment and care services and 
resource mobilization. The Government of Lebanon is 
developing a national five-year strategy to begin in 
2010. With the technical assistance of UNODC and in 
partnership with UNAIDS, authorities will develop an 
action plan on drug abuse and HIV; substitution 
therapy will also be included in the plan.  
630. At its 29th session, held in Muscat in late 
December 2008, the Supreme Council of the 
Cooperation Council for the Arab States of the Gulf 
approved the establishment in Qatar of the Gulf 
Cooperation Council criminal information centre for 
combating drugs. 
631. The Israeli Anti-Drug Authority participated in 
regional law enforcement workshops organized by the 
United Nations, participated in the joint meetings of 
Israeli and Palestinian law enforcement officers and 
began building channels of communication with Jordan 
by conducting research trips. 
 
 3. National legislation, policy and action 
 
632. The Government of Afghanistan ratified the 
United Nations Convention against Corruption50 and 
established the High Office of Oversight and Anti-
Corruption in August 2008. However, the enactment of 
revised drug control legislation, the law on extradition 
and mutual legal assistance, the Criminal Procedure 
Code, and amendments to the Penal Code reflecting 
penal sanctions for corruption are still awaiting 
approval of the National Assembly and/or the 
President. Corruption continues to be a serious 
problem in Afghanistan, hampering efforts to eradicate 
illicit opium poppy cultivation and combat illicit drug 
trade in general. The Board urges the Government of 
Afghanistan to expedite adoption of the necessary 
legislative base that will enhance its ability to take 
strong measures to fight corruption, report the main 
drug traffickers to the Security Council and prosecute 
those, including government officials, involved in 
Afghanistan’s illicit drug industry. 
633. The Government of the Islamic Republic of Iran, 
one of the countries most affected by the illicit trade in 
Afghan opiates, significantly increased its resources 
allocated for drug control in the year starting 20 March 
2008 and, in particular, strengthened its capacity for 
the prevention and treatment of drug abuse. The 
Government has also continued to strengthen border 
control through the deployment of additional personnel 
and the construction of barriers and other border 
structures. 
634. In May 2009, the parliaments of Azerbaijan, 
Kazakhstan, Kyrgyzstan, Tajikistan and Turkmenistan 
ratified the framework agreement on the establishment 
of CARICC; and the parliament of the Russian 
Federation ratified the framework agreement in 
September 2009. With those ratifications, CARICC 
begins the transition from its pilot phase to full-fledged 
functionality as a regional focal point for 
communication, analysis and the real-time exchange of 
operational information in order to prevent and combat 
transborder drug trafficking and international 
organized criminal groups involved in drug trafficking. 
Among achievements to date, CARICC served as the 
regional focal point for the Targeted Anti-trafficking 
Regional Communication, Expertise and Training 
(TARCET) in the areas of precursors and controlled 
__________________ 
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delivery operations. Efforts within the framework of 
CARICC to foster cooperation and share information 
among the participating countries resulted in the 
seizure of 200 kg of heroin and the dismantling of 
more than 10 drug trafficking groups. The Board notes 
that the CARICC strategic plan for the period 2010-
2011, which was approved at the first meeting of the 
CARICC Council, held in Almaty, Kazakhstan, in 
February 2009, recognizes the openness of CARICC to 
developing partnerships with non-member States and 
organizations. 
635. Over 20 partner countries and international and 
regional organizations participate in Operation 
TARCET, which is aimed at facilitating cross-border 
cooperation in interceptions and seizures of 
consignments of precursor chemicals smuggled into 
Afghanistan for use in the illicit manufacture of heroin. 
During 2008, in the framework of TARCET I, such 
joint activities resulted in the seizure of over 19 tons of 
acetic anhydride (14 tons in Pakistan, 5 tons in the 
Islamic Republic of Iran and 500 kg in Afghanistan), 
over 27 tons of other chemicals (6.8 tons of sulphuric 
acid in Kyrgyzstan, 1.6 tons of acetic acid in 
Uzbekistan, 16 tons of acetyl chloride in the Islamic 
Republic of Iran and 3 tons of diverse chemicals in 
Afghanistan). During the first month of the second 
phase of the operation (TARCET II), which started in 
July 2009 and is expected to last until early 2010, 
5 tons of acetic anhydride were reported to have been 
seized in Quetta, Pakistan. 
636. In May 2009, the Government of Kazakhstan 
adopted a new programme for combating drug abuse 
and drug trafficking for the period 2009-2011, focusing 
on implementation of the second stage of the national 
drug control strategy for the period 2006-2014. The 
main purpose of the programme is to dismantle illicit 
drug distribution networks in the country and reverse 
the increasing trends in the abuse of psychoactive 
substances and in drug dependence by enhancing 
coordination and regional drug control measures and 
promoting primary prevention activities and healthy 
lifestyles among the public. The programme entails a 
15-fold increase in the financing of the national drug 
control authorities with the aim of increasing by 
30-50 per cent the amount of opiates seized each year. 
637. The Government of Armenia issued several 
decrees in January 2008, strengthening its national 
drug control mechanisms by approving licence formats 
and licensing procedures for all processing activities 
related to the manufacture, distribution and medical 
and scientific use of narcotic drugs and psychotropic 
substances and their precursors. In April and 
September 2008, the country’s drug control legislation 
was amended with a view to strengthening controls 
over licit movement and stocks of narcotic drugs, 
psychotropic substances and their precursors. 
638. The Board takes note of the achievements 
obtained through enhanced drug law enforcement and 
interdiction efforts in Israel. In 2008, the Israeli police 
established a new drug interdiction unit named 
“Magen” to patrol the Israeli-Jordanian border in the 
Dead Sea area, resulting in increased drug seizures. 
Israeli police reported that the number of drug 
trafficking and smuggling cases increased by 40 per 
cent from 2007 to 2008.  
639. The Government of Jordan carries out initiatives, 
including seminars and lectures at schools and 
universities, to raise public awareness of the dangers of 
drug abuse. Governmental institutions, non-
governmental organizations, correction and 
rehabilitation centres, youth clubs and the media will 
all be involved in those initiatives which are aimed at 
making drug demand reduction efforts more successful. 
 
 4. Cultivation, production, manufacture and 
trafficking 
 
  Narcotic drugs 
 
640. According to “Afghanistan Opium Survey 2009: 
Summary Findings”, issued by UNODC in 
September 2009, opium poppy cultivation in 
Afghanistan decreased from a peak of 193,000 ha in 
2007 to 157,000 ha in 2008 (a decrease of 19 per cent) 
to 123,000 ha in 2009 (a decrease of 22 per cent). The 
most significant decrease was recorded in Helmand 
province, where such cultivation declined by a third, 
from 103,590 ha in 2008 to 69,833 ha in 2009. The 
number of provinces free from opium poppy 
cultivation has increased from 18 to 20. Kapisa, 
Baghlan and Faryab provinces became poppy-free, 
while Nangarhar province could not retain the poppy-
free status that it had achieved in 2008. The Board 
urges the Government of Afghanistan, as well as the 
international community, to continue to enhance the 
effectiveness and sustainability of measures to curb 
opium poppy cultivation and to ensure that farming 
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communities involved in illicit crop cultivation are 
provided with sustainable, legitimate livelihoods. 
641. Despite the decrease of 22 per cent in the total 
cultivation area, because of the record opium poppy 
yield of 56 kg per hectare in 2009 — an increase of 
15 per cent over 2008 — opium production fell by only 
10 per cent, from 7,700 tons in 2008 to 6,900 tons in 
2009. The prices of fresh and dry opium poppies have 
fallen by a third in the past year, causing the total 
farm-gate value of opium production in Afghanistan to 
fall by 40 per cent, from $730 million in 2008 to 
$438 million in 2009. The number of people involved 
in opium production also dropped significantly: from 
2.4 million to 1.6 million. 
642. Afghan opiates are smuggled predominantly 
through Iran (Islamic Republic of), Pakistan and 
countries of Central Asia. Those countries are faced 
with a wide range of problems related to large-scale 
drug trafficking such as organized crime, corruption 
and relatively high illicit demand for opiates. As a 
result, the Islamic Republic of Iran has the highest rate 
of abuse of opiates in the world. In the countries of 
Central Asia, the rate of abuse of opiates continues to 
increase, and HIV/AIDS transmission through the 
sharing of needles among persons who abuse drugs by 
injection continues to be a problem.  
643. Significant drug seizures were made in 
Afghanistan, though those seizures were small in 
comparison with the scale of illicit drug production in 
the country. Of the estimated 7,700 tons of opium 
produced in 2008, 42.8 tons were seized, for a seizure 
ratio of 0.56 per cent, while the ratio of heroin seized 
to heroin produced is 0.43 per cent (2.8 tons of heroin 
seized of an estimated 658 tons of heroin produced). It 
has been reported that in the first half of 2009, drug 
law enforcement operations involving military units of 
the International Security Assistance Force (ISAF) of 
Afghanistan and NATO resulted in the seizure of 
459 tons of poppy seeds, 50 tons of opium, 7 tons of 
morphine, 2 tons of heroin and 19 tons of cannabis 
resin. In addition, the Counter Narcotics Police of 
Afghanistan reported the seizure of 36 tons of opium, 
5 tons of heroin, 2 tons of morphine and 338 tons of 
cannabis resin.  
644. The Islamic Republic of Iran, through whose 
territory more than half of illicit Afghan opiates is 
reported to be smuggled, continues to seize more 
opiates than any other country in the world. In the first 
half of 2008, 180 tons of opiates were seized in the 
Islamic Republic of Iran (an increase of 37 per cent 
over the first half of 2007), mainly on the country’s 
eastern border with Afghanistan. In the first three 
months of 2009, 146 tons of opium, 6.5 tons of heroin, 
over 3 tons of morphine and 21 tons of cannabis resin 
were seized by Iranian law enforcement authorities. 
645. Pakistan continues to be used as a major transit 
area for Afghan opiates, but to a lesser extent than is 
the Islamic Republic of Iran. According to Pakistan 
officials, one third of illicit opiates of Afghan origin 
are smuggled through Pakistan. According to 
Government data, until 2006, increasing quantities of 
Afghan opiates were seized in Pakistan. The total 
amount of seized opiates increased from 25 tons of 
heroin equivalent in 2005 to 36.4 tons of heroin 
equivalent in 2006, an increase of 46 per cent. The 
latest officially reported data suggest that, while 
seizures of opium increased by 77 per cent (from 
15.4 tons in 2007 to 27 tons in 2008), seizures of 
heroin and morphine during that period each fell by 
one third (seizures of heroin fell from 2.8 tons to 
1.9 tons and seizures of morphine fell from 10.9 tons to 
7.3 tons). 
646. Turkey reported an increase in the amount of 
heroin seized: in 2008, the amount of heroin seized in 
Turkey exceeded 15 tons, an increase of 14 per cent 
over the 13.2 tons seized in 2007. However, the 
amount of opium seized, after peaking at 519 kg in 
2007, fell to 202 kg in 2008, a decrease of 61 per cent. 
Cocaine seizures in Turkey followed an upward trend 
until 2008. The amount of cocaine seized totalled only 
3 kg in 2003 but increased to 40 kg in 2005, 77 kg in 
2006 and 114 kg in 2007. In 2008, cocaine seizures 
dropped to 105 kg.  
647. According to UNODC estimates, approximately 
121 tons of heroin and 293 tons of opium transited 
through Central Asian countries in 2008, as most 
opiates produced and trafficked in north-eastern 
Afghanistan are smuggled across the border into the 
countries of Central Asia, due to their proximity and 
strong ethnic links. Official data on opiates seizures in 
2008 indicate that Central Asian countries seized 
5.3 tons of heroin (almost 2 tons more than in 2007) 
and 4.5 tons of opium (1.7 tons less than in 2007). 
Some of those seizures were carried out through joint 
operations, such as Operation Channel 2008 of CSTO, 
which resulted in the detection of 12,782 cases of drug 
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trafficking and the seizure of over 25 tons of 
precursors and 30 tons of illicit drugs, including 
3.4 tons of heroin, 983 kg of opium, 1.9 tons of 
cannabis, 11.7 tons of cannabis resin and 1.6 tons of 
cocaine. 
648. Several large seizures of opiates (up to 500 kg 
each) have been reported by the law enforcement 
agencies of Kazakhstan, Turkmenistan and Uzbekistan. 
Tajikistan continues to seize the largest quantities of 
opiates in Central Asia (53 per cent of seizures in the 
subregion in 2008) and remains the gateway for most 
opiate smuggling through the subregion. Heroin 
seizures effected in Central Asian States increased by 
60 per cent, primarily due to the dramatic increase in 
seizures in Kazakhstan (1.6 tons of heroin seized, an 
increase of 214 per cent over 2007) and Uzbekistan 
(1.5 tons of heroin seized, a 207 per cent increase from 
2007). Heroin seizures in Tajikistan increased by 6 per 
cent from 2007, reaching 1.6 tons in 2008. In contrast, 
opium seizures in Central Asia decreased by 28 per 
cent (4.5 tons seized). The largest portion of the opium 
seized in this subregion continued to be accounted for 
by Tajikistan (1.7 tons), followed by Turkmenistan 
(1.5 tons) and Uzbekistan (1 ton). Statistics released by 
the Government of Turkmenistan indicate that the total 
amount of drugs seized in 2008 exceeded 2 tons, 
including 245 kg of heroin, 261 kg of cocaine, 1.5 tons 
of opium and 135 kg of cannabis and cannabis resin. 
649. Official data suggest that the quantities of heroin, 
opium and cocaine smuggled through the Southern 
Caucasus are increasing. In 2008, 650 kg of drugs were 
seized in Azerbaijan, including 55 kg of opium and 
49 kg of heroin. The number of offences recorded for 
drug possession, abuse and trafficking exceeded 1,670. 
The opiates originating in Afghanistan are entering 
Azerbaijan mostly by land and rail from the Islamic 
Republic of Iran and countries in Central Asia en route 
to Georgia, the Russian Federation and countries in 
Western Europe. 
650. The Middle East has become a market for illicit 
drugs such as cocaine that had not previously been 
known to be abused to any significant extent in the 
subregion. For example, Jordan is confronted with new 
drug smuggling trends. In the first four months of 
2009, 25.4 kg of cocaine from South America were 
seized in the country, compared with a total of 6.3 kg 
in 2008. While in recent years only small quantities of 
cocaine and heroin reached Lebanon, mainly to meet 
local demand, in 2008 Lebanese authorities intercepted 
61 kg of cocaine and 14.5 kg of heroin, a significant 
increase over the corresponding figures for 2007. 
651. The largest increase in cocaine seizures in 2007 
was reported in the countries of the Arabian Peninsula 
(seizures of 141 kg in 2007 compared with 72 kg in 
2006). The Syrian Arab Republic reported total 
seizures of 77 kg in 2007 compared with 2 kg in 2006.  
652. Because it is situated between drug-producing 
countries to the north and east and drug-consuming 
countries to the south and west, Jordan continues to be 
primarily a transit area for illicit drugs. The Public 
Security Directorate of Jordan has noted that the 
amount of drugs smuggled through Jordan continues to 
grow. The drugs of choice among individuals arrested 
for drug possession in Jordan are cannabis and heroin, 
and the majority of individuals arrested for drug-
related crimes are between the ages of 18 and 35 years. 
653. According to UNODC estimates, the production 
of cannabis resin in Afghanistan has been increasing 
since 2003. In 2007, the total area under cannabis plant 
cultivation in Afghanistan (70,000 ha) equalled more 
than one third of the total area under opium poppy 
cultivation. The Board continues to be concerned that 
the vast oversupply of opiates and the widely reported 
decrease in opiate prices could prompt a shift to 
cannabis cultivation and smuggling. As an indication 
of that shift, it was reported that the total amount of 
cannabis resin seized in Pakistan increased by 23 per 
cent in the period 2005-2006 (from 93.5 to 115.4 tons) 
and by 33 per cent in the period 2007-2008 (from 101 
to 135 tons). 
654. Cannabis continues to be the drug most 
commonly seized in Central Asia. In addition to the 
fact that cannabis plants grow wild in Kazakhstan and 
Kyrgyzstan, more and more shipments of Afghan 
cannabis and cannabis resin are being discovered in 
Central Asia. The law enforcement agencies of Central 
Asian countries seized over 33 tons of cannabis and 
more than 1 ton of cannabis resin in 2008. Similarly, in 
Turkey, the amount of cannabis resin seized increased 
by 23 per cent, to 39.1 tons, in 2008. Authorities in 
Azerbaijan seized 555 kg of cannabis and cannabis 
resin. 
655. Lebanon is not a major producer of illicit drugs. 
However, Lebanese authorities reported a small 
increase in cannabis cultivation in 2008 and growing 
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drug abuse particularly among young persons, due to 
the greater availability and reduced price of most illicit 
drugs. Israeli police have occasionally reported the 
arrest of farmers for clandestinely growing cannabis 
plants using hydroponic techniques. 
 
  Psychotropic substances 
 
656. In Turkey, the amount of seized synthetic drugs, 
predominantly MDMA (“ecstasy”) and Captagon 
(containing mainly amphetamine), increased until 
2005, when 1.7 million tablets were seized. After 2005, 
the amount of “ecstasy” seized in Turkey decreased by 
about 35 per cent, averaging 1 million tablets each year 
in the period 2005-2008. Half of the seized tablets 
were subsequently identified as fake “ecstasy”, 
containing meta-chlorophenylpiperazine instead of 
MDMA. The amount of Captagon tablets seized in 
Turkey also decreased by approximately 63 per cent in 
2008, from 7.5 million tablets in 2007 to 2.7 million in 
2008. The Government of Turkey has indicated that the 
decrease may be partly attributable to inadequate 
cooperation with law enforcement agencies in 
neighbouring countries. 
657. Counterfeit Captagon tablets containing 
amphetamine continue to be seized mainly in Jordan, 
Saudi Arabia, the Syrian Arab Republic and the United 
Arab Emirates. Trafficking in and abuse of counterfeit 
Captagon remain serious problems in the countries on 
the Arabian Peninsula, where Captagon appears to have 
become the drug of choice. In 2008, most of the 
amphetamine seized worldwide was seized in the 
Middle East (accounting for 73 per cent of the world 
total), followed by Western Europe (19 per cent of the 
world total). According to UNODC, in Saudi Arabia, 
the amount of seized amphetamine-type stimulants, 
mostly in the form of Captagon, increased from 
0.3 tons in 2002 to 14 tons in 2007.51 The Board is 
concerned about the marked increase in Captagon 
seizures effected in that country. The Board urges the 
authorities of Saudi Arabia to investigate the reasons 
behind that development and to take the appropriate 
monitoring and control measures. 
658. Captagon tablets illicitly manufactured in 
laboratories in Eastern Europe are transported through 
Turkey from the Bulgarian border en route to West 
__________________ 
 51  Amphetamine and Ecstasy: 2008 Global ATS Assessment 
(United Nations publication, Sales No. E.08.XI.12). 
Asia through the Syrian Arab Republic by land and 
sea. Drug law enforcement operations involving the 
close cooperation of Bulgaria, Saudi Arabia and 
Turkey resulted in the seizure of nearly 3 million 
Captagon tablets in 2008. In the same year, Saudi 
Arabia seized 52 million counterfeit Captagon tablets. 
Several other countries of the subregion have reported 
dramatic increases in seizures of counterfeit Captagon 
since 2004. 
659. According to Iraqi health authorities, 
pharmaceutical preparations containing the controlled 
substance diazepam (Valium) is the drug most 
commonly abused among the Iraqi population. 
Diazepam is available in correctional and health 
institutions throughout Iraq. The Board calls upon the 
Iraqi authorities to take appropriate regulatory 
measures to ensure that the distribution of controlled 
substances, in particular diazepam, is always carried 
out under medical supervision and dispensed in 
accordance with legitimate medical prescriptions. In 
Jordan, benzodiazepines are reported to be abused. The 
Pharmaceutical Crime Unit of the Ministry of Health 
of Israel, which monitors the diversion of prescription 
drugs, is investigating the illicit trade in buprenorphine 
(Subutex) and the use of forged prescriptions to obtain 
methylphenidate. 
 
Precursors 
 
660. The destruction of clandestine drug laboratories 
in Afghanistan has continued: 69 facilities illicitly 
manufacturing heroin were destroyed in 2008. The 
seizure of 14,233 litres of acetic anhydride in 2008, 
although an increase over the quantity seized in 2007, 
constitutes less than 1 per cent of the quantity of that 
chemical estimated to be used for heroin manufacture 
in Afghanistan. As a result of the new emphasis on 
addressing the link between drugs and the insurgency, 
operations in the first half of 2009 involving military 
units of ISAF and NATO resulted in the destruction of 
98 tons of precursor chemicals and 27 illicit drug 
laboratories in Afghanistan. In addition, the Counter 
Narcotics Police of Afghanistan reported the seizure of 
61 tons of precursor chemicals and destruction of 
74 clandestine opium processing laboratories. 
661. The amount of acetic anhydride reported to have 
been seized in Turkey increased by 250 per cent from 
2006 to 2007, reaching 13.3 tons. That trend was 
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reversed in 2008, when seizures of that precursor 
totalled less than 5 tons.  
 
 5. Abuse and treatment 
 
662. The abuse of opiates continues to pose a major 
problem in Afghanistan and neighbouring countries. 
Nearly all those countries have high rates of drug 
abuse. For example, the Islamic Republic of Iran has 
the world’s highest rate of abuse of opiates: more than 
2 million people are reported to abuse opiates, 
resulting in an estimated prevalence rate of 2.8 per 
cent. Pakistan also has a high abuse rate for opiates: 
the estimated rate of drug abuse among the population 
aged 15-64 years in 2006 was 0.7 per cent. In 2008, the 
Government of Pakistan reported that there were an 
estimated 628,000 “severe/problem” opioid abusers in 
the country, 77 per cent of whom were heroin abusers. 
Many countries in Central Asia have similar levels of 
drug abuse, heroin having replaced cannabis and opium 
as the most commonly abused illicit drug. In Central 
Asia, the incidence of heroin dependence among 
registered drug abusers ranges from 50 to 80 per cent, 
with Tajikistan and Uzbekistan reporting the highest 
rates.  
663. Drug abuse in the countries of Central Asia is 
reaching alarming proportions, due especially to the 
sharp increase in the use of opiates in recent years. In 
2008, more than 94,000 drug abusers were registered 
in clinics of the countries in the subregion. As a result 
of the wide availability of cheap heroin, patterns of 
drug abuse have shifted from smoking opium and 
cannabis to abuse of heroin by injection and, to a lesser 
extent, the abuse of some opium concoctions. Heroin is 
the most commonly abused drug (70 per cent of 
registered drug users), followed by cannabis (15 per 
cent) and opium (11 per cent). 
664. Drug abuse remains a serious concern in the 
Southern Caucasus. In Azerbaijan, the drugs of choice 
are opioids and cannabis, followed by non-prescribed 
sedatives and tranquillizers. In 2008, among drug users 
aged 15-64 years, 70 per cent abused opioids, 20 per 
cent abused cannabis and 10 per cent abused 
benzodiazepines; among adolescents, 10 per cent 
abused opioids, 30 per cent abused cannabis and 60 per 
cent abused benzodiazepines. At the end of 2008, 
514 persons who abused drugs by injection were 
infected with hepatitis or HIV, while 26 of the 48 drug-
related deaths in the country were caused by the abuse 
of benzodiazepines. The Board urges the Government 
of Azerbaijan to closely monitor that worrying 
situation and increase the resources allocated for the 
prevention and treatment of drug abuse, especially 
among youth. 
665. While there are very little data on drug abuse in 
the Middle East, heroin abuse is reported to have 
increased in the subregion, and the age of initial abuse 
is decreasing and the demand for treatment is 
increasing. However, many countries in the Middle 
East lack the capacity to collect and analyse data on 
drug abuse. The Board encourages the Governments of 
those countries to conduct comprehensive surveys and 
rapid assessments of the drug abuse situation and to 
take effective measures in the area of demand 
reduction. 
666. According to Lebanese authorities, the number of 
male drug abusers increased from 488 in 2001 to 1,381 
in 2008, and the most prevalent drugs of abuse 
remained cannabis and cannabis resin (“hashish”), 
followed by heroin and, to a lesser extent, cocaine. 
667. In Israel, an epidemiological survey on the 
prevalence of drug abuse among the general population 
is carried out every four years. The data for 2008 show 
that 60 per cent of the 20,000 problematic drug abusers 
in Israel abuse opioids by injection. The reported 
prevalence of HIV among persons who abuse drugs by 
injection is 2 per cent. The Israel Anti-Drug Authority 
administers treatment programmes targeting specific 
segments of the population, such as women, youth, 
new immigrants and the homeless, providing 
counselling, sanitary services and food. 
668. According to official reports, 120 new HIV cases 
were reported in Afghanistan in 2008, bringing the 
national total to 556. The main cause of HIV 
transmission in the country is exposure to 
contaminated drug injecting equipment. The Board 
notes that the Afghanistan National Development 
Strategy aims to keep the country’s HIV prevalence 
rate below 0.5 per cent of the population and reduce 
the rates of mortality and morbidity associated with 
HIV/AIDS by the end of 2010. To achieve that goal, 
the Government is taking guidance from the National 
Strategic Framework for HIV/AIDS for the 
period 2006-2010. 
669. According to the Ministry of Health of the 
Islamic Republic of Iran, a total of 19,435 cases of 
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HIV/AIDS infection were identified from January 1986 
to March 2009, up to 7 per cent of those individuals 
being female. Drug abuse by injection remains the 
most prevalent factor in HIV transmission in the 
Islamic Republic of Iran (78 per cent), although the 
role of sexual transmission is now increasing. Given 
that 60 per cent of the country’s population of 
71 million is under the age of 30, the Board is 
concerned of the danger of HIV infection spreading in 
the country. 
670. In the Central Asian countries, HIV and other 
blood-borne infections are strongly associated with 
drug abuse by injection. According to UNODC 
estimates (for 2008), in Kazakhstan approximately 
100,000 individuals aged 15-64 years abuse drugs by 
injection, compared with 80,000 in Uzbekistan, 25,000 
in Kyrgyzstan and 15,000 in Tajikistan. In Central 
Asian countries, the lifetime prevalence of injecting 
drug abuse among problematic opiate users ranges 
from 68 per cent (in Uzbekistan) to 95 per cent (in 
Kyrgyzstan). Of that group, 90-99 per cent have 
injected opiates at least once in the past 12 months. 
671. Official statistics provided by Governments of 
Central Asian countries showed 6,664 new HIV cases 
in 2008, for a cumulative total of 31,000 HIV cases. 
That represents an increase of 24 per cent in the total 
number of registered HIV cases in one year and a 
19-fold increase since 2000. According to the most 
recent UNAIDS estimate, in 2005 approximately 
52,000 people were living with HIV/AIDS in Central 
Asia, while UNODC estimates that more than 
2,700 people died of HIV/AIDS during the 
period 2006-2008. The Board urges the Governments 
of Central Asian countries and the international 
community to take prompt action to stop this 
concentrated HIV/AIDS epidemic, focusing on persons 
who abuse drugs by injection. 
 
 
 D. Europe 
 
 
 1. Major developments 
 
672. The Board notes that the Government of the 
United Kingdom reclassified cannabis in January 2009, 
which means that cases involving cannabis are subject 
to stricter law enforcement. The decision reflects the 
fact that highly potent forms of cannabis (such as 
“skunk”) have become dominant on the illicit drug 
market of the United Kingdom. In February 2009, the 
Government of the United Kingdom rejected the 
recommendation by the Advisory Council on the 
Misuse of Drugs that MDMA (“ecstasy”) should be 
downgraded (see paragraph 695 below).  
673. The abuse of certain drugs appears to be stable or 
declining in some countries in Europe. Information 
from recent national surveys suggests that cannabis use 
is stabilizing in many countries in the region. 
Similarly, the most recent data available support 
reports that the abuse of amphetamines and MDMA 
(“ecstasy”) in Europe is stabilizing or even decreasing, 
after having increased in the 1990s. Data from some 
countries suggest that some drug abusers may be 
replacing amphetamines and “ecstasy” with cocaine. 
That may be the case in Denmark, Spain (to a limited 
extent) and the United Kingdom. 
674. Europe has a large market for cannabis and is 
reportedly the only region into which cannabis herb 
from other regions is smuggled. Western Europe 
remains the largest market in the world for cannabis 
resin. The Western European country in which the 
largest amount of cannabis resin is seized is Spain, 
followed by Portugal and France. The main sources of 
the cannabis resin found in Western Europe are 
Morocco and countries in South-West Asia, notably 
Afghanistan. 
675. In Western Europe, the number of cocaine 
seizures has decreased substantially, particularly in the 
main ports of entry. According to the World Customs 
Organization, most of the cocaine entering Western 
Europe has been smuggled out of the Bolivarian 
Republic of Venezuela. Central Africa and West Africa 
continue to be used by traffickers as storage and transit 
areas for cocaine, although a decline has been noted in 
both the total amount of cocaine seized and the number 
of cocaine seizures.  
676. In 2008, cocaine arrived in Europe mainly by 
ship. Consignments of cocaine from Colombia and 
Ecuador were hidden in sea freight and sent to 
countries in Europe, mainly Croatia, followed by the 
Netherlands and Montenegro. The increasing number 
of shipments of cocaine from South America to 
countries in Eastern Europe reflects a fairly new 
development in cocaine trafficking: cocaine is 
frequently smuggled into Western Europe via the 
Balkan route, the route traditionally used for 
smuggling opiates. 
 E/INCB/2009/1
 
 107 
 
677. The illicit market for opiates in Eastern European 
countries has continued to expand. In 2008, the abuse 
of opiates was reported to be increasing in most 
Eastern European countries, particularly Albania, 
Belarus, Croatia, the Republic of Moldova and the 
Russian Federation, as well as in countries along the 
Balkan route. 
678. The United Kingdom, Italy, France and Germany 
(listed in decreasing order) account for most of the 
heroin seized in Europe. Heroin shipments bound for 
Western Europe leave mainly from the Netherlands, 
followed by Turkey, Belgium and Pakistan. Heroin 
from Central and Eastern Europe is increasingly being 
transported by air to Western Europe. Despite recent 
increases in the quantity of opium seized, seizures of 
that drug continue to be less significant than heroin 
seizures. 
 
 2. Regional cooperation 
 
679. The second phase of the operation Channel 2008 
was conducted by CSTO and the Federal Drug Control 
Service of the Russian Federation in November 2008, 
with the participation of Armenia, Belarus, 
Kazakhstan, Kyrgyzstan, the Russian Federation, 
Tajikistan and Uzbekistan. The goal of the operation 
was to build a system of enhanced collective security 
to prevent trafficking in drugs from Afghanistan and 
the entry of precursor chemicals into Central Asian 
countries and Afghanistan. Representatives of the law 
enforcement agencies of Afghanistan, Azerbaijan, 
Bolivia, Colombia, Estonia, Finland, Italy, Latvia, 
Lithuania, Poland, Spain and the United States took 
part in the operation. The joint operation resulted in the 
seizure of over 18.7 tons of drugs, including more than 
2.4 tons of heroin, 1.6 tons of cocaine, 7.3 tons of 
cannabis resin, 6.8 tons of cannabis herb and 20.8 tons 
of precursor chemicals. 
680. In December 2008, senior international drug 
control officials attended a meeting in Vienna to 
coordinate efforts to stem the supply of illicit drugs 
from Afghanistan. The meeting was organized by 
UNODC within the framework of the Paris Pact 
Initiative, aimed at countering trafficking in and abuse 
of opiates from Afghanistan. Specific topics discussed 
at the meeting included drug law enforcement; 
financial flows linked to the production of and 
trafficking in Afghan opiates; preventing and treating 
drug abuse and HIV epidemics in Afghanistan and 
neighbouring countries; and trafficking in precursors 
used to manufacture heroin. 
681. The Council of the European Union endorsed the 
European Union Drugs Action Plan for 2009-2012 in 
December 2008. The Action Plan for 2009-2012 is the 
second of two consecutive action plans to implement 
the European Union Drugs Strategy for the 
period 2005-2012 endorsed in 2004. The Strategy is 
centred on two key dimensions of drug policy — drug 
demand reduction and drug supply reduction — 
complemented by three cross-cutting themes: 
coordination; international cooperation; and 
information, research and education. The Action Plan 
is focused on five priorities: reducing the demand for 
drugs; reducing the supply of drugs; improving 
international cooperation; improving understanding of 
the problem; and improving coordination and 
cooperation and raising public awareness. 
682. The sixteenth European Cities against Drugs 
(ECAD) Mayors’ Conference and the Second World 
Mayors’ Conference were held in Göteborg, Sweden, 
in February 2009. The main theme of the joint 
conference was to offer stronger support of the 
international drug control treaties in preparation of the 
high-level segment of the fifty-second session of the 
Commission on Narcotic Drugs, held in March 2009. 
683. On 27 March 2009, a special conference on 
Afghanistan, organized within the framework of the 
Shanghai Cooperation Organisation, was held in 
Moscow. The conference participants discussed the 
impact of the situation in Afghanistan on neighbouring 
countries and identified ways to combine efforts to 
fight drug trafficking and organized crime emanating 
from that country. The conference was dedicated to 
combating drugs and finding ways to resolve the 
serious drug control situation in Afghanistan. One 
important item on the agenda was the proposal by the 
Russian Federation to call on the international 
community to increase interaction for strengthening the 
security belts around Afghanistan. Twenty countries 
and eight international organizations were represented 
at the conference. 
684. EMCDDA held a conference on the theme 
“Identifying Europe’s information needs for effective 
drug policy” in Lisbon in May 2009. The conference 
brought together some 300 policymakers, researchers 
and practitioners from Europe, North America and 
Oceania. The conference participants took stock of 
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progress in European drug control policy, considered 
future key issues in drug control in Europe and 
discussed the possible impact of those issues on the 
need for information. 
685. Representatives of 33 countries participated in 
the Eighth Meeting of Heads of National Drug Law 
Enforcement Agencies, Europe, held in Vienna in 
June 2009. The participants reviewed trends, strategies 
and effective responses to drug trafficking, the 
importance of information in dismantling drug 
trafficking organizations and the influence of the 
Internet and other electronic media on drug trafficking. 
686. The Board welcomes the Livestrong Global 
Cancer Summit, held in Dublin in August 2009. The 
Summit was a landmark event, bringing together world 
leaders, industry, non-governmental organizations and 
individuals to spotlight their collective commitment to 
the global fight against cancer. Several specialized 
agencies and other organizations in the United Nations 
system, such as WHO and the International Atomic 
Energy Agency, were also represented by high-ranking 
officials. 
687. The Board takes note of the work of the Council 
of Europe’s Ad Hoc Committee on Counterfeiting of 
Medical Products and Similar Crimes Involving 
Threats to Public Health, which met in the course of 
2009 to prepare a draft convention on the subject. 
688. Several joint law enforcement operations in 
Western Europe have resulted in the interception of 
large quantities of illicit drugs. The operations required 
close cooperation with European agencies such as the 
Maritime Analysis and Operations Centre – Narcotics 
(MAOC-N), an intergovernmental task force set up to 
prevent drug trafficking by sea.  
 
 3. National legislation, policy and action 
 
689. In Finland, Narcotics Act No. 373/2008 entered 
into force in September 2008. The Act aligns Finnish 
drug control legislation with the corresponding 
European regulations and is aimed at enhancing drug 
control by increasing cooperation among national 
authorities. The Act outlines the main principles of 
drug control and covers all substances controlled under 
the 1961 Convention, the 1971 Convention and the 
1988 Convention. The Act prohibits the cultivation of 
coca bush, khat plants and psilocybin mushrooms, as 
well as the cultivation of opium poppy, hemp and 
cactus plants containing mescaline for use as drugs or 
raw material for drugs. 
690. In November 2008, a series of referendums were 
held in Switzerland to decide on the national drug 
control policy. Voters decided in favour of offering 
prescribed heroin to drug abusers on a permanent basis 
but rejected the decriminalization of cannabis. 
691. In Montenegro, the National Strategic Response 
to Drugs (2008-2012) and Action Plan 2008/2009 was 
adopted. The document includes comprehensive 
measures to reduce illicit drug supply and demand in 
the country. The national office on drugs is the 
coordinating agency for activities aimed at reducing 
the spread of drug abuse, especially among young 
people, and increasing the possibilities for the 
rehabilitation and social reintegration of drug addicts. 
692. In January 2009, the Government of the 
Netherlands established an advisory committee on drug 
control policy to review the national drug control 
policy. In its conclusions, presented in June 2009, the 
committee stated that the national drug control policy 
was achieving its objective of limiting damage to the 
health of drug users. In addition, the committee 
identified areas where the policy was in urgent need of 
change, such as the use of drugs by minors. A 
memorandum on drug control policy, based partly on 
the recommendations of the committee, is expected to 
be issued.  
693. In February 2009, the Government of Romania 
reorganized the Pharmaceutical Department of the 
Ministry of Health, creating a general directorate for 
strategies and medicine policy. The responsibilities of 
the general directorate include monitoring the national 
system for the distribution of narcotic drugs and 
psychotropic substances and overseeing activities to 
control the manufacture and export and import of 
controlled substances. The Board encourages the 
Government to continue improving the mechanism for 
controlling the manufacture and distribution of narcotic 
drugs and psychotropic substances used for medical 
and scientific purposes. 
694. In Spain, the national drug control strategy for 
the period 2009-2016, which had been adopted by the 
Council of Ministers in January 2009, was published in 
the Official State Gazette in February 2009. The 
objectives of the strategy include delaying the age of 
initial drug abuse; reducing the use of licit and illicit 
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drugs; guaranteeing the provision of quality assistance 
to all people directly or indirectly affected by drug 
abuse; reducing or limiting the consequences, in 
particular the health consequences, of drug abuse; 
facilitating the integration of people into the 
rehabilitation process, through training, for example; 
and increasing the effectiveness of measures aimed at 
regulating the licit supply of and controlling the illicit 
demand for psychotropic substances. The strategy is 
also intended to optimize coordination and cooperation 
at the national, regional and international levels. The 
main elements of the strategy are prevention, supply 
reduction and training. The strategy has an evaluation 
component, for assessing the value of the strategy, 
determining whether the aims have been achieved and 
proposing corrective measures. 
695. In February 2009, the Advisory Council on the 
Misuse of Drugs in the United Kingdom issued a report 
on MDMA (“ecstasy”), reviewing its harmfulness and 
classification under the Misuse of Drugs Act 1971. The 
report contained 13 recommendations to the 
Government, 11 of which were accepted. The 
Government rejected the recommendation that 
“ecstasy” should be downgraded, citing concerns that 
the downgrading of the substance could lead to an 
adverse impact on patterns of use and attitudes and that 
a change in classification might encourage the 
development of international trafficking in “ecstasy” 
by organized criminal groups. The Government also 
rejected the recommendation to explore a national 
scheme to enable “ecstasy” to be tested for individual 
use, stating that that might obscure the messages that 
“ecstasy” was harmful and should not be used. The 
Board welcomes those decisions by the Government of 
the United Kingdom. 
696. In March 2009, the Government of Serbia 
adopted the National Palliative Care Strategy, which 
focuses on the use of opioids for pain relief. One 
important objective of the strategy is the revision of 
national laws regulating palliative care in Serbia. 
697. In April 2009, the Government of Bosnia and 
Herzegovina established an agency for medicines and 
medical products in accordance with the law on 
medicines and medical products that had entered into 
force in July 2008. The law applies to medicinal 
products containing narcotic drugs and psychotropic 
substances, as well as the precursor chemicals used in 
their manufacture. In addition, the law covers areas 
such as licensing requirements, the maximum allowed 
substance content in doses of medication, the quality of 
drugs crossing borders, manufacturing methods, the 
use of equipment, transport and the required 
documentation for transportation. The new law is 
expected to strengthen control of the movement of 
narcotic drugs, psychotropic substances and their 
precursors within the country. 
698. In May 2009, Germany’s lower house of 
parliament voted in favour of a law allowing the 
provision of diamorphine (pharmaceutically 
manufactured heroin) to severe drug abusers who 
failed to respond to other forms of treatment. The law 
is based on the results of a study by the Ministry of 
Health involving persons severely addicted to opiates, 
comparing their response to treatment with heroin with 
their response to treatment with methadone. The results 
showed that diamorphine-supported treatment was 
successful with respect to the person’s overall health 
condition, abstinence, drug abuse reduction and social 
reintegration. Diamorphine-supported treatment will be 
offered to about 1,500-3,000 drug abusers. Heroin-
supported treatment is also offered in a few other 
countries in Western Europe. 
699. In the United Kingdom, a curriculum on 
substance misuse in undergraduate medical schools has 
been developed and is now being implemented at all of 
the medical schools in England. One of the core aims 
of the curriculum is to enable doctors to assist in the 
prevention of substance misuse and management of 
substance dependence. The other core aims include: to 
enable schools to help future doctors and doctors in 
training to be aware of the risks posed by substance 
misuse to their own health and to their professional 
practice and conduct; and to promote the proper care 
and protection of the general public.  
 
 4. Cultivation, production, manufacture and 
trafficking 
 
  Narcotic drugs 
 
700. Cannabis plants are illicitly cultivated in many 
countries in Europe. Albania, Bulgaria and Serbia have 
emerged as some of the main countries in Eastern 
Europe in which cannabis is illicitly cultivated. In 
2009, as in 2008, the Federal Criminal Police Office 
(BKA) of Germany reported that the illicit cultivation 
of cannabis, both outdoors and indoors, had intensified. 
More than 500 illicit cannabis cultivation sites, ranging 
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from small indoor facilities to large outdoor 
plantations, were uncovered in Germany in 2008. In 
Switzerland, where there is significant illicit cannabis 
cultivation, there was a reduction in the total area 
under illicit cannabis cultivation and in the number of 
facilities illicitly producing cannabis on a smaller 
scale. In the Netherlands, intensified law enforcement 
efforts targeting the illicit cultivation of cannabis 
plants is said to have contributed to a decline in the 
quality and an increase in the prices of cannabis on the 
domestic market. While European cannabis cultivation 
sites appear to be the source of a growing proportion of 
the cannabis herb found in Europe, large quantities of 
cannabis herb continue to be smuggled into the region. 
Europe is the only region in the world into which 
significant quantities of cannabis herb from other 
regions, such as Africa or Asia, are smuggled.  
701. Albanian cannabis is smuggled by land on a route 
leading through the former Yugoslav Republic of 
Macedonia and Bulgaria to Turkey and on another 
route leading to Croatia, Bosnia and Herzegovina, 
Montenegro, Serbia, Slovenia and countries in Western 
Europe. Illicit cannabis cultivation has also been 
reported in the Republic of Moldova, the Russian 
Federation and Ukraine; about half of the cannabis 
cultivated in those countries is for the domestic market. 
702. Western Europe remains the largest market in the 
world for cannabis resin. Each year, Spain accounts for 
more than 70 per cent of the cannabis resin seizures 
reported in Western and Central Europe and accounts 
for the largest total amount of cannabis resin seized 
worldwide (628 tons in 2008). In some countries in 
Europe, there has been an increase in the amount of 
cannabis resin seized; in Portugal, for example, 61 tons 
of cannabis resin were seized in 2008. For 
consignments of cannabis resin, the most frequently 
cited European destination is France, followed by the 
Netherlands, Belgium, Portugal and Italy. 
703. Trafficking in cannabis resin, though limited in 
most Eastern European countries, is slightly more 
widespread in the Russian Federation. In 2008, the 
total amount of cannabis resin seized in the Russian 
Federation was 329 kg. Most of the cannabis resin was 
found in motor vehicles or on-board trains. Most of the 
cannabis resin smuggled into Europe continues to be 
from Morocco or countries in Central Asia.  
704. There continues to be a significant level of 
trafficking in cannabis herb in Eastern Europe and 
Central Europe. Most of the cannabis herb produced in 
those subregions originates in Albania, Montenegro, 
the Republic of Moldova, Serbia, the former Yugoslav 
Republic of Macedonia and Ukraine. In Albania, more 
than 145,000 cannabis plants were eradicated in about 
360 operations and more than 3,941 kg of cannabis 
herb were seized in 2008. In Croatia, 220 kg of 
cannabis herb and 4 kg of cannabis resin were seized in 
2008. In Bosnia and Herzegovina, more than 57 kg of 
cannabis herb were seized in 686 seizures in 2008. In 
Bulgaria, the Government reported that 14,806 kg of 
cannabis plants were destroyed and 1,026 kg of 
cannabis herb were seized in 2008. The Board urges 
the Governments of countries in Eastern and Central 
Europe to further intensify their efforts to counter 
cannabis trafficking. 
705. European countries continue to account for 
virtually all cocaine seizures occurring outside the 
Americas. In 2008, the amount of cocaine seized in 
Europe declined considerably compared with previous 
years, which were characterized by record seizures. 
The considerable decrease in the total amount of 
cocaine seized in the region is primarily attributable to 
the fact that fewer seizures of cocaine were made in 
Portugal and Spain, two of the main entry points for 
the drug, for two consecutive years. The decrease is 
believed to also be the result of recent changes in the 
routes used for smuggling cocaine into those countries.  
706. The smuggling of cocaine through Eastern 
European countries has significantly increased over the 
past few years. The most significant seizures made in 
2008 were 381 kg of cocaine, seized at the port of 
Koper, in Slovenia, and liquid cocaine with a gross 
weight of 163 kg, seized by the customs authorities in 
Slovakia. 
707. A new modus operandi for cocaine used by 
cocaine traffickers was uncovered in February 2008, 
when law enforcement authorities in Slovakia found 
164 kg of cocaine in wine shipped from South America 
via Germany. The World Customs Organization 
reported that the cocaine had been dissolved to form a 
viscous fluid and poured into several bottles that were 
subsequently declared as “red wine”.  
708. “Crack” cocaine continues to be of marginal 
importance in Western Europe. Nevertheless, the 
amount of “crack” cocaine seized in Germany 
increased from almost 5 kg in 2007 to about 8 kg in 
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2008. Most (96 per cent) of those seizures of “crack” 
cocaine were made in the city of Hamburg.  
709. Heroin seizures increased in Western Europe in 
2007 and 2008. The increase in heroin seizures in 
Europe as a whole was attributed to South-Eastern 
Europe and Eastern Europe, which are believed to be 
used as transit areas for opiates destined for Western 
and Central Europe. In Europe, most of the heroin 
seizures are made in France, Germany, Italy and the 
United Kingdom. In 2008, the amount of heroin seized 
in Germany fell by 53 per cent. The United Kingdom, 
Italy, France, Germany and Norway (listed in 
descending order) were the main countries of 
destination of heroin consignments entering Western 
Europe. The heroin is sent in consignments of 
50-1,000 kg. 
710. Almost all of the heroin on the illicit markets in 
Eastern Europe originated in Afghanistan. Turkey 
continues to be the starting point for the Balkan route, 
used for smuggling heroin into Europe. In addition, 
heroin continues to be smuggled along the “silk route”, 
through Central Asia into the Russian Federation, 
where it is abused or, to a lesser extent, smuggled 
further into other CIS member States.  
711. Heroin is smuggled mainly by car and by train. 
According to the World Customs Organization, no 
heroin seizure was made along air traffic routes in 
Eastern and Central Europe during 2008. Train 
connections between the Russian Federation and the 
countries to the west of it — Belarus, Poland and 
Ukraine — are increasingly being used for smuggling 
heroin into Western Europe. Reports suggest that 
heroin is increasingly being smuggled into Western 
Europe along air routes from Eastern and Central 
European countries: more than 90 seizures of heroin, 
totalling 637 kg, were made in major airports in 
Western Europe in 2008. 
712. In 2008, heroin accounted for 92 per cent of all 
the seizures of opiates effected in Eastern and Central 
European countries. In the Russian Federation, heroin 
accounted for approximately 42 per cent of all the 
seizures of opiates. In Eastern and Central Europe, 
major seizures of heroin were reported in Albania, 
Bosnia and Herzegovina, Bulgaria, Croatia, Greece, 
Romania and Slovenia. Heroin seizures in Poland, 
Serbia and Ukraine decreased in 2008 compared with 
the previous year. In 2008, Bulgarian law enforcement 
authorities intercepted heroin consignments for the 
first time: four consignments of heroin, totalling 
422 kg, were seized on a route used as an alternative to 
the classic Balkan route, leading from the Islamic 
Republic of Iran through Armenia, Azerbaijan and 
Georgia and then crossing the Black Sea by ferry boat 
from Poti, Georgia, to Burgas, Bulgaria. 
713. In Western European countries, the total amount 
of opium seized was significantly lower than the total 
amount of heroin seized. The largest amount of opium 
seized was reported in Sweden.  
 
  Psychotropic substances 
 
714. According to UNODC, the quantity of 
amphetamine seized in Eastern Europe increased 
significantly from 24 kg in 2007 to 129 kg in 2008. 
Poland accounted for more than 77 per cent of the 
seizures of amphetamine effected in Eastern Europe in 
2008. More than 100 kg of amphetamine were seized 
by Bulgarian authorities. In Croatia, 15 kg of 
amphetamine were seized in 2008. 
715. In Europe, the amount of amphetamine seized 
rose by 40 per cent, to 8.2 tons, in 2007. That was the 
highest total ever registered for Europe, representing 
more than one third of the world total in 2007. The 
increase in 2007 was mainly attributable to Western 
Europe and Central Europe, which together accounted 
for more than 90 per cent of the European total, for the 
first time since 2002. The largest increase was 
registered in the Netherlands, where 2.8 tons of 
amphetamine were reported to have been seized in 
2007, more than four times the highest amount ever 
reported by a European country. The amount of 
amphetamine seized also increased in France, Germany 
and Norway but declined in Sweden.  
716. In Germany, seizures of amphetamine and 
methamphetamine increased, together amounting to 
1,283 kg in 2008. German authorities reported that by 
far the largest share of seized amphetamine of known 
origin came from the Netherlands. Amphetamine was 
also smuggled out of Belgium, Poland or, in smaller 
amounts, the Czech Republic.  
717. Until now, illicit methamphetamine manufacture 
has often involved small groups of persons 
manufacturing the drug principally to meet their own 
needs. While that is still the case, EMCDDA has noted 
an increasing level of professionalization in illicit 
methamphetamine manufacture (and trafficking), 
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together with the possible involvement of organized 
criminal groups. Given the capacity of modern illicit 
production processes, that development could lead to 
methamphetamine becoming more widely available on 
illicit markets in Europe. There is recent evidence of 
more manufacturing and tableting, which might 
indicate that the methamphetamine manufacturing sites 
are increasing in size.  
718. Although methamphetamine seizures made in 
Europe are small in comparison with those made in 
North America and East and South-East Asia, they 
increased from 187 kg in 2006 to 390 kg in 2007. The 
largest increase was registered in Norway, but 
methamphetamine seizures also rose in Lithuania and 
Sweden. In Belgium and the Netherlands, seizures of 
methamphetamine were reported in 2007 for the first 
time ever. In Germany, methamphetamine seizures are 
mostly made in areas bordering the Czech Republic.  
719. Seizures of MDMA (“ecstasy”) declined in 
Western Europe in 2008, a development that is partly 
attributable to the fact that the drug is increasingly 
being manufactured in the countries in which it is 
abused — in Europe, as well as in North America and 
South-East Asia. The largest portion of the seized 
“ecstasy” with a known origin or transit route is from 
the Netherlands. The second most common source of 
“ecstasy” continued to be Belgium. As in the case of 
amphetamine, the “ecstasy” tablets were often seized 
while en route to Southern and Eastern Europe.  
720. According to Europol, the illicit manufacture of 
methamphetamine takes place mainly in countries in 
Central and Eastern Europe, above all in the 
Czech Republic and the Russian Federation. In 2008, 
the Czech Republic accounted for 96 per cent (or 457) 
of the clandestine methamphetamine laboratories 
dismantled in Europe. The Russian Federation reported 
the seizure of 137 methamphetamine manufacturing 
sites. In addition, four such sites were seized in 
Slovakia and three were seized in Poland. 
721. In Europe, seizures of MDMA (“ecstasy”) 
remained low in 2008, totalling 63 kg. The biggest 
single seizure of “ecstasy”, amounting to 56 kg, was 
made by Bulgarian authorities. 
 
  Precursors 
 
722. According to UNODC, Bosnia and Herzegovina, 
Bulgaria, Montenegro and Serbia are emerging as 
countries used for the illicit manufacture of 
amphetamine. In Eastern European countries, seizures 
of precursors of amphetamine have increased in the 
past few years. According to information submitted to 
the Board, major seizures of P-2-P in 2007 were 
reported in Poland (a total of 241 litres), the Russian 
Federation (194 litres), Estonia (96 litres) and Bulgaria 
(32 litres).  
723. Traffickers’ attempts to use countries in Europe 
as sources of acetic anhydride have continued. Large 
amounts of the substance have been seized in States 
members of the European Union. Investigations have 
determined that the seized shipments of acetic 
anhydride had been diverted from legitimate trade 
within the European Union (for more details, see the 
2009 report of the Board on the implementation of 
article 12 of the 1988 Convention).52 
 
  Substances not under international control  
 
724. Khat, a substance not under international control, 
is often smuggled into Europe via the Netherlands and 
the United Kingdom, where it has not been placed 
under national control, and then shipped to other 
countries in Europe. Significant amounts of khat (more 
than 100 kg) have been seized in Belgium, Denmark, 
Finland, France, Germany, Italy, Norway, Sweden and 
Switzerland. In 2008, Estonian authorities seized khat 
for the first time. 
725. The abuse of khat is often not noticed in 
countries in Europe. Khat is used almost exclusively in 
migrant communities in Finland, Sweden, the United 
Kingdom and other countries in the region.  
726. In May 2009, the Government of the Czech 
Republic adopted an amendment to the act on 
dependency-producing substances, placing under 
national control the substance benzylpiperazine. The 
amendment to the national drug law is expected to 
strengthen further the control of the movement of 
__________________ 
 52  Precursors and Chemicals Frequently Used in the Illicit 
Manufacture of Narcotic Drugs and Psychotropic 
Substances: Report of the International Narcotics 
Control Board for 2009 on the Implementation of 
Article 12 of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (United Nations publication, Sales 
No. E.10.XI.4). 
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psychotropic substances and precursors within the 
country.  
 
 5. Abuse and treatment 
 
727. While cannabis resin remains the most commonly 
abused drug in Europe, the abuse of products 
containing cannabis herb has increased in the past few 
years. According to EMCDDA, the average annual 
prevalence of cannabis abuse among Europeans 
15-64 years old is 6.8 per cent (more than 23 million 
persons). National figures range from 0.8 to 11.2 per 
cent, the lowest figure being in Malta, followed by 
Bulgaria, Greece and Sweden, and the highest being in 
Italy, followed by Spain, the Czech Republic and 
France. Lifetime prevalence of cannabis abuse is 
21.8 per cent (or more than 71 million persons 
aged 15-64), national estimates range from 1.7 to 
36.5 per cent. The lowest lifetime prevalence rate was 
reported in Romania, followed by Malta, Bulgaria and 
Cyprus, and the highest was reported in Denmark, 
followed by France, the United Kingdom and Italy. 
728. In Europe, cannabis abuse appears to be stable or 
declining in a number of countries. Intensified 
prevention efforts and increased availability of 
information on the health risks may have contributed to 
that development. In the United Kingdom, a clear 
downward trend has been observed over the years; in 
England and Wales, for example, the prevalence of 
cannabis abuse among the population aged 16-59 fell 
from 10.9 per cent in the reporting year 2002/03 to 
7.9 per cent in the reporting year 2008/09. In Spain, the 
prevalence of cannabis abuse among secondary school 
students aged 14-18 also declined, from a peak of 
25.1 per cent in 2004 to 20.1 per cent in 2008. Those 
and other data suggest that a reversal of the strong 
upward trend of the period 1993-2003 has begun. That 
is confirmed by the results of the European School 
Survey Project on Alcohol and Other Drugs (ESPAD), 
which show that there was no increase in recent use of 
cannabis in any European country between 2003 and 
2007. 
729. The ESPAD results published in March 2009 
reveal that, on average, 23 per cent of male students 
between 15 and 16 years of age and 17 per cent of 
female students in the same age group have tried illicit 
drugs at least once during their lifetime. Reported 
illicit drug use continues to vary considerably in all 
countries. In the Czech Republic, almost half of the 
students (46 per cent) reported illicit drug use, whereas 
in Cyprus, Finland, Norway, Romania and Sweden 
8 per cent or less reported illicit drug use.  
730. In Europe, the vast majority of students who tried 
illicit drugs used cannabis. Lifetime cannabis use was 
reported by 19 per cent of the students. That was 
followed by the use of MDMA (“ecstasy”), cocaine or 
amphetamines (about 3 per cent). LSD, “crack” 
cocaine and heroin were reported to have been used 
less frequently. The highest lifetime prevalence of 
“ecstasy” use was in Bulgaria, Estonia, Latvia, 
Slovakia and the United Kingdom (Isle of Man): 
6-7 per cent. 
731. The abuse of cocaine appears to be concentrated 
in a few countries in Western Europe, while the abuse 
of the drug is relatively low in most other European 
countries. A decline in cocaine abuse has been recorded 
in Spain and the United Kingdom. In Spain, a country 
with a high rate of cocaine abuse, the levels of lifetime, 
annual and last-month use of cocaine among secondary 
school students aged 14-18 years have declined; for 
example, annual prevalence of cocaine use among 
secondary school students fell from a peak of 7.2 per 
cent in 2004 to 3.6 per cent in 2008. In the United 
Kingdom, data from England and Wales also suggest a 
slight decline in the annual prevalence of cocaine use. 
Declining or stable cocaine abuse has also been 
reported in Austria, Germany and Switzerland, whereas 
an increase in cocaine abuse has been reported in 
France and Ireland. 
732. Heroin abuse appears to be relatively stable in 
most countries in Western Europe. However, a 
substance abuse survey indicated an increase in the 
lifetime prevalence of heroin use among young people 
aged 17 years in France, from 0.7 per cent in 2005 to 
1.1 per cent in 2008.  
733. According to UNODC, the number of opiate 
users in Eastern Europe is estimated to be between 
2 million and 2.5 million. According to the World Drug 
Report 2009, the Russian Federation is the largest 
market for opiates in the region, with an estimated 
1.68 million opiate abusers. The second largest market 
for opiates in the region is Ukraine, with an estimated 
323,000-423,000 opiate abusers. In 2008, the abuse of 
opiates was reported to be increasing in most Eastern 
European countries, particularly in Albania, Belarus, 
Croatia, the Republic of Moldova and the Russian 
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Federation, as well as in the countries along the Balkan 
route. 
734. According to the Federal Drug Control Service of 
the Russian Federation, there are 2.5 million drug 
addicts and more than 5.1 million abusers of drugs 
other than heroin in that country, almost double the 
figures for 2002. The abuse of heroin and other opiates 
predominate. The Federal Drug Control Service 
estimates that 10,000 heroin addicts die from overdose 
each year. Almost 65 per cent of newly detected HIV 
cases in the Russian Federation are linked to the abuse 
of drugs by injection.  
735. In the past five years, the reported demand for 
treatment related to methamphetamine abuse has been 
increasing in both the Czech Republic and Slovakia. In 
the Czech Republic, 61 per cent of all persons 
receiving treatment for drug abuse reported 
methamphetamine as their primary drug of abuse. 
Abusers of methamphetamine account for about two 
thirds of all problematic drug abusers. In 2008, 
methamphetamine abuse was reported in 26 per cent of 
all requests for treatment for drug abuse in Slovakia. In 
the Czech Republic, 82 per cent of patients in 
treatment for methamphetamine abuse reported having 
abused drugs by injection; in Slovakia, the figure was 
41 per cent.  
736. Methamphetamine abuse continues to be limited 
in Eastern Europe, especially in comparison with the 
abuse of other stimulants such as cocaine and 
amphetamine. In European countries, the highest 
prevalence of the abuse of methamphetamine, known 
locally as “pervitin”, is in the Czech Republic and 
Slovakia. Some data indicate increased availability of 
the drug in Hungary and Poland, although the overall 
level of abuse appears to have remained relatively low.  
737. The Board notes the results of the survey on the 
prevalence of use of sedatives or tranquillizers and 
antidepressants in Ireland and Northern Ireland (in the 
United Kingdom). The survey revealed that older 
adults reported higher prevalence of use in their 
lifetime, in the past year and in the past month than 
younger adults for the use of sedatives or tranquillizers 
and antidepressants and that women reported higher 
prevalence rates than men for antidepressants. Lifetime 
prevalence rates for the use of sedatives or 
tranquillizers and antidepressants were higher among 
respondents who were separated, divorced or widowed. 
Various indicators of deprivation (lower socio-
economic groups, not being in paid work and lower 
educational attainment) were associated with higher 
prevalence rates for sedatives or tranquillizers and 
antidepressants. The Board encourages the 
Governments of other countries in Europe to carry out 
similar surveys, as the excessive use of psychotropic 
substances is often under-diagnosed.  
738. In 2008, according to the Ministry of Health and 
Social Development of the Russian Federation, of the 
389,302 drug abusers registered in treatment centres, 
46,976 (12.1 per cent) were HIV-positive. On average, 
8,000 people die every year in the Russian Federation 
as a result of the toxic effects of narcotic drugs and 
psychotropic substances; about 1,000 of those people 
die of an overdose of drugs, mainly opiates. 
739. The HIV epidemic in Eastern Europe is largely 
concentrated among persons who abuse drugs by 
injection. It is estimated that in Eastern Europe, 
110,000 people became infected with HIV in 2007, 
while some 58,000 died of AIDS. A high level of HIV 
infection has been reported among persons who abuse 
drugs by injection in Belarus (52 per cent). The 
number of newly reported HIV cases is rising in 
Georgia and the Republic of Moldova.  
740. In 2008, 1,449 drug-related deaths were 
registered in Germany, an increase of 3.9 per cent 
compared with the previous year; the reasons for the 
increase have not been established. In the United 
Kingdom, the National Programme on Substance 
Abuse Deaths reported that it had received from 
coroners in England and Wales, Northern Ireland, the 
Channel Islands and the Isle of Man notifications of 
1,490 drug-related deaths occurring in 2008, a decrease 
of 3.2 per cent compared with the number reported in 
the previous year (1,539). 
741. In December 2008, an analysis of drug-related 
deaths between 1998 and 2005 was published in 
Ireland. Of the 2,442 drug-related deaths recorded in 
that period, 1,553 were directly drug-related deaths 
(poisonings) and 889 were indirectly drug-related 
deaths (non-poisonings). The annual number of deaths 
by poisoning increased from 178 in 1998 to 232 in 
2005. The majority of deaths by poisoning were males. 
Moreover, the majority of the cases of death by 
poisoning involved people aged 20-40 years. Of the 
1,553 cases of death by poisoning, 714 (46.0 per cent) 
were attributable to a single drug or substance. Heroin 
and unspecified opiates accounted for 159 (22.3 per 
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cent) of the single-drug poisonings, analgesics 
containing an opiate compound accounted for 
85 (11.9 per cent) deaths and methadone accounted for 
a further 61 (8.5 per cent) deaths. The number of 
deaths by poisoning in which cocaine was implicated 
rose from 5 in 1998 to 34 in 2005. Cocaine was 
implicated in 100 cases (6.4 per cent of all deaths by 
poisoning). Of the deaths where cocaine was involved, 
29 per cent were attributable to cocaine alone. 
Prescription medication and over-the-counter 
medication were implicated in many of the deaths by 
poisoning. Benzodiazepines played a major role in 
poly-substance poisonings. Benzodiazepines were 
involved in 30 per cent of deaths by poisoning.  
742. The Board takes note of the EMCDDA 
publication on Internet-based drug treatment 
interventions, a new and complementary approach to 
drug abuse treatment in some European Union member 
States. An Internet-based drug treatment intervention is 
defined as “an Internet-based programme that 
comprises a specially developed/adapted, structured 
and scheduled drug treatment intervention”. The report 
identifies several Internet-based drug treatment 
interventions designed for abusers of cannabis, cocaine 
and “club drugs” (such as MDMA (“ecstasy”)). Despite 
the need for further investigation and the evaluation of 
existing Internet-based drug treatment interventions, 
the available data show promising results for further 
research and development in the European Union. 
Internet-based drug treatment interventions may prove 
to be a useful option for reaching a population of drug 
users in need of support who are often not reached 
through more traditional approaches.  
743. Access to opioid substitution treatment has 
expanded considerably over the past few years. 
According to EMCDDA, the total number of drug 
abusers receiving substitution treatment in member 
States of the European Union and in Norway in 2007 is 
estimated at 600,000, up from 570,000 in 2005 and 
500,000 in 2003. The available data on the number of 
drug abusers in substitution treatment suggest an 
increase in all European countries except France, 
Hungary, Luxembourg, the Netherlands (countries in 
which the situation remained nearly stable) and Spain 
(where a decline that started already in 2002 has 
continued). The most rapid scaling up of such 
treatment was seen in Bulgaria (where in 2007 nearly 
3,000 treatment places were available, compared with 
only 380 in 2003) and in Estonia (where the number of 
drug abusers in substitution treatment increased from 
60 to more than 1,000 within five years). The number 
of drug abusers in substitution treatment more than 
doubled in the period 2003-2007 in the Czech 
Republic, Finland, Latvia and Norway. An increase in 
excess of 40 per cent was reported in Greece, Poland, 
Portugal, Romania and Sweden. 
 
 
 E. Oceania 
 
 
 1. Major developments 
 
744. Demand for MDMA (“ecstasy”) in Australia has 
increased in recent years. According to the World 
Customs Organization, approximately 36 per cent of 
the total amount of “ecstasy” seized globally in 2008 
was destined for that country, where widespread use 
and stable prices underpin demand for that drug. While 
Canada has remained a significant source of “ecstasy” 
destined for Australia, Mauritius was also identified as 
the country from which a shipment of “ecstasy” 
departed for Australia, an indication that traffickers are 
devising new routes for smuggling that substance into 
Australia.  
745. In recent years, there has been a significant 
increase in the smuggling of pharmaceutical 
preparations containing pseudoephedrine into New 
Zealand, indicating continued illicit manufacture of 
amphetamine-type stimulants in that country. The 
number of pseudoephedrine tablets seized in 2008 was 
almost 13 times that seized in 2002. Most shipments of 
preparations containing pseudoephedrine appear to be 
organized by Asian organized criminal groups based in 
New Zealand that use Asian students studying in that 
country and other temporary visitors as “receivers” for 
those shipments. China has emerged as a major source 
of pseudoephedrine tablets seized at the New Zealand 
border. There have also been reports that 
pseudoephedrine tablets are smuggled into New 
Zealand from several countries in Oceania, including 
Fiji, Papua New Guinea and Tonga. 
746. The annual prevalence rate of amphetamine and 
methamphetamine abuse in New Zealand is among the 
highest in the world; nevertheless, that rate declined 
gradually from its peaked level at 5 per cent in 2001 to 
3.4 per cent in 2006. A recent survey suggested that 
among persons aged 15-45, the annual prevalence rate 
further decreased to 1.4 per cent in 2009. 
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747. In Oceania, a number of regional initiatives, 
including meetings and training courses, to address 
drug control issues have been successful, and countries 
in the region continue to participate actively in those 
initiatives. In spite of that, the Board noted that with 
the exception of Australia and New Zealand, all 
countries in the region have reported limited drug-
related data to the Board. In view of the information 
available, the Board is concerned that countries in the 
region other than Australia and New Zealand are being 
targeted for trafficking in and illicit manufacture of 
drugs. The Board has also noted the involvement of 
organized crime syndicates in drug trafficking in those 
countries. The low rate of accession by States in 
Oceania to the international drug control treaties and 
the geographical proximity of the region to illicit drug 
manufacturing countries in South-East Asia make 
Oceania more vulnerable to drug trafficking. The 
Board urges the States in the region that are not yet 
parties to the international drug control treaties to 
ratify those instruments and encourages them to 
provide comprehensive drug-related data. 
 
 2. Regional cooperation 
 
748. A number of regional conferences continued to 
bring countries in Oceania together to address drug 
control issues. The annual meeting of the Regional 
Security Committee of the Pacific Islands Forum, held 
in Fiji in June 2009, addressed the need for closer 
regional cooperation in combating transnational 
organized crime, including drug trafficking, in 
Oceania. Participants also highlighted the importance 
of training programmes offered by Australia and New 
Zealand relating to detection skills, intelligence-
gathering and other core skills such as document 
examination. In July 2009, the fourth meeting of the 
Pacific Drug and Alcohol Research Network was held 
in Vanuatu. Representatives of 11 countries in Oceania, 
WHO, UNODC and research institutions shared 
information on the latest trends in drug and alcohol 
abuse at both the regional and national levels. 
Participants agreed that more comprehensive data 
should be developed throughout the region and that 
more funding should be provided for drug abuse 
research and treatment.  
749. Trafficking in precursor chemicals in Oceania has 
become an issue of particular concern. In 
September 2008, the South Pacific Precursor Control 
Forum convened a workshop in Samoa to consider the 
implementation in the region of further legislative and 
regulatory measures to prevent the diversion of 
precursors for use in the illicit manufacture of 
amphetamine-type stimulants, in particular the 
development of model laws on drugs. Participants also 
discussed the importance of regional compliance with 
the international drug control treaties. The twelfth 
National Chemical Diversion Congress of Australia 
was hosted by New Zealand in November 2008. The 
Congress, which was attended by representatives of 
Governments of States in Asia and the Pacific, 
addressed the situation regarding the diversion of 
substances in New Zealand and made 
recommendations regarding ways to reduce the 
diversion of precursors of amphetamine-type 
stimulants from domestic distribution channels.  
750. Australian and New Zealand law enforcement 
agencies continued to provide support for capacity-
building initiatives in Oceania. The customs authorities 
of both countries organized training programmes for 
law enforcement agencies in Papua New Guinea and 
the Solomon Islands. The New Zealand Police 
continued to expand its Overseas Police Liaison 
Network, through which New Zealand police officers 
are posted to what are believed to be major transit 
areas for illicit drugs and precursor chemicals destined 
for New Zealand, including the South and West 
Pacific. The network has helped to reduce the 
smuggling of drugs into New Zealand and improve 
intelligence-sharing among law enforcement 
authorities in Oceania. The Board encourages the 
Governments of Australia and New Zealand to 
continue to strengthen regional cooperation by sharing 
expertise and providing assistance in drug control in 
the region. 
 
 3. National legislation, policy and action 
 
751. The Board appreciates the efforts of the 
Government of Australia to control precursors of 
amphetamine-type stimulants. In 2008, the Australian 
Crime Commission established the National 
Clandestine Laboratory Database as a repository for 
information provided by law enforcement and forensic 
agencies in Australia with regard to clandestine 
laboratories. The database is expected to strengthen the 
intelligence-gathering capacity of the Australian law 
enforcement agencies. As one of the priorities under its 
National Amphetamine-Type Stimulant Strategy 2008-
2011, Australia has developed a precursor chemical 
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information resource which will be made available to 
law enforcement, forensic and health officers to enable 
them to identify precursor chemicals more easily. In 
August 2007, the Pharmacy Guild of Australia 
introduced “Project Stop”, an online tool which has 
been playing an important role in preventing the 
diversion of pseudoephedrine for use in the illicit 
manufacture of methamphetamine by enabling 
pharmacies to monitor sales of pharmaceutical 
preparations containing pseudoephedrine in real time. 
To date, approximately 63 per cent of pharmacies in 
Australia have registered to use the tool.  
752. In April 2009, the Government of Australia 
launched a national campaign against illicit drugs, 
entitled “Illicit Drug Use — Targeting Young 
Methamphetamine Users”, the overall aim of which is 
to help to reduce the abuse of methamphetamines, 
“ecstasy” and cannabis among young Australians aged 
15-25 by raising awareness of the harms associated 
with illicit drug use and directing young drug abusers 
to relevant support, counselling and treatment services. 
The Australian Customs and Border Protection Service 
has developed a drug and precursor strategy for the 
period 2008-2010 to strengthen its capacity to detect, 
investigate and prosecute the smuggling of drugs and 
the illegal importation of precursor chemicals into 
Australia. 
753. In view of the high prevalence rate of abuse of 
N-benzylpiperazine (BZP) abuse in New Zealand, in 
2008, the Government of that country strengthened the 
control of BZP and related substances that are active 
ingredients in most “party pills”, drugs which have a 
similar effect to that of MDMA (“ecstasy”). The new 
control measures prohibit the possession, use, sale, 
supply, import, export and manufacture of BZP.  
754. In February 2009, the New Zealand Police 
launched its “Illicit Drug Strategy to 2010”, the aim of 
which is to reduce the supply of and demand for illicit 
drugs, particularly cannabis and methamphetamine, 
which are the drugs most widely abused in New 
Zealand. The Strategy also provides for tightened 
precursor control, the strengthening of the National 
Intelligence Centre to provide more effective 
assistance in drug-related investigations and the 
implementation, by 2010, of the Government’s 
Organized Crime Strategy, which targets the 
relationship between illicit drug manufacture and 
organized crime. In order to reduce cannabis supply, 
the New Zealand Police has been conducting a 
nationwide operation to counter the illicit cultivation, 
distribution and abuse of cannabis and related crime. 
During the period 2008-2009, the operation resulted in 
the eradication of a total of 141,000 cannabis plants — 
the highest number in 10 years — and the arrest of 
1,100 offenders. The New Zealand Police has also 
established special response teams to detect and 
dismantle methamphetamine laboratories with the aim 
of reducing supply of that drug. In addition, the entry 
into force of the Criminal Proceeds (Recovery) Act 
2009 is expected to strengthen the capacity of the 
Police to recover the proceeds of illicit drug crop 
cultivation and illicit drug manufacture and trafficking.  
755. In October 2009, the Government of New 
Zealand announced a new national action plan to tackle 
the problems of methamphetamine in the country. The 
action plan is aimed at reducing the use of 
methamphetamine by restricting public access to 
pseudoephedrine (the precursor used in the illicit 
manufacture of methamphetamine), strengthening the 
capacity of law enforcement authorities and improving 
treatment service for methamphetamine abusers. 
756. The Board welcomes the initiatives undertaken 
by the Governments of Fiji and Samoa to tackle the 
growing problems of illicit drug manufacture and 
trafficking. Samoa is considering amendments to its 
Narcotics Act in order to strengthen precursor control 
and increase penalties for drug-related offences. In 
view of the growing problem of the illicit cultivation of 
cannabis plants in Fiji, the Police of Fiji have 
developed a community policing model whereby the 
community joins forces with the police in eradicating 
cannabis plants. The initiative has gained significant 
momentum and will eventually be adopted nationwide. 
In 2009, the Drug Unit of the Fiji Police Force 
developed a programme to raise awareness of the risks 
associated with drug abuse through presentations in 
prisons, schools and villages throughout Fiji. 
 
 4. Cultivation, production, manufacture and 
trafficking  
 
  Narcotics 
 
757. Illicit cannabis cultivation continues to be 
reported in Oceania. Cannabis plants are illicitly 
cultivated not only in Australia and New Zealand but 
also in Fiji, Papua New Guinea, Samoa and Tonga. It 
appears that in recent years, organized criminal groups 
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have been involved in the illicit manufacture of and 
trafficking in cannabis in those countries. There is 
concern that the development of the “cannabis 
industry” will facilitate the investment of profits from 
that industry in the illicit manufacture of other drugs, 
in particular methamphetamine. In view of the lack of 
systematic surveillance systems in those countries, the 
Board urges the Governments in question to take 
measures to prevent the illicit production of and 
trafficking in cannabis. 
758. Cannabis continues to be the drug most 
commonly seized in Oceania. Most of the cannabis 
seized in the region had been produced domestically, 
while a very small proportion has been smuggled from 
other regions. During the reporting period 2007/08, 
Australia seized a total of 5,400 kg of cannabis 
nationwide, including 54 kg seized at the customs 
border. Major sources of the cannabis seized at the 
border include the Netherlands, Papua New Guinea, 
Thailand and the United States of America. In New 
Zealand, 98 per cent of cannabis abusers surveyed in 
2008 as part of an annual study described the 
availability of cannabis as “very easy” or “easy”. In 
2008, New Zealand reported the seizure of 700 kg of 
cannabis herb and 156,000 cannabis plants. In 2009, 
Fiji also reported large seizures of cannabis plants, 
including 15,000 cannabis plants eradicated by the Fiji 
Police Force during “Operation Yadra Viti Rua”.  
759. While cocaine seizures in Oceania account for 
only a very small proportion of global seizures of that 
drug (0.1 per cent in 2007, according to UNODC), the 
quantity of cocaine reported to have been seized in the 
region has increased in the past few years. Australia 
accounted for 99 per cent of such seizures effected in 
the region in 2007 and reported the seizure of 842 kg 
of cocaine in 2008. Eighty per cent of the cocaine 
seized at the border had been concealed in sea cargo 
shipments. The smuggling of cocaine from Canada 
continues to pose a serious problem in Australia. In 
addition, cocaine is increasingly being smuggled into 
Australia through China (including Hong Kong). West 
African criminal groups are believed to have been 
involved in a number of cases of cocaine smuggling 
detected at the Australian border. Mexico has also 
emerged as the country from which a shipment of 
cocaine departed for Australia. In early 2009, 
Australian law enforcement authorities detected an 
organized criminal group that was attempting to 
smuggle 144 kg of cocaine from Mexico into Australia. 
Cocaine seizures in New Zealand remained at a low 
level in 2008, while Samoa reported one incident in 
2008 in which an attempt had been made to smuggle 
cocaine into that country by mail. Very limited 
information on cocaine trafficking and seizures in other 
countries in the region was reported to the Board.  
760. South-West and South-East Asia remain major 
sources of the heroin smuggled into Australia. 
Australian criminal groups with long-established links 
to South-East Asian heroin traffickers continue to be 
actively involved in smuggling that drug. Heroin 
smuggled out of Malaysia and Viet Nam has also been 
detected in Australia. In May 2009, Australia reported 
the seizure at Sydney Airport of 2 kg of heroin from a 
passenger arriving from Malaysia and a further 1.4 kg 
of the drug from a passenger arriving from Viet Nam. 
Heroin is smuggled into Australia chiefly by mail, air 
cargo and air passenger. New Zealand reported the 
seizure of only a very small amount of heroin 
(34.5 grams) in 2008. Very limited information 
regarding trafficking in and seizures of heroin in 
countries in Oceania other than Australia and New 
Zealand has been reported. 
 
  Psychotropic substances 
 
761. Combating the illicit manufacture of 
amphetamine-type stimulants remains a priority for 
law enforcement authorities in Oceania. Domestic 
clandestine manufacture remains the main source of 
such substances in Australia, where 271 laboratories 
engaged in such manufacture (including MDMA 
(“ecstasy”) laboratories) were seized during the 
period 2007-2008, a number consistent with the steady 
trend observed since 2004. While the clandestine 
laboratories found to be manufacturing amphetamine-
type stimulants in Australia tend to be large, so-called 
“box labs” — small and highly mobile laboratories that 
can be easily packed away for storage and 
transportation — have also been detected in that 
country. 
762. Most of the methamphetamine seized in New 
Zealand had been illicitly manufactured in that country. 
In 2008, a total of 133 clandestine methamphetamine 
laboratories were dismantled in that country, a 
significant decrease from 190 in 2007 and 211 in 2006. 
While stricter legislative control measures and the 
introduction of the Organized Crime Strategy may have 
played a significant role in reducing illicit 
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methamphetamine manufacture in New Zealand, the 
decrease in the number of laboratories dismantled and 
the fact that the amount of precursors seized at the 
border remains large suggest that illicit drug 
manufacturers may be devising new methods.  
763. Although amphetamine-type stimulants are 
supplied primarily by domestic clandestine 
manufacturers, evidence shows that they are 
increasingly being smuggled into Oceania. In 
Australia, the quantity of amphetamine-type stimulants 
seized at the border has increased almost 10-fold from 
27 kg during the reporting period 2006/07 of the 
Australian Customs and Border Protection Service to 
263 kg during the reporting period 2007/08 of that 
body. Major source regions include North America and 
South-East Asia. In November 2008, Australian law 
enforcement authorities in Adelaide seized 80 kg of 
methamphetamine concealed in a shipment from 
China. The seizure was one of the largest 
methamphetamine seizures reported in Adelaide to 
date. New Zealand reported the seizure of 96 kg of 
methamphetamine in December 2008, one of the 
largest seizures of methamphetamine in that country to 
date. 
764. There is evidence that other countries in Oceania 
are also being targeted by traffickers of amphetamine-
type stimulants. The Board notes that in French 
Polynesia in 2008, a methamphetamine trafficking 
network was detected and 19 persons were sentenced 
for drug-related offences. The network was believed to 
have been operating in that territory for at least a few 
years before it was dismantled.  
 
  Precursors 
 
765. The quantity of precursors seized in Oceania is 
increasing. During the reporting period 2007/08, 
Australia reported the seizure of a total of 1,169 kg of 
precursor chemicals at the border, a dramatic increase 
compared with the 295 kg seized during the reporting 
period 2006/07. According to the New Zealand 
Customs Service, the number of seizures of precursors 
has increased by 12 times in the past six years. 
766. Trafficking in ephedrine and pseudoephedrine as 
raw materials — mainly concealed in cargo transported 
by air or ship or in international mail items — 
continued to be reported in Australia and New Zealand. 
East and South-East Asia remains the major source 
region for most of the consignments seized. In 2008, 
Australian law enforcement agencies seized 1,100 kg 
of ephedrine, a large proportion of which had 
originated in China (including Hong Kong), India, 
Malaysia, the Republic of Korea or Viet Nam. Japan 
was also identified as the source of a seized shipment 
of ephedrine destined for Australia. In June 2009, the 
Australian Customs Service reported a large seizure of 
1.8 tons of precursor chemicals, including 200 kg of 
pseudoephedrine, concealed in a shipment from China. 
In 2008, New Zealand reported the seizure of 14.5 kg 
of ephedrine that had originated in India and 154 kg of 
pseudoephedrine concealed in cement plaster shipped 
from China. In the latter case, two men were 
subsequently sentenced to life imprisonment for their 
involvement. 
767. While the illicit manufacture of MDMA 
(“ecstasy”) continued to be reported in Australia, the 
quantity of seized precursors of MDMA decreased. In 
2008, Australia reported having seized 1 litre of 
isosafrole compared with a total of 255 litres of 
isosafrole and 1,900 litres of 3,4-MDP-2-P seized in 
that country in 2007. No seizures of those substances 
were reported in other countries in Oceania, including 
Fiji and New Zealand. 
 
  Substances not under international control 
 
768. An increasing quantity of GBL is reported to 
have been seized in Oceania. In 2008, the Australian 
Customs and Border Protection Service detected 
18 shipments of GBL, the combined weight of which 
was 2,263 kg (equivalent to 2,534 litres). The 
shipments had originated mainly in China, Germany, 
Japan, Poland or the United Kingdom. Seizures of 
GHB continued to be reported in Australia in 2009, 
while New Zealand reported the seizure of a combined 
total of 837 litres of GBL and GHB in 2008, a sharp 
increase from 5 litres in 2007.  
769. While the annual prevalence of ketamine abuse 
has remained low in Australia (0.3 per cent in 2004 and 
0.2 per cent in 2007), seizures of that substance have 
continued to be reported. In 2008, 26 consignments of 
ketamine totalling 3.8 kg were seized in Australia, 
having been detected primarily in mail items or 
smuggled by air passengers. The majority of the 
consignments had originated in China (including Hong 
Kong), India, New Zealand, Peru or Thailand. 
770. Evidence shows that traffickers are turning to 
natural plant extracts in an effort to circumvent 
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tightened controls over ephedrine. In September 2008, 
Australian law enforcement authorities seized a 
shipment from India consisting of five drums of 
powdered extract of the plant Sida cordifolia; 
approximately 6 kg of ephedrine could have been 
obtained from that shipment.  
771. In recent years, New Zealand has reported having 
seized an increasing quantity of iodine and 
hypophosphorous acid. It is believed that the seized 
substances were to have been used for the illicit 
manufacture of methamphetamine. In 2008, New 
Zealand reported 63 seizures of solid iodine totalling 
52 kg, a significant increase of 58 per cent compared 
with the 33 kg seized in 2007. Moreover, 45 litres of 
hypophosphorous acid were seized in that country in 
2008, almost three times the amount seized in 2007.  
 
 5. Abuse and treatment 
 
772. In Australia, according to the results of the 2007 
National Drug Strategy Household Survey, 38.1 per 
cent of the population aged 14 or older had used an 
illicit drug at some time in their lives, while 13.4 per 
cent had used an illicit drug in the past 12 months, a 
considerable decrease from 15.3 per cent in 2004. 
Female teenagers were more likely than male teenagers 
(both in the age group 14-19) to have ever used an 
illicit drug (26.5 per cent compared with 21.1 per 
cent). However, in all other age groups, males were 
more likely than females to have ever used an illicit 
drug (41.4 per cent compared with 34.8 per cent). The 
average age at which respondents had first tried illicit 
drugs was about 19 years old. 
773. The prevalence rate of drug abuse by injection 
remained low in Australia (an annual prevalence rate of 
0.5 per cent in 2007), consistent with the trend of the 
past several years (0.6 per cent in 2001 and 0.45 per 
cent in 2004). Methamphetamine and amphetamine are 
the drugs most commonly injected, followed by heroin. 
About 30 per cent of persons who abuse drugs by 
injection do so daily, and approximately 59 per cent 
obtain needles and syringes from pharmacies; 62.5 per 
cent had never shared a needle or other injecting 
equipment with another person. 
774. Although cannabis remains the drug most 
commonly abused in New Zealand, the prevalence rate 
of cannabis abuse in that country has declined in recent 
years. The annual prevalence rate of cannabis abuse 
among persons aged 15-45 decreased from 20.4 per 
cent in 2003 to 17.9 per cent in 2006. Despite low 
demand for cocaine in New Zealand, cocaine abuse in 
that country has increased in recent years. In 2006, 
1.1 per cent of the population aged 15-45 had used 
cocaine in the past 12 months, a significant increase 
from 0.5 per cent in 2003. The annual prevalence rate 
of the abuse of MDMA (“ecstasy”) abuse in New 
Zealand has increased in recent years, from 2.9 per 
cent in 2003 to 3.9 per cent in 2006. 
775. According to a recent survey in New Zealand, 
70 per cent of persons who abused drugs frequently 
were male, 63 per cent of persons who frequently 
abused MDMA (“ecstasy”) were college and 
secondary-school students and 81 per cent of persons 
who frequently abused drugs by injection were 
unemployed or receiving sickness benefits. The drug 
most commonly injected was heroin. Eighty-nine per 
cent of frequent drug abusers obtained needles through 
a needle exchange programme in 2007; 91 per cent had 
not shared a needle with another person in the past six 
months. 
776. For most of the countries in Oceania other than 
Australia and New Zealand, published surveys on drug 
abuse are not available. However, according to 
information available to the Board, cannabis is the 
drug most commonly abused in those other countries, 
mainly on account of its ready availability and low 
cost. Cannabis is generally consumed in combination 
with alcohol. The number of male cannabis abusers is 
significantly higher than that of female cannabis 
abusers. The majority of cannabis abusers are young 
persons aged 15-20. The Board urges States in the 
region to develop surveillance systems to monitor the 
situation with regard to drug abuse. 
777. In 2007 and 2008, a total of 658 agencies were 
registered as providing treatment for the abuse of 
alcohol and other drugs in Australia; of these, 50 per 
cent were non-governmental providers. The drugs for 
the abuse of which treatment was most commonly 
sought were cannabis, amphetamine-type stimulants 
and heroin. Counselling was the most common type of 
treatment in the period 2007-2008, followed by 
withdrawal management (detoxification), assessment, 
education and rehabilitation. 
778. In Australia, opioid addicts have been treated 
using opioid pharmacotherapy for a number of 
decades. According to a survey by the Government of 
Australia, as at 30 June 2008, a total of 41,347 persons 
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were receiving pharmacotherapy treatment, 2,500 more 
than in 2007. Of that total, about two thirds were male. 
Persons aged 30-39 accounted for the largest 
proportion of those receiving treatment (38 per cent); 
persons in the age group 20-29 accounted for 25 per 
cent, while those aged 40-49 accounted for a further 
25 per cent. Seventy per cent of those receiving 
treatment were treated with methadone; the remainder 
were treated with buprenorphine or buprenorphine with 
naloxone, a combined preparation that is used more 
commonly in Australia than buprenorphine alone as a 
treatment for opioid dependence. Approximately 65 per 
cent of those surveyed received treatment from a 
private treatment provider. In 2008, there were some 
1,400 practitioners authorized to prescribe 
pharmacotherapy drugs in Australia, a slight increase 
since 2007.  
779. During the period 2007-2008 in New Zealand, an 
estimated 23,500 drug abusers received treatment from 
public services. Of that number, 35 per cent were 
female. The service most commonly sought by persons 
who frequently abused drugs by injection was the 
needle exchange programme, whereas persons who 
frequently abused methamphetamine and MDMA 
(“ecstasy”) were more likely to seek the help of a 
social worker or counsellor. The source of assistance 
most commonly sought by secondary-school students 
with drug-related problems in New Zealand was 
consultation with friends, followed by discussions with 
parents, school counsellors, family doctors and 
services for the treatment of drug abuse. 
 
780. The Government of New Zealand has established 
drug treatment units in prisons as part of a programme 
to reduce drug abuse among prisoners. The units offer 
an intensive six-month programme that includes 
behavioural therapy and the provision of information 
on the dangers of drug addiction. The establishment of 
the drug treatment units has yielded satisfactory results 
to date. It is expected that the units will be able to 
provide treatment for alcohol and drug abuse to 
1,000 prisoners by 2011. 
781. Countries in Oceania other than Australia and 
New Zealand have reported limited information on 
treatment for drug abuse to the Board. However, it is 
noted that in certain countries, such as Fiji, Papua New 
Guinea and the Solomon Islands, treatment for drug 
abuse is provided mainly by general or psychiatric 
hospitals. In general, such treatment is received on a 
voluntary basis and drug abuse issues are usually 
addressed through counselling. The Board encourages 
countries in the region other than Australia and New 
Zealand to develop comprehensive and effective 
programmes for the treatment of drug abuse and 
demand reduction strategies. 
E/INCB/2009/1  
 
122 
 IV. Recommendations to Governments, the United Nations and other 
relevant international and regional organizations 
 
 
782. The Board monitors the implementation of the 
international drug control treaties by Governments and 
examines the functioning of the international drug 
control regime at the national and international levels. 
Based on its analysis, the Board makes 
recommendations to Governments, international and 
regional organizations. 
783. In the present chapter, the Board highlights key 
recommendations contained in chapters II and III of its 
annual report. The recommendations contained in 
chapter I are not included in chapter IV. The Board 
invites all Governments and relevant international and 
regional organizations to examine all recommendations 
made by the Board in its annual report and to 
implement them, as appropriate. The Board calls upon 
those concerned to keep it informed of their action in 
response to the recommendations.  
 
 
 A. Recommendations to Governments 
 
 
784. The recommendations to Governments are 
grouped according to the following subject areas: 
treaty accession; treaty implementation and control 
measures; prevention of illicit drug production, 
manufacture, trafficking and abuse; prevention of 
diversion of precursors into the illicit traffic; 
availability and rational use of narcotic drugs and 
psychotropic substances for medical purposes; and 
illegal Internet pharmacies. 
 
 1. Treaty accession 
 
785. The 1961 Convention as amended by the  
1972 Protocol, the 1971 Convention and the  
1988 Convention form the basis of the international 
drug control system. The accession of all States and the 
universal implementation of the provisions of the 
conventions are a fundamental prerequisite for efficient 
drug control worldwide. 
Recommendation 1: While nearly all States have 
acceded to the international drug control treaties, there 
are still a few States which are not yet parties to one or 
more of the treaties.53 The Board requests those 
__________________ 
 53  The following States are not parties to the international 
States which are not yet parties to one or more of 
the international drug control treaties to accede to 
the treaties without further delay. 
 
 2. Treaty implementation and control measures 
 
786. Universal accession to the three main 
international drug control treaties will, however,  
not be sufficient without effective and universal 
implementation of all the provisions of the treaties and 
the application of the necessary control measures by all 
Governments. 
Recommendation 2: The provisions of the treaties must 
be implemented in the entire territory of each State 
party, including its federated states or provinces. Local, 
regional and/or state measures that violate the 
provisions of the international drug control treaties 
facilitate the trafficking in and abuse of narcotic drugs 
and psychotropic substances. The Board calls upon 
States to ensure that the provisions of the 
international drug control treaties are implemented 
on their entire territory and that drug control laws 
and policies are nationally consistent and in line 
with the provisions of those treaties.  
 
Recommendation 3: The timely submission to the 
Board of information required under the international 
drug control conventions is one of the key elements of 
the international drug control system. The Board calls 
upon Governments to furnish in a timely manner all 
__________________ 
drug control treaties and/or the 1972 Protocol amending 
the 1961 Convention: 
  (a) States not parties to the 1961 Convention as 
amended by the 1972 Protocol or to the 
1961 Convention in its unamended form: Cook Islands, 
Equatorial Guinea, Kiribati, Nauru, Samoa, Timor-Leste, 
Tuvalu and Vanuatu; 
  (b) States not parties to the 1972 Protocol 
amending the 1961 Convention: Afghanistan and Chad; 
  (c) States not parties to the Convention of 
1971: Cook Islands, Equatorial Guinea, Haiti, Kiribati, 
Liberia, Nauru, Samoa, Solomon Islands, Timor-Leste, 
Tuvalu and Vanuatu; 
  (d) States not parties to the 1988 Convention: 
Equatorial Guinea, Holy See, Kiribati, Marshall Islands, 
Naura, Palau, Papua New Guinea, Solomon Islands, 
Somalia, Timor-Leste and Tuvalu. 
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statistical reports required under the conventions. 
Governments are encouraged to seek from the 
Board any information that will help them in 
meeting their reporting obligations under the 
conventions. 
 
  Narcotic drugs and psychotropic substances 
 
Recommendation 4: The Governments of some 
countries did not submit to the Board their estimates of 
requirements for narcotic drugs for 2010; therefore, the 
estimates for those countries were established by the 
Board. The Board urges the Governments concerned 
to examine their national requirements for narcotic 
drugs for 2010 and provide their own estimates to 
the Board for confirmation as soon as possible, in 
order to prevent any potential difficulties in 
importing the quantities of narcotic drugs required 
for medical and scientific purposes. 
Recommendation 5: Supplementary estimates continue 
to be an important tool for meeting unexpected 
shortfalls in the availability of narcotic drugs. The 
Board notes that the number of supplementary 
estimates submitted by Governments is increasing. The 
Board requests Governments to determine their 
annual estimates of requirements for narcotic drugs 
as accurately as possible, so that resorting to 
supplementary estimates is reserved only for 
unforeseen circumstances. However, when 
developments in medical treatment, including use of 
new medicaments, result in additional needs for 
narcotic drugs, Governments should not hesitate to 
submit supplementary estimates.  
Recommendation 6: The system of assessments of 
annual medical and scientific requirements for 
psychotropic substances, as recommended by the 
Economic and Social Council in its resolutions 1981/7 
and 1991/44, is a very effective control measure 
applied to international trade in psychotropic 
substances. However, some Governments issued import 
authorizations for psychotropic substances in absence 
or in excess of the corresponding assessments. Among 
those Governments, some have for several years not 
updated the assessments of their requirements for 
psychotropic substances. The Board requests 
Governments not to authorize imports of 
psychotropic substances in quantities exceeding 
their assessments and calls upon Governments to 
examine their assessments of requirements for 
psychotropic substances on a regular basis. Changes 
in the annual licit requirements of psychotropic 
substances should be communicated to the Board 
without delay. 
Recommendation 7: The import and export 
authorization system for all psychotropic substances 
has proved particularly effective in preventing the 
diversion of those substances from international trade. 
The Board requests Governments that have not yet 
done so to introduce the requirement of import  
and export authorizations for substances in  
Schedules III and IV of the 1971 Convention, in 
accordance with Economic and Social Council 
resolutions 1985/15, 1987/30, 1991/44, 1993/38 and 
1996/30. 
Recommendation 8: Traffickers keep using falsified 
import authorizations when attempting to divert 
narcotic drugs or psychotropic substances from 
international trade. The Board encourages 
Governments of exporting countries to continue to 
examine the legitimacy of orders for narcotic drugs 
and psychotropic substances and to use the 
estimates for narcotic drugs and the assessments for 
psychotropic substances, which are published by the 
Board, for this purpose. Import orders identified as 
suspicious because they exceed the estimates or 
assessments of the relevant importing country 
should be verified with the Board, or brought to the 
attention of the importing countries, prior to 
authorizing such export. 
Recommendation 9: In some countries, the advertising 
of psychotropic substances to the general public 
continues through various communication channels, 
including mass media and the Internet. Direct-to-
consumer advertising may lead to the excessive use 
and, ultimately, the abuse of pharmaceutical 
preparations containing psychotropic substances.  
The Board requests the Governments concerned  
to comply with the requirements of the  
1971 Convention and to prohibit the advertisement 
of psychotropic substances to the general public.  
 
  Precursors 
 
Recommendation 10: Governments report to the Board 
seizures of substances in Tables I and II of the  
1988 Convention on form D. While such seizure data 
are useful, they would be more valuable for the 
analyses carried out by the Board if the circumstances 
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of the seizures, such as methods used for the diversion 
and the illicit manufacture of the substances, were 
included in the reports. The Board requests 
Governments to furnish to the Board information 
on the results of investigations concerning seizures 
and intercepted shipments of precursors. 
Recommendation 11: An increasing number of 
Governments have furnished to the Board estimates of 
their annual requirements for selected precursors of 
amphetamine-type stimulants. Those estimates are 
published each year in the report of the Board on the 
implementation of article 12 of the 1988 Convention 
and are posted on the website of the Board 
(www.incb.org). That information has assisted 
Governments in identifying shipments with the 
potential for diversion. The Board encourages 
Governments to review the estimates they have 
furnished and to inform the Board of any changes 
or updates to ensure that the estimates published by 
the Board remain as accurate as possible. 
Recommendation 12: PEN Online, the automated 
online system for the exchange of pre-export 
notifications, has continued to demonstrate its 
usefulness in identifying suspicious shipments of 
precursors and the prevention of their diversion. The 
Board encourages all Governments that have not 
yet done so to register for and utilize the  
PEN Online system, pursuant to Security Council 
resolution 1817 (2008). 
 
 3. Prevention of illicit drug production, 
manufacture, trafficking and abuse 
 
787. One of the key objectives of the international 
drug control treaties is to limit to legitimate purposes 
the production, manufacture, export, import and 
distribution of, trade in and use of internationally 
controlled substances and to prevent their diversion 
and abuse. 
Recommendation 13: The Board remains concerned 
that the level of illicit opium poppy cultivation in 
Afghanistan continues to be high. In addition, 
Afghanistan has become a significant manufacturer of 
heroin and other opiates, as well as a major source of 
cannabis. Afghanistan also has one of the world’s 
highest rates for the abuse of opiates. The Board 
urges the Government of Afghanistan to pursue its 
National Drug Control Strategy in order to achieve 
a substantial and permanent reduction in opium 
poppy and cannabis plant cultivation and in opium 
and cannabis production, trafficking and abuse. 
The Board calls upon the international community 
to continue to assist the Government of 
Afghanistan. 
Recommendation 14: Countries in South-East Asia 
have made significant progress in reducing illicit 
opium poppy cultivation over the years. However, the 
Board notes with concern that in 2008, the total area 
under illicit opium poppy cultivation in the region 
increased by over 3 per cent compared with 2007. 
Increases were reported in countries such as the Lao 
People’s Democratic Republic, Myanmar, Thailand and 
Viet Nam. The Board urges the Governments 
concerned to strengthen their efforts to eradicate 
the illicit cultivation of opium poppy. 
Recommendation 15: Surveys conducted by the 
Government and UNODC indicate that in 2008 illicit 
coca bush cultivation in Colombia declined 
substantially compared with the previous year and that 
such cultivation returned to levels recorded at the 
beginning of the decade. The Board encourages the 
Government of Colombia to continue its eradication 
programme and to further strengthen its efforts in 
addressing drug abuse and drug trafficking in the 
country.  
Recommendation 16: The Board notes with concern 
that both the reported total area under coca bush 
cultivation and the expected coca leaf production have 
increased over the past few years in the Plurinational 
State of Bolivia. The Board recalls the expressed 
commitment of the Government when introducing its 
present policies towards coca bush cultivation and coca 
leaf production: zero tolerance of trafficking in cocaine 
and all related activities (cultivation, production etc.). 
The Board urges the Government of the 
Plurinational State of Bolivia to adopt more 
effective policies and strengthen its efforts to 
eradicate illicit coca bush cultivation in the country, 
as well as to address in a decisive manner the illicit 
manufacture of and trafficking in cocaine.  
Recommendation 17: The Board is also concerned that 
both the reported total area under coca bush cultivation 
and the potential cocaine manufacture have increased 
over the past few years in Peru. In 2008, the total area 
of illicitly cultivated coca bush eradicated in the 
country decreased compared with the previous year. 
The Board urges the Government of Peru to 
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strengthen its eradication efforts and, in particular, 
to prevent the expansion of coca bush cultivation in 
the country. 
Recommendation 18: In Morocco, there continues to be 
significant illicit cultivation of cannabis plants. 
Morocco is also an important source of illicitly 
produced cannabis and cannabis resin. The Board 
encourages the Government of Morocco to continue 
its efforts in implementing eradication measures, 
alternative livelihood programmes and awareness-
raising campaigns in areas where illicit cannabis 
cultivation takes place and to ensure that further 
progress is made in addressing such cultivation and 
related problems.  
Recommendation 19: The Board notes that countries in 
Africa are used as transit areas for consignments of 
cocaine from South America destined for Europe and 
are also used for the diversion of precursor chemicals, 
for subsequent use in the illicit drug manufacture in 
other regions. The Board is concerned by evidence 
uncovered in Guinea in 2009 suggesting that, to some 
degree, the processing of cocaine, as well as the illicit 
manufacture of MDMA (“ecstasy”), had taken place in 
that country. The Board calls upon Governments of 
African countries to be aware of the risk that their 
countries might be used for illicit drug manufacture 
and to take appropriate measures to prevent such 
illicit activities from taking place in their countries.  
Recommendation 20: In most countries in Africa, 
medical facilities for the treatment and rehabilitation of 
drug dependence are inadequate or non-existent. 
Frequently, only small numbers of drug-dependent 
patients can be accommodated in the psychiatric wards 
of national general hospitals. The treatment and 
rehabilitation of drug-dependent persons often depend 
on assistance provided by relevant international 
organizations, such as WHO and UNODC, and non-
governmental organizations. The Board encourages 
African Governments to conduct surveys on the 
extent and nature of drug abuse in their countries, 
and to design appropriate programmes for drug 
abuse prevention and demand reduction that target 
young people. The Board also urges African 
Governments to provide adequate support to 
existing treatment services and facilities, in order to 
ensure proper treatment of drug-dependent 
persons, and to provide the support necessary to 
establish and maintain suitable rehabilitation 
facilities.  
Recommendation 21: The diversion of pharmaceutical 
preparations containing narcotic drugs and 
psychotropic substances from domestic distribution 
channels has increased. In addition, now there are new 
channels for trafficking in those pharmaceutical 
preparations, such as illegally operating Internet 
pharmacies and smuggling through the mail. Most 
countries do not systematically collect data on the 
abuse of and/or trafficking in pharmaceutical 
preparations containing controlled substances. As a 
result, drug control authorities and policymakers have 
little or no relevant information on which to base their 
decisions. The Board calls upon Governments to 
include pharmaceutical preparations containing 
controlled substances in their national surveys on 
drug abuse, in order to obtain information on the 
types of controlled substances abused and the extent 
of their abuse, which would allow them to introduce 
the most appropriate drug control strategies.  
Recommendation 22: The diversion and abuse of 
pharmaceutical preparations containing narcotic drugs 
and psychotropic substances for which prescriptions 
are required under the international drug control 
treaties represent a serious problem in some countries. 
The Board encourages the Governments concerned 
to introduce or expand programmes for monitoring 
the domestic distribution of prescription drugs. 
Furthermore, in order to reduce the problem of 
improper prescribing practices, Governments 
should consider carrying out programmes to inform 
health-care professionals and the general public of 
the dangers of misusing prescription drugs 
containing narcotic drugs and psychotropic 
substances.  
Recommendation 23: Diversion of preparations 
containing buprenorphine for subsequent trafficking 
and abuse continues, particularly in countries where 
buprenorphine is used for the treatment of opioid 
addicts. The Board calls upon Governments to 
inform the Board of new developments regarding 
trafficking in and abuse of preparations containing 
buprenorphine. The Board urges the Governments 
of countries in which buprenorphine is used to 
review the adequacy of the current controls applied 
to buprenorphine, identify any gaps that might need 
to be closed and consider enhancing the control 
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mechanisms applied to the distribution of 
buprenorphine in their territory, with a view to 
preventing illicit activities. 
Recommendation 24: The use of methylphenidate, a 
stimulant in Schedule II of the 1971 Convention, for 
medical purposes continues to increase, as more and 
more countries are using the substance for such 
purposes. The diversion and abuse of preparations 
containing methylphenidate have been noted, in 
particular in countries with a high level of consumption 
of methylphenidate. The Board calls upon the 
Governments concerned to ensure that the control 
measures foreseen by the 1971 Convention are fully 
applied to methylphenidate and to take additional 
measures to prevent both the diversion from licit 
distribution channels and the abuse of preparations 
containing that substance. 
Recommendation 25: Some countries in Central 
America lack forensic expertise in analysing the 
composition of seized pharmaceuticals, including those 
containing substances under international control. The 
Board invites countries in the Americas with 
advanced forensic capabilities to provide assistance 
to partner countries within the framework of 
regional agreements to combat drug trafficking and 
abuse, in order to improve the forensic  
capabilities of those other countries (see also  
recommendations 46 and 50 below). 
Recommendation 26: The Commission on Narcotic 
Drugs, in its resolution 52/8, on the use of 
pharmaceutical technology to counter drug-facilitated 
sexual assault, urged Member States to take measures 
to address the emerging problem of the use of 
psychoactive substances to facilitate the commission of 
sexual assault. The substances covered by that 
resolution include internationally controlled narcotic 
drugs and psychotropic substances and substances not 
under international control. The Board calls  
upon Governments to implement Commission  
resolution 52/8 as soon as possible. The Board 
encourages Governments to alert vulnerable 
segments of their population to that problem, to 
share information on the subject with law 
enforcement agencies and the judiciary and to 
solicit the support of the industry. 
Recommendation 27: The Commission on Narcotic 
Drugs, in its resolution 51/13, on responding to the 
threat posed by the distribution of internationally 
controlled drugs on the unregulated market, requested 
Member States to continue to offer to affected States 
cooperation and support in dealing with the problem 
and encouraged affected States to consider adopting 
measures to enable the swift detection of new forms of 
illicit distribution of internationally controlled drugs. 
The Board calls upon Governments to implement 
Commission resolution 51/13 without delay. In that 
regard, the Board encourages Governments to 
consider providing training and introducing the use 
of technology by customs authorities to identify 
counterfeit medicaments.  
Recommendation 28: Traffickers continue to smuggle 
opium poppy seeds from countries where the 
cultivation of opium poppy is prohibited. The 
Economic and Social Council in its resolution 1999/32, 
on the international regulation and control of trade in 
poppy seeds, called upon Member States to take 
measures to fight such international trade in poppy 
seeds from countries in which no licit cultivation of 
opium poppy is permitted. The Board calls upon the 
Governments of countries that permit the 
importation of poppy seeds to implement the 
provisions of Council resolution 1999/32 and to 
require a certificate from the country of origin of 
the seeds as the basis for importation.  
Recommendation 29: A number of Governments have 
reported an increase in the illicit cultivation of 
cannabis plants, especially indoor cultivation. The 
increasing availability of cannabis seeds, in particular 
over the Internet, is contributing to that development. 
Related sale sites and advertisement obviously incite 
illicit cultivation of cannabis plants. The Board notes 
that article 3, paragraph 1 (c) (iii), of the  
1988 Convention requires States parties to establish as 
a criminal offence, inter alia, public incitement or 
inducement of others to engage in the illicit cultivation 
of the cannabis plant or to use cannabis illicitly. The 
Board calls upon Governments to apply the relevant 
provisions of the 1988 Convention and to take 
appropriate measures against the sale of cannabis 
seeds for illicit purposes, including through the 
Internet.  
Recommendation 30: Herbal mixtures sold under the 
name “Spice” have recently been the focus of attention 
of health authorities and drug regulators in many 
countries. The identification of synthetic cannabinoids 
in some of those herbal mixtures has raised concern 
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about their abuse liability and their potential health 
effects. Those concerns have prompted several 
countries to adopt measures to regulate the use of and 
trade in some synthetic cannabinoids and products that 
contain them. The Board urges Governments to 
closely monitor new developments with regard to 
the abuse of synthetic cannabinoids, which are often 
marketed as innocuous products such as herbal 
incense. The Board encourages Governments to 
identify the manufacturers of Spice products 
containing synthetic cannabinoids. The Board 
requests Governments to provide to the Board and 
to WHO all information available regarding the 
abuse in their countries of herbal mixtures such as 
Spice products and the synthetic cannabinoids 
contained therein. 
Recommendation 31: Governments should be aware 
that changes in drug abuse patterns may require 
adjustments in programmes for the treatment of drug 
addiction. If the controlled substance that is abused is 
contained in a prescription drug, adequate treatment 
options will need to be identified and implemented. 
The Board encourages Governments of countries in 
which prescription drugs containing narcotic drugs 
or psychotropic substances are abused to develop 
and pursue adequate treatment options.  
Recommendation 32: The Board notes with concern 
that, in a small number of countries, “drug 
consumption rooms” and “drug injection rooms”, 
where persons can abuse with impunity drugs acquired 
on the illicit market, continue to operate. The Board 
calls upon Governments to close those facilities and 
similar outlets and to promote the access of drug 
abusers to health and social services, including 
services for the treatment of drug abuse, in 
conformity with the provisions of the international 
drug control treaties.  
 
 4. Prevention of diversion of precursors into the 
illicit traffic 
 
788. One of the objectives of the 1988 Convention is 
to prevent the diversion of precursors for subsequent 
use in the illicit manufacture of narcotic drugs or 
psychotropic substances. 
Recommendation 33: The Board prepares each year a 
report on the implementation of article 12 of the  
1988 Convention containing recommendations to 
Governments on the control of precursors. The Board 
calls upon Governments to implement 
recommendations contained in the 2009 report of 
the Board on the implementation of article 12 of the 
1988 Convention.54 
Recommendation 34: The Board is concerned that 
traffickers have continued to divert precursors from 
domestic distribution channels, as indicated by the fact 
that most of the acetic anhydride seized in 2008 had 
been diverted from such channels. The Board calls 
upon Governments to take effective measures to 
prevent the diversion of precursors from domestic 
distribution channels. 
Recommendation 35: Ephedrine and pseudoephedrine 
in the form of pharmaceutical preparations are 
increasingly being diverted for subsequent use as 
precursors in the illicit manufacture of amphetamine-
type stimulants. The Board urges Governments to 
control ephedrine and pseudoephedrine in the form 
of pharmaceutical preparations in the same manner 
as they control the scheduled substances themselves. 
Recommendation 36: As many Governments have 
introduced or strengthened controls over precursors, 
traffickers are increasingly attempting to divert those 
substances through countries or regions with less 
stringent controls. The Board urges Governments to 
continue to ensure that adequate controls over 
precursors are in place to prevent the diversion of 
those substances on their territory and to notify the 
Board about any new substances that they have 
identified as being used in illicit drug manufacture. 
Recommendation 37: In Africa, there is a need to build 
capacity, including in the form of forensic skills, at the 
national level in the area of precursor control. The 
Board calls upon the Governments of all African 
countries to strengthen their national mechanisms 
for precursor control and to cooperate with the 
Governments of other countries in the region and 
relevant international bodies in that regard. 
Recommendation 38: Although seizures of large 
amounts of precursor chemicals under international 
control, as well as precursor chemicals under national 
control, continue to be reported in South America, 
__________________ 
 54  Precursors and Chemicals Frequently Used in the Illicit 
Manufacture of Narcotic Drugs and Psychotropic 
Substances: Report of the International Narcotics 
Control Board for 2009 … . 
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information on the trafficking routes and diversion 
methods used and, in particular, on the sources of 
seized chemicals is scarce. The Board calls upon 
Governments of countries in South America to 
design strategies similar to those developed in the 
framework of Project Cohesion, in order to identify 
gaps in precursor control measures and the sources 
of precursors used in illicit drug manufacture. 
 
 5. Availability and rational use of narcotic drugs 
and psychotropic substances for medical 
purposes 
 
789. One of the fundamental objectives of the 
international drug control treaties is to ensure the 
availability of narcotic drugs and psychotropic 
substances for medical and scientific purposes and to 
promote access to and rational use of narcotic drugs 
and psychotropic substances. 
Recommendation 39: Significant discrepancies in 
consumption levels of narcotic drugs and psychotropic 
substances continue to be observed in different regions. 
Although some of those differences can be explained 
by differences in medical treatment and by varieties in 
prescription patterns, excessively high or low levels in 
drug consumption require special attention. The Board 
calls upon Governments to examine trends in  
the consumption of internationally controlled 
substances in their countries, to promote access to 
and rational use of narcotic drugs and psychotropic 
substances, to adopt measures against unlawful 
medical practice and to ensure that domestic 
distribution channels are adequately controlled.  
Recommendation 40: Discrepancies in the consumption 
levels of opioid analgesics in different countries 
continue to be very significant. Factors such as 
knowledge limitations and administrative barriers 
stricter than the control measures required under the 
1961 Convention affect the availability of opioid 
analgesics. The Board requests the Governments 
concerned to identify the impediments in their 
countries to access to and adequate use of opioid 
analgesics for the treatment of pain and to take 
steps to improve the availability of those narcotic 
drugs for medical purposes, in accordance with the 
pertinent recommendations of WHO. 
Recommendation 41: The consumption of opioid 
analgesics for the treatment of pain in many countries 
remains very low. The Access to Controlled 
Medications Programme, to be implemented by WHO, 
will provide effective assistance to Governments in 
promoting rational use of opioid analgesics. The 
Board calls upon Governments to support and 
cooperate with WHO in the implementation of the 
Access to Controlled Medications Programme.  
 
 6. Illegal Internet pharmacies 
 
790. The global nature of the problems of illegal sales 
of controlled substances through the Internet and the 
smuggling of controlled substances by mail require 
concerted action by the international community.  
Recommendation 42: The Guidelines for Governments 
on Preventing the Illegal Sale of Internationally 
Controlled Substances through the Internet,55 
developed by the Board, were launched in March 2009. 
The Board hopes that the Guidelines will help each 
Government to identify the control measures most 
appropriate for its country. The Board calls upon 
Governments to implement the recommendations 
contained in the Guidelines without delay and to the 
fullest extent possible.  
Recommendation 43: In Commission on Narcotic 
Drugs resolution 50/11, on international cooperation in 
preventing the illegal distribution of internationally 
controlled licit substances via the Internet, 
Governments were encouraged to notify the Board, in a 
regular and standardized manner, of seizures of 
internationally controlled licit substances ordered via 
the Internet and delivered through the mail. The Board 
distributed in February 2009 to all Governments a 
standard format to be used for reporting such seizures. 
The Board invites Governments that have not yet 
done so to establish national mechanisms for 
collecting data on seizures as requested by the 
Commission in its resolution 50/11 and to report to 
the Board using the standard format sent to them. 
The information received by the Board will allow it 
to analyse the situation with respect to 
internationally controlled substances ordered via 
the Internet and delivered through the mail and to 
report on that situation to the Commission. 
Recommendation 44: An increasing number of illegal 
transborder trade transactions involving internationally 
controlled substances are carried out using modern 
information technology and communication 
__________________ 
 55  United Nations publication, Sales No. E.09.XI.6. 
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technology, such as the Internet and international call 
centres. The Board calls upon Governments to take 
appropriate action to prevent such misuse of 
modern information technology and communication 
technology. The Board also requests Governments 
to consider measures to influence those responsible 
for the management of Internet websites and other 
forms of modern communication technology to 
ensure that illegal activities are prevented or 
stopped. 
 
 
 B. Recommendations to the United 
Nations Office on Drugs and Crime 
and to the World Health Organization 
 
 
791. UNODC is the primary United Nations entity 
responsible for providing technical assistance in drug 
control matters and for coordinating the provision of 
such assistance by Governments and organizations. 
The treaty-based function of WHO is to provide 
recommendations, based on medical and scientific 
assessments, regarding changes in the scope of control 
of narcotic drugs under the 1961 Convention and 
psychotropic substances under the 1971 Convention. In 
addition, WHO plays a key role in supporting access to 
and rational use of substances under international 
control.  
Recommendation 45: The Board notes that the lack of 
qualified drug control administrators is at the origin of 
persistent difficulties in many countries in 
implementing the control measures for licit activities 
involving narcotic drugs, psychotropic substances and 
precursor chemicals. The Board encourages UNODC 
to provide training for national drug control 
administrators responsible for the control of licit 
activities involving narcotic drugs, psychotropic 
substances and precursors. 
Recommendation 46: Some countries in Central 
America lack the forensic expertise necessary to 
analyse the composition of seized pharmaceutical 
preparations, including those containing substances 
under international control. The Board requests 
UNODC to include, in the programmes on building 
capacity in countries in Central America, the 
provision of assistance to improve their forensic 
capabilities (see also recommendation 25 above and 
recommendation 50 below). 
Recommendation 47: The capacity to provide treatment 
to drug addicts remains limited in many low- and 
middle-income countries. The Board requests WHO 
to increase its support of Governments’ efforts to 
strengthen their capacity to provide treatment for 
drug abuse and to ensure that the treatment is of 
high quality. 
 
 
 C. Recommendations to other relevant 
international organizations 
 
 
792. International organizations such as INTERPOL 
and the World Customs Organization play an important 
role in international drug control. In cases where States 
require additional operational support in specific areas, 
such as drug law enforcement, the Board addresses 
relevant recommendations pertaining to the specific 
spheres of competence of the relevant international and 
regional organizations, including INTERPOL and the 
World Customs Organization. 
Recommendation 48: Drug traffickers are attempting to 
increase the illicit manufacture of and trafficking in 
various narcotic drugs and psychotropic substances and 
some psychoactive substances not under international 
control. The Board requests INTERPOL and the 
World Customs Organization to share with the 
Board, WHO and UNODC any information they 
may have on new developments regarding the illicit 
manufacture of and trafficking in narcotic drugs, 
psychotropic substances and psychoactive 
substances not under international control, such as 
synthetic cannabinoids and ketamine. 
Recommendation 49: In several countries, the 
awareness of customs officers of diversion of and 
trafficking in precursor chemicals continues to be 
insufficient. The Board encourages the World 
Customs Organization to ensure that its training 
programmes include guidance for customs officers 
on the prevention of trafficking in precursor 
chemicals. The World Customs Organization may 
also develop tailor-made training programmes 
focusing on the control of precursors in regions 
where trafficking in precursors represents a serious 
problem.  
Recommendation 50: Some countries in Central 
America lack the forensic expertise necessary to 
analyse the composition of seized pharmaceutical 
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preparations, including those containing substances 
under international control. The Board invites CICAD 
to include, in its programmes on capacity-building, 
the provision of assistance to member States to 
improve their forensic capabilities (see also 
recommendations 25 and 46 above). 
 
 
(Signed) (Signed) 
Sevil Atasoy Camilo Uribe Granja 
President Rapporteur 
 
(Signed) 
Koli Kouame 
Secretary 
 
 Vienna, 13 November 2009 
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Annex I 
 
 
  Regional groupings used in the report of the International 
Narcotics Control Board for 2009 
 
 
 The regional groupings used in the report of the International Narcotics 
Control Board for 2009, together with the States in each of those groupings, are 
listed below. 
Africa 
 
Algeria 
Angola 
Benin 
Botswana 
Burkina Faso 
Burundi 
Cameroon 
Cape Verde 
Central African Republic 
Chad 
Comoros 
Congo 
Côte d’Ivoire 
Democratic Republic of the Congo 
Djibouti 
Egypt 
Equatorial Guinea 
Eritrea 
Ethiopia 
Gabon 
Gambia 
Ghana 
Guinea 
Guinea-Bissau 
Kenya 
Lesotho 
Liberia 
  
Libyan Arab Jamahiriya 
Madagascar 
Malawi 
Mali 
Mauritania 
Mauritius 
Morocco 
Mozambique 
Namibia 
Niger 
Nigeria 
Rwanda 
Sao Tome and Principe 
Senegal 
Seychelles 
Sierra Leone 
Somalia 
South Africa 
Sudan 
Swaziland 
Togo 
Tunisia 
Uganda 
United Republic of Tanzania 
Zambia 
Zimbabwe 
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Central America and the Caribbean 
 
Antigua and Barbuda 
Bahamas 
Barbados 
Belize 
Costa Rica 
Cuba 
Dominica 
Dominican Republic 
El Salvador 
Grenada 
 
Guatemala 
Haiti 
Honduras 
Jamaica 
Nicaragua 
Panama 
Saint Kitts and Nevis 
Saint Lucia 
Saint Vincent and the Grenadines 
Trinidad and Tobago 
 
 
North America 
 
Canada 
Mexico 
 
United States of America 
 
 
South America 
 
Argentina 
Bolivia (Plurinational State of) 
Brazil 
Chile 
Colombia 
Ecuador 
 
Guyana 
Paraguay 
Peru 
Suriname 
Uruguay 
Venezuela (Bolivarian Republic of) 
 
East and South-East Asia 
 
Brunei Darussalam 
Cambodia 
China 
Democratic People’s Republic of 
    Korea 
Indonesia 
Japan 
Lao People’s Democratic Republic 
Malaysia 
 
Mongolia 
Myanmar 
Philippines 
Republic of Korea 
Singapore 
Thailand 
Timor-Leste 
Viet Nam 
 
South Asia 
 
Bangladesh 
Bhutan 
India 
 
Maldives 
Nepal 
Sri Lanka 
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West Asia 
 
Afghanistan 
Armenia 
Azerbaijan 
Bahrain 
Georgia 
Iran (Islamic Republic of) 
Iraq 
Israel 
Jordan 
Kazakhstan 
Kuwait 
Kyrgyzstan 
 
Lebanon 
Oman 
Pakistan 
Qatar 
Saudi Arabia 
Syrian Arab Republic 
Tajikistan 
Turkey 
Turkmenistan 
United Arab Emirates 
Uzbekistan 
Yemen 
 
 
Europe 
 
Albania 
Andorra 
Austria 
Belarus 
Belgium 
Bosnia and Herzegovina 
Bulgaria 
Croatia 
Cyprus 
Czech Republic 
Denmark 
Estonia 
Finland 
France 
Germany 
Greece 
Holy See 
Hungary 
Iceland 
Ireland 
Italy 
Latvia 
Liechtenstein 
 
Lithuania 
Luxembourg 
Malta 
Monaco 
Montenegro 
Netherlands 
Norway 
Poland 
Portugal 
Republic of Moldova 
Romania 
Russian Federation 
San Marino 
Serbia  
Slovakia 
Slovenia 
Spain 
Sweden 
Switzerland 
The former Yugoslav Republic of 
    Macedonia 
Ukraine 
United Kingdom of Great Britain 
    and Northern Ireland 
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Oceania 
 
Australia 
Cook Islands 
Fiji 
Kiribati 
Marshall Islands 
Micronesia (Federated States of) 
Nauru 
New Zealand 
Niue 
Palau 
Papua New Guinea 
Samoa 
Solomon Islands 
Tonga 
Tuvalu 
Vanuatu 
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Annex II 
 
 
  Current membership of the International Narcotics 
Control Board 
 
 
  Joseph Bediako Asare 
 
 
 Born in 1942. National of Ghana. Private 
Consultant Psychiatrist. 
 Medical Academy of Krakow, Poland (1965-
1971); postgraduate training at Graylands and 
Swanbourne Psychiatric Hospitals, Perth, Australia 
(1976-1977); Leicestershire Area Health Authority 
(1977-1980). Senior Registrar in Psychiatry, West 
Berkshire and South Oxford Area Health Authority 
(1981-1982); Chief Psychiatrist, Ghana Health Service; 
specialist in charge at Accra Psychiatric Hospital; 
Chairman, Ghana Chapter, West African College of 
Physicians; Vice-President, West African College of 
Physicians (2000-2004); Adviser to the Ministry of 
Health of Ghana (1984-2004); member of the Narcotics 
Control Board of Ghana (1990-2004); Chairman, 
Subcommittee on Demand Reduction, Narcotics 
Control Board of Ghana (1991-2004). Part-time 
lecturer in psychiatry, University of Ghana medical 
school (1991-2004). Faculty Fellow of the 
International Council on Alcohol and Addictions 
training programme on alcohol and drug abuse in 
Benin City, Nigeria (1986 and 1987); President, 
Psychiatric Association of Ghana (1999-2002). 
Member, Royal College of Psychiatrists (1980); 
Fellow, Royal College of Psychiatrists (2008); Fellow, 
West African College of Psychiatrists; Fellow, Ghana 
College of Physicians and Surgeons. Author of 
numerous works, including: Substance Abuse in 
Ghana; The Problem of Drug Abuse in Ghana: a Guide 
to Parents and Youth (1989); Alcohol Use, Sale and 
Production in Ghana: a Health Perspective (1999); 
Alcohol and Tobacco Abuse in Deheer (1997); 
“Psychiatric co-morbidity of drug abuse”, Assessing 
Standards of Drug Abuse (1993); “Baseline survey of 
the relationship between HIV and substance abuse in 
Ghana” (2004). Recipient of the Grand Medal (Civil 
Division) of the Republic of Ghana (1997). Participant 
in numerous meetings, including: consultative group 
that developed the manual on assessment standards of 
care in drug abuse treatment (1990-1992); NGO World 
Forum on Drug Demand Reduction, Bangkok (1994); 
drug programme expert meeting, Cleveland, United 
States of America (1995); Drug Expert Forum for 
Western and Central Africa, Cameroon (1995); local 
expert meeting for Western Africa, Dakar (2003). 
Member of the local expert network in West Africa 
(LENwest) (2002-2004).  
 Member of the International Narcotics Control 
Board (since 2005). Chairman of the Committee on 
Finance and Administration (since 2007). Member of 
the Standing Committee on Estimates (2006, 2008 and 
2009).  
 
 
  Sevil Atasoy 
 
 
 Born in 1949. National of Turkey. Professor of 
Biochemistry and Forensic Science, Istanbul 
University (since 1988). Expert witness in civil and 
criminal courts (since 1980). President of the Center of 
Crime Control and Prevention, Istanbul, Turkey (since 
2006). President of the International Forensic Science 
Services, Istanbul, Turkey (since 2003). 
 Recipient of the following degrees: Bachelor of 
Science in Chemistry (1972), Master of Science in 
Biochemistry (1976) and Doctor of Philosophy (Ph.D.) 
in Biochemistry (1979), Istanbul University. Hubert H. 
Humphrey Fellow, United States Information Agency 
(1995-1996); German Academic Exchange Service 
(DAAD) Fellow (1976, 1978 and 1994); European 
Molecular Biology Organization Fellow (1985); North 
Atlantic Treaty Organization Fellow (1978). Director, 
Institute of Forensic Science, Istanbul University 
(1988-2005). Director, Department of Narcotics and 
Toxicology, Ministry of Justice of Turkey (1980-1993). 
Chairperson, Department of Forensic Basic Sciences, 
Istanbul University (1983-1987); Professor of 
Biochemistry, Cerrahpasa School of Medicine, Istanbul 
University (1988-2005). Guest scientist, School of 
Public Health, University of California, Berkeley, and 
Drug Abuse Research Center, University of California, 
Los Angeles; Department of Genetics, Stanford 
University; Department of Genetics, Emory University; 
California Criminalistics Institute; Federal Bureau of 
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Investigation, Virginia; Crime Laboratories, Los 
Angeles Sheriff’s Department; Federal Criminal Police 
(BKA), Wiesbaden, Germany. Chairperson, Regional 
Symposium on Criminalistics (2000); and Chairperson, 
third European Academy of Forensic Sciences Meeting 
(2003). Member of the Experts Group on Technical 
Challenges to the Drug Community, United Nations 
Office on Drugs and Crime (UNODC) and Office of 
National Drug Control Policy of the United States 
(2003 and 2004); member of the expert group on risk 
reduction linked to substance use other than by 
injection, Pompidou Group of the Council of Europe 
(2002); member of the Mediterranean Network of the 
Pompidou Group (2001). Member of the Turkish 
delegation to the Commission of Narcotic Drugs (2001 
and 2002). Founding editor, Turkish Journal of Legal 
Medicine (1982-1993). Member of the scientific board 
of the International Criminal Justice Review, the 
Turkish Journal on Addiction, the Turkish Journal of 
Forensic Sciences and the Croatian Journal of Legal 
Medicine. Founding President, Turkish Society of 
Forensic Sciences, Honorary Member of the 
Mediterranean Academy of Forensic Sciences. Member 
of the International Society of Forensic Toxicology; the 
Indo-Pacific Association of Law, Medicine and 
Science; the International Association of Forensic 
Toxicologists; the American Academy of Forensic 
Sciences; the American Society of Crime Laboratory 
Directors; the Forensic Science Society, United 
Kingdom of Great Britain and Northern Ireland; the 
American Society of Criminology. Participant in 
projects on illicit drug issues, including: Crime 
Mapping of Drug Offences for the Ministry of Home 
Affairs (1998-2000); Global Study of Illicit Drug 
Markets: Istanbul, Turkey, for the United Nations 
Interregional Crime and Justice Research Institute 
(2000-2001); National Assessment of Nature and 
Extent of Drug Problems in Turkey, for UNODC 
(2002-2003); European School Survey on Alcohol and 
Other Drugs (2002-2003); Modelling the World Heroin 
Market, for the RAND Drug Policy Research Center 
and the Max Planck Institute (2003). Author of over 
130 scientific papers, including papers on drug testing, 
drug chemistry, drug markets, drug-related and drug-
induced crime, drug abuse prevention, clinical and 
forensic toxicology, crime scene investigation and 
deoxyribonucleic acid (DNA) analysis.  
 Member of the International Narcotics Control 
Board (since 2005). Member of the Committee on 
Finance and Administration (2006). Chairman (2006) 
and Member (2007) of the Standing Committee on 
Estimates. Second Vice-President of the Board (2006). 
Rapporteur (2007). First Vice-President of the Board 
(2008). President of the Board (2009). 
 
 
  Tatyana Borisovna Dmitrieva 
 
 
 Born in 1951. National of the Russian Federation. 
Director, V. P. Serbsky State Research Centre for 
Social and Forensic Psychiatry (since 1998). Chief 
Expert Psychiatrist, Ministry of Health and Social 
Development of the Russian Federation (since 2005). 
Administrative Board Member of the Foundation, 
Institute of Modern Development (since 2008). 
 Graduate of the Ivanovskii State Medical Institute 
(1975). Master of Science (1981) and Doctor of 
Medical Sciences (M.D.) (1990). Professor of 
Medicine (since 1993). Head of the Department of 
Psychiatry (1986-1989), Deputy Director of Research 
(1989-1990) and Director (1990-1996), V. P. Serbsky 
State Research Centre for Social and Forensic 
Psychiatry. Minister of Health of the Russian 
Federation (1996-1998). Chairman, Russian Security 
Council Commission on Health Protection (1996-
2000), Chairperson, Council of Trustees, Public 
Charitable Foundation Health (since 1997); Vice-
Chairman, Russian Society of Psychiatrists (since 
1995); Vice-President, World Association for Social 
Psychiatry Academician; Corresponding Member of 
the Russian Academy of Medical Sciences (since 
1997); member of the Russian Academy of Medical 
Sciences (since 1999). Author of over 450 scientific 
works, recipient of five authors’ certificates for 
inventions and author of five books on drug abuse 
therapy, including Abuse of Psychoactive Substances: 
Clinical and Legal Aspects (2003) and Narcology 
Diseases in Practice: Forensic and General Psychiatry 
(2008); Editor-in-Chief, Russian Psychiatric Journal. 
Editor-in-Chief, Clinical Research on Medication in 
Russia. Member of the editorial boards of several 
Russian and foreign medical journals, including the 
journal Narcology. Member of the editorial council, 
International Medical Journal; and member of the 
editorial council, Siberian Journal of Psychiatry and 
Narcology. Recipient of the Order for Services to the 
Country, fourth class (2001) and third class (2006); and 
the Order of Honour (1995). Participant and speaker on 
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psychiatry and drug abuse therapy at national and 
international congresses and conferences, including 
those organized by the World Health Organization 
(WHO), the European Union, the Council of Europe, 
the World Psychiatric Congress and the World 
Psychiatric Association. 
 Member of the International Narcotics Control 
Board (since 2005). Rapporteur of the Board (2006). 
Member (2006) and Chairman (2007) of the Standing 
Committee on Estimates. Second Vice-President of the 
Board (2007). First Vice-President of the Board (2009). 
 
 
  Philip Onagwele Emafo 
 
 
 Born in 1936. National of Nigeria. 
 Lecturer, Biochemistry, University of Ibadan 
(1969-1971). Lecturer and Senior Lecturer, 
Pharmaceutical Microbiology and Biochemistry, 
University of Benin, Nigeria (1971-1977). Chief 
Pharmacist and Director, Pharmaceutical Services, 
Federal Ministry of Health of Nigeria (1977-1988). 
Chairman, Pharmacists Board of Nigeria (1977-1988). 
Member of the WHO Expert Advisory Panel on the 
International Pharmacopoeia and Pharmaceutical 
Preparations (1979-2003). Rapporteur-General, 
International Conference on Drug Abuse and Illicit 
Trafficking, Vienna (1987). Chairman, Commission on 
Narcotic Drugs at its tenth special session (1988). 
Member of the Secretary-General’s Group of Experts 
on the United Nations Structure for Drug Abuse 
Control (1990). Member of the WHO Expert 
Committee on Drug Dependence (1992, 1994 and 
1998). Consultant to the United Nations International 
Drug Control Programme (1993-1995). Member of the 
ad hoc intergovernmental advisory group established 
by the Commission on Narcotic Drugs to assess 
strengths and weaknesses of global drug control efforts 
(1994). Member of the expert group convened by the 
Secretary-General pursuant to Economic and Social 
Council resolution 1997/37 to review the United 
Nations machinery for drug control (1997-1998). 
Member of the Advisory Group of the International 
Narcotics Control Board to review substances for 
control under article 12 of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988 (1998-1999). 
Consultant to the Organization of African Unity, Addis 
Ababa (1998-1999). Officer of the Order of the Federal 
Republic of Nigeria (2008). 
 Member of the International Narcotics Control 
Board (since 2000). Rapporteur of the Board (2001). 
First Vice-President of the Board (2005). President of 
the Board (2002, 2003, 2006 and 2007). Member of the 
Standing Committee on Estimates (2000-2004, 2008 
and 2009). 
 
 
  Hamid Ghodse 
 
 
 Born in 1938. National of the Islamic Republic of 
Iran. Professor of Psychiatry and of International Drug 
Policy, University of London (since 1987). Director, 
International Centre for Drug Policy, St. George’s 
University of London (since 2003); President, 
European Collaborating Centres for Addiction Studies 
(since 1992); Non-Executive Director, National Patient 
Safety Agency, United Kingdom (since 2001); 
Chairman, Higher Degrees in Psychiatry, University of 
London (since 2003); Chairman, Honours Committee, 
Royal College of Psychiatrists, United Kingdom (since 
2006). 
 Recipient of the following degrees, qualifications 
and awards: Doctor of Medicine (M.D.), Islamic 
Republic of Iran (1965); Diploma Psychological 
Medicine (D.P.M.), United Kingdom (1974); Doctor of 
Philosophy (Ph.D.), University of London (1976); and 
Doctor of Science (D.Sc.), University of London 
(2002). Fellow of the Royal College of Psychiatrists 
(F.R.C.Psych.), United Kingdom (1985); Fellow of the 
Royal College of Physicians (F.R.C.P.), London 
(1992); Fellow of the Royal College of Physicians of 
Edinburgh (F.R.C.P.E.), Edinburgh (1997); Fellow of 
the Faculty of Public Health Medicine (F.F.P.H.), 
United Kingdom (1997); Fellow of the Higher 
Education Academy (F.H.E.A.), United Kingdom 
(2005); Honorary Fellow, Royal College of 
Psychiatrists (R.C.Psych.) (2006); Honorary Fellow, 
World Psychiatric Association (2008). Member of the 
WHO Expert Advisory Panel on Alcohol and Drug 
Dependence (since 1979); Adviser, Joint Formulary 
Committee, British National Formulary (since 1984); 
Honorary Consultant Psychiatrist, St. George’s and 
Springfield University Hospitals, London (since 1978); 
Honorary Consultant Public Health, Wandsworth 
Primary Care Trust, London (since 1997). Consultant 
Psychiatrist, St. Thomas’s Teaching Hospital and 
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Medical School, London (1978-1987); member, 
rapporteur, chairman and convener of various WHO 
and European Community expert committees, review 
groups and other working groups on drug and alcohol 
dependence; M. S. McLeod Visiting Professor, 
Southern Australia (1990); Honorary Professor, Peking 
University (since 1997). Author or editor of over 
300 scientific books and papers on drug-related issues 
and addictions, including the following books: The 
Misuse of Psychotropic Drugs, London (1981); 
Psychoactive Drugs and Health Problems, Helsinki 
(1987); Psychoactive Drugs: Improving Prescribing 
Practices, Geneva (1988); Substance Abuse and 
Dependence, Guildford (1990); Drug Misuse and 
Dependence: The British and Dutch Response, 
Lancashire, United Kingdom (1990); Misuse of Drugs 
(3rd ed.), London (1997); Young People and Substance 
Misuse, London (2004); Addiction at Workplace, 
Aldershot (2005); International Drug Control into the 
21st Century, Aldershot (2008). Ghodse’s Drugs and 
Addictive Behaviour: A Guide to Treatment (4th ed.), 
Cambridge (forthcoming); Editor-in-Chief, 
International Psychiatry; Honorary Editor-in-Chief 
Chinese Journal of Drug Dependence; member of the 
Editorial Board, International Journal of Social 
Psychiatry; member of the Editorial Board, Asian 
Journal of Psychiatry. Convener of WHO expert 
groups on medical education (1986), pharmacy 
education (1987), nurse education (1989) and rational 
prescribing of psychoactive drugs. Chairman, 
Association of Professors of Psychiatry of the British 
Isles (since 1991); Chairman, Association of European 
Professors of Psychiatry; Director, National 
Programme on Substance Abuse Deaths (since 1997); 
member of the International Association of 
Epidemiology (since 1998).  
 Member of the International Narcotics Control 
Board (since 1992). Member of the Standing 
Committee on Estimates (1992). President of the Board 
(1993, 1994, 1997, 1998, 2000, 2001, 2004, 2005 and 
2008). 
 
 
  Carola Lander 
 
 
 Born in 1941. National of Germany. 
 Pharmacist, doctoral degree in natural science; 
Certified Specialist in Public Health (Chamber of 
Pharmacists). Research assistant and assistant 
professor, University of Berlin (1970-1979); person in 
charge of pharmaceutical quality control of herbal 
drugs, Federal Institute for Drugs and Medical 
Devices, Berlin (1979-1990); head of the division for 
the control of manufacturers of narcotic drugs, Federal 
Opium Agency of Germany (1990-1992). Head of the 
Federal Opium Agency, the German authority with 
competence under article 17 of the Single Convention 
on Narcotic Drugs of 1961 and article 6 of the 
Convention on Psychotropic Substances of 1971, and 
Chairperson of the federal expert group for narcotic 
drugs (1992-2006). Member of the German delegation 
to the Commission on Narcotic Drugs (1990-2006). 
Lecturer on drug regulatory affairs, University of Bonn 
(2003-2005). Recipient of a certificate of appreciation 
for outstanding contributions in the field of drug law 
enforcement awarded by the Drug Enforcement 
Administration of the United States and recipient of a 
certificate of appreciation awarded by the former 
Yugoslav Republic of Macedonia. 
 Member of the International Narcotics Control 
Board (since 2007). Member (2007), Vice-Chairperson 
(2008) and Chairperson (2009) of the Standing 
Committee on Estimates. Second Vice-President of the 
Board (2009). 
 
 
  Melvyn Levitsky 
 
 
 Born in 1938. National of the United States. 
Retired Ambassador in the United States Foreign 
Service. Professor of International Policy and Practice 
and Senior Fellow, International Policy Center, Gerald 
R. Ford School of Public Policy, University of 
Michigan (since 2006). Faculty Associate, Center for 
Russian and East European Studies, Faculty Advisor, 
Weiser Center for Emerging Democracies, University 
of Michigan. Member of the Operating Committee, 
Substance Abuse Research Center, University of 
Michigan.  
 United States diplomat for 35 years, serving as, 
inter alia, Ambassador of the United States to Brazil 
(1994-1998); Assistant Secretary of State for 
International Narcotics Matters (1989-1993); 
Executive Secretary and Special Assistant to the 
Secretary of the United States Department of State 
(1987-1989); Ambassador of the United States to 
Bulgaria (1984-1987); Deputy Director, Voice of 
America (1983-1984); Deputy Assistant Secretary of 
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State for Human Rights and Humanitarian Affairs 
(1982-1983); Director, Office of United Nations 
Political Affairs, Bureau of International Relations 
(1980-1982); Officer-in-Charge for Bilateral Relations, 
Office of Soviet Union Affairs (1975-1978); Political 
Officer, United States Embassy in Moscow (1973-
1975); Consul, United States consulates in Frankfurt, 
Germany (1963-1965), and Belem, Brazil (1965-1967). 
Professor of International Relations and Public 
Administration, Maxwell School of Citizenship and 
Public Affairs, Syracuse University (1998-2006). 
Recipient of several United States Department of State 
Meritorious and Superior Honor Awards, Presidential 
Meritorious Service Awards and the United States 
Secretary of State’s Distinguished Service Award. 
Member of the Washington Institute of Foreign Affairs, 
the American Academy of Diplomacy and the 
American Foreign Service Association. Member of the 
Advisory Board, Drug Free America Foundation. 
Member of the Institute on Global Drug Policy. 
Member of the Board, Global Panel of the Prague 
Society. Member of the Public-Private Working Group 
on Sale of Controlled Substances via the Internet 
(Harvard University Law School). Distinguished 
Fellow, Daniel Patrick Moynihan Institute of Global 
Affairs, Maxwell School of Citizenship and Public 
Affairs, Syracuse University. Member of the University 
of Michigan Substance Abuse Research Center. Listed 
in Who’s Who in American Politics, Who’s Who in 
American Government and Who’s Who in American 
Education. 
 Member of the International Narcotics Control 
Board (since 2003). Chairman of the Committee on 
Finance and Administration (2004). Chairman of the 
Working Group on Strategy and Priorities (2005). 
 
 
  Jorge Montaño 
 
 
 Born in 1948. National of Mexico. Professor of 
International Organizations and Mexican Foreign 
Policy, Instituto Tecnológico Autónomo de México, 
private consultant on the enforcement of the North 
American Free Trade Agreement (NAFTA). 
 Law and Political Science, Universidad Nacional 
Autónoma de México; Master of Arts and Doctor of 
Philosophy in International Affairs, London School of 
Economics. 
Director General de Educación Superior – Secretaría 
de Educación Pública (1976-1979); Member of the 
Mexican Foreign Service (1979-2008); Director of 
International Agencies (1979-1982); Assistant 
Secretary of Multilateral Affairs (1982-1988); 
Permanent Representative of Mexico to the United 
Nations organizations (1989-1992); Chairman of the 
Group of Experts to enhance the efficiency of the 
United Nations structure for drug abuse control (1990); 
Ambassador of Mexico to the United States (1993-
1995); member of the Multilateral Evaluation 
Mechanism on drugs (2001-2003) of the Inter-
American Drug Abuse Control Commission (CICAD). 
Author of the following publications: Partidos y 
política en América Latina; Implicaciones legales de la 
presencia de Estados Unidos en Viet Nam; Análisis del 
Sistema de Naciones Unidas; ACNUR en América 
Latina; Negociaciones del Tratado de Libre Comercio 
de America del Norte; Cooperación México-Estados 
Unidos en materia de narcotráfico; Debilidades de la 
certificación del Congreso de Estados Unidos; Retos 
de la frontera norte de México; Tráfico de armas en las 
fronteras mexicanas. Author of 50 articles published in 
specialized journals. Weekly contributor to the editorial 
pages of La Jornada, Reforma and El Universal. 
President and founding member of Foreign Affairs 
Latinoamérica (formerly Foreign Affairs en Español). 
Founding President, Asesoría y Análisis, S.C., Mexican 
Council on Foreign Relations (COMEXI). Recipient of 
awards from the Governments of Chile, El Salvador, 
Greece and Guatemala. Participant in many meetings 
of organizations in the United Nations system, the 
Organization of American States and the Movement of 
Non-Aligned Countries. 
 Member of the International Narcotics Control 
Board (2009). 
 
 
  Sri Suryawati 
 
 
 Born in 1955. National of Indonesia. Director, 
Centre for Clinical Pharmacology and Medicines 
Policy Studies, Gadjah Mada University. Coordinator, 
Master Degree Program for Medicine Policy and 
Management, Gadjah Mada University. Lecturer in 
Pharmacology/Clinical Pharmacology (since 1980); 
supervisor for more than 110 master’s and doctoral 
theses on medicine policy, the rational use of 
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medicines, clinical pharmacokinetics and drug 
management. 
 Pharmacist (1979). Specialist in pharmacology 
(1985); doctoral degree in clinical pharmacokinetics 
(1994). Former Head of Clinical Pharmacology, 
Faculty of Medicine, Gadjah Mada University, 
Indonesia (1999-2006 and 2008-2009). Member of the 
WHO Expert Advisory Panel for Medicine Policy and 
Management. Member of the Executive Board of the 
International Network for the Rational Use of Drugs 
(INRUD). Member of the WHO Expert Committee on 
the Selection and Use of Essential Medicines (2002, 
2003, 2005 and 2007). Member of the WHO Expert 
Committee on Drug Dependence (2002 and 2006). 
Member of the United Nations Millennium Project 
Task Force on HIV/AIDS, Malaria and Tuberculosis 
and Access to Essential Medicines (Task Force 5) 
(2001-2005). Consultant in essential medicine 
programmes and promoting rational use of medicines 
in Bangladesh (2006-2007), Cambodia (2001-2008), 
China (2006-2008), Fiji (2009), the Lao People’s 
Democratic Republic (2001-2003), Mongolia (2006-
2008) and the Philippines (2006-2007). Consultant in 
medicine policy and drug evaluation in Cambodia 
(2003, 2005 and 2007), China (2003), Indonesia (2005-
2006) and Viet Nam (2003). Facilitator in various 
international training courses in medicine policy and 
promoting the rational use of medicines, including 
WHO and INRUD courses on promoting the rational 
use of medicines (1994-2007), training courses on 
hospital drugs and therapeutics committees (2001-
2007) and international courses on drug policy in 
developing countries (2002-2003). 
 Member of the International Narcotics Control 
Board (since 2007). Member (2008) and Vice-
Chairperson (2009) of the Standing Committee on 
Estimates. 
 
 
  Camilo Uribe Granja 
 
 
 Born in 1963. National of Colombia. Medical 
Director, Hospital of San Martín (Meta); toxicologist, 
Marly and Palermo clinics; General Director, New 
Clinic Fray Bartolomé de las Casas; consultant, 
National Drug Council. Numerous university teaching 
posts in forensics and clinical toxicology. Director-
General, the Integral Toxicology Unit (UNITOX), 
University Children’s Hospital of Saint Joseph (since 
2008). Member of the Commission of Public Health 
(since 2006), Member of the Commission of Mental 
Health (since 2007) and Chairman of the Commission 
of Drug Abuse (since 2008), National Academy of 
Medicine. 
 Member of the International Narcotics Control 
Board (since 2005). Member of the Committee on 
Finance and Administration (since 2007). Vice-
Chairman (2006 and 2007), Second Vice-President 
(2008) and Chairman (2008) of the Standing 
Committee on Estimates. Member of the Standing 
Committee on Estimates (2009). Rapporteur (2009). 
 
 
  Brian Watters 
 
 
 Born in 1935. National of Australia. Chairman, 
Australian National Council on Drugs (2005). 
 Arts degree, majoring in medical sociology, 
University of Newcastle, Australia; trained in addiction 
counselling at University of Newcastle; qualified 
psychiatric chaplain. Major in the Salvation Army 
(1975-2008), including work as Commander of the 
Salvation Army’s addiction treatment programme in 
eastern Australia; consultant and media spokesman on 
addiction issues; adviser to the Salvation Army’s 
HIV/AIDS services in eastern Australia; former 
President of the Network of Alcohol and Drug 
Agencies in New South Wales; former member of New 
South Wales’ Health Minister’s Drug Advisory 
Council. Patron, “Drug Arm, Australia”; Board 
member, “Drug Free Australia”. Member of several 
Australian government committees, including: the 
expert advisory group on sustained release naltrexone; 
the state and national reference groups on the Council 
of Australian Governments “Diversion of Offenders” 
scheme; and the national “Tough on Drugs” reference 
group for non-governmental organization treatment 
grants. Frequent contributor to Australian newspapers, 
magazines and journals, including the journal of the 
National Drug and Alcohol Research Centre; several 
publications, including Drug Dilemma: a Way 
Forward, and contributor to “Prevention, demand 
reduction and treatment: a way forward for Australia”, 
Heroin Crisis (1999). Officer of the Order of Australia 
(2003), for outstanding services in anti-drug policy 
development and drug treatment. Keynote speaker at 
national and international conferences, including: 
International Council on Alcohol and Addictions, 
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Vienna; European Cities against Drugs, Stockholm; 
Australian Conference on Drugs Strategy, Adelaide; 
International Substance Abuse and Addiction 
Coalition, Madrid. Participant, Commission on 
Narcotic Drugs (2003). Speaker of the National 
Chemical Diversion Conference, Darwin, Australia 
(2005). 
 Member of the International Narcotics Control 
Board (since 2005). First Vice-President of the Board 
(2007). Member of the Standing Committee on 
Estimates (2006, 2008 and 2009). Member of the 
Committee on Finance and Administration (2009). 
 
 
  Raymond Yans 
 
 
 Born in 1948. National of Belgium.  
 Graduate in Germanic philology and in 
philosophy (1972). Belgian Foreign Service: Attaché, 
Jakarta (1978-1981); Deputy-Mayor of Liège (1982-
1989); Consul, Tokyo (1989-1994); Consul, Chargé 
d’affaires, Luxembourg (1999-2003); Head of the Drug 
Unit, Ministry of Foreign Affairs (1995-1999 and 
2003-2007); Chairman of the Dublin Group (2002-
2006); Chairman of the European Union Drug Policy 
Cooperation Working Group during the Belgian 
Presidency of the European Union; charged with the 
national coordination of the ratification and 
implementation process of the Convention on 
Psychotropic Substances of 1971 and the United 
Nations Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988 (1995-
1998); liaison between the Ministry of Foreign Affairs 
and the National Police for drug liaison officers in 
Belgian embassies (2003-2005); participation in the 
launching by the European Union Joint Action on New 
Synthetic Drugs of an early warning system to alert 
Governments to the appearance of new synthetic drugs 
(1999); active in the creation of the Cooperation 
Mechanism on Drugs between the European Union, 
Latin America and the Caribbean (1997-1999). Author 
of numerous articles and speeches including: “The 
future of the Dublin Group” (2004) and “Is there 
anything such as a European Union Common Drug 
Policy” (2005). Member of the Belgian delegation to 
the Commission on Narcotic Drugs (1995-2007); all 
the preparatory sessions (on amphetamine-type 
stimulants, precursors, judicial cooperation, money-
laundering, drug demand reduction and alternative 
development) for the twentieth special session of the 
General Assembly; European Union Seminar on Best 
Practices in Drug Enforcement by Law Enforcement 
Authorities, Helsinki (1999); Joint European 
Union/Southern African Development Community 
Conferences on Drug Control Cooperation, Mmabatho, 
South Africa (1995) and Gabarone (1998); United 
Nations Office on Drugs and Crime/Paris Pact round 
tables, Brussels (2003), Tehran and Istanbul (2005); 
meetings of the High-level Dialogue on Drugs between 
the Andean Community and the European Union, the 
European Community, Lima (2005) and Vienna (2006). 
 Member of the International Narcotics Control 
Board (since 2007). Member of the Standing 
Committee on Estimates (since 2007). Member of the 
Committee on Finance and Administration (since 
2007). 
 
 
  Yu Xin 
 
 
 Born in 1965. National of China. Clinical 
Professor of Psychiatry, Institute of Mental Health, 
Peking University (since 2004). Licensed Psychiatrist, 
China Medical Association (since 1988). Founding 
President, Chinese Psychiatrist Association (2005-
2008); Chairperson, Credential Committee for 
Psychiatrists, Ministry of Health of China; President-
elect, Chinese Society of Psychiatry (since 2006); 
Vice-President, Management Association for 
Psychiatric Hospitals (2009); Vice-Chairman, 
Alzheimer’s Disease, China (since 2002). 
 Bachelor of Medicine, Beijing Medical 
University (1988); Fellow in Psychiatry, University of 
Melbourne, Australia (1996-1997); Fellow in 
Substance Abuse, Johns Hopkins University (1998-
1999); Doctor of Medicine (M.D.), Peking University 
(2000); Senior Fellow in Social Medicine, Harvard 
University (2003). Residency in psychiatry (1988-
1993) and Psychiatrist (1993-1998), Institute of Mental 
Health, Beijing Medical University; Head, Associate 
Professor of Psychiatry, Geriatric Psychiatrist, 
Department of Geriatric Psychiatry, Institute of Mental 
Health, Peking University (1999-2001); Assistant 
Director (2000-2001) and Executive Director (2001-
2004), Institute of Mental Health, Peking University. 
Author and co-author of numerous works on various 
topics in psychiatry, such as psychopharmacology, 
early intervention of schizophrenia, mental health and 
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HIV/AIDS and drug use, mental health outcome of 
harmful alcohol use, neuropsychology of mental 
disorders, neuroimaging of late life depression, late 
onset psychosis, and assessment, treatment and care for 
dementia. Editor of several textbooks, including 
Geriatric Psychiatry, Textbook of Psychiatry for Asia 
and Psychiatry for Medical Students. Recipient of the 
Outstanding Clinician Award, Beijing Medical 
University, and the Innovation and Creation Award, 
Beijing Medical Professional Union (2004). Member of 
the expert group for the section on analgesics and 
sedatives of the State Food and Drug Administration 
(since 2000). Evaluator of the effectiveness of 
methadone clinics. Leader of a project to follow up the 
neurocognitive and mental functioning of patients 
infected with HIV/AIDS as a result of intravenous drug 
abuse. Chief Psychiatrist, National Community Mental 
Health Service Programme. Senior consultant, Chinese 
Association on Tobacco Control. Senior consultant, 
Chronic Pain Treatment Programme. 
 Member of the International Narcotics Control 
Board (since 2007). Member of the Standing 
Committee on Estimates (since 2007). Chairman of the 
Committee on Finance and Administration (2009). 
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Annex III 
 
 
  Statement made by Hamid Ghodse, President of the 
International Narcotics Control Board, on 26 February 
2009 at the event marking the centennial of the convening of 
the International Opium Commission in Shanghai, China 
 
 
 At the outset, allow me to thank the Government of China for organizing and 
hosting this magnificent event. It is a unique privilege for me to speak before this 
august gathering convened to mark 100 years of multilateral drug control. The 
International Narcotics Control Board and the Government of China have long 
historical ties and a record of excellent cooperation. 
 The international community has come a long way since the International 
Opium Commission met in February 1909 in this beautiful city of Shanghai, which, 
at the time, was the main importation point of opium into China. 
 The situation faced by the 13 nations represented in the Shanghai Commission 
was extremely difficult. The demand for opium, morphine and other highly 
addictive substances was high and since these substances were unregulated, 
addiction problems had started to develop, not only in China but also in other 
countries of the world. Delegates to the Shanghai Commission were aware of the 
wider geographical scope of the drug problem and the nascent addiction of 
manufactured opiates. 
 On the other hand, the opium trade was very lucrative, bringing in millions of 
dollars. The value of Indian opium exported to China, for example, is said to have 
amounted to 3 million pounds sterling in 1907. Such enormous sums provided a 
livelihood for a large number of ordinary people. It is therefore all the more 
remarkable that the International Opium Commission took the daring step of putting 
public health issues above commercial interests and decided to call for a global 
effort to regulate drugs in order to protect the health of the people. 
 The Shanghai Declaration, which was adopted at the Commission, was historic 
in many ways. For the first time, a community of nations agreed that the non-
medical use of opium should be a matter for careful regulation, or even prohibition. 
For the first time, the international community expressed the fact that certain drugs 
could be dangerous. The Commission agreed that the unrestricted manufacture, sale 
and distribution of morphine constituted a grave danger and called on Governments 
to make efforts to control it. And, for the first time, the efforts by the Government of 
China to eradicate the production and consumption of opium throughout its empire 
received unanimous international recognition. 
 The Shanghai Declaration was thus the first pronouncement of the 
international community’s intensity to act against the growing drug problem. And 
although the Commission was never intended to establish binding obligations, it 
nevertheless accelerated the efforts that, only three years later, led to the Hague 
Opium Convention of 1912, which established control of narcotic drugs as an 
institution of international law on a multilateral basis. 
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 Like many great ideas, international drug control was achieved gradually over 
a long period of time. The conferences of Shanghai and the Hague were followed by 
a series of multilateral agreements that addressed the cultivation, manufacture, 
trafficking and abuse of opium and other narcotic drugs. The efforts of the 
international community culminated in the international drug control treaties that 
are the current framework for action in international drug control today: the Single 
Convention on Narcotic Drugs of 1961, the Convention on Psychotropic Substances 
of 1971 and the United Nations Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances of 1988. Even decades after their adoption, these 
treaties enjoy the overwhelming support of the international community. More than 
90 per cent of Member States, representing 99 per cent of the world’s population, 
have agreed to be bound by their provisions. 
 One hundred years is a very respectable period and enough time has elapsed to 
demonstrate the value of our institutions. The international drug control institutions 
have proven their worth. The licit control system established by the international 
drug control treaties has expanded from when it was first created, managing an ever-
increasing number of substances and a continuously rising demand for drugs needed 
for medical and scientific purposes. 
 In spite of these great efforts and successes, challenges remain to be addressed 
by the international community One is the underutilization of narcotic drugs for 
medical purposes. In line with its mandate, the Board has consistently highlighted 
this issue, urging Governments to critically examine their methods of assessing 
domestic medical needs for opiates and to take the stops necessary to remove 
impediments to the adequate availability of those drugs for medical and scientific 
purposes. This has not been without effect. A review of trends in global 
consumption of opiates and synthetic opioids for the 20-year period 1988-2007 
indicates that the consumption of opiates has increased steadily, almost tripling 
since 1987. The consumption of synthetic opioids almost quadrupled during the 
same period. 
 Nevertheless, access to these drugs is far from global. According to the World 
Health Organization, as many as 86 million people may still experience unnecessary 
suffering due to lack of adequate drugs. Together with WHO, the Board has 
therefore examined the reasons for the lack of availability. As a result, the WHO 
Access to Controlled Medications Programme has been developed, which assists 
Governments in their efforts to improve the availability of drugs for medical 
purposes. The Board encourages all Governments to make use of that programme. 
 Governments must also seriously address the question of demand reduction. 
The international drug control system has made an important contribution to 
reducing the demand for drugs worldwide. The amount of opiates abused in China 
alone at the beginning of the twentieth century is estimated at more than 3,000 tons 
in morphine equivalent. In comparison, the amount of opiates illicitly used 
worldwide each year is currently estimated at about 400 tons in morphine 
equivalent. Nevertheless, drug abuse is a problem in most countries in the world and 
vigorous action must be taken to counter it. 
 In its annual report for 1993, the Board called for decisive action to reduce the 
demand for drugs and urged Governments to give a higher priority to that issue. To 
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achieve a lasting reduction of drug abuse, demand reduction programmes have to 
have a long-term view and must be sustainable and be adequately funded. 
 Drug abuse prevention programmes should received the attention they deserve. 
The Board has emphasized for many years that Governments must seriously address 
the problem, heeding the adage that “an ounce of prevention is world a pound of 
cure”. Compared with the cost of treating and rehabilitating drug abusers, the cost 
of implementing measures aimed at preventing first use of drugs is minute. 
 It is also essential that, in devising drug abuse prevention programmes, the 
causes generating illicit demand for drugs should be analysed and the necessary 
measures identified to address the problem of drug abuse at its roots. Special 
attention should be given to the social causes underlying the drug problem, which 
should be adequately addressed by social policies. Successful prevention 
programmes are often the result of long-term investment and dedicated programmes 
that teach young people and other vulnerable groups the skills they need to resist 
non-medical drug use. If a substantial change in attitudes can be achieved, success 
in drug abuse prevention will not be far behind. 
 Successive technological revolutions have changed our world to such an extent 
that it would probably be hardly recognizable to the delegates that participated in 
the International Opium Commission in 1909. These developments have been 
beneficial to many but have also brought opportunities for drug traffickers. The 
deregulation and liberalization of commercial practices in the licit drug market has 
tended to weaken the regulatory power of Governments. Drug trafficking 
organizations can design and manufacture psychoactive substances with the explicit 
aim of bypassing the restriction imposed by international drug control regulations 
and then distribute those drugs outside the control system. The Internet can be 
misused to become a worldwide Web for trafficking in internationally controlled 
substances and drugs. The Board is convinced that a global coordinated response is 
needed to address these challenges and encourages Governments to support 
multilateral initiatives. 
 These are important challenges. Governments and the international community 
as a whole have to find a way to tackle them, bearing in mind the principles of 
shared responsibility, the sovereignty of nations, the territorial integrity of States 
and the need to address the world drug problem in a balanced and integrated 
manner. But while these challenges are significant, they are dwarfed by the 
enormous problems that the world faced at the time of the Shanghai Opium 
Commission. 
 Over the past 100 years, the commitment of the international community to 
international drug control has not wavered. All this time, Governments and 
intergovernmental and non-governmental organizations have worked together to 
examine how the international drug control system can be further improved. 
 A high-level segment of the Commission on Narcotic Drugs will be held in 
Vienna in March 2009 to review the progress made since the 1998 special segment 
of the General Assembly, on countering the world drug problem, and to adopt a 
political declaration that will chart the future course of international drug control. 
 Both this meeting in Shanghai and the meeting in Vienna are ideal 
opportunities for the international community to renew its commitment to the spirit 
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of the 1909 Shanghai Commission and the multilateral agreements that followed it. 
The conventions continue to be highly relevant in the face of contemporary 
problems and challenges and may in fact be more necessary now than in the past. 
And while the international drug control system is not perfect, it has stood the test 
of time with credit. 
 In 1909, the Chairman of the Commission concluded his opening statement by 
saying that “much still needs to be done by our respective Governments and the 
nations we represent. As we move out to meet our responsibility, the appeal of one 
of the world’s more recent heroes comes to us — let us have faith that right makes 
might, and in that faith let us to the end dare to do our duty as we understand it.” I 
echo those sentiments wholeheartedly and look forward to working with all 
Governments on a new Shanghai Declaration that will embody a similar spirit and 
commitment. 
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Annex IV 
 
 
  Shanghai Declaration adopted at the event marking the 
centennial of the convening of the International Opium 
Commission 
 
 
 We, the representatives of the Republic of Austria, the Kingdom of Cambodia, 
the People’s Republic of China, the French Republic, the Federal Republic of 
Germany, the Islamic Republic of Iran, the Italian Republic, Japan, the Lao People’s 
Democratic Republic, the Union of Myanmar, the Kingdom of the Netherlands, the 
Portuguese Republic, the Russian Federation, the Kingdom of Thailand, the United 
Kingdom of Great Britain and Northern Ireland, the United States of America and 
the Socialist Republic of Viet Nam participating in the event on 26 February 2009 
marking the centennial of the convening of the International Opium Commission in 
Shanghai, China, 
 Recalling that the International Opium Commission, the first multinational 
initiative in the field of narcotics control, was convened in Shanghai, China, from 
1 to 26 February 1909, during which the representatives of thirteen nations, namely, 
Austria-Hungary, China, France, Germany, Great Britain, Italy, Japan, the 
Netherlands, Persia, Portugal, Russia, Siam, and the United States of America, 
participated in the deliberations, and that the Shanghai conference, which laid the 
groundwork for the elaboration of the first international drug control treaty, the 
1912 Hague International Opium Convention, is a landmark event in the history of 
the international anti-drug campaign;  
 Paying tribute to those who made unremitting efforts and even dedicated their 
lives to the international endeavour to countering the problem of illicit drugs, and 
appreciating their great visions and important contributions; 
 Recognizing the great progress made by the international community in 
narcotics control and international cooperation since 1909, in particular, the 
remarkable achievements, successful experience and useful lessons in significantly 
reducing illegal opium poppy cultivation and actively promoting sustainable 
alternative development in the Southeast Asia in the past decades which could be 
shared with other parts of the world; 
 Reaffirming our political commitment to pursuing on the basis of shared 
responsibility, a comprehensive, balanced and mutually reinforcing approach to 
supply and demand reduction, devoting more resources and international 
cooperation at the national, regional and international levels in addressing drug 
abuse as a health and social issue, while upholding the law and its enforcement; 
 Deeply concerned that, despite continued increased efforts by States and 
relevant organizations, the world drug problem remains a serious threat to public 
health, safety, harmonization and the well-being of humanity, in particular children 
and young people and their families, and to the national security and sovereignty of 
States, and that it undermines socio-economic and political stability and sustainable 
development;  
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 Noting with concern the fact that the lack of adequate financial and technical 
support to evidence-based demand and supply reduction policies seriously impedes 
the effectiveness of the global endeavour against illicit drugs;  
 Recognizing in some instances the links between poverty, lack of licit 
economic alternatives, social marginalization, social exclusion, gender-based 
violence and the production, trafficking and abuse of drugs, as well as the 
increasing hazard posed by synthetic drugs and their precursors, and abuse of licit 
prescription drugs;  
 Taking note of the possible connections between drug-related crime and other 
transnational organized crime, such as, money laundering, trafficking in firearms 
and corruption in some parts of the world, and their links with terrorism;  
 Underlining the importance of full implementation of the relevant United 
Nations conventions, in particular the Single Convention on Narcotic Drugs of 
1961, the Convention on Psychotropic Substances of 1971, the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 
1988, the 2000 United Nations Convention against Transnational Organized Crime 
and its related protocols and the 2003 United Nations Convention against 
Corruption, and relevant resolutions of the United Nations;  
 Reaffirm that international drug control cooperation must be in full conformity 
with the purposes and principles of the Charter of the United Nations, in particular 
with full respect for the sovereignty and territorial integrity of States, the principle 
of non-intervention in the internal affairs of States and all human rights and 
fundamental freedoms, on the basis of the principles of equal rights and mutual 
respect among States;  
 Reaffirm also the Political Declaration adopted by the General Assembly at its 
twentieth special session, the Declaration on the Guiding Principles of Drug 
Demand Reduction and its Action Plan, the Action Plan on International 
Cooperation on the Eradication of Illicit Drug Crops and on Alternative 
Development; 
 Urge all States to act in accordance with the spirit of this conference and 
increase efforts in monitoring and eradicating the illicit cultivation of crops used for 
the production of narcotic drugs and psychotropic substances and promoting 
sustainable alternative development with due consideration of the protection of the 
environment，as well as in monitoring and preventing the diversion of chemical 
precursors; strengthen information exchange and law enforcement cooperation in 
the fight against transnational drug-related crimes, share experiences and promote 
research in the fields of drug treatment and reduction of adverse health 
consequences of drug use, mobilize resources for drug prevention and education, 
and raise public awareness and resistance against illicit drugs;  
 Urge also all States Parties to fully implement the international drug control 
conventions and fulfil other relevant international drug control obligations in 
accordance with their own national laws and regulation;  
 Support the United Nations in its important role in international drug control, 
continue to mobilize resources in drug control and pledge to consistently and 
closely cooperate with the United Nations Office on Drugs and Crime and the 
International Narcotics Control Board; 
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 Invite international financial institutions, major development banks, 
foundations and, where appropriate, private donors to continue to provide financial 
and technical support to countering the drug problem;  
 Thank the Government of the People’s Republic of China for generously 
hosting this conference and according thoughtful arrangements and warm 
hospitality to the delegates, which has served as a good platform for delegates to 
explore solutions for the world drug problem; 
 Request the Government of the People’s Republic of China that this 
declaration, along with the results of the Conference of the Centennial of the 
International Opium Commission, be presented at the high-level segment of the 
fifty-second session of Commission on Narcotic Drugs. 
 
 
 
  
  
About the International Narcotics Control Board 
 
 
 The International Narcotics Control Board (INCB) is an independent and quasi-judicial control organ, established by 
treaty, for monitoring the implementation of the international drug control treaties. It had predecessors under the former drug 
control treaties as far back as the time of the League of Nations. 
 
Composition 
 
 INCB consists of 13 members who are elected by the Economic and Social Council and who serve in their personal 
capacity, not as Government representatives (see annex II of the present publication for the current membership). Three 
members with medical, pharmacological or pharmaceutical experience are elected from a list of persons nominated by the 
World Health Organization (WHO) and 10 members are elected from a list of persons nominated by Governments. Members 
of the Board are persons who, by their competence, impartiality and disinterestedness, command general confidence. The 
Council, in consultation with INCB, makes all arrangements necessary to ensure the full technical independence of the Board 
in carrying out its functions. INCB has a secretariat that assists it in the exercise of its treaty-related functions. The INCB 
secretariat is an administrative entity of the United Nations Office on Drugs and Crime, but it reports solely to the Board on 
matters of substance. INCB closely collaborates with the Office in the framework of arrangements approved by the Council 
in its resolution 1991/48. INCB also cooperates with other international bodies concerned with drug control, including not 
only the Council and its Commission on Narcotic Drugs, but also the relevant specialized agencies of the United Nations, 
particularly WHO. It also cooperates with bodies outside the United Nations system, especially the International Criminal 
Police Organization (INTERPOL) and the World Customs Organization. 
 
Functions 
 
 The functions of INCB are laid down in the following treaties: the Single Convention on Narcotic Drugs of 1961 as 
amended by the 1972 Protocol; the Convention on Psychotropic Substances of 1971; and the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. Broadly speaking, INCB deals with the 
following: 
 (a) As regards the licit manufacture of, trade in and use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs are available for medical and scientific uses and that the diversion of 
drugs from licit sources to illicit channels does not occur. INCB also monitors Governments’ control over chemicals used in 
the illicit manufacture of drugs and assists them in preventing the diversion of those chemicals into the illicit traffic; 
 (b) As regards the illicit manufacture of, trafficking in and use of drugs, INCB identifies weaknesses in national and 
international control systems and contributes to correcting such situations. INCB is also responsible for assessing chemicals 
used in the illicit manufacture of drugs, in order to determine whether they should be placed under international control. 
 In the discharge of its responsibilities, INCB: 
 (a) Administers a system of estimates for narcotic drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs through a statistical returns system, with a view to assisting 
Governments in achieving, inter alia, a balance between supply and demand; 
 (b) Monitors and promotes measures taken by Governments to prevent the diversion of substances frequently used in 
the illicit manufacture of narcotic drugs and psychotropic substances and assesses such substances to determine whether there 
is a need for changes in the scope of control of Tables I and II of the 1988 Convention; 
 (c) Analyses information provided by Governments, United Nations bodies, specialized agencies or other competent 
international organizations, with a view to ensuring that the provisions of the international drug control treaties are 
adequately carried out by Governments, and recommends remedial measures; 
 (d) Maintains a permanent dialogue with Governments to assist them in complying with their obligations under the 
international drug control treaties and, to that end, recommends, where appropriate, technical or financial assistance to be 
provided. 
 INCB is called upon to ask for explanations in the event of apparent violations of the treaties, to propose appropriate 
remedial measures to Governments that are not fully applying the provisions of the treaties or are encountering difficulties in 
applying them and, where necessary, to assist Governments in overcoming such difficulties. If, however, INCB notes that the 
measures necessary to remedy a serious situation have not been taken, it may call the matter to the attention of the parties 
concerned, the Commission on Narcotic Drugs and the Economic and Social Council. As a last resort, the treaties empower 
  
INCB to recommend to parties that they stop importing drugs from a defaulting country, exporting drugs to it or both. In all 
cases, INCB acts in close cooperation with Governments. 
 INCB assists national administrations in meeting their obligations under the conventions. To that end, it proposes and 
participates in regional training seminars and programmes for drug control administrators. 
 
Reports 
 
 The international drug control treaties require INCB to prepare an annual report on its work. The annual report contains 
an analysis of the drug control situation worldwide so that Governments are kept aware of existing and potential situations 
that may endanger the objectives of the international drug control treaties. INCB draws the attention of Governments to gaps 
and weaknesses in national control and in treaty compliance; it also makes suggestions and recommendations for 
improvements at both the national and international levels. The annual report is based on information provided by 
Governments to INCB, United Nations entities and other organizations. It also uses information provided through other 
international organizations, such as INTERPOL and the World Customs Organization, as well as regional organizations. 
 The annual report of INCB is supplemented by detailed technical reports. They contain data on the licit movement of 
narcotic drugs and psychotropic substances required for medical and scientific purposes, together with an analysis of those 
data by INCB. Those data are required for the proper functioning of the system of control over the licit movement of narcotic 
drugs and psychotropic substances, including preventing their diversion to illicit channels. Moreover, under the provisions of 
article 12 of the 1988 Convention, INCB reports annually to the Commission on Narcotic Drugs on the implementation of 
that article. That report, which gives an account of the results of the monitoring of precursors and of the chemicals frequently 
used in the illicit manufacture of narcotic drugs and psychotropic substances, is also published as a supplement to the annual 
report. 
 Since 1992, the first chapter of the annual report has been devoted to a specific drug control issue on which INCB 
presents its conclusions and recommendations in order to contribute to policy-related discussions and decisions in national, 
regional and international drug control. The following topics were covered in past annual reports: 
 1992:  Legalization of the non-medical use of drugs 
 1993:  The importance of demand reduction 
 1994:  Evaluation of the effectiveness of the international drug control treaties 
 1995:  Giving more priority to combating money-laundering 
 1996:  Drug abuse and the criminal justice system 
 1997:  Preventing drug abuse in an environment of illicit drug promotion 
 1998:  International control of drugs: past, present and future 
 1999:  Freedom from pain and suffering 
 2000:  Overconsumption of internationally controlled drugs 
 2001:  Globalization and new technologies: challenges to drug law enforcement in the twenty-first 
  century 
 2002:  Illicit drugs and economic development 
 2003:  Drugs, crime and violence: the microlevel impact 
 2004:  Integration of supply and demand reduction strategies: moving beyond a balanced approach 
 2005:  Alternative development and legitimate livelihoods 
 2006:  Internationally controlled drugs and the unregulated market 
 2007:  The principle of proportionality and drug-related offences 
 2008:  The international drug control conventions: history, achievements and challenges 
 Chapter I of the report of the International Narcotics Control Board for 2009 is entitled “Primary prevention of drug 
abuse”. 
 Chapter II presents an analysis of the operation of the international drug control system based primarily on information 
that Governments are required to submit directly to INCB in accordance with the international drug control treaties. Its focus 
is on the worldwide control of all licit activities related to narcotic drugs and psychotropic substances, as well as chemicals 
used in the illicit manufacture of such drugs. 
 Chapter III presents some of the major developments in drug abuse and trafficking and measures by Governments to 
implement the international drug control treaties by addressing those problems. 
 Chapter IV presents the main recommendations addressed by INCB to Governments, the United Nations Office on 
Drugs and Crime, WHO and other relevant international and regional organizations. 
Reports published by the International Narcotics
Control Board in 2009
 The Report of the International Narcotics Control Board for 2009 
(E/INCB/2009/1) is supplemented by the following reports:
  Narcotic Drugs: Estimated World Requirements for 2010; Statistics for 2008 
(E/INCB/2009/2)
  Psychotropic Substances: Statistics for 2008; Assessments of Annual Medical 
and Scientific Requirements for Substances in Schedules II, III and IV of the 
Convention on Psychotropic Substances of 1971 (E/INCB/2009/3)
  Precursors and Chemicals Frequently Used in the Illicit Manufacture of 
Narcotic Drugs and Psychotropic Substances: Report of the International 
Narcotics Control Board for 2009 on the Implementation of Article 12 of the 
United Nations Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988 (E/INCB/2009/4)
 The updated lists of substances under international control, comprising 
narcotic drugs, psychotropic substances and substances frequently used in the illicit 
manufacture of narcotic drugs and psychotropic substances, are contained in the 
latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” 
and “Red List”), which are also issued by the Board.
Contacting the International Narcotics Control Board
 The secretariat of the Board may be reached at the following address:
   Vienna International Centre
   Room E-1339
   P.O. Box 500
   1400 Vienna
   Austria
 In addition, the following may be used to contact the secretariat:
Telephone: (+43-1) 26060
Telex: 135 612
Fax: (+43-1) 26060-5867 or 26060-5868
Cables: unations vienna
E-mail: secretariat@incb.org 
The text of the present report is also available on the website of the Board (www.incb.org).
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